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Chemotherapy is one of the most predominantly used treatments for cancer. Identifying desirable 
features required of anticancer agents has rapidly developed alongside our growing understanding 
of the disease. Metal complexes are of interest as drug candidates as they provide advantages over 
purely organic systems via modular synthesis, variable geometries and oxidation states. Currently, 
platinum drugs such as cisplatin remain the most common metal-based treatments, despite their 
known toxicity towards healthy cells. Viable complexes are therefore sought as alternatives that 
overcome the limitations of platinum drugs. 
The synthesis and analysis of three piano-stool metal complex series are described, each 
investigating a distinct mechanism of action. Firstly, pyridylphosphinate complexes were employed 
as potential DNA-binding agents. The complexes possess a labile monodentate halide ligand, 
which exchanges intracellularly, forming the aqua species, enabling the binding of DNA. The 
metal, arene and ligand substituents were varied to tune the properties of the complexes. Of the 
resulting systems, few displayed notable cytotoxicity, and these complexes were pursued no 
further.  
The bulk of this thesis focusses on HDAC enzymes as a discrete target for anticancer therapy. New 
complexes were developed incorporating arene-metal motifs along with ligands designed to trigger 
HDAC inhibition. The biological properties of this series were explored and revealed moderate to 
good cytotoxicity, as well as HDAC inhibition to be the likely mechanism of action. Structural 
modifications of the parent complexes were devised to optimise selectivity between HDAC enzyme 
isoforms. Relative to the ligand alone, an increase in specificity of the metal-ligand complexes was 
observed, successfully demonstrating the benefits of incorporating a metal-arene motif.  Biological 
assays including cellular uptake, catalytic domain selectivity and uptake mechanism are reported to 
examine the varied behaviour of these complexes.  
Hypoxic activation was the final mechanism of action studied. Two complexes were synthesised 
possessing a reducible protecting group, to produce the active species selectively under conditions 
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Ala   alanine 
Asp   aspartic acid 
ASAP   atmospheric solids analysis probe 
BHT   butylated hydroxytoluene 
bpy   2,2’-bipyridine 
BSA   bovine serum albumin 
CDCl3   deuterated chloroform 
CD3OD   deuterated methanol 
CHCl3   chloroform 
d   doublet 
DCF   2’,7’-dichloro fluorescein 
DCM   dichloromethane 
dd   doublet of doublets 
ddq   double of doublet of quartets 
DMAP   dimethylaminopyridine 
DMF   dimethylformamide 
DMSO   dimethylsulfoxide 
DFT   density functional theory 
DIP   4,7-diphenyl-1,10-phenanthroline 
DNA   deoxyribonucleic acid 
en   diaminoethane 




ESI   electrospray ionisation 
EtG   ethylguanine 
EtOH   ethanol 
FDA   Food and Drug Administration 
Glu   glutamic acid 
Gly   glycine 
GSH   glutathione 
GST   glutathione S-transferase 
h   hour 
HAT   histone acetyltransferase 
HDAC   histone deacetylase 
HeLa   immortal human cell line 
His   histidine 
HRMS   high resolution mass spectrometry 
Hz   hertz 
ICP   inductively coupled plasma 
IC50   half maximal inhibitory concentration 
In situ   in the original place 
In vivo   in the living organism 
In vitro   in the glass 
K   Kelvin 
Ka   acid dissociation constant 
Leu   leucine 




M   molar concentration 
MeOH   methanol 
MFI   mean fluorescence intensity 
MHz   megahertz 
min   minutes 
mM   millimolar 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NAD   nicotinamide adenine dinucleotide 
NaOMe  sodium methoxide 
nm   nanometer 
NMR   nuclear magnetic resonance 
NSCLC  non-small cell lung cancer 
1O2   singlet oxygen 
PDT   photodynamic therapy 
Phe   phenylalanine 
P-pg   plasma membrane glycoprotein 
Pro   proline 
pta   1,3,5-triaza-7-phosphaadamantane 
quin   quintet 
RNA   ribonucleic acid 
ROS   reactive oxygen species 
s   singlet 
SCLC   small cell lung cancer 




Ser   serine 
SNP   sodium nitroprusside 
TEM   transmission electron microscopy 
Tf   transferrin 
TFA   trifluoroacetic acid 
THF   tetrahydrofuran 
TopoII   topoisomerase II 
TSA   trichostatin A 
Tyr   tyrosine 
UV   ultraviolet 
wt.   weight 
Å   angstrom 
σ   sigma 
π   pi 
λ   wavelength 
μL   microliter 
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1.1 Background to Cancer 
1.1.1 Development of Medicine and Treatment 
Our understanding of cancer has progressed significantly in the last few decades. The relationship 
between prevention, cure and treatment has been widely discussed and studied. In modern 
medicine, initial screening of patients for cancer can prevent the spread of primary tumours by 
metastasis to other sites or organs. Early prognosis can improve patients’ overall chances of 
survival and general recovery rate.1 
The advancement in technology and medicine has spawned a variety of treatments including: 
radiotherapy,2 hormone therapy,3 chemotherapy,4 immunotherapy5 and other alternatives. The 
predominant combination method to treat cancer remains the surgical removal of malignant 
tumours, allied with chemotherapeutics or radiation therapy.6 Although this is the most common 
method of treatment, it is far from infallible. It is exceptionally difficult to remove every remnant 
of a tumour through surgery. This can inevitably lead to a resurgence of the cancer by metastasis or 
malignant cell proliferation.6 The use of both drug agents and ionizing radiation can also be 
damaging to normal, healthy cells.  
A prominent issue facing cancer treatment development is the constant mutability of various types 
of cancer, including (but not limited to) oncogenic mutations of the p53 tumour suppressor protein 
which regulates cell cycle.7 Certain drug-based treatments may be successful initially, but the 
abnormally high mutation rate can cause rapid resistance. In such cases, the resistance can arise 
through prolonged use of a particular drug or with similar, analogous drug candidates. Current 
anticancer therapies often rely on the direct drug binding to DNA, leading to apoptosis. When 
normal cells undergo DNA damage they will arrest their cell cycle until they are repaired.6  
The exposure to multiple chemotherapeutic agents (combination therapy) is becoming more and 
more common to target heterogenous tumour cell populations.6 It is also becoming more prevalent 
in anticancer drug research to target specific biomolecules that aim to prevent high levels of 
toxicity to normal cells and pin-point precise cancer mutations on a subcellular level. The progress 
of chemotherapy in this direction will be discussed further during the course of this work. 





Humans have relied upon natural products with medicinal properties for centuries; the treatment of 
cancer is no different. Both doxorubicin and taxol (Figure 1.1) are early examples of natural 
products used as anticancer agents.  
Doxorubicin is an organic molecule classified as an anthracycline, isolated from the bacterium 
Streptomyces. It has multiple sites of stereoisomerism and a large conjugated ring system providing 
its characteristic red pigmentation.8 Doxorubicin shows significant activity towards solid tumours 
e.g. small lung cell, breast cancer and ovarian carcinomas. It also has high efficacy for 
lymphomas.9 
Anthracyclines including doxorubicin enter cells by passive diffusion.10 Once inside the cell, 
multiple pathways are thought to be the cause of the cytotoxicity. Kiyomira et al. suggest the 
mechanism proceeds by doxorubicin forming a drug-proteasome complex which is translocated to 
the nucleus of neoplastic cells.10 In the nucleus it preferentially binds via intercalation to the DNA 
of chromatin, mediating apoptosis. The basicity of the free amino-group allows hydrogen bonding 
to cytosine-19, increasing the affinity of the doxorubicin-DNA adduct.9  
 
Figure 1.1 Examples of natural product anticancer agents. 
Taxol is isolated from the Taxus brevifolia (yew tree) and is another example of a complex natural 
product used in cancer treatment. It was approved through clinical trials in 1992 and is primarily 
used in the treatment of breast and ovarian cancer.11  
The structure-activity relationship of taxol has been widely discussed because of the many 
functional groups and stereochemical topographies within the structure. Although considered a 
relation to the diterpene group of molecules, taxol includes an unusual oxetane ring addition (seen 




at C4-C5). It has been observed that ring-opening of the oxetane moiety, yields products that are 
less active in cytotoxic assays.11 
Taxol works as an antimitotic drug, targeting the polymerisation of the cellular protein tubulin. By 
binding to tubulin, it promotes the intracellular assembly of microtubules causing defects in cell 
division ultimately triggering apoptosis.11 At concentrations of 0.25 µM the division of 
exponentially replicating HeLa cells can be inhibited, suggesting the proficiency of taxol as an 
antiproliferative agent as well.12  
While the merits of natural products are observed keenly in these examples, both taxol and 
doxorubicin harbour significant disadvantages as cancer drugs. The isolation of taxol is 
exceptionally low yielding with even improved methods only reaching 0.014% of the desired 
product from the source.11 Considering high doses of taxol are required for treatment, the issue of a 
limited supply lends to an equally unfavourable synthetic approach to produce this drug. In contrast 
the isolation of doxorubicin is much simpler due to its metal co-ordinating ability.13  
Side effects such as vomiting, hair loss and myalgia are common with most forms of 
chemotherapy. However, specific side effects for taxol and doxorubicin vary in severity. The 
administration of taxol requires an emulsion with a polyethoxylated castor oil due to its poor 
solubility in water. Frequently, patients incur varying degrees of allergic reactions to this emulsion 
due to the quantity dosed intravenously11. By comparison, treatment using doxorubicin has shown 
drug induced congestive heart failure, increasing the mortality risk to patients; especially those of 
advanced age.9,14  
1.2 Metal Complexes as Anticancer Agents 
Not all metal ions are found naturally in biological systems. Labile metal ions that allow fast ligand 
exchange in their coordination sphere are preferred. These include Na+, K+, Mg2+ and Ca2+, as well 
as first row transition metal ions - particularly Mn, Fe, Co, Ni, Cu and Zn. The first-row transition 
metals are often stabilised by binding to biomolecules and often form catalytic sites in 
metalloenzymes. The concentration of such metals is regulated by cellular processes to limit the 
potential toxicity in the body.  
Heavy metal ions of the second and third-row transition metals are not commonly found in biology. 
Although originally displaying high levels of toxicity in biological systems, they have emerged as 
potent chemotherapeutics and valuable to diagnostic medicine.15 The use of transition metal-
centred complexes as alternatives to organic extracts in chemotherapy provides some key 
advantages. Functional properties for drug design of inorganic compounds include: exchangeable 




ligands, modular synthesis, as well as variable oxidation states and geometries. These factors allow 
metal centred complexes to be tuned for targeted treatment. 
1.2.1 Platinum Complexes 
The interest in platinum complexes was initiated by the serendipitous discovery of their ability to 
inhibit cell division in Escherichia coli. The discovery was made by Barnett Rosenberg and co-
workers in 1965 during a biophysics experiment.16 It was proposed that the production of 
long-lived complexes occurred during electrolysis, from a reaction between the medium used and 
oxidised species formed from the platinum electrode. No specific species was identified at this 
time, but the low concentration of complexes (1 to 10 ppm) required to inhibit cell division in E. 
coli while not interfering with cell growth prompted further investigation. 
 
Figure 1.2 Platinum compounds tested for antitumour activity.17,18 cisplatin cis-[Pt(NH3)2Cl2]; Pt1 [Pt(1,2-
diaminoethane)Cl2]; Pt2 cis-[Pt(NH3)2Cl4]; and Pt3 [Pt(1,2-diaminoethane)Cl4].   
By 1969 a range of platinum complexes were identified as potent antitumour agents (Figure 1.2). 
Both Pt(II) (cisplatin and Pt1) and Pt(IV) (Pt2 and Pt3) complexes were tested in vivo against 
sarcoma 180 and leukaemia L1210. Cisplatin displayed the highest efficacy as an antileukemic 
agent with some mice appearing tumour free months after the treatment.17  By the late 1970s, 
cisplatin had completed phase III clinical trials and showed promising results in combination 
therapy for the treatment of numerous human cancers including bladder, testicular, ovarian and 
prostate.18 It was approved for medical use in 1978. 
 
Figure 1.3 Aquated cisplatin at increasingly basic conditions. (pKa1 : 5.51, pKa2 : 7.31).18 
The properties of cisplatin were later determined, to help elucidate correlations between its 
biological mechanism and chemical structure. As cisplatin is injected intravenously, high chloride 
ion concentration of extracellular fluid (0.1 M) prevents the exchange of chloride ligands, 
maintaining the chemical composition of the drug. Once inside the cell, the lower chloride ion 




concentration (0.004 M) shifts the thermodynamic equilibrium, promoting dissociation of chloride 
ligands in favour of water or hydroxyl ligands.19 Using conductimetry, it was shown in vitro that 
the structure of the aqua species was pH dependent (Figure 1.3).18 In neutral conditions the 
molecule is predominantly the dihydoxy species Pt4.3, while a charged state at more acidic pH as 
aqua ligands are favoured (Pt4.1 and Pt4.2).  
After cisplatin crosses the cell membrane, the subsequent hydrolysis products can bind to their 
desired targets. Lippard discussed the significance of cisplatin forming the most stable linkages to 
definite nucleobases, detailing a binding preference for the N7 atom of guanine with a stabilised 
intramolecular hydrogen bonding by co-ordinated water and the exocyclic oxygen atom.20 Gowda 
and co-workers would later conclude that the affinity of cisplatin for guanine bases can produce 
interstrand, intrastrand (Figure 1.4) and monofunctional adducts cross-linking DNA. This suggests 
the binding of cisplatin is not always exclusive to adjacent guanosine nucleosides.21  
 
Figure 1.4 Cisplatin guanine-guanine base pair binding in DNA showing a) 1,2 crosslinks and b) 1,3 
crosslinks.21 
As early as 1970, Rosenberg was an advocate of the ability of cisplatin to selectively inhibit DNA 
synthesis.22 Nucleic acid interactions in vitro were further studied by Roberts and Pera displaying 
DNA as the most susceptible target at pharmacologically relevant doses, compared to previously 
speculated RNA and protein binding.23 Inactivation of the DNA template for replication occurs 
when cisplatin is bound and the change is not recognised by repair enzymes. This causes drug-
induced cell death as a function of chromosome damage, observed in the first or second mitotic 
cycle after treatment.23 The cis-square planar geometry is integral to the highly mutagenic effects of 
cisplatin by allowing a bidentate chelate to the metal centre from the DNA double helix. The trans 
derivative is unable to form the same intrastrand cross-links in d(GpG),24 showing the significance 
of isomerism and structure, for both the mechanism of action and potency of cisplatin.20,22,23,25   
Unfortunately, therapeutic complications are becoming more ubiquitous across a broad range of 
cell lines as tumour resistance to cisplatin continues to develop. Primary investigation of resistance 
in both ovarian and lung cancers found a correlation between levels of glutathione S-transferase 




(GST) and platinum drug toxicity.26,27 A comparison of small cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC) by Nakagawa et al. showed a higher sensitivity to cisplatin in 
SCLCs than NSCLCs, which possess much lower mRNA expression of the GST gene.27 It is 
hypothesised that GSTs form cisplatin-thiol conjugates with highly reactive aquated cisplatin, 
prohibiting binding to DNA.28  
Resistance is now considered to be multifactorial. Various signalling pathways from cisplatin-
induced cellular effects culminate in apoptosis, however resistance interferes with the activation of 
these pathways. For instance, drug accumulation within the cell has been reduced between 20-70% 
in many cases.28 This mode of resistance arises from limiting passive diffusion by inhibition of 
drug uptake or increased drug efflux from the cell. Topoisomerase II - an enzyme linked to the 
repair of cisplatin-DNA adducts - is overexpressed in clinical cancer cases. The improved 
recognition of DNA damage is another factor associated with cisplatin resistance.28  
 
Figure 1.5 Alternative platinum drug candidates. 
Cisplatin could evidently not be relied upon as the only inorganic anticancer drug candidate. Low 
solubility, systemic toxicity to normal tissues and more frequently reported cases of cisplatin 
resistance prompted the synthesis of second generation platinum compounds (Figure 1.5). The role 
of the ligands within cisplatin analogues was analysed by Zunino et al. in 1987.25 Ligands bound 
too strongly were found to produce kinetically inert complexes while highly labile ligands 
produced candidates which were too toxic. Bidentate dicarboxylate ligands – seen in both 
carboplatin and oxaliplatin – are often favoured due to the requirement of intercellular metabolism 
to activate their cytotoxic effects. The non-leaving groups tend to be amines (aliphatic, branched or 




bidentate) and generally accompany platinum to the target macromolecule. They appear to play a 
significant role in hydrogen bond interactions with polar groups of DNA, modulating toxicity and 
tumour effects depending on their structure.25  
Both carboplatin and oxaliplatin produced a comparable effect profile to cisplatin with less severe 
side effects and were approved for worldwide use in 1978 and 2002, respectively.29 Unfortunately, 
carboplatin developed rapid cross-resistance to cisplatin, showing similar lack of drug 
accumulation. Complex oxaliplatin contains a 1,2-diaminocyclohexane ligand, that is thought to be 
responsible for the different spectrum of activity and the lack of cross-resistance it presents.25 
Subsequent trials explored combination therapies and found dosing cisplatin and oxaliplatin in an 
additive manner yielded promising synergistic results.30 
Satraplatin is a prospective candidate in the analogous cisplatin series, possessing more favourable 
physiochemical properties. Unlike existing platinum drugs that are limited to intravenous 
administration, the axial acetate ligands in satraplatin increase lipophilicity of the complex 
improving oral bioavailability.31 The reduction of satraplatin from its substitutionally inert, parent 
Pt(IV) form to the Pt(II) active complex, produces an analogous complex to cisplatin (Pt5), 
considered essential for activity. Initially, reduction of satraplatin was thought to proceed by 
reductive elimination and dissociation of the two axial acetate ligands in the blood, largely 
dependent on the presence of biological nucleophiles (GSH) or antioxidants (ascorbate).32 
However, it was deemed naturally occurring concentrations of such biological molecules were not 
sufficient to reduce satraplatin to its active species (Pt5). An alternative mechanism was proposed 
by McLeage et al. suggesting red blood cells were necessary for the production of Pt5. Through in 
vitro experiments, they determined the involvement of iron atoms found within haem complexes 
(abundant in red blood cells) produced the reduced form of satraplatin (Pt5), concurrent with the 
oxidation of haemoglobin.33 Binding of carbon monoxide to haemoglobin, inhibited this particular 
biotransformation, implying metal-containing redox proteins are required for the activation of 
satraplatin.32,33 
The asymmetric structure of Pt5 adhered to the same mode of binding as cisplatin through inter- 
and intrastrand cross-links of DNA. However it is reported, DNA mismatch repair proteins fail to 
recognise the larger cyclohexylamine adduct, signalling a successful apoptotic response.34 In some 
cisplatin-resistant cell lines, the DNA mismatch repair protein is defective. This mode of resistance 
is therefore avoided when using satraplatin as a chemotherapeutic agent.31,34 Although the attributes 
of satraplatin as a drug candidate are promising, it is yet to gain FDA approval. 
For all its pitfalls, cisplatin remains one of the most extensively used anticancer agents in modern 
day chemotherapy. While platinum responsiveness is high in many patients, a relapse due to 




resistance is commonplace. Combinatorial strategies employ existing natural product drugs 
(Section 1.1.2) which when used in tandem, can overcome toxicity towards normal tissue and 
increase sensitivity by targeting multiple mechanisms.35 Alternative inorganic drug candidates are 
being currently investigated to find less hindered chemotherapeutic options. 
1.2.2 Ruthenium Complexes – A Platinum Group Alternative 
In response to platinum resistance, other platinum group metal complexes are being studied and, in 
some cases, have exhibited promising efficacy against solid tumours. Ruthenium is of particular 
interest as it displays notably lower toxicity towards healthy cells. Not only this, ruthenium boasts a 
variety of suitable biological properties encouraging its candidacy for medicinal applications. 
As discussed previously, the benefits of tuneable ligand exchange are often linked to activity in 
anticancer agents. This promoted the use of Ru(II) and Ru(III) complexes as they host similar 
ligand exchange kinetics to Pt(II) centred complexes36. Under physiological conditions, ruthenium 
is unique within the platinum group as Ru(II), Ru(III) and Ru(IV) oxidation states are all 
accessible. More biologically inert Ru(III) complexes are easily reduced by glutathione, single-
electron transfer proteins or by cellular conditions like pH and oxygen concentration (Figure 1.6). 
It has been suggested that ruthenium drugs are also believed to mimic iron by binding to 
biomolecules such as transferrin (Tf).37 Cancerous cells require heightened levels of iron due to 
rapid cell division. To accommodate this, transferrin receptors are overexpressed on the surface of 
these cells. This is thought to account for low levels of toxicity shown by ruthenium complexes 
towards healthy cells due to their potential affinity for transferrin.37 
 
Figure 1.6 Observed oxidation state changes of ruthenium in cancer and healthy cells.37  
NAMI-A and KP-1019 are two examples of ruthenium based anticancer agents that entered clinical 
trials. They share an octahedral geometry, Ru(III) oxidation state and four in-plane chloride 




ligands. Both complexes contain nitrogen-bound aromatic heterocycles as ligands; NAMI-A 
possessing asymmetry with the presence of a dimethylsulfoxido ligand trans to an imidazole.  
 
A study in 1999 by Sava et al. probed the potential activity of NAMI-A compared to cisplatin. 
Predictions based upon similarities with cisplatin – sharing a heavy metal centre from the same 
group – were revoked when NAMI-A showed virtually no cytotoxicity in vitro at concentrations up 
to 100 µM.38 Surprisingly, NAMI-A displayed unprecedented behaviour in vivo causing a marked 
reduction on lung metastasis in mice, implanted with Lewis lung carcinoma, TS/A adenocarcinoma 
or MCa mammary carcinoma. Post-surgical treatment with NAMI-A caused an increase in life 
expectancy comparable to cisplatin, in particular of mice bearing a MCa mammary carcinoma.38  
Following up on previous findings, Sava examined tissue samples from the organs of transplanted 
mice. Using TEM analysis, electron-dense ruthenium is highly visible. An abundance of NAMI-A 
was located along collagen fibres of the lung, particularly around collagen-rich metastatic foci 
regions.39 The binding to extracellular matrix collagen is attributed to the slower release of 
NAMI-A from the lungs compared to other organs.39 A dual-activity was proposed by Sava et al. 
suggesting not only is antimetastasic activity retained by the presence of NAMI-A in the lungs, but 
also through selective targeting of metastasising tumour cells.39 
The classical DNA-binding mechanism was also investigated as a mode of action by Pluim and co-
workers in 2004.40 Calf thymus DNA incubated with both cisplatin and NAMI-A showed both 
drugs bound in a linear fashion with NAMI-A mirroring the interstrand adducts formed by 
cisplatin. This experiment was not a concerted approach to assigning activity as it was already well 
publicised that NAMI-A enters cells by a facilitated mechanism like cisplatin but with much 
greater difficulty.40 The poor cytotoxicity detailed by Pluim also fails to support DNA binding as 
the cause of activity. DNA interactions overall required concentrations which are not 
physiologically relevant when considering a drug candidate and despite numerous studies, the 
mechanism of NAMI-A is still debateable.41 Regrettably, during phase II clinical trials, no patients 




exhibited partial remission as a best response from combination treatment of NAMI-A with 
gemcitabine. These results prompted the termination of clinical trials.42     
KP1019 is another ruthenium-based example of a tumour-inhibiting drug.43 Primary issues with 
solubility were overcome by formulating the indazolium salt in situ from the more soluble sodium 
salt. Models using colorectal carcinomas in rats, which closely resemble the same tumours in 
humans, showed superiority of KP1019 over the standard drug administered.43 Decrease in tumour 
volume to 40% was observed for 5-fluorouracil, an established and effective treatment for 
colorectal cancer, while KP1019 caused a more pronounced reduction in volume to only 8%.44 
Studies run in parallel, found KP1019 to maintain the general low toxicity improved upon from 
platinum drugs, similar to NAMI-A. 
The glycoprotein transferrin (Tf) - already briefly mentioned - is credited for the low toxicity of 
KP1019 towards healthy cells, according to Keppler et al, along with serving as the pathway of 
uptake45. Tf has two specific Fe(III) binding sites and a concentration of 35 µM in the blood, 
enabling it to act as an abundant, natural drug carrier for KP1019.46 Keppler used a variety of tests 
to determine the likelihood of transferrin mediated transport. Adducts of KP1019 onto 
apolactotransferrin (a protein with high sequence homology to human transferrin) observed from 
crystal structure data, showed KP1019 bound specifically to histidine-253 amino acid and 
preserved co-ordination of the indazole ligands.44 Saturation of transferrin is preferable as it binds 
more strongly to receptors on the surface of the cell when both iron-binding sites are occupied. 
Although competitive binding of Fe(III) ions and KP1019 was confirmed, in vitro experiments 
using SW480 cells loaded with equimolar concentrations of KP1019 and physiological Fe(III) 
(30%) showed a 2-fold higher uptake of ruthenium species into the cells versus incubation with 
only KP1019.44 The bulky ligands of KP1019 are thought to cause conformational distortion of 
transferrin when bound to both sites which is less recognisable by the transferrin receptor, therefore 
binding of stoichiometric amounts of Fe(III) and KP1019 is desirable. 
Apotransferrin binds KP1019 strongly and requires mild acidic conditions for its removal. Hypoxic 
conditions of tumours promote the release of KP1019 compared to that of normal tissue.47 
Activation by reduction is hypothesised to be the mechanism of action of some prodrugs. Ascorbic 
acid (a mild reducing agent) is predominantly found in the blood environment where minimal 
reduction of KP1019 is detected. Instead, it is proposed that once released from transferrin, 
KP1019 is reduced by thiol containing glutathione found between 0.5 to 10 mM concentration 
within the cell48. This suggestion correlates an increase of Ru(III) reduction potential with 
increased antiproliferative activity in SW480 colon carcinoma cell line supporting the activation by 
reduction mode of action. Keppler and co-workers also noted apoptosis of SW480 cells occurs 
through the intrinsic mitochondrial pathway when dosed with KP1019 through a loss in 




mitochondrial membrane potential. This implies the significance of ruthenium redox chemistry of 
this promising drug candidate.47 
A combined effort of NAMI-A and KP1019 display the potential for ruthenium drug candidates.  
Even though both NAMI-A and KP1019 are structurally similar, it is apparent they do not share a 
mechanism of action or a specific target for activity.44,47 Indeed, the unconventional antimetastasic 
activity towards lung cancer of NAMI-A could not be more disparate to the colorectal, carcinoma 
neoplastic agent KP1019. Despite the shared oxidation state and geometry, these contrasting 
differences advocate the continued examination of ruthenium based anticancer drugs.  
1.2.3 Ruthenium(II) – Piano-Stool Complexes 
A more contemporary approach to metal-centred anticancer complex design has exploited the 
pseudo-octahedral, or “piano-stool” complexes. Unlike the coordination compounds discussed 
previously, the complexes here on in conform to the class of organometallic complexes, containing 
a lipophilic arene motif, stabilising the Ru(II) oxidation state. Reviews published by Dyson49, Suss-
Fink50 and Sadler51 (among others) have detailed and compared a myriad of examples of half-
sandwich piano-stool compounds that show varying success as potential anticancer agents. The 
following section will highlight the functionalities and properties of piano-stool complexes that are 
of key relevance to this project.  
1.2.3.1 The First Examples  
One of the earliest demonstrations of anticancer activity from a half-sandwich complex was by 
Kondapi et al. in 1999. A simple molecule RuDMSO, comprising a benzene arene, two chloride 
ligands and a dimethysulfoxide ligand around a Ru(II) metal centre, was linked to poisoning of 
topoisomerase II (topoII) – an important enzyme in DNA religation – and yielded antiproliferative 
effects.52 At drug concentrations of 300 µM, Crit-2 (nonhodkins human lymphoma) displayed 87% 
inhibition of cell growth. Whilst the potency of this drug is considerably lower than other examples 
of antineoplastic agents, it was an intriguing result from a piano-stool complex at this time. 
Inhibition of enzyme targets as a mode of action for anticancer activity will be further analysed in 
Section 1.3.   
 




In 2001, Sadler et al. synthesised a range of positively charged piano-stool compounds containing a 
bidentate diaminoethane (en) ligand. Complex RAED-C showed good solubility in water, with 
substitution of the chloride ligand for water in dilute solution (0.2 mM) to provide 60% as the aqua 
adduct. Approximate physiological conditions of NaCl (0.1 M) suppressed hydrolysis leaving 81% 
of complex RAED-C intact. Known intercellular conditions indicate the potential activation of 
these complexes to the aqua species, permitting reactions with DNA by a similar mechanism to 
cisplatin.53  
 
Cellular assays on the human ovarian cancer cell line A2780 gave IC50  values of 9 and 6 µM for 
RAED-C and RAED-bp respectively, comparable to the control carboplatin (6 µM).53 Increased 
hydrophobicity marked an overall trend in cytotoxicity. Follow up studies investigated in vitro and 
in vivo effects of the [(η6-arene)Ru(en)Cl]+ complexes on the A2780 cisplatin resistant (A2780cis) 
cell line and parent xenografts. A 10 mg kg-1 dose was the maximum tolerated administering 
cisplatin whereas, RAED-C allowed 25 mg kg-1 dose without weight loss of mice with an A2780 
xenograft.54 However, both complexes RAED-C and RAED-bp displayed significant cross-
resistance with the A2780cis cell line, a reduced potency which was mirrored in the xenograft 
results.54 The resistance mechanism was rationalised exclusively as an overexpression of the 
plasma membrane glycoprotein P-pg in A2780cis cells. Lipophilicity and a cationic centre are 
favourable in P-pg substrate recognition, increasing the efflux of [(η6-arene)Ru(en)Cl]+ complexes 
from the cell, reducing drug accumulation.54 
The positive results against A2780 cells prompted scrutiny into mode of action of these complexes. 
Crystallisation of RAED-bp with 9-ethylguanine and guanoside base (Figure 1.7) in place of the 
chloride ligand allowed spatial interpretations of potential DNA binding. Simultaneous N7 binding 
of guanine to the ruthenium centre, along with π-stacking interactions between the pendant phenyl 
of RAED-bp and the 5-membered purine ring encourage intercalation as a mechanism.55 Strong 
hydrogen bonding of the carboxyl oxygen of guanine and the closest NH of the en ligand was 
specific to this base. These features support DNA recognition at guanine, correlating with 
oligonucleotide experiments which observed a favourable monoruthenated species at G7 on DNA 
14-mer d(ATACATG7GTACATA).53,55,56 Continued optimisation of the [(η6-arene)Ru(en)Cl]+ 




complexes by Sadler et al. was justified by the specific DNA binding and promising antitumour 
activity of these complexes. 
 
Figure 1.7 X-ray crystal structure of RAED-bp with chloride exchanged for a guanoside base showing 30% 
probability ellipsoids. H-bonding interactions of enamine NH and G O6 are indicated with a dotted line.55  
1.2.3.2 RAPTA Complexes 
Another group of ruthenium half-sandwich complexes to consider are the RAPTA complexes 
(Figure 1.8) studied by Dyson et al. extensively. These compounds encompass a monodentate 
1,3,5-triaza-7-phosphaadamantane (pta) ligand, bound through the phosphorus atom and are highly 
water soluble. Like many of the compounds mentioned previously, the prototype RAPTA complex 
(RAPTA-C) was tested for DNA binding in early experiments. Running gel electrophoresis on 
supercoiled (SC) DNA incubated with RAPTA-C over a 6.0-8.0 pH range showed a progressive 
increase in retardation of the DNA at reduced pH.57  The pKa of  pta (6.5) would inherently 
promote the protonated species at such lower pH, facilitating interactions between negatively 
charged DNA slowing migration. These initial observations suggested the possibility of a higher 
affinity of RAPTA-DNA binding in a hypoxic environment.57  





Figure 1.8 A selection of RAPTA complexes.  
Behaviour of RAPTA-C in solution is partially akin to that of cisplatin. While cisplatin sees rapid 
hydrolysis of one chloride once inside the cell, the second chloride-water exchange is much slower, 
unlike RAPTA-C which undergoes rapid hydrolysis of both chloride ligands almost concurrently.58 
Adverse production of hydrolysis products have been known to stunt drug development, as the 
exact intercellular hydrolysed species is often unknown and interactions difficult to predict. For this 
reason, Dyson et al. modified RAPTA-C, by substituting a bidentate carboxylate for the chloride 
ligands to provide RAPTA-O. This adaptation enabled RAPTA-O to resist hydrolysis, improved 
solubility and lowered the pKa of the coordinated pta ligand. Compared to its precursor, RAPTA-O 
showed little change in biological properties, exhibiting similar inhibition of cell proliferation and 
equally poor cytotoxicity (>200 µM) in the cell lines tested. This included negligible toxicity 
towards the HBL-100, non-tumourgenic cell line.59   
Further testing primarily utilised RAPTA-T which showed the best selectivity towards cancer cells 
over normal cells.58 Along with standard in vivo tests, to simulate the main steps of metastasis 
progression, Dyson et al. used in vitro experiments on three cell lines: invasive MDA-MB-231 
breast cancer, non-invasive MCF7 breast cancer and HBL-100 normal cells. In the detachment 
assay, when seeded onto extracellular matrix proteins (collagen and fibronectin), MDA-MB-231 
cells remained up to 9-fold more attached to the substrate than control cells, upon treatment with 
RAPTA-T. Complex RAPTA-T also prevented re-adhesion in the comparative assay. Plasticity 
required for detachment and adhesion of cells is thought to be modified by RAPTA-T by hardening 
the cell body, hindering these processes. Effects on the MCF7 and HBL-100 cell lines were 
negligible for these assays. The migration tests were measured using both chemical and contact 
stimulus to encourage cell movement. Cell specificity was observed in these tests with only MDA-
MB-231 cells inhibited from migration and invasion up to 50% compared to controls.60 Structure of 
the cytoskeleton is also thought to be crucial for motility, additionally supporting RAPTA-T effect 
on plasticity. In vivo lung metastasis weight was reduced to 35% of the control weight dosing 
RAPTA-T into MCa mammary carcinoma. Tumour growth was not maintained after treatment, 
consistent with previous reports of fast elimination of RAPTA-T from organs.58 Together these 
results showed that RAPTA complexes are effective antimetastatic agents. 




The most recent work on these compounds in 2017 utilised nanoscale secondary ion mass 
spectrometry and transmission electron microscopy to visualise the localisation of RAPTA-T at a 
subcellular level.61 Accumulation in the nucleolus of MDA-MB-231 cells was observed, 
corroborating with earlier studies of histone protein adduct formation of RAPTA-T in the 
nucleosome core.62 Distribution of RAPTA-T in MDA-MB-231 cells correlated accumulation with 
sulfur-rich regions. In contrast, treatment of MCF7 resulted in neither accumulation in the nucleus 
nor the cell membrane.61 The lower degree of malignancy in MCF7 cells appears to mitigate the 
effects of RAPTA-T claiming specificity instead over the invasive MDA-MB-231 cell line that 
possess the stronger inclination to invade and metastasise.60,61 The data discussed suggest a control 
of metastasis is through targeting proteins either prominently in the cell membrane or 
intracellularly.   
In summary, a general comparison can be drawn between NAMI-A and RAPTA-T based on 
distinct similarities of results in vitro and in vivo despite starkly different chemical conformations 
of the complexes. Anti-metastatic activity prevails as a clinical benefit of these compounds, 
although NAMI-A is overall more potent, it nevertheless validates continued experiments within 
the RAPTA series. 
1.2.3.3 Modifications of Half-Sandwich Complexes to Tune Activity  
Already, it should be clear that half-sandwich complexes can provide different degrees and types of 
activity ostensibly linked to their combined structural components. There remains ample room to 
manipulate the various coordination sites to distinctly design a complex with a desired specific 
target and tuned activity. While some factors have already been discussed briefly (e.g. arene 
expansion to increase lipophilicity and potency), alternative ligand systems, the monodentate halide 
ligand and the metal centre are all readily interchangeable and worth discussion.   
An ambidentate picolinate ligand system (Figure 1.9) was considered by McGowan et al. to 
evaluate the coordination of its complexes and their biological properties.63 The simplest complex 
Rupic1 was synthesised using readily available starting materials; picolinamide and dichloro(p-
cymene)ruthenium dimer to form the N,O-chelated product. Poor cytotoxicity of complex Rupic1 
was attributed to the lability of the N,O-chelated picolinate system.63  Incorporating a strongly 
electron withdrawing group adjacent to the amide was found to force the formation of the N,N 
chelated system seen in complex Rupic2. The para-nitrophenyl substituent of Rupic2 increases the 
acidity of the amide proton facilitating anion formation in solution, enabling N,N-coordination.64  





Figure 1.9 Half-sandwich complexes containing a picolinamide-based bidentate ligand system. 
NMR studies showed linkage isomerism was pH-dependent as well as temperature dependent. At 
low temperatures the kinetic N,O coordination is preferred while the thermodynamic N,N  product 
is irreversibly formed  at 323 K.64 Dynamic interconversion of the isomers was achieved by 
changing the pH of solution. At low pH the amide generally remained protonated, however some of 
the thermodynamic product was observed in equilibrium. Reversible coordination over pH range 
7.1-8.6 suggested potential for ligand design to allow conversion between N,N and N,O under 
biological conditions.  
Cytotoxicity trends of these complexes showed an increase in lipophilicity providing heightened 
potency. The quinaldimide containing complex Rupic3 gave an IC50 value in the same magnitude 
as cisplatin for MCF7 breast cancer cells (3.4 and 2.0 µM, respectively).63 Lower toxicity was also 
associated with the N,O ligand which consistently showed poor cytotoxic effects, independent of 
metal centre. For example, the trimethylphenyl containing osmium complex Ospic2, is forced into 
the N,O coordination due to the added steric bulk of the methylene groups and showed low potency 
(>50 µM).64 





Within this series, an overarching relationship between rate of hydrolysis and potency is observed. 
This can be rationalised by considering the neutral complexes undergo rapid hydrolysis in solution 
compared to those that are positively charged. It is unfavourable for the Group VIII metal 
complexes in this case to gain an overall 2+ positive charge by loss of coordinated halide and 
therefore show significantly slower hydrolysis. Even though a π-acceptor ligand usually slows 
hydrolysis, when paired with the anionic character of the deprotonated amide (seen in Rupic2, 
Rupic3 and Ospic1), the negative coordinated ligand forms a neutral complex which hydrolyses too 
fast to measure by 1H-NMR.64 This is the case for both ruthenium and osmium analogues. By 
comparison, the Sadler diaminoethane N,N-chelating neutral ligand forms positive complexes, 
displaying the expected slower rate of hydrolysis in the osmium complex (RAED-Os) compared to 
the ruthenium analogue (RAED-bp). The slower ligand exchange rate and the lower pKa (6.3) of 
the aquated RAED-Os could be the cause of the negligible toxicity of the complex (IC50 = 
>100 µM) compared to the ruthenium RAED-bp congener (IC50 = 5 µM) in this case.65  
 
Keppler et al. investigated complexes incorporating the natural product maltol and its derivatives. 
Similar to McGowan’s anionic N,N coordinated complexes, the negative O,O maltol ligand also 
provided complexes Mal1 and Mal2 which observed rapid hydrolysis to the monocationic species 
under aqueous conditions; irrespective of their metal centres.66 However, limitations arose at both 
physiological temperature (310 K) and in dilute solution. The maltol ligand was completely 
dissociated at 310 K in concentrations of 2 µM after ten minutes in both Mal1 and Mal2. In 
solution, to mimic extracellular conditions of 0.1 M NaCl, the ligand was also fully dissociated in 
favour of the inert hydroxo-bridged dimer [(p-cymene)2M2(OH)3]+.66 Proton-donor solvents such as 




water were predicted by DFT to form hydrogen bonds with the coordinated oxygen promoting the 
hydrolysis.  
Unsurprisingly, these complexes gave insignificant IC50 values (>50 µM) when dosed to both A549 
lung cancer and A2780 ovarian cancer cells, assumed to be due to the formation of 
[(p-cymene)-2M2(OH)3]+ under physiological conditions. The weakly coordinated carbonyl oxygen 
was replaced by a thiocarbonyl derivative in complex Mal3. Complex Mal3 was significantly more 
stable in aqueous conditions observing only a small amount of dimer formation over 24 h. The 
stronger binding of the O,S-chelated complex is thought to be responsible for the improved potency 
of Mal3 compared to its O,O analogues with 13 and 5.1 µM IC50 values against CH1 and SW480 
cancer cell lines, respectively.67 
 
The monodentate halide is the remaining coordination site available for variation. Sadler et al. 
presented a study of the contrasting cellular uptake pathways of chloride versus iodide 
iminopyridine ruthenium complexes.68 An immediate distinction in cytotoxicity between the 
complexes was apparent when testing the antiproliferative activity in A2780 ovarian cancer cells. 
The iodide complex Ruim2 showed similar potency to cisplatin (3.0 and 1.2 µM, respectively) and 
was 5-fold more active than the chloride analogue Ruim1 (15 µM).68 The cellular accumulation of 
drug Ruim2 after 24 h incubated at 310 K was also greater than Ruim1, showing the correlation 
between higher drug accumulation and increased potency.  
At low temperatures (277 K) no cellular accumulation of cisplatin was observed in contrast to 
Ruim2, which showed significant uptake at 277 K; increasing uptake with increasing temperature. 
This result indicates a partially passive uptake pathway which is energy-independent, compared to 
cisplatin which requires facilitated diffusion into the cell. Both complexes exhibit hydrolysis up to 
64% at 2 µM concentrations and yet iodide in Ruim2 is not exchanged for chloride in 
physiologically relevant concentrations of NaCl. As the structure of these complexes is retained 
extracellularly, their biological behaviour can likely be attributed to cell recognition and specific 
transport of the iodo and chloride species. This could intrinsically be linking to membrane potential 
as displayed by in vitro tests of the endocytosis pathway. Ruthenium accumulation of both 
complexes was reduced by co-administration with ouabain, which modifies the function of the 
Na+/K+ pump and alters the membrane potential. DFT calculations suggested the chloride face of 




Ruim1 is less positively-charged than the iodide face of complex Ruim2. These combined factors 
enhance the proposition that the difference in polarisation between complexes Ruim1 and Ruim2 
plays a substantial role in overall cellular uptake.   
1.2.4 Summary 
Metal complexes offer many qualities that are advantageous to drug design including: modular 
synthesis, exchangeable ligands, variable geometries and oxidation states. It is apparent from the 
examples of half sandwich complexes discussed, that a combination of ligands in the available 
coordination sites, along with the metal centre must possess complementary characteristics to 
provide desirable anticancer activity. While only a few have been analysed in detail here, there are 
evidently thousands of possible complexes with the pseudo-octahedral geometry that could be 
synthesised and explored for medicinal applications.  
It has been shown that the tuning of ligands can strongly influence the properties of the complex 
and can evoke changes in the mechanism of action seen explicitly when comparing the ruthenium 
complexes RAPTA-C and RAED-C. Dyson’s complex RAPTA-C has a proclivity for forming 
adducts on chromatin-associated proteins and displays activity as an antimetastatic agent.57,69,70 The 
subtle ligand substitution with ethylene diamine provides the RAED-C complex, which by contrast 
displays preferential binding to DNA.53,55 Although these complexes are structurally similar, they 
illustrate the influence coordinating ligands can have on the target of a complex.71 
 
Current drug limitations including chemotherapeutic resistance and toxicity to healthy tissue can be 
circumvented by the use of less toxic platinum group metals such as ruthenium. This valuable 
property is a contributing factor to the promising use of half-sandwich complexes as alternative 
anticancer agents. Still, it is clear that more understanding and investigation is necessary to 
determine the fate of such half-sandwich complexes within the cellular environment and to 
establish how such structural changes can directly affect their activity.  




1.3 Enzymes as Anticancer Targets 
There are a copious amount of processes occurring simultaneously inside and outside of cells. 
Factors within the cell cycle vary between healthy and cancerous cells; providing more discrete 
therapeutic targets at a subcellular level. The manipulation of these vital biological processes by 
drug targets can have a variety of consequences. Complexes already discussed have exhibited 
inhibition of antimetastasic activity through protein binding, while other compounds trigger 
apoptotic pathways in malignant cells by DNA adduct formation, DNA intercalation or even 
enzyme poisoning.  
Enzymes are naturally occurring biomolecules that catalyse numerous regulatory processes and 
metabolic pathways. The catalytic activity of enzymes is often selective to a single substrate 
different to each enzyme family. Dysregulation of enzyme function is associated with mutations in 
cancerous cells propagating the disease.72 For this reason, enzymes are considered an appropriate 
target for metal-based drug design, with frequently targeted examples displayed in Table 1.1.  
Candidates will most commonly interact with the enzyme through weak intermolecular forces, 
hydrogen bonding or binding to the catalytic site, inhibiting activity. The role of the metal centre 
within the drug influences the classification of potential enzyme inhibitors.72  
1) The metal centre of the complexes does not directly bind to the enzyme. The ligands are 
the biologically active motif, while the metal’s redox potential may enhance the overall 
effects of the compounds. 
2) The metal ion is the active part of the molecule; directly interacting with the enzyme target. 
In this case the ligands are used to stabilise the reactive metal centre. 
3) Complexes where the metal and ligand components are biologically active and both are 
responsible for activity. 
4) The metal atom can add electron density and facilitate x-ray phasing for cocrystal structure 
determinations. 
The protein kinase inhibitor FL172 uses ruthenium as an inert metal scaffold, acting as a 
hypervalent carbon. The complex carries the active organic ligand, analogous to the natural product 
kinase inhibitor staurosporine.73 The rigid three-dimensional structure of FL172 enabled a highly 
competitive binding affinity with ATP substrates for protein kinase and acts as a potent inhibitor in 
the nanomolar range (130 nM).74 Complex CoIII-mmst also falls into the first category as the 
Co(III) metal centre is a reduction activated chaperone for the existing marimastat antimetastatic 
agent. The hypoxic environment of tumour sites causes Co(III) to Co(II) reduction and 
subsequently allows displacement of the stereospecific ligand and increases the magnitude of 




activity two-fold compared to the organic molecule alone. This activation inhibits matrix 
metalloproteinase activity, linked to metastasis.75 Meanwhile, Marmion et al. demonstrated the 
ability of a metal containing prodrug Pt-SAHA to possess dual action upon hydrolysis. While the 
cisplatin fragment binds DNA, the organic ligand inhibits histone deacetylase enzymes 
demonstrating dual activity within a single complex.76 Metallocene dihalides (Cp2MCl2) have been 
noted to possess qualities of the second example, inhibiting the activity of topoisomerase II by 
metal coordination to the enzyme surface.77 Rapid hydrolysis of the chloride ligands forms the 
active species (Cp2Mn+), enabling the formation of enzyme-complex adducts, with overall cellular 
accumulation aided by the presence of the hydrophobic Cp ligands.  




Table 1.1 Possible enzyme targets for inhibition and examples of metal-based inhibitors.74–77 
Enzyme 
family 




of protein substrates, 
altering their cellular 
location and function. 
Tissue remodelling and degradation of 
protein mass which provides structural 
and biochemical support extracellularly. 




chromosomes prior to 
cell division. 






coordination of cellular 
processes. 
Cause excessive degradation of 
extracellular matrices. 
Rapid proliferation. Dysregulation of DNA damage repair, 
cell cycle control, autophagy, 
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1.3.1 Post-Translational Modification  
Chromatin is the highly ordered storage structure of DNA in the nucleus. Nucleosomes, the 
structural subunits of chromatin comprise DNA wrapped around basic histone proteins (Figure 
1.10). The complex structure of chromatin helps control the regulation of DNA repair, replication 
and gene expression. Mechanisms such as methylation, acetylation and phosphorylation of proteins 
are dynamic processes that coordinate transcription, culminating in cell proliferation. These post-
translational modifications occur on histone proteins, creating or stabilising binding sites for 
regulatory proteins, DNA damage-repair proteins and transcription factors; modulating biological 
signals and response.78 Deviation from the balance shaped by these post-translational modifications 
can alter gene expression, generating cellular transformation and malignancies.78 
 
Figure 1.10 Structure and composition of chromatin.79 
1.3.2 Histone Deacetylase Enzymes 
The acetylation of histone lysine residues is a post-translational covalent modification. Lysine 
acetylation is reversible and primarily occurs at the flexible N-terminal tails that extend from the 
nucleosome core. The dynamic equilibrium of this modification is controlled by cooperative 
deacetylase and acetylase enzymes (Figure 1.11). The acetylation process is catalysed by histone 
acetyltransferase (HAT) enzymes, generally associated with transcriptional activation via 
chromatin relaxation.80 The new surface topology promotes transcriptional factor recognition. 
Histone deacetylase (HDAC) enzymes work with opposing effect to catalyse removal of acetyl 
groups. Positively charged lysine residues formed from deacetylation increase ionic interactions 
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with the negatively charged DNA-phosphate backbone, making the chromatin structure more 
compact. This conformational change reduces accessibility of transcription proteins causing 
transcriptional repression.  
Traditionally, histone acetylation is known to play an important role in chromatin remodelling, 
however HDACs have also been documented to deacetylate non-histone proteins regulating other 
cellular functions including cell-cycle progression, differentiation and apoptosis.80,81 Aberrant 
HDAC activity has been characterised in tumours, through abnormal recruitment, translocation or 
overexpression. Due to the prolific activity of the HDAC enzyme family in various processes, 
along with showing a marked change in cancerous cells compared to healthy cells, HDAC enzymes 
are considered a viable target for anticancer therapy.82    
 
Figure 1.11 Reversible acetylation of lysine residues by histone deacetylase (HDAC) and histone 
acetyltransferase (HAT) enzymes.83 
The function of individual HDACs is largely dependent on their intracellular location and domain 
organisation. There are eighteen known mammalian HDAC enzymes that are divided into four 
classes (namely I, II, III and IV) based upon their comparative structural homology to yeast 
HDACs.82 Classes I and II are considered “classical HDACs” and share a Zn2+ catalytic domain 
character with class IV. Class III are divergent as NAD+-dependent proteins and will not be 
covered in this work.  
Class I HDACs (including 1, 2, 3, and 8) are found almost exclusively in the nucleus. HDAC3 is an 
exceptional case, with the ability for recruitment outside of the nucleus by nuclear localisation 
signals or co-localisation with other proteins.84 Class II HDACs shuttle in and out of the nucleus 
via similar cellular signals and can be further subdivided into Class IIa and IIb. Class IIa (4, 5, 7 
and 9) HDACs are carefully regulated by a calmodulin(Ca2+)-dependent kinase channel while class 
IIb (6 and 10) are predominantly confined to the cytoplasm.82,84 
1.3.3 Histone Deacetylase Inhibitors 
HDAC inhibitors block the catalytic site of histone deacetylase enzymes, directly altering the 
acetylation levels of chromatin and other non-histone proteins. This dysregulation modifies gene 
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expression initiating cell death, apoptosis, cell cycle arrest and causes inhibition of angiogenesis 
and metastasis.85 Treatment with HDAC inhibitors can promote tumour cell apoptosis by both 
intrinsic and extrinsic pathways through inactivation of anti-apoptotic proteins and/or the 
upregulation of pro-apoptotic proteins. An advantage of utilising HDAC inhibitors is their 
enhanced sensitivity towards transformed cells compared with normal cells, alleviating any 
undesirable toxicity in healthy tissue.85      
1.3.3.1 Clinically-Trialled Small Molecules 
Currently, there are many structurally disparate organic based HDAC inhibitors at different stages 
of clinical trials. Structural similarities of these compounds assist in HDAC inhibitor classification. 
Groups under investigation include, but are not limited to: cyclic tetrapeptides, benzamides, 
aliphatic acids and hydroxamic acids.82 The strong zinc-binding character of the bidentate 
hydroxamic acid moiety encouraged a particular interest in this group as potent classical HDAC 
inhibitors.86   
The natural product (R)-Trichostatin A (Figure 1.12, TSA) was formerly isolated from 
Streptomyces hygroscopicus and utilised as an antifungal antibiotic in the 1970s.87 Yoshida et al. 
later described nanomolar concentrations (10 ng/mL) of TSA caused apparent hyperacetylation to 
histones in vivo and strongly inhibited the activity of partially purified histone deacetylase in 
vitro.88 Neither the synthesised (S)-TSA nor the trichostatic acid analogue displayed any signs of 
biological activity.89 The difference in activity between the TSA enantiomers indicates the target 
molecule is stereospecific to (R)-TSA as a substrate.      
 
Figure 1.12 Hydroxamic derived HDAC enzyme inhibitors. (R)-Trichostatin A (TSA); Vorinostat 
(Suberoylanilide, SAHA); Belinostat (PXD101); Panobinostat (LBH589). 
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Experiments to extend the suggestion of TSA involvement in histone deacetylase inhibition were 
undertaken using a pulse-chase method. The protocol exposed mice FM3A cells to labelled 
[3H]acetate for 30 minutes (pulse) followed by dosing with TSA (100 ng/mL, chase) in parallel 
with an absence of TSA as a control.88 Distribution of radioactive species was analysed using 
fluorography of the cellular histone, H4. All bands on the electrophoresis gel disappeared in the 
chase without TSA present, while radioactivity of tri-and tetra-acetylated species of H4 increased 
in the presence of TSA. This result implied histone deacetylase enzyme inhibition as the mode of 
action for TSA, enhancing its potency.  
Although TSA was one of the first hydroxamic acids to be noted for its inhibitory effects of HDAC 
enzymes, it was pulled from clinical trials in 2013 owing to its adverse pharmacokinetic profile 
including metabolic instability.90,91 A study by Singh and co-workers compared the structurally 
similar TSA and SAHA (Figure 1.12) and proposed a rationale for the preferred thermodynamic 
and kinetic binding ability of SAHA to HDAC 8.91 At a molecular level, SAHA possesses a much 
more flexible aliphatic chain and can rotate more freely within the enzyme pocket than the 
rotationally constrained, bulkier TSA. Enthalpic favourability is thought to directly link to such 
structural features of the TSA-HDAC8 and SAHA complexes. Binding to HDAC8 of SAHA 
requires more structural adjustments but the interactions are more specific. For example, the 
carbonyl of the amide group in SAHA forms a hydrogen-bond with Asp101 of HDAC8 which 
could stabilize the SAHA complex by 3-4 kcal/mol.91 
 
Figure 1.13 SAHA (suberoylanilide hydroxamic acid) bound to an HDAC1-like protein.92 
Association and dissociation of the inhibitors was also measured. A two-step binding mechanism 
was determined for both TSA and SAHA with HDAC8: fast bimolecular association step driven by 
enthalpic changes followed by a slower isomerisation step, to enhance binding affinity of the 
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enzyme-inhibitor complex contributed solely by entropic changes. The rate constant for binding of 
both steps individually was higher for TSA to HDAC8 with a magnitude difference in the slow 
isomerisation step: 0.21 s-1 and 0.08 s-1 for TSA and SAHA, respectively.91 The dissociation rate of 
TSA from the enzyme’s site was also four times slower than that of SAHA. Reduced existence 
time of the SAHA-enzyme complex in a physiological system could be considered advantageous 
by avoiding unwanted side effects associated with extended residence time like those of TSA 
where slow dissociation can be problematic, often correlated with too high toxicity.91 Amongst its 
kinetic properties, the penchant for TSA to bind to multiple off target proteins by non-specific 
hydrophobic interactions is another undesirable characteristic. These cumulative results contribute 
to the non-suitability of TSA as a drug candidate. 
 
Figure 1.14 SAHA-HDLP enzyme schematic displaying the chelation interactions and hydrogen bonds of 
the inhibitor in the active site.93 
Structural deviation from the more rigid, enantiospecific TSA is clearly of benefit to the simpler 
SAHA in relation to activity. A space filling representation of SAHA bound to a HDAC1-like 
protein (Figure 1.13) shows a tubular pocket that is filled by the alkyl chain. The walls of the 
pocket in HDAC1 are formed by aromatic and hydrophobic residues (Pro22, Gly140, Phe141, 
Phe198, Leu265 and Tyr297) promoting interactions with the aliphatic chain.94 A pharmacophoric, 
metal binding domain is considered a prerequisite for HDAC enzyme inhibitory activity. Hydrogen 
bonding between the inhibitor hydroxamic acid moiety (Figure 1.14) and histidine-aspartate salt 
bridges (H131, H132, D166 and D173) along with tyrosine (Y297) H-bonding to the hydroxamate 
carbonyl provide multiple interactions for good binding efficacy to the active site. Finally, the 
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phenyl head group of SAHA acts as a surface recognition domain, promoting additional 
interactions with the rim of the enzyme pocket.93  
SAHA displayed promising results along with favourable pharmacokinetics and has been 
investigated as an anticancer agent extensively. The anticancer activity of SAHA was initially 
studied by Marks et al. measuring the induced differentiation of murine erythroleukemia (MEL) 
cells.95 The optimal concentration of SAHA for MEL cell differentiation was 2 µM along with 
inhibition of cell proliferation in the micromolar range.95 This early, auspicious result encouraged 
testing in a broader range of transformed cells.  
The follow up study examined the effects of SAHA on the growth suppression of prostate cancer 
cells in vitro and in vivo. SAHA displayed a dose-dependent inhibition of proliferation in three 
prostate cancer cell lines (LNCaP, PC-3 and TSU-Pr1) at micromolar concentrations 
(2.5-7.5 µM).96 LNCaP was the most sensitive cell line and at higher doses (5-7.5 µM), cell death 
was induced within 48 h of culture. In vivo daily dosage of SAHA (50 mg/kg/day) for 21 days 
showed a mean 97% reduction of CWR22 tumour xenograft in nude mice compared to the vehicle 
control (DMSO), with minimal evidence of side effects.96 An increased accumulation of core 
acetylated histones was also observed in both LNCaP prostate cancer cells and in the CWR22 
tumours after treatment with SAHA. Results from other experiments96,97 show an increase of 
acetylation in both normal and malignant cells implying HDAC inhibition remains a likely 
mechanism of action. Nevertheless, these reports maintain the apoptotic and growth-suppression 
induced by SAHA to be confined to only transformed cells.96  
As an HDAC inhibitor, SAHA alters the expression of a number of genes (2% - 17%).98 One of the 
most common upregulated genes in transformed cells induced by the treatment of SAHA is the 
cyclic dependent kinase inhibitor p21WAF1.99 Zhang et al. examined the effects of SAHA on 
cutaneous T-cell lymphoma (CTCL) cells in 2005, finding low concentrations of SAHA (1-5 µM) 
selectively induced apoptosis via the p21WAF1 pathway.99 The therapeutic action of SAHA was also 
investigated using peripheral blood lymphocytes from patients with high levels of malignant 
T-cells to provide mirrored results to the in vitro testing. The suitability of SAHA as a specific 
HDAC inhibitor with anticancer activity was evidenced by Marks, Zhang and others alongside 
successful progression through clinical trials. In 2006, shortly after the study by Zhang, SAHA was 
approved by the FDA for the treatment of cutaneous T-cell lymphoma.100 More recently, alternative 
hydroxamic acid containing HDAC inhibitors belinostat and panobinostat (Figure 1.12) were 
approved for the same treatment, most recently panobinostat in 2015.101 
Moreover, it is imperative to note that while hydroxamic acids demonstrate potent examples of 
HDAC inhibitors, their less favourable attributes should not be neglected. Aside from off target 
Introduction  Chapter 1 
36 
 
binding, hydroxamic acids including TSA have shown mutagenic effects, often through formation 
of isocyanates via a Lossen rearrangement.102 Isocyanates are unstable and can react readily with 
imidazole groups within enzymes, with the subsequent ureatype products more suceptible to 
hydrolysis and breakdown. While deprotonation of the N atom within the hydroxamic acid 
(required for the Lossen rearrangement to take place) is unlikely under physiological conditions 
(pKa ~8.5), metal catalytic sites have been shown to aid this unwanted transformation.102 
Alternative zinc-binding groups have been designed to curtail such effects (discussed in Section 
1.3.4), however the use of hydroxamic acids has prevailed due to their efficacy in vivo. 
1.3.3.2 Metal-Based HDAC Inhibitors 
The concept of exploiting metals in medicine with specific target molecules has been briefly 
explored (Section 1.3). Incorporating a metal centre can provide a scaffold for biologically active 
ligands, enable transport of an active metal ion by the stabilisation of coordinated ligands or 
combine activity of both the metal and organic component of a complex.72 Although metal-based 
HDAC inhibitors are limited across the literature, examples exist utilising each kind of metal centre 
classification.  
Short-chain fatty acids primarily target class I and IIa HDAC enzymes and are considered the 
weakest group of organic HDAC inhibitors, with activity in the millimolar range.98,103 However, 
valproic acid (Figure 1.15) has displayed not only antitumour effects but an ability to potentiate the 
chemotherapeutic action of cisplatin in ovarian cancer cells.104 Marmion et al. synthesised 
Pt(II)-(va)2 as a modified derivative of the biologically inactive transplatin. While substitution of 
an amino ligand with a N-donor heterocycle (such as pyridine) was already documented to enhance 
the cytotoxicity profile of trans-platinum compounds,105 the additional use of valproate ligands was 
intended to also utilise HDAC inhibitory activity. Testing of Pt(II)-(va)2 against A2780 and 
A2780cis ovarian cancer cell lines gave high IC50 values of 86.5 and 76.3 µM, respectively.106 In 
this instance, the attempt to create a viable platinum based drug with dual action and improved 
potency was unsuccessful and would require significant development.   




Figure 1.15 HDAC inhibitor valproic acid and some metal complex derivatives. 
An alternative approach to employ valproic acid as a bioactive ligand within a complex was 
achieved by Yang et al. Analogous to the previously synthesised Pt(IV) prodrug satraplatin 
(Figure 1.5), complex Pt(IV)-(va)2 is designed with the same octahedral geometry, chloride 
ligands and axial aliphatic carboxylic acid ligands adding valuable lipophilic character. Satraplatin 
also possessed desirable low toxicity in the more kinetically inert Pt(IV) oxidation state prior to 
intracellular reduction to the active Pt(II) species.31  
Biological studies analysed the HDAC inhibitory activity of valproic acid and Pt(IV)-(va)2 using 
nuclear extract from HeLa cells. At 5 mM dose concentrations valproic acid inhibited HDAC 
activity 66% while Pt(IV)-(va)2 showed less than half the inhibitory activity at 24%.107 When 
incubating Pt(IV)-(va)2 with a reducing agent ascorbic acid for 10 h, the HDAC inhibitory activity 
of Pt(IV)-(va)2 dramatically increased to 70%. This improvement in activity advocated the 
reduction of Pt(IV)-(va)2 to Pt(II) and subsequent dissociation of valproic acid to elicit HDAC 
inhibitory activity. Complex Pt(IV)-(va)2 continued to display high potency in both in vitro and in 
vivo assessment. Across a range of cell lines (SKOV-3 ovarian, HepG2 liver and A549 lung 
cancer), Pt(IV)-(va)2 exhibited significantly increased activity compared to the cisplatin control 
with the lowest IC50 concentration of 0.15 µM against A549 lung epithelial carcinoma cells, 
12-fold more than that of cisplatin.107 Mice bearing A549 xenograft tumours when dosed with 
Pt(IV)-va2 (10 mg/kg twice a day for 12 days) showed an 87% inhibition of tumour growth with 
gradual increase in mice weight, indicating minimal side effects.  
The pronounced potency of Pt(IV)-(va)2 was attributed to its cellular accumulation and dual 
activity. Over 4 h the platinum accumulation of Pt(IV)-(va)2 increased from 80.6 ng (2 x 107 cells) 
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located mostly in the cell membrane, up to 252.2 ng (2 x 107 cells) distributed between the cytosol 
and cell membrane after 24 h incubation. By comparison, the hydroxy counterpart Pt(IV)-(OH)2 
showed a decrease in cytosol Pt accumulation from 28.6 ng (2 x 107 cells) to 9.4 ng (2 x 107 cells) 
over 24 h suggesting rapid cellular efflux. The lipophilic character of the valproic ligands of 
Pt(IV)-(va)2 is thought to aid the cell membrane accumulation, followed by efficient diffusion into 
the cytosol.107 Considering the design of this prodrug, the mechanism of action was proposed to 
involve the loss of valproic ligands intracellularly to promote acetylation of nuclear histones 
through HDAC inhibition, relaxing chromatin and allowing the synergistic DNA binding action of 
the Pt(II) complex to yield such potent cytotoxicity. Further investigation into the drug efficacy of 
Pt(IV)-(va)2 as a conjugate Pt(IV) prodrug is notable due to the combination of these positive 
primary biological results.   
 
Herchel et al. provide another complex designed to merge the HDAC inhibitory activity of a short-
chain fatty acid (in this case 4-phenyl butyric acid108) with the DNA binding capability of an 
iridium(III) half sandwich complex.109 Release of the O-monodentate phenyl butyrate ligand from 
Ir-PB was measured using 1H-NMR experiments in the presence of the biologically prevalent 
glutathione (GSH). At ambient temperatures in aqueous conditions, equilibrium of free phenyl 
butyrate (60%) was reached within 4 h. By contrast, complete dissociation of the carboxylate 
ligand was observed within 30 mins using 2 molar equivalents of GSH where new signals were 
observed in the spectrum, implying formation of a GSH adduct - [Ir(η5-Cpph)(phen)(SG)]+ as the 
major species.109  
Cisplatin resistant ovarian A2780cis cells contain higher levels of GSH than the cisplatin-sensitive 
A2780 cells. Differences in intracellular levels of GSH was thought to provoke the similar trend in 
potency of Ir-PB towards A2780 and A2780cis cell lines with IC50 concentrations of 15.8 and 13.0 
µM, respectively. Compared to its monodentate chloride analogue, Ir-PB shows 2-fold higher 
potency towards A2780cis cells, implying the concept of GSH-activation increases cytotoxicity of 
Ir-PB through release of the bioactive phenyl butyrate.109 HDAC inhibitory activity was reduced to 
66.6% by Ir-PB in a cell free assay in contrast to 74.5% by the sodium phenyl butyrate salt.109 
HDAC inhibition by Ir-PB suggests the half sandwich iridium(III) fragment could play a role in 
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this activity. Complex Ir-PB is an interesting enzyme inhibitor example as it also uses the 
previously discussed piano-stool complex structure.   
 
Marmion et al. synthesised two other conjugate platinum compounds Pt-SAHA and Pt-bel which 
incorporate O,O-malonate analogues of the FDA approved HDAC inhibitor drugs, SAHA and 
belinostat (Figure 1.11). The bidentate binding motif in these platinum complexes is also similar to 
the cyclobutane-1,1-dicarboxylate ligand of carboplatin (Figure 1.5). Compared to the 
aforementioned aliphatic acids, the hydroxamic acids are significantly more potent and utilising 
such an organic fragment was intended to reduce the indiscriminate toxicity to healthy cells, often 
associated with platinum containing drugs.   
A gel electrophoresis technique was used to monitor DNA-metal interactions between negative 
supercoiled DNA (closed circular pUC19 plasmid) and complex Pt-SAHA. DNA incubated with 
Pt-SAHA at 10 µM concentration observed a decrease in the rate of migration, suggesting 
uncoiling of DNA through formation of DNA adducts.76 There was an apparent correlation 
between Pt accumulation in the cancer cell lines tested with Pt-SAHA and its corresponding IC50 
values; the higher the Pt uptake the lower the IC50. However, despite general cellular uptake of Pt 
for cisplatin being almost 10-fold less in all cell lines compared to Pt-SAHA, cisplatin was more 
toxic in each case.110 This observation could be attested to by multiple factors. Firstly, the aliphatic 
chain of the SAHA-derived ligand is likely to provide increased lipophilicity to the overall 
complex, facilitating transport into cells more efficiently than cisplatin. Secondly, a chelating effect 
of the malonate ligand was shown to reduce hydrolysis of the complex76, while testing in situ with 
sulfur containing biomolecules such as GSH showed DNA binding of Pt from Pt-SAHA was 
enhanced by a factor of 5.110 It was proposed that the mechanism of action when binding DNA is 
aided by the coordination of a bionucleophile causing ring opening, followed by ligand 
displacement. This activates the compound in a prodrug manner which could be either rate 
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dependent or biomolecular concentration dependent, hence the lower toxicity of Pt-SAHA 
compared to the cisplatin control. 
In a cell-free assay, inhibition of HDAC1 by Pt-SAHA was studied. The complex Pt-SAHA gave 
an IC50 of 1.1 µM, lower in potency than the control HDAC inhibitor SAHA with an IC50 value of 
0.08 µM.76 The malonate ligand alone gave an IC50 value of 0.14 µM suggesting the HDAC 
activity is hindered by the complex retaining its structure, assuming hydrolysis or facilitated 
dissociation of the ligand are unlikely in cell-free conditions. Complex Pt-bel containing the 
belinostat-malonate ligand displayed heightened potency for cisplatin resistant cell line A2780cis 
(11.7 µM) compared to Pt-SAHA (70.0 µM).111 Most importantly, both Pt-bel and Pt-SAHA 
showed significantly reduced toxicity towards the non-tumorgenic cell line NHDF. While there is 
no specific HDAC inhibition data for Pt-bel currently, the HDAC IC50 for belinostat is 0.03 µM 
demonstrating the potential in future analysis of Pt-bel.     
 
A novel organometallic SAHA analogue (JAHA), containing a ferrocenyl capping group as a 
phenyl bioisostere was developed by Spencer et al. Docking studies were performed using an 
existing HDAC8-SAHA complex to illustrate any similar binding modes between SAHA and 
JAHA. The archetypal chelating effect of hydroxamic acid with the zinc catalytic site was 
observed in both molecules, along with a hydrogen-bond interaction with the amide carbonyl and 
Asp101 (Figure 1.16).112 The malleable, shallow pocket of the enzyme was also able to 
accommodate the ferrocene motif, forming key interactions with Tyr100, Phe152 and Tyr306 at the 
enzyme surface.112 In vitro, complex JAHA gave selective HDAC inhibition towards class I over 
class IIa HDACs which showed no notable inhibition. HDAC8 inhibition by JAHA (IC50 value 
1.36 µM) was akin to that of SAHA (1.41 µM), a similarity alluded to from the docking study.112  
Initially, the cytotoxicity of JAHA was tested against MCF7 breast adenocarcinoma cells, which 
showed potency similar to SAHA; 2.44 and 0.73 µM, respectively.112 Continued testing of JAHA 
explored its toxicity towards the more aggressive, triple-negative MDA-MB231 breast cancer cells, 
known for their poor response to hormone therapy. MDA-MB231 cells exposed to JAHA for 72 h 
yielded an IC50 value of 8.45 µM113, compared to the SAHA control (0.73 µM)112. Such low 
micromolar potency against highly tumourgenic cells as well as distinct non-apoptotic cell death 
compared to other HDAC inhibitors99 prompted further insight into the biological profile of JAHA 
and its mechanism of action. It was later determined that multiple processes were involved in the 
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cytotoxicity of JAHA. Cell cycle transitions were perturbed through incubation with JAHA, 
similar to activity of other HDAC inhibitor examples, while additional factors such as up-
regulation of reactive oxygen species (ROS) and inhibition of autophagy were also attributed to 
overall cytotoxicity.113  
 
Figure 1.16 Docking of JAHA into HDAC8. The zinc ion is shown in cyan.112 
Intracellular ROS are usually maintained by the mitochondria to balance requirements of ROS in 
the cellular environment. However, an increase in ROS generation by an external factor can 
overwhelm the mitochondria, propagating ROS production, leading to mitochondrial membrane 
potential collapse.113,114 Total intracellular ROS in MDA-MB231 cells increased 3-fold after 24 h 
incubation with JAHA (using IC50 concentration, 8.45 µM). To demonstrate up-regulation of ROS 
triggered by JAHA was contributing to cytotoxicity, the same experiment was run in the presence 
of the antioxidant butylated hydroxytoluene (BHT). Cotreatment of MDA-MB231 cells with 
JAHA and BHT (50 µM) induced reversing of the cytotoxic effect with a marked increase in 
viable cells after 24 h compared to JAHA alone, implying ROS production and subsequent 
oxidative damage is vital for the activity of JAHA.113  
Depolarisation of the mitochondrial membrane is also reported to inhibit autophagy in the 
malignant MDA-MB231 cells. Due to heightened levels of metabolic stress in cancerous tissue, 
autophagy is conceptually utilised as a prosurvival mechanism to deliver necessary nutrients to 
tumour cells.115 Therefore, inhibition of autophagy is thought to indirectly sensitise MDA-MB231 
cells. This was tested by comparing dosing of MDA-MB231 cells with JAHA versus coincubation 
of JAHA with autophagy promoter, rapamycin. Similar to cotreatment with BHT to reduce cellular 
ROS, incubation with rapamycin also reversed the JAHA-triggered decrease in cell number.113  
Impaired gene expression caused by JAHA showed selective 4-fold increase in expression of 
oxidative-stress related genes NTRK-2 and RAD-50. The latter is of particular interest due to its 
function within the DNA damage repair complex MRN, with MRE11 and NBS1 proteins.116 The 
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HDAC inhibitory activity acting simultaneously with an up-regulation of DNA repair proteins of 
JAHA is not demonstrated by its parent analogue SAHA. Complex JAHA displays a more unique 
impact at a cellular level than its organic SAHA derivative and the cytotoxic pathways discussed 
provide substantial evidence towards continued investigation of this organometallic anticancer 
agent. 
Multifaceted system design was approached in a different way by Mao and co-workers. Their 
octahedral complexes primarily contained ligands analogous to SAHA to coerce desirable HDAC 
inhibitory effects, while the remaining coordination sites were tuned with stringent luminescent 
properties in mind. The development of such complexes (Figure 1.17) that combined therapeutic 
HDAC inhibition effects and exploitable luminescence was aimed to target photodynamic therapy 
(PDT) which presents high efficacy and reduced side effects compared to radiotherapy and 
chemotherapy.  
The prototype in the luminescent series synthesised by Mao et al. was the Ru(II) polypyridyl 
complex (RuDIP) which incorporated two 4,7-diphenyl-1,10-phenanthroline (DIP) ligands and a 
phenanthroline derivative of SAHA (N1-hydroxy-N8-(1,10-phenanthrolin-5-yl)octanediamide).117 
Cellular accumulation of RuDIP was measured using mean fluorescence intensity (MFI) of the 
incubated cell population. After 6 h, the control cells exhibited MFI : 2.41 background fluorescence 
which increased drastically with 50 µM dose of RuDIP to give MFI : 503. High cellular uptake 
was attributed to the bulky hydrophobic DIP ligands, thought to correlate with low IC50 values in a 
range of cell lines, compared to cisplatin. Notably, complex RuDIP was 16-fold less cytotoxic than 
cisplatin towards healthy liver LO2 cells (IC50 = 33.2 µM) as well as being particularly potent 
towards the cisplatin resistant A549cis cell line (IC50 = 1.41 µM) indicating the ability of RuDIP to 
overcome resistance.117 
 




Figure 1.17 A range of multifunctional systems from the Mao group with HDAC inhibitory activity.117–119 
In some cases, modification to the capping group of existing HDAC inhibitors although intended to 
be beneficial for activity i.e. increasing interactions between inhibitor and enzyme can be flawed. 
Surprisingly, the large DIP ligands of complex RuDIP did not appear to hinder the HDAC 
inhibitory activity when measured against nuclear extract from HeLa cells, providing an IC50 value 
in the micromolar range (6.66 µM).117 Docking studies using the aforementioned HDAC8-SAHA 
complex suggested HDAC8 was capable of accommodating the Ru(II)-polypyridyl groups of 
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RuDIP into the shallow pocket with even remote interactions between a phenyl group of the DIP 
ligand and residue Leu308 at the enzyme surface a probable occurrence (Figure 1.18).  
 
Figure 1.18 Docking conformation of complex RuDIP as a ball and stick representation in the active site of 
HDAC8. The zinc ion is shown in yellow.117 
As previously reported for other HDAC inhibitors, elevation of ROS species can be intrinsically 
linked to death of cancer cells. Oxidation of 2’,7’-dichlorofluorescein diacetate to its fluorescent 
product 2’7’-dichlorofluorescein (DCF) was used to measure the increase in ROS production by 
flow cytometric analysis. The SAHA control showed no significant DCF fluorescence in cells 
incubated for 6 h at 25 µM, whereas treatment with RuDIP resulted in a 4.4-fold increase in DCF 
fluorescence (MFI : 419) compared to the vehicle control (MFI : 96).117 Irregular production of 
ROS was considered the likely cause of activity for complex RuDIP, along with HDAC inhibition.   
Existing cyclometalated Ir(III) complexes exhibit high quantum yields, good cell permeability and 
long-lived luminescence; behaviour that was also exploited for selective photodynamic cancer 
therapy by Mao et al. Complex Ir-ppy was synthesised with the active HDAC inhibitor N1-
hydroxy-N8-(1,10-phenanthrolin-5-yl)octanediamide ligand along with two 2-phenylpyridine 
cyclometalated ligands. In vitro cytotoxicity of Ir-ppy was tested against A549, A549cis and HeLa 
malignant cells, in the absence and presence of UV light (365 nm). Poor toxicity (>100 µM) was 
displayed across all cell lines incubated in the dark with complex Ir-ppy. However, exposure to 
UV light (365 nm) showed an increase in cytotoxicity of Ir-ppy across all cell lines, including 
HeLa cells which gave an IC50 value of 6.8 µM under visible light (425 nm).118 Irradiation at this 
wavelength was also able to produce singlet oxygen (1O2) in the presence of Ir-ppy in aerated 
DMSO, known to be the most cytotoxic species generated from PDT. Clinically-approved PDT 
agents typically make use of excitation wavelengths in the therapeutic window (600 – 800 nm).120 
Despite the low wavelength of excitation required to generate activity of Ir-ppy, it still represents 
an interesting approach in combining PDT and HDAC inhibition.  
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Similar to the ruthenium complex (RuDIP) tested by Mao et al., complex Ir-ppy was also 
examined for up-regulation of ROS using the DCF fluorescence assay. In the dark, a moderate 
concentration-dependent increase in ROS generation was observed in HeLa cells over 6 h, 
compared to the considerable 5-fold increase in fluorescence upon irradiation at 365 nm.118 
Additionally, the HDAC inhibitory activity was measured using nuclear HeLa extract which 
showed similar potency of Ir-ppy to SAHA with IC50 concentrations of 0.11 and 0.072 µM, 
respectively.118 Dosing HeLa cells with Ir-ppy led to an increase in histone H3 acetylation level, 
irrespective of the presence of irradiation. The anticancer mechanism of complex Ir-ppy was 
surmised to employ both photo-induced toxicity originating from the reaction of Ir(III) and oxygen 
alongside HDAC inhibition to induce cell death.  
Rhenium(I) tricarbonyl complexes are another example that possess valuable luminescent 
properties and have been widely studied for the purpose of cell imaging and biological probes.121 
Complex ReDIP contains the rhenium(I) tricarbonyl motif, a pyridine derivative of SAHA as an N-
donor ligand and a single DIP ligand previously utilised in complex RuDIP. The DIP ligand serves 
a dual purpose, increasing the hydrophobic surface within the molecule and allowing high-energy 
intrastand (π-π*) transitions improving overall emission. Countless examples already advocate that 
enhancing lipophilic character can play a major role in cellular location and uptake.  
As anticipated, complex ReDIP was effectively taken up by HeLa cells after 2 h incubation at 
37 °C, compared to a significant reduction of cellular uptake observed at 4 °C. Treatment with a 
metabolic inhibitor (carbonyl cyanide 3-chloro-phenylhydrazone) also showed a decrease in 
accumulation efficiency, implying an energy-dependent pathway was responsible for cellular 
uptake.119 Cytotoxicity of ReDIP was evaluated against the same range of cell lines (A549, 
A549cis, HepG2 and LO2) as the previously discussed Mao complexes. Unlike complex Ir-ppy, 
irradiation was not required to illicit cytotoxic effects of complex ReDIP which showed low IC50 
values between 7.5 and 12.2 µM without any illumination. Selectivity was exhibited by ReDIP 
with a  7-fold higher toxicity for cancerous HepG2 cells over healthy LO2 cells.119 Continuing the 
general trend for these luminescent complexes, production of ROS species was measured to 
determine if it was attributed to the activity of ReDIP. Using DCF as a measure of oxidation 
induced fluorescence, HeLa cells dosed with 50 µM showed a marked increase of luminescence 
(MFI : 551) compared to the vehicle control (MFI : 90). Cytotoxicity was reduced in cells pre-
treated with N-acetylcysteine - a known ROS scavenger - suggesting activity of ReDIP relies 
somewhat on upregulation of ROS.119  
Intracellular localisation of ReDIP was preferential towards the mitochondria, thought to be 
influenced by a unique combination of lipophilicity and positive charge. Localisation of class IIa 
HDAC7 to the inner mitochondrial membrane prompted testing inhibition of recombinant HDAC7 
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enzyme specifically, with incubation of both complex ReDIP and SAHA displaying moderate IC50 
values; 0.68 and 0.53 µM, respectively. Investigation into the morphological changes of organelles 
such as mitochondria in HeLa cells treated with ReDIP suggested cell death was not caused by the 
classical apoptotic pathway. Cells incubated with 20 µM of ReDIP for 12 h were analysed using 
TEM which revealed an increase in mitochondria-derived vacuoles and widening of the nuclear 
membrane space although the nucleus remained intact.119 Caspase involvement was also tested 
showing no increase in activity when treated with ReDIP (50 µM, 6 h) in contrast with the 
cisplatin control which caused a 6-fold increase in caspase-3/7 activity, a common observation in 
cell apoptosis.119 Morphological dysfunction of organelles and a caspase-independent mechanism 
are distinguishing features of paraptosis. 
The complexes described in Section 1.3.3.2 reveal the wealth and variety of properties that can be 
combined with HDAC enzyme inhibition to create potential theranostic (therapeutic and 
diagnostic), multifunctional systems. Specific development of compounds with tuneable PDT 
application offers the advantage of spatial control of treatment, circumventing undesirable toxicity 
in healthy tissue that can arise from other less selective drugs such as cisplatin. While Mao present 
a novel direction of HDAC inhibitors, there are no in vivo results reported thus far regarding 
complexes RuDIP, Ir-ppy and ReDIP.117–119 Future experiments could probe their potential as 
genuine anticancer drug candidates with multifaceted character.  
1.3.4 Isoform-Selective HDAC Inhibitors 
As our understanding of specific biomolecular targets for drugs has advanced, first generation 
HDAC inhibitors such as SAHA are now recognised as pan-inhibitors due to their lack of 
selectivity within the classical HDAC family. The discrete intracellular localisation and substrate 
diversity122 of the HDAC classes means pan-HDAC inhibition can result in unwanted side effects 
including gastrointestinal disturbances and arrhythmia.123 Hence the current design of HDAC 
inhibitors is focussed heavily on specificity. To target the distinct biological topographies of 
individual isoforms the pharmacophore model of HDAC inhibitors (Figure 1.19) can be modified 
in a variety of ways. The most popular zinc binding group (ZBG) is the hydroxamic acid due to its 
strong chelating ability to the Zn2+ catalytic site, however other moieties have shown increased 
potency for selective classes, improving efficacy of those drug candidates. The capping group and 
chain linker have also been extensively varied to enhance surface and pocket recognition by 
increasing inhibitor-residue interactions.124  




Figure 1.19 Typical structural features of an HDAC inhibitor. 
1.3.4.1 Class I – HDAC1, 2 and 3 
With the exception of HDAC8, the class I HDAC enzymes form co-complexes with other proteins 
to form large macromolecules that define their function. Interaction between HDAC1 and HDAC2 
is essential for their catalytic activity, forming the core of transcription repressor Sin3A and 
chromatin remodelling NuRD multiprotein complexes.123 This is demonstrated in the role of 
HDAC1 and HDAC2 in cell cycle regulation and DNA damage control of both malignant and 
healthy cells. HDAC3 on the other hand assists activity of nuclear receptor corepressors and can 
also form complexes with class IIa HDACs.123 A general feature shared by the multiprotein 
complexes of HDAC 1-3 is their feature of sequence-specific DNA interactions causing 
transcriptional repression. It is important to note that the occurrence and regulation of these 




Figure 1.20 (A) Comparison of bound ligand (light blue) and unbound (yellow). Internal hydrogen bond 
indicated by pink dashed line. (B) X-ray crystal co-complex of bound RGFP966, zinc atom is displayed in 
orange and the enzyme surface in green.125 
Specificity towards HDACs 1-3 has been proposed by several groups in the form of 2-
aminoanilides. Crystal structures of these enzymes showed a pocket region adjacent to the Zn2+ 
catalytic site that could be accessed by the 2-aminoanilide group with room for functionality at the 
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5-position.125  Bressi et al. investigated the structure activity relationship of a range of 
2-aminoanilides with HDAC2 and determined that time-dependent inhibition was crucial for some 
candidates. Compound RGFP966 saw a marked increase in inhibition of HDAC2 activity from an 
IC50 value of 0.90 µM in the 1 h assay to 0.027 µM when pre-incubated for 24 h with the 
enzyme.125 Simulation software showed unbound RGFP966 formed an internal hydrogen bond 
between the ortho-NH2 and the carbonyl of the amide (Figure 1.20A). The bound form does not 
contain this hydrogen bond, instead forming complementary interactions with the enzyme active 
site. Hydrogen atoms of the ortho-NH2 group form H-bonds with histidine 145 and 146 residues, 
while the nitrogen of this moiety forms part of the chelate to zinc. The time-dependence inhibition 
is thought to be due to the conformation change needed to reach an equilibrium where the phenyl 
moiety can fit the foot pocket of the enzyme (Figure 1.20B) and form these favourable interactions 
that the hydroxamate of SAHA cannot.125 Essentially, while the kinetics are slow for the inhibitor 
to access the foot pocket, the enzyme-inhibitor complex with RGFP966 is much more 
thermodynamically favourable.  
 
An example of cell-type HDAC abundancy is HDAC3 which is the most highly expressed class I 
HDAC in the brain and has been linked to learning and memory formation.126 Compound PDAA-
01 displayed substantial selectivity towards HDAC3 with an IC50 value of 0.08 µM and no 
inhibition towards any other HDACs up to 15 µM.123 The potent inhibition of HDAC3 was adapted 
by Malvaez et al. into potential behavioural therapy for drug-seeking disorders due to its 
specificity. In mice, they showed treatment with PDAA-01 (10 mg/kg) was able to block relapse of 
cocaine-seeking behaviour suggesting HDAC3 inhibition induced a positive response against 
maladaptive behaviours.127 Although not a potential anticancer treatment, this clearly illustrates the 
outcome through unique targeting of selective isozymes.    
1.3.4.2 Class I - HDAC8 
Of the class I HDACs, HDAC8 is anomalous in structure. Substitution of tryptophan 141 in place 
of a leucine residue prevents the accommodation of bulky groups such as 2-aminoanilides into the 
active site pocket.128 However, a region of high plasticity adjacent to the active site channel of 
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HDAC8 allows dynamic changes that can form a hydrophobic binding cavity if required by an 
inhibitors conformation. HDAC8 does not contain the C-terminal domain for recruiting other 
proteins, acting as an individual protein regulating the differentiation of smooth muscle cells and 
inducing antiproliferation, particularly in neuroblastoma cells.128,129  
Table 1.2 Inhibition constants (IC50 values) for PCI-34051 against a selection of HDAC enzyme isoforms.130  
 







Balasubramanian and co-workers synthesised compound PCI-34051 to encourage interactions of 
the tryptophan moiety with the aforementioned subpocket. Compound PCI-34051 exhibited 
>200-fold selectivity of HDAC8 (IC50 = 0.01 µM) compared to HDACs 1-3, 6 and 10 (Table 1.2), 
while showing higher potency than its hydroxamic counterpart SAHA (IC50 = 0.41 µM); thought to 
have a lower affinity for HDAC8 due to negligible available interactions around the malleable 
active site.130 In vitro testing of PCI-34051 revealed antiproliferative activity of T-cell derived lines 
with IC50 values ranging from 2.4 – 4 µM with PCI-34051 showing no such effect on solid 
tumours.130  
 
Compound HUA1 is another HDAC8-selective inhibitor, utilising ortho-coplanar phenyl groups as 
the hydrophobic substituents to increase selectivity. Huang et al. found HUA1 gave moderate IC50 
values for HDAC 1 and 3 (3 µM) but obvious specificity for HDAC8 with an IC50 value of 0.027 
µM.129 The superiority of HUA1 over compound PCI-34051 was attested to by the additional 
cytotoxicity of HUA1 towards lung cancer cell lines A549 and H1299 (IC50 values of 7.9 and 7.2 
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µM, respectively).129 The limited flexibility shown by PCI-34051 and HUA1 is evidently not 
detrimental to HDAC8-selective inhibitor design. 
1.3.4.3 Class IIa HDACs 
HDACs 4, 5, 7 and 9 are of the class IIa HDAC family and contain a C-terminal domain and an 
N-terminal adaptor domain. The N-terminal domain distinguishes class IIa from class I by 
providing binding sites for chaperone proteins (14-3-3) which regulate the localisation of class IIa 
HDACs between the nucleus and the cytoplasm, along with sites that allow nuclear localisation 
signalling.131 Generally, the class IIa HDAC isoforms show restricted expression levels and activity 
relative to class I isoforms. HDAC4 is moderately expressed in the brain and is integral to skeleton 
formation, HDAC5 and 9 are fundamental to muscle and heart growth and function while HDAC7 
is relevant in vascular cohesion.123 Their involvement in cancer ranges from cell proliferation and 
survival to differentiation. Most importantly, although class IIa largely retain the conserved 
structure of class I HDACs, a tyrosine residue in the active site is replaced with a histidine residue. 
The tyrosine is professed to stabilise the transition-state of acetyl-lysine hydrolysis94 and in its 
absence, the in vitro activity of class IIa HDACs is weakened for the canonical acetyl-lysine 
substrate.132 
 
A class IIa inhibitor (MRK19) was synthesised by Marek et al. containing a novel alkoxyamide 
connecting unit in the linker region of the molecule. MRK19 was tested against A2780 and 
chemoresistant A2780cis ovarian cell lines in an MTT assay. The subsequent IC50 values yielded 
were 0.49 and 0.32 µM respectively; equipotent to the control drug SAHA.133 Upon screening for 
HDAC isoform selectivity, MRK19 showed particularly low IC50 values for HDAC4 and 5 (0.012 
and 0.004 µM), at least 5-fold more potent than against class I or IIb HDACs, while the analogous 
SAHA displayed >2000-fold less inhibition for class IIa compared to MRK19.133 Docking studies 
were used to investigate the possible binding mode of MRK19 to HDAC4 and HDAC8. The 
phenyl capping group was shown to orientate itself into the groove of the HDAC4 surface, enabling 
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a more favourable interaction with the catalytic site than for HDAC8. The nitrogen of the 
alkoxyamide formed a hydrogen bond with the carboxylate group of Asp115 in HDAC4, whereas 
the equivalent Met274 residue in HDAC8 formed a much weaker interaction.133 While MRK19 
retains the common hydroxamic acid zinc binding group, the novel functionality of the linker is the 
likely promoter of its selectivity.  
Due to the poor deacetylation activity of acetyl-lysine, alternative substrates were explored. The 
synthetic substrate trifluoroacetyl-lysine was identified by Lahm et al. as a more readily 
deacetylated substrate by class IIa HDACs. This increased activity is thought to be due to the more 
electrophilic trifluoroacetamide group containing a weaker amide bond, removing the need for a 
tyrosine mediated transition-state.132 Knowledge of this moiety was exploited by GlaxoSmithKline 
through screening to offer the trifluoromethyloxadiazole as a binding group for potential inhibitors 
(seen in TMP269), possessing bulky character that can also be accommodated by the class IIa 
subpocket.134 This unusual group formed interactions with the zinc catalytic site through the 
oxadiazole oxygen and a fluorine atom (Figure 1.21B). While the large volume of the site is not 
fully occupied by SAHA, the lipophilic tail of TMP269 was able to displace the His843 residue to 
allow an additional edge to face interaction of the phenyl group adjacent to the oxadiazole ring with 
Phe679 (Figure 1.21A). 
 
 
Figure 1.21 (a) Collapsed U-shape of TMP269 to fill active site. (b) Active site zinc interactions. Bond 
lengths of zinc-trifluro fluorine and oxygen of the oxadiazole ring displayed.134  
TMP269 gave IC50 values ranging from 0.13 to 0.019 µM against the class IIa HDACs, with 
10-fold less inhibition of the other isoforms.134 The existing clinical success of SAHA against 
cutaneous T-cell lymphoma prompted Lobera et al. to test the activity of class IIa inhibition on the 
genome expression of white blood cells (T-cells, B-cells and monocytes). Although TMP269 
showed an overall minimal influence on aberrant gene expression in lymphocytes, CD14+ 
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monocytes were transcriptionally sensitive to class IIa HDAC inhibition, suggesting the overall 
suitability of immunological diseases as a target for class IIa inhibition.123,134 The most significant 
advantage of the trifluoromethyloxadiazole functionality was its generally weak affinity for metal 
binding, predicted to limit off-target biomolecule interactions. The zinc anion containing matrix 
metalloproteases 9 and 12 were incubated with TMP269 up to 50 µM and failed to yield an IC50 at 
this concentration. This result postulated the novel trifluoromethyloxadiazole metal-chelating 
approach could enhance the efficacy of class IIa HDAC inhibitors like TMP269 by reducing 
competitive interactions with other enzymes, often brought about by strongly chelating moieties 
such as hydroxamic acids.134  
1.3.4.4 Class IIb – HDAC6 
Of all the HDAC enzymes, HDAC6 exclusively features two independent catalytic domains as well 
as cysteine and histidine-rich regions responsible for ubiquitin protein binding.123,135 HDAC6 is 
located primarily in the cytoplasm by a nuclear export signal (NES) motif and incorporation of a 
Ser-Glu tetrapeptide (SE14).123,135 Within the class II HDACs, a predominant substrate unique to 
HDAC6 is α-tubulin. Deacetylation of α-tubulin by HDAC6 both in vitro and in vivo has been 
shown to mediate cytoskeleton regulation, cell migration and cell-cell interactions.136 Due to its 
localisation, non-histone proteins are the favoured substrates of HDAC6 with minor substrates 
including the chaperone protein Hsp90; possessing the ability to stabilise particular proteins 
required for tumour growth.135  
 
Aberrant HDAC6 activity has been reported to produce effects ranging from tumorigenesis, cell 
proliferation, increased cell motility leading to metastasis, along with an irregular translational or 
transcriptional response in transformed cells.135 For example, overexpression of HDAC6 has 
demonstrated an increase in chemotactic fibroblast cell motility, intrinsically linked to tumour 
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metastasis. Inhibition of HDAC6, promoting acetylation of α-tubulin has displayed stabilisation of 
microtubule growth; reducing cell movement with antimetastatic effect.137 HDAC6 is also involved 
in neurological diseases such as central nervous system (CNS) injury, although the exact 
mechanism remains undecided it was proposed that HDAC6 regulates the formation of aggresomes 
(groupings of misfolded proteins) which can be poisonous to neurons causing cell death.138 
HDAC6 inhibition appeared to encourage regeneration of neurons, promoting its specific inhibition 
for CNS injury.138 
Using combinatorial chemistry, tubacin was identified as an HDAC6-selective inhibitor in 2003.139 
Screening against all 11 HDAC isozymes revealed an IC50 value of 0.004 µM for tubacin against 
HDAC6; displaying over 300-fold selectivity for HDAC6 compared to the other HDAC enzymes. 
Cultured A549 cells were dosed with 10 µM tubacin which induced a 3-fold increase in α-tubulin 
acetylation, consistent with HDAC6 enzyme inhibition. The carboxylate analogue (nil-tubacin) of 
tubacin showed no notable change in α-tubulin acetylation levels, suggesting the hydroxamic acid 
zinc-binding group is essential for tubacin activity.139  
Marks et al. explored the possible synergistic effects of HDAC6 inhibition by tubacin with existing 
anticancer agents. Transformed LNCaP human prostate cancer cells displayed an enhanced loss of 
cell viability (80%) when dosed with both SAHA and tubacin (2.5 and 8.0 µM, respectively) after 
72 h incubation, while SAHA alone (2.5 µM) showed no change in cell viability.137 To determine if 
the cytotoxicity was increased as a result of selective HDAC6 inhibition, nil-tubacin was co-
incubated with SAHA and did not increase LNCaP cell death. LNCaP cells were also used to 
determine a potential pathway for cell death and whether influenced - in part - by tubacin. 
Poly(ADP ribose) polymerase (PARP) is specifically cleaved by caspase-3 from 116-kDa to the 
smaller 85-kDa protein fragment and can be used as a marker for apoptosis. Incubation of LNCaP 
cells with SAHA at 2.5 µM (a concentration demonstrated to not cause cell death), showed no 
PARP cleavage. An increase in cleaved PARP resulted from co-incubation with tubacin and SAHA 
(2.5 µM), illustrating the contribution of caspase activation to the pathway for cell death when 
treated with tubacin.137 Although tubacin was shown to be highly specific in its biomolecular 
target, its high lipophilicity and challenging synthesis inspired scope for more appropriate drug 
candidates as HDAC6 inhibitors.  




Prompted by the superior selectivity of tubacin, Kozikowski et al. proposed the rational design of 
the drug-like molecule tubastatin-A as a simpler alternative. Due to the high lipophilicity of 
carbazole, the large capping group was adapted to reduce planarity by introducing a tertiary amine 
that could also aid the formation of pharmaceutical salts improving solubility.140 Homology models 
of HDAC1 and HDAC6 were generated to predict interactions of tubastatin-A with the different 
classes of protein. While the catalytic site is highly conserved in both isozymes, the channel and 
pocket rim dimensions greatly differ. The channel rim of HDAC6 is much wider and shorter than 
HDAC1, providing a region to target specifically for HDAC6.140 The tolyl linker of tubastatin A 
was predicted to form interactions with the apolar channel lining (Phe620, Pro608 and Cys621 
residues) of HDAC6, forcing a bent conformation which also enhanced interactions of the tricyclic 
group with the channel rim. The bulky capping group allowed π-π stacking of the aromatic ring 
with phenylalanine residues along with polar interactions of the tertiary amine with surface Asp567 
and Ser568.140 The multiple interactions of tubastatin A with HDAC6 was reflected in its 
preferential activity towards this isozyme. The IC50 value against HDAC6 was 0.015 µM for 
tubastatin A, similar to that of tubacin (0.004 µM) and 50-fold more potent than against any other 
HDAC enzyme. The large capping group motif in both tubacin and tubastatin A is thought to 
enable this selectivity. 
Table 1.3 Selected HDAC isoform inhibition IC50 values for nexturastat A.141 
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Kozikowski et al. proceeded to exploit an additional lipophilic side cavity of the HDAC6 shallow 
channel rim using branched urea linkers. Nexturastat A was designed with an n-butyl group from 
the nitrogen distal to the phenyl capping group to occupy the cavity with the desire to enhance 
potency and specificity.141 Increased selectivity was achieved by nexturastat A, providing IC50 
values of 3.02 and 0.005 µM for HDAC1 and HDAC6 (Table 1.3), respectively; 3-fold more potent 
towards HDAC6 than tubastatin A.123,140,141 Hyperacetylation of the major HDAC6 substrate 
α-tubulin was measured in B16 murine melanoma cells treated with nexturastat A. At nanomolar 
concentrations a dose-dependent increase in α-tubulin acetylation was observed with no elevation 
in H3 histone acetylation until micromolar concentrations were used.141 This result correlates the 
inhibition profile of nexturastat A with the preference of HDAC6 inhibition over HDAC1 (whose 
major substrate is histone proteins), within a cellular environment. Nexturastat A displayed 
moderate growth inhibition of B16 melanoma cells (IC50 = 14.3 µM) compared to more polar 
analogues and tubastatin A. While the full mechanism leading to cell death is not yet explored, the 
ideal parameters of drug-likeness suggest the lipophilic n-butyl group contributes to efficient cell 
permeability and activity of nexturastat A.141  
1.3.4.5 Metal-Based Isoform-Selective HDAC Inhibitors  
While metal-based HDAC inhibitors are becoming more frequently utilised due to their exploitable 
oxidation states, geometries and modular synthesis, isoform selective metal-based HDAC inhibitors 
remain scarce in the literature. JAHA for example (Section 1.3.3.2), although displaying good 
potency for HDAC inhibition, showed no distinguishable selectivity for an individual isoform with 
IC50 values for class I HDACs 1, 2 and 3 in the small range between 0.011 and 0.018 µM. With this 
in mind, in 2017 Spencer et al. synthesised Pojamide: an HDAC3-selective inhibitor analogous to 
the ferrocene containing complex JAHA, incorporating the aforementioned 2-aminoanilide class I 
selective zinc-binding group (Section 1.3.4.1). Docking studies were performed to determine 
selective interactions of Pojamide with the HDAC3 isozyme. Hydrogen bonds formed between the 
amide N-H and the carbonyl of the Asp90 residue, benzamide amide N-H and the carbonyl of 
Gly143, along with the an interaction between the aniline NH2 and the nitrogen of the His134 in the 
catalytic site.142 Shortening of the carbon chain linker forced rotation of the benzamide group 
which reduced these key interactions.  
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Pojamide activity towards HDAC isozymes was comparable to other 2-aminoanilide inhibitors, 
displaying an IC50 of 0.09 µM against HDAC3, 11- and 22-fold more active than against HDAC1 
and 2 along with no notable inhibition of the other HDAC enzymes (>30 µM)142. 
HDAC3-specificity of Pojamide was measured using Xenopus laevis embryos as a model for 
deacetylase activity. H4K12 is a histone lysine residue shown to be deacetylated specifically by 
HDAC3143, accumulation of acetylated H4K12 in the Xenopus laevis was observed in a 
concentration-dependent manner when dosed with Pojamide, while no apparent affect on α-tubulin 
was shown. Along with HDAC3-isoform selectivity, Pojamide displayed moderate inhibition of 
cell proliferation in HCT116 human colon carcinoma cells providing a GC50 value (the amount of 
compound required to cause 50% reduction in cell proliferation) of 8.9 µM.142 
The ability of the ferrocenium cation to induce DNA damage by generation of reactive oxygen 
species (hydroxyl radicals specifically) is documented in MCF-7 and MCF10A cells.144 Through 
oxidation of the ferrocene capping group with nitrosium (NO+) tetrafluoroborate, Spencer et al. 
were able to exploit the additional cytotoxicity of ferrocenium in the form of Fe(III)-Poj. 
Intracellular sodium nitroprusside (SNP) produces NO+ which can be balanced by the antioxidant 
GSH. Due to the high toxicity of SNP alone (>30 µM can cause apoptosis), optimal concentrations 
of SNP and GSH were dosed alongside the Pojamide inhibitor. In combination with SNP/GSH, at 
4 µM concentration of Pojamide for 6 days, similar levels of DNA damage were observed in 
HCT116 cells as the cisplatin control.142 Reactive oxygen species generation in HCT116 cells was 
shown to increase 3.3-fold when dosed with Pojamide/SNP despite the presence of GSH. The 
results from combination treatment suggest the oxidation of Pojamide to the Fe(III)-Poj species by 
SNP increases ROS production enhancing cytotoxicity. This metal-based isoform selective 
inhibitor is of particular interest due to its two distinct modes of action. While Pojamide possesses 
HDAC3 selective inhibitory character, the addition of the ferrocene provides a novel redox quality 
not found in organic HDAC inhibitor examples; providing DNA damage alongside enzyme 
inhibition, enhancing the efficacy of Pojamide as a potential drug candidate.  




Chiral bis-cyclometalated octahedral organoiridium(III) complexes are another recent example 
displaying moderate HDAC-isoform selectivity. Meggers et al. wanted to determine any specific 
molecular recognition of iridium complex enantiomers by designing propeller type complexes that 
could bind the enzyme active site and allow the coordination sphere to accommodate the enzyme 
pocket.145 A pair of enantiomeric iridium propeller complexes (IrΛ and IrΔ) were tested for HDAC 
inhibition against HDACs 1, 6 and 8. Both enantiomers exhibited 10-fold more potency towards 
HDAC6 than HDAC1 in the nanomolar range (HDAC6 IC50 values for IrΛ and IrΔ: 110 and 
202 nm, respectively).145 Interestingly, complex IrΛ observed 2-fold increase in potency for all 
HDAC enzymes tested compared to IrΔ. It was proposed that in this instance, the low 
stereodiscrimination between enantiomers is driven by the hydrophobic nature of these complexes. 
Stronger stereodiscrimination is thought to occur more readily between functional groups and 
specific aminoacid residues, enhancing molecular recognition for a single enantiomer.  
1.3.5 Summary 
Remarkable progress has been made into identifying specific molecular targets in the treatment for 
cancer. Upregulation of HDAC enzyme activity is one of many mutations observed in malignant 
cells and therefore exploited as a suitable target for anticancer drug candidates. The first generation 
of HDAC inhibitors (including SAHA) provided a new platform for drug design, displaying high 
selectivity towards cancerous cells over healthy cells establishing early improvements to 
therapeutic efficacy. Gradually, as our understanding of subcellular processes has advanced, the 
undesirable qualities of pan-inhibitors such as SAHA became more apparent and the need for 
HDAC-isoform specificity was recognised.  
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Like many enzyme families, HDAC isoforms are divided into classes dependent on their 
topological similarities. Their classes also denote more specific substrates and cellular localisation. 
These findings prompted the design of second generation HDAC inhibitors with much higher 
degrees of selectivity. It is clear that while the literature is awash with small organic molecule 
examples, metal-based HDAC-isoform selective inhibitors offer alternative properties in enzyme 
inhibition design and could be further exploited.  
1.4 Hypoxic Activation 
Although briefly touched upon in some previous examples, a key point of consideration when 
formulating anticancer agents is their behaviour in the targeted environment. For instance, solid 
tumours contain low levels of oxygen (hypoxia) due to an imbalance between oxygen supply and 
consumption.146 Rapid tumour growth, whilst increasing the demand for oxygen gives rise to cells 
located too distant from blood vessels that deliver essential metabolites including oxygen, 
generating regions of hypoxia and internal tumour necrosis.147 Tumour hypoxia is known to 
promote the development of a more aggressive phenotype that has demonstrated an upregulation in 
genes associated with angiogenesis and enhanced metastasis.148,149 Not only do these factors 
compromise the efficacy of tumour removal by surgery, such a malignant phenotype also boasts 
resistance to ionising radiation and chemotherapeutic treatment.146,148,150  
Radiotherapy creates radicals on DNA which are either oxidised (largely by oxygen), propagating 
the damage to DNA or competitively reduced by thiol containing biomolecules, evading any 
permeant DNA damage. In the absence of oxygen, less DNA damage occurs rendering 
radiotherapy less effective under hypoxic conditions.148 By contrast, resistance to chemotherapy is 
multifaceted. Some classes of drugs act during specific phases of the cell cycle, which is slower in 
hypoxic cells reducing overall drug performance. Hypoxic conditions increase the activity of 
DNA-repair enzymes, compromising the efficacy of DNA-binding drugs. The location of viable 
hypoxic cells is between 50 – 250 µm from blood vessels,151 restricting drug delivery and 
distribution. And finally, while normal intracellular pH is maintained during tumorigenesis, the 
extracellular hypoxic conditions possess a much lower pH, creating a pH gradient which can 
reduce intracellular accumulation of weakly basic drug candidates.146 These collective drawbacks 
in treating solid tumours can be overcome by designing drugs that exploit such unique hypoxic 
conditions. Designing hypoxia-activated prodrugs is one strategy that utilises initially non-toxic 
compounds that generate an active species upon bioreduction. This objective has been pursued 
extensively using organic frameworks including: quinones, nitroaromatics, tertiary amine N-oxides 
and aromatic di-N-oxides.150 
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One of the first hypoxia-activated drugs to show distinctive specificity towards hypoxic cells was 
developed by Brown et al. as tirapazamine (TPZ, Figure 1.22), a benzotriazine di-N-oxide.152 
Testing was undertaken on human malignant cell lines HCT-8 and A549 as well as normal AG 
1522 cells under aerobic and hypoxic conditions with cells dosed in a concentration range between 
1.5 mM and 5 µM. A hypoxic cytotoxicity ratio was calculated (concentration of drug in aerobic 
conditions divided by concentration of drug in hypoxic conditions to produce the same level of cell 
death) and was found to be between 15 – 50 for the cell lines tested.152 In vivo experiments were 
performed using SCC VII murine tumours in a clonogenic assay to measure the surviving fraction 
of the tumour after injection of TPZ (0.3 mmol/kg). After 24 h incubation, tumours treated alone 
with TPZ showed the surviving fraction reduced by a factor of 3.1 compared to those treated with 
additional radiation that reduced by a factor of 43.1.152 A decrease in the hypoxic cell survival 
implied TPZ not only possess its own intrinsic cytotoxicity but significantly sensitises hypoxic 
cells to radiation therapy.  
 
Figure 1.22 Clinical trialled, hypoxic active benzotriazine drug Tirapazamine and predicted mechanism of 
action.153,154  
Further investigation by Brown and Peters into the properties of tirapazamine revealed the 
formation of highly reactive free radical species as the mechanism of action (Figure 1.22). TPZ is 
converted to a TPZ• radical by one electron reductase enzymes, found to be highly expressed in 
hypoxic tumours.155 If oxygen is present, TPZ• is back-oxidised to the nontoxic parent 
compound.154 Spontaneous decay of TPZ• provides the oxidising OH• radical or an BTZ• radical. 
While these oxidizing radicals were considered directly responsible for DNA double-strand breaks 
(DBSs), later evidence suggested the involvement of topoisomerase II (topoII) poisoning.148 To test 
the participation of topoII in TPZ toxicity, H69 small cell lung carcinoma were co-incubated with 
TPZ and aclarubicin – a topoII inhibitor – under hypoxic conditions. DNA DSBs caused by TPZ 
were reduced by over 60% when co-incubated with aclarubicin.156 Hydroxyl radicals are 
documented to damage topoII enzymes, stimulating topoII-mediated cleavage creating DNA DSBs. 
It is therefore proposed that cytotoxicity of TPZ is in part, through poisoning of topoII by hydroxyl 
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radicals formed by TPZ• decay under hypoxic conditions.156 Despite the promising results shown 
by TPZ in phase I and II clinical trials over the past decade, phase III trials failed to demonstrate 
any survival benefit to patients when using TPZ alongside conventional chemotherapy or 
radiotherapy.157 However, phase III trials are still ongoing. 
 
Figure 1.23 Attachment of the 4-nitrobenzyl group to the terminal hydroxyl group of CH-1 kinase inhibitor. 
Under hypoxic conditions the nitro group is reduced to give the active drug CH-1.158 
Enzyme inhibitors are an alternative class of compounds where applying the principle of 
bioactivation under hypoxic conditions has also produced encouraging results. One noteworthy 
example is the protected Chk1 kinase inhibitor (CH-01) synthesised by Conway et al. which 
utilises a bioreductive 4-nitrobenzyl group, that upon reduction releases the active inhibitor CH-1 
(Figure 1.23).158,159 The simple synthetic modification by addition of the 4-nitrobenzyl group and 
its subsequent reduction and removal under hypoxic conditions was effectively monitored using 
multiple reduction assays. Initially the prodrug CH-01 was treated with zinc in a solution of DMF 
and NH4Cl (1 : 1 x 10-5) to mimic enzyme reduction and the reaction was monitored by HPLC over 
24 h. The 4-nitro group was fully reduced to provide the amine product which was combined with a 
potassium phosphate buffer (pH 7.4), promoting fragmentation (Figure 1.23) to afford the active 
kinase inhibitor CH-1.158 In an alternative assay, bactosomal human NADPH-cytochrome (CYP) 
reductase was incubated in potassium phosphate buffer with the CH-01 prodrug. Under normoxic 
conditions CH-01 remained intact with no fragmentation observed compared to complete release of 
the active CH-1 species under hypoxic conditions.158 These results suggest CH-01 is reduced via 
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chemical conditions and through incubation under hypoxic conditions in the presence of reductase 
enzyme; consistent with the proposed mechanism. 
Chk1 is involved in the cell cycle and its inhibition can directly induce DNA damage. In vitro 
testing of CH-01 was undertaken to determine such potential toxicity and measure the extent of 
inhibitor activity under varying conditions. The DNA damage response protein 53BP1 accumulates 
after DNA double-strand breaks occur. Using Western blotting analysis, Conway et al. determined 
an accumulation of 53BP1 foci in over 50% of RKO colon carcinoma cells exposed to CH-01 
under hypoxia.159 A colony survival assay followed to discern the effects of CH-01 on RKO cell 
viability at oxygen tensions between 20% to ≤0.02% O2. At 3% O2 (normal tissue concentration), 
little to no effect was observed on cell viability, whereas lower levels of O2 incubation suggested 
reduced cell viability was oxygen-dependent.159 Control tests with an ethanol substituted 
4-nitrobenzyl compound which released ethanol upon reduction had no effect on cell viability 
when dosed to RKO cells alone under hypoxic conditions, implying the reduced side-product is 
nontoxic and was not an additive towards toxicity. Under normoxic conditions neither CH-01 or 
the control compound exhibited significant effect on cell viability, correlating with early findings 
that suggested alkylation of the primary hydroxyl markedly reduced overall activity of CH-1.159 
These results display the extent of improved sensitivity of the protected Chk1 kinase inhibitor CH-
01 towards hypoxic cells via an oxygen-dependent activation pathway, with the enzyme inhibitor 
properties retained as the parent compound, CH-1.158,159  
Hypoxic-activation is not just limited to organic systems, it can also be effectively utilised through 
the redox properties of metals. As previously discussed in Section 1.3, metal-based enzyme 
inhibitors can contain a metal acting as a chaperone for a biologically active ligand and upon 
reduction the organic drug is released. In forming coordination complexes, metals can associatively 
change the pharmacological properties of organic based drugs through tumour targeting, cellular 
localisation and can even enhance cellular uptake with additional lipophilic carrier ligands.160  
The matrix metalloproteinase inhibitor CoIII-mmst seen in Table 1.1 (Section 1.3) is reiterated as 
one of two particular examples discussed here of exploitable redox activity of a metal complex. 
Clinical trials of the organic drug marimastat (active species of CoIII-mmst, Figure 1.24) were 
terminated as the drug failed to display progressive results when compared to existing therapies.161 
It was proposed that the chelating ability of the hydroxamate to other metal ions contributed to the 
reduced efficacy of marimastat in vivo. Hambley and co-workers used a scaffold comprising a 
tris(methylpyridyl)amine (tpa) around an inert Co(III) metal centre, leaving two free coordination 
sites for the active marimastat molecule to bind. The use of the Co(III)tpa chaperone had been 
previously documented to possess a suitable reduction potential, consistent with reduction induced 
under hypoxic conditions.75 Therefore, the design of CoIII-mmst encompassed the binding of the 
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active species to a carrier complex, which could be selectively reduced under hypoxic conditions 
from Co(III) to the more labile Co(II) oxidation state, releasing the active species. 
 
Figure 1.24 Examples of redox-active metal complexes. The active species are displayed in green. 
The contribution of the metal in CoIII-mmst implied a more effective method of delivering the 
active species.162 Hambley et al. however found that contrary to expected, they observed that both 
CoIII-mmst and marimastat potentiated metastasis rather than preventing it. Due to this 
inconsistency with previous reports, it was desirable to repeat these in vivo experiments. Shortly 
after, Hambley et al. showed the carrier ligands of the Co(III) centre could be tuned to improve 
cellular uptake and release, with tumour region targeting via a reduction potential-dependent 
mechanism.163 These combined observations clearly indicate that while drug release from a 
reduction activated chaperone complex appears promising, refinement is clearly required for this 
type of hypoxia-activated system and investigations are ongoing.  
Platinum is another metal utilised frequently in therapeutic applications due to its redox properties. 
Initially, platinum was encountered in the form Pt(II) in cisplatin (Section 1.2.1) which had 
significant drawbacks including non-discriminate binding once inside the cell, leading to unwanted 
side effects such as nephrotoxicity and possessed a general toxicity towards healthy cells.160 To 
alleviate some of these issues, attention instead has diverted to the use of Pt(IV) as a six-coordinate 
prodrug that can be activated in a reducing environment to the Pt(II) active species (satraplatin, 
Figure 1.24), allowing DNA binding to occur. Similar to the Co(III) example, Pt(IV) prodrugs 
possess tuneable ligands only in the axial positions, to enhance overall lipophilicity and can alter 
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the redox potential of the platinum metal centre. Although, unlike the Co(III) complexes, upon 
reduction and subsequent ligand substitution, it is the Pt(II) metal centre binding directly to DNA 
that is the cause of platinum drug cytotoxicity.160,164 While the Pt(IV) prodrug satraplatin 
(Section 1.2.1) has progressed through clinical trials, there is still great contention over the 
reduction mechanism of Pt(IV) prodrugs and the resulting efficacy of the active species. It is 
widely accepted that naturally occurring biomolecules such as ascorbate and glutathione can reduce 
Pt(IV) prodrugs by distinct mechanisms often dependent on the axial ligands.164 The examples 
illustrated above give a keen insight into the exploitable redox properties of metals, a characteristic 
often favoured when utilising metals in attempting to progress the efficacy of a drug candidate 
beyond in vitro testing.  
Rational drug design in organic chemistry is often inspired by nature and focuses on a compounds 
shape. This factor can be enhanced by the presence of a metal adding a 3D geometry, difficult to 
achieve with a purely organic system. One solution that could combine the two areas that is 
relatively untouched in the literature is the use of the metal complex to provide a specific shape - 
whether this allows enhanced DNA-binding or selective enzyme targeting - while incorporating an 
organic ligand that is activated in a reducing environment. This amalgamation of characteristics, if 
considered judiciously, could enhance overall activity by a new and interesting pathway. Naturally, 
the construction of such a complex would require a strongly chelating motif to the metal centre, 
along with a metal centre that would be largely unaffected under hypoxic conditions, meanwhile 
retaining the intended anticancer properties. Such an alternative could expose a novel use for metal 
complexes as hypoxic-active prodrugs.   
1.4.1 Summary 
The presence of hypoxia in solid tumours is an impediment on the effects of preferred treatments 
such as radiotherapy and chemotherapy. However, the existence of hypoxia presents an opportunity 
for tumour-selective therapy. One of the predominant methods to target these regions is via 
hypoxia-activated prodrugs. The initial form of a prodrug is designed to be inert prior to activation, 
which largely avoids damage to healthy tissue and aids specific tumour targeting in the more 
reducing environment. In some cases, part of the drug is intended to act as a carrier aiding the 
delivery to the appropriate area where the active species can be released. It has been shown in this 
section that there are multiple chemical pathways to exploit hypoxia, depending on the structure of 
the inactive species. Furthermore, the examples discussed have highlighted the requirement for 
tuning complimentary properties to ensure that hypoxia-activated prodrugs are fit for purpose. 
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1.5 Aims and Specification 
The aim of this project is to design, synthesise and characterise novel piano-stool complexes to act 
as anticancer agents while investigating their potential mechanisms of action, as described above. 
Currently, there are countless examples of complexes which employ the pseudo-octahedral 
geometry to formulate potential drug candidates with varying degrees of success. It is clear from 
such examples discussed that the combined properties of the metal ion along with its coordinating 
ligands must complement each other to conserve the most desirable properties for biological 
applications. Factors which must be taken into account include: aqueous stability, behaviour in 
variable physiological conditions and specific biomolecular targets. The specification for the 
piano-stool complexes is as follows: 
a) Design and synthesise DNA binding piano-stool complexes with good cytotoxicity against 
transformed cells. 
i. Incorporation of a 31P spectroscopic handle into a bidentate ligand system –
Allowing a secondary mode of monitoring complex properties under various 
conditions using 31P-NMR Spectroscopy. 
ii. Aqueous availability – The design should ensure the monodentate halide ligand is 
able to undergo exchange in intracellular conditions for the labile aqua species and 
favour this formation to allow subsequent DNA-binding.  
iii. Retention of phosphinate ligands – Complex structure should be kinetically and 
thermodynamically stable towards dissociation induced by competing ligands. 
Substituents within the phosphinate ligand should promote the strength of ligand 
coordination. 
b) Target histone deacetylase enzyme inhibition with piano-stool complexes. 
i. The specific biomolecule should have clear influence and contribution to 
malignancies – dysregulation of epigenetic modifiers such as HDAC enzymes 
directly affect gene expression leading to cellular transformation. From the 
discussion in Section 1.3.4, this biomolecular target was considered appropriate.  
ii. Determine inhibition of the target molecule is the likely mechanism of action 
providing cytotoxicity – This could be achieved using DNA-binding, protein-
binding and enzyme inhibition assays. 
c) Optimise selectivity towards specific HDAC isoforms. 
i. Choose suitable complex modifications – Maximise enzyme-surface interactions 
by constructing a more complex arene. Improve selectivity through adjusting the 
chain-linker. From the discussion in Section 1.3.4.4 introducing a tolyl linker 
should promote HDAC6 selectivity. 
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ii. Minimise off-target binding – optimised complexes should observe minimal 
additive effects from off-target binding, minimising unwanted side-effects. 
d) Incorporate a hypoxic-active motif – modify the organic ligand through protection of the 
catalytic-site binding group.  
i. Assess the efficiency of the protecting group – Ease of reducibility under hypoxic 
conditions and monitor formation of the desired active species. The discussion in 
Section 1.4, suggests the use of a p-nitrobenzyl group would be the simplest 
synthetic route to a protected hydroxamic acid. 
ii. Ensure reduction to the active species in vitro – Provide appropriate changes in 
cytotoxicity under conditions of hypoxia and normoxia.  
The following chapters detail the synthesis and characterisation of a range of piano-stool 
complexes which aim to meet one or more of the specifications above. The focus of Chapter 2 
is to show a selection of pyridylphosphinate containing complexes and their properties. 
Chapter 3 introduces the concept of alternative biomolecular targets, followed by optimisation 
of enzyme class specificity in Chapter 4. Finally, Chapter 5 details the early stages of 
developing a hypoxic active piano-stool complex, not yet seen in the literature. 
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2. Pyridylphosphinate Metal Complexes 
2.1 Introduction 
The pyridylphosphinate ligand was established by Parker et al. and has been used in a variety of 
systems with applications in numerous areas of bioinorganic chemistry.165–167 This study reports the 
synthesis, structural characterisation, aqueous behaviour and toxicity of a series of 25 novel 
half-sandwich piano-stool complexes (Table 2.1) incorporating the pyridylphosphinate ligand 
(Table 2.2) to investigate the potential anticancer properties of this ligand system.    
Table 2.1 Pyridylphosphinate complexes (pCy = p-cymene; Bnz = benzene). aSynthesised by other members 






Complex R YZ X Complex YZ X  Complex YZ X 
Ru1PP1a pCy PP1 Cl OsPP1a PP1 Cl  Ir1PP1a PP1 Cl 
Ru1PP2a pCy PP2 Cl OsPP2a PP2 Cl  Ir1PP2a PP2 Cl 
Ru1PP3 pCy PP3 Cl     Ir1PP6 PP6 Cl 
Ru1PP4 pCy PP4 Cl 
 
Ir2PP1a PP1 I 
Ru1PP5 pCy PP5 Cl Ir2PP2a PP2 I 
Ru1PP6 pCy PP6 Cl     
Ru1PP7 pCy PP7 Cl    
 
Ru1PP8a pCy PP8 Cl Complex YZ X      
Ru1PP9a pCy PP9 Cl RhPP1a PP1 Cl      
Ru2PP1a pCy PP1 I RhPP2a PP2 Cl      
Ru2PP2a pCy PP2 I RhPP5 PP5 Cl      
Ru2PP6a pCy PP6 I  RhPP6 PP6 Cl       
Ru2PP3a pCy PP3 I           
Ru3PP1a Bnz PP1 Cl           
Ru3PP2a Bnz PP2 Cl           
Advantages of the pyridylphosphinate ligand include: the inclusion of a 31P-NMR spectroscopic 
handle; biocompatibility; lipophilic control of the R1 group on the phosphorus; modular synthesis 
and the presence of stereogenic phosphorus, presenting the opportunity to develop enantiomerically 
pure metal-based drugs.168 
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Table 2.2 Pyridylphosphinate ligands (asynthesised by other members of the Walton group). 
 
Ligand R R1 
PP1a H Ph 
PP2a H Me 
PP3 3-Me Ph 
PP4 3-Me Me 
PP5 4-Me Ph 
PP6 4-Me Me 
PP7 4-OCD3 Ph 
PP8a 4-Cl Ph 
PP9a 4-NH2 Ph 
 
2.2 Synthetic Aspects 
2.2.1 Pyridylphosphinate Ligand Synthesis 
The initial step to synthesise pyridylphosphinate involves the formation of ethyl methylphosphinate 
(1) from commercially available diethyl methylphosphonite. The synthesis of 1 has been previously 
published169 and proceeds by cooling the starting material diethyl methylphosphonite to 0 °C under 
an argon atmosphere, followed by the addition of water (1 equivalent) and the solution allowed to 
heat to room temperature overnight (Scheme 2.1). The product, 1, was formed in quantitative yield 
and confirmed by 1H NMR along with an equimolar amount of ethanol. The phenyl analogue of 1 
is commercially available. A mechanism is suggested in Scheme 2.1 inspired by the known 
Michaelis-Arbuzov reaction. While this mechanism would likely encourage scepticism, a 
proton-phosphorus bond is undoubtably formed denoted from the large coupling constant 
(1JHP 537 Hz) observed in the 1H-NMR spectrum. 
 
Scheme 2.1 
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The following step involved the palladium catalysed coupling of a range of substituted and 
unsubstituted 2-bromopyridines (2) with 1 or the readily available ethyl phenylphosphinate 
precursors. The respective phosphinate, 2 and triethylamine were dissolved in toluene and the 
mixture degassed. After 1 h the Pd-catalyst was added and the reaction heated overnight at 120 °C 
(Scheme 2.2). The resulting reaction mixture was diluted into dichloromethane and washed with 1 
M HCl and water. The organic layer was dried over MgSO4 and purified by column 
chromatography on silica using a gradient mobile phase of varying DCM:MeOH ratios, depending 
on the compound (3-7). The yields for compounds 3-7 are displayed in Table 2.3.  
 
Scheme 2.2 
Table 2.3 Yields (%) of compounds 3-7. 
 
 
 R R1 
Yield (%) 
 3 3-Me Ph 80 
 4 3-Me Me 32 
 5 4-Me Ph 34 
 6 4-Me Me 51 
 7 4-F Ph 17 
A solution of 6 M HCl was used to hydrolyse the ethyl group of compounds 3-6 by stirring at 
90 °C overnight (Scheme 2.3). The majority of the acid was removed by repeated washing with 
MeOH to give quantitative yields for ligands PP3-PP6. The reaction is catalysed by the formation 
of a hydroxonium ion in acidic solution, proceeding via an addition-elimination mechanism. A 
change to lower frequency (between 22-16 ppm) of the phosphorus peak was observed in the 
31P-NMR spectra for compounds PP3-PP6, confirming formation of the phosphinic acid group. In 
addition, no observed aliphatic ethyl protons were observed in the 1H NMR spectra, confirming the 
successful cleavage of the ethoxy group. All ligands from Table 2.2 were synthesised using the 
same acid hydrolysis method unless otherwise stated.   





The synthesis of ligands PP7 and PP8 proceeded via the 4-fluoropyridylphosphinate (7) 
intermediate. The removal of the ethyl group was attempted using either an acid or base catalysed 
mechanism (Scheme 2.4). In both cases, nucleophilic aromatic substitution was observed of the 
fluorine atom from 7 to form an electron-rich 4-OCD3 substituted ligand (PP7) or an electron-poor 
4-Cl substituted pyridylphosphinate (PP8), depending on the hydrolysis conditions.  
 
Scheme 2.4 
The synthesis of ligand PP7 was undertaken in deuterated solvent to monitor the 19F-NMR signal. 
As the reaction progressed, alongside the removal of the ethyl group protons, the absence of the 
fluorine signal was also apparent. The formation of the 4-OCD3 substituted ligand was confirmed 
by mass spectrometry, providing an m/z of 236.0483 in the positive ion spectrum implying the 
substitution of the fluorine by –OCD3 acting as the nucleophile. Although unplanned, these ligands 
were taken forward as electron-rich (PP7) and electron-poor (PP8) derivatives.  
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2.2.2 Pseudo-Octahedral Pyridylphosphinate Complexes 
 
Scheme 2.5 
Nine half-sandwich complexes were synthesised using ligands PP3-PP7. The ligands PP3-PP6 
were neutralised to pH 7 using a freshly prepared solution of NaOMe in methanol before reacting 
with the commercially available metal chloride dimers (8). To neutralise PP7 a drop of conc. HCl 
was added to the ligand dissolved in MeOH. The chosen ligand and half an equivalent of metal 
dimer were dissolved in MeOH and the reaction mixture was stirred at either room temperature or 
40 °C overnight, depending on the desired complex (Scheme 2.5). The resulting solution was 
reduced in volume and dropped into a solution of cold diethyl ether to afford the complexes as a 
precipitate in various yields (Table 2.4). The synthesis of the complexes was confirmed using 1H, 
13C, 31P NMR and High-Resolution Mass Spectrometry. Reasoning for the poor yields of 
complexes Ru1PP7 and Ru3PP5 are indeterminate. The benzene arene (Ru1PP7) could be less 
stable than the other arenes, lending to a lower yield of the final complex. By contrast, the low 
yield of complex Ru1PP7 could be due to the previous ligand solution neutralisation step if the 
solution remained slightly basic, subsequently affording some of an unwanted hydroxyl-bridged 
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Table 2.4 Half-sandwich complexes: structural aspects and yields.  
 
Complex R R1 {M(R2)} 
Yield 
[%] 
Ru1PP3 3-Me Ph {Ru(p-cymene)} 52 
Ru1PP4 3-Me Me {Ru(p-cymene)} 54 
Ru1PP5 4-Me Ph {Ru(p-cymene)} 86 
Ru1PP6 4-Me Me {Ru(p-cymene)} 45 
Ru1PP7 4-OCD3 Ph {Ru(p-cymene)} 17 
Ru3PP5 4-Me Ph {Ru(benzene)} 7 
Ir1PP6 4-Me Me {Ir(Cp*)} 38 
RhPP5 4-Me Ph {Rh(Cp*)} 33 
RhPP6 4-Me Me {Rh(Cp*)} 63 
The 1H-NMR spectra are compared in Figure 2.1 to show the clear proton shift from the free ligand 
(PP3) versus coordination to the metal (Ru1PP3). The pyridylphosphinate is coordinated in an 
N,O-bidentate fashion to the metal through the nitrogen atom of the pyridine and the negative 
oxygen of the phosphinate. The σ-donor character of the pyridine moiety causes a characteristic 
downfield shift of the adjacent proton (H6) when bound in Ru1PP3. This shift to a higher 
frequency by 0.27 ppm is observed in all the complex NMR spectra and aids confirmation of the 




Figure 2.1 1H-NMR analysis of ligand PP3 and complex Ru1PP3 (MeOD-d4, 298 K, 400 MHz). 
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2.3 X-Ray Crystallography 
A single crystal of Ru1PP3 was grown using a slow diffusion method. Ru1PP3 (2.1 mg, 
0.0039 mmol) was dissolved in MeOH (0.2 mL) and the anti-solvent diethyl ether (2 mL) was 
added to an external vial and left for 6 days. The resulting crystal was analysed by x-ray diffraction 
to provide the structure shown in Figure 2.2A of complex Ru1PP3 in the solid state. Complex 
Ru1PP3 crystallised in a monoclinic crystal system with P21/c space group symmetry and 
displayed the expected pseudo-octahedral geometry, with the ƞ6 bound p-cymene occupying one 
vertex. The bond lengths observed in Ru1PP3: Ru-Cl (2.4155(6) Å), Ru-O (2.0809(14) Å) and 
Ru-N (2.1109(17) Å) are comparable to those reported for the analogous picolinate complex 
[(ƞ6-p-cymene)Ru(picolinate)Cl].63 The picolinate complex N-Ru-O bite angle (77.95(7)°) is 
slightly smaller than the corresponding phosphinate N-Ru-O bite angle (80.50(6)°) a consequence 
of the larger size of the phosphinate group.  
 
Figure 2.2 (A) X-ray crystal structure of complex Ru1PP3 (RuSPR) and (B) 1H-NMR spectrum (MeOD-d4, 
298 K, 400 MHz) with expansion of the p-cymene protons and the methyl substituents between 2.5 and 2.0 
ppm. 
Due to the incorporation of stereogenic centres at the ruthenium and the phosphorus atoms (R or S 
at Ru and P, denoted by RuR/S and PR/S, respectively), the pyridylphosphinate complexes can form 
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four possible stereoisomers. In the solid-state structure only one enantiomeric pair is observed- 
RuRPS and RuSPR (Figure 2.2A showing RusPR), this is also evidenced in solution with 1H NMR 
displaying one set of diastereotopic p-cymene protons between 5 and 6 ppm (Figure 2.2B). The 
isopropyl CH3 groups of the p-cymene also show diastereotopic environments as two doublets 
rather than a single doublet due to the presence of the ruthenium stereogenic centre leading to 
chemical inequivalence hence the slight difference in chemical shift. The stereoselectivity observed 
in complex Ru1PP3 has been previously reported in lanthanide pyridylphosphinate complexes170 
and is rationalised in terms of steric interactions between the arene and phosphorus substituents. 
The conformation observed in the crystal structure (Figure 2.2A) of Ru1PP3 is the most favourable 
diastereomer, providing minimal interactions between the P-phenyl group and the p-cymene ligand. 
Other interactions that may contribute to the preferred stereochemistry are weak hydrogen bonds 
between the P=O and p-cymene methyl-H (2.587 Å) and P-phenyl with pyridyl methyl-H 
(3.065 Å). Broadening of the pyridyl Me peak (Figure 2.2B) reflects its proximity to the aromatic 
P-phenyl group, while the p-cymene Me appears as a sharp singlet suggesting the free rotation of 
the arene ligand; expected in ƞ6-arene-metal systems.171   
 
Figure 2.3 X-ray crystal structure of complex Ir1PP6.  
Complex Ir1PP6 (0.0014 g, 0.0025 mmol) was dissolved in DCM (0.2 mL) and crystallised by 
slow diffusion using hexane as an anti-solvent. Ir1PP6 crystallised in a monoclinic crystal system 
with a Cc space group, displaying longer bond lengths between the metal and coordinated ligands 
(Ir-Cl = 2.4328(11) Å, Ir-N = 2.1112(3) Å and Ir-O = 2.125(3) Å) than the ruthenium 
pyridylphosphinate complex Ru1PP3, as well as a wider N-Ir-O bite angle (80.00(11)°). Complex 
Ir1PP6 was crystallised in a 1:1 stoichiometric ratio with water (Figure 2.3), which formed a 
hydrogen bond to the P=O oxygen in the crystal lattice, however no intramolecular H-bonds were 
observed in the solid state as seen for complex Ru1PP3. Although the P-methyl substituted ligand 
PP6 is less sterically demanding, only a single diastereomer was observed - IrRPS and IrSPR. The 
lack of intramolecular ligand interactions observed in complex Ir1PP6 implies the 
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pyridylphosphinate ligand structure has little influence on stereoselectivity of the final complex and 
may originate instead from the initial attack of the phosphinate ligand on the metal dimer. 
2.4 Aqueous Behaviour of Pyridylphosphinate Complexes 
2.4.1 Hydrolysis and Ligand Exchange  
As seen in other examples, the aqueous behaviour of half-sandwich complexes is often relevant to 
their activity.59,65,66,172 Complexes containing a monodentate halide often exhibit ligand exchange in 
aqueous conditions to form an aqua species. The subsequent complex offers more lability at the 
monodentate coordination site, allowing DNA binding within the cell as a potential mechanism for 
activity.  
 
Figure 2.4 1H-NMR spectra (D2O : MeOD-d4 9:1, 298 K, 400 MHz) of complex Ru1PP4 (A) in D2O, (B) 
0.1 M NaCl solution and (C) addition of AgNO3 and filtration of AgCl. 
To test the properties of the pyridylphosphinate complexes under aqueous conditions, complex 
Ru1PP4 was dissolved in a D2O : CD3OD (9 : 1) mix and 1H-NMR was used to determine the 
extent of ligand exchange by monitoring the p-cymene protons (5.4-6.0 ppm). Equilibrium was 
reached between the chloride (Ru1PP4) and aqua (Ru1PP4.1) species in solution (Figure 2.4A) 
within 5 min and remained stable at room temperature over 24 h. To mimic extracellular chloride 
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concentration, the complex was dissolved in 100 mM NaCl solution (Figure 2.4B) to provide 
chloride bound species (Ru1PP4) as the major adduct and confirmed the chemical shift of the 
p-cymene protons of the chloride species in D2O. To remove the chloride ligand and force the 
formation of the aqua species (Ru1PP4.1), AgNO3 was dissolved in solution, followed by filtration 
of the AgCl salt through a 0.2 μm pore filter to provide only the aqua species in solution 
(Figure 2.4C). Having identified the respective chloride (Ru1PP4) and aqua (Ru1PP4.1) 
diastereotopic proton peaks, the equilibrium reached in D2O after 24 h (Figure 2.4A) displays 
approximately 62% of the aqua and 38% of the chloride species. These NMR experiments suggest 
the chloride complex would be the major species in the extracellular environment (chloride 
concentration of approximately 100 mM) while once inside the cell, the lower chloride 
concentration (approximately 20 mM) would encourage the formation of the aqua species. The 
analogous Ru-iodide complex also undergoes rapid hydrolysis in D2O however 60% of the iodide 
species remains intact, implying an increased stability of the Ru-I bond compared to Ru-Cl.   
2.4.2 Variable pH Conditions 
Alongside hydrolysis, other physiological factors such as pH can play a significant role in the 
activity of potential metal complexes as anticancer agents.173 While generally pH varies depending 
on cell location and function, rapid proliferation of malignant cells causes a reduction in oxygen 
supply to tumour areas which become more hypoxic (acidic).173 This microenvironment can 
directly affect the structure and hence overall efficacy of a drug candidate. The stability of the aqua 
species is desirable within the cellular environment, with the pH influencing deprotonation of the 
bound water molecule, forming the hydroxyl ligand (Figure 2.5). The hydroxyl ligand is much less 
labile than water and could prevent binding of the metal centre to nucleobase.173 Due to the fast rate 
of hydrolysis observed for the pyridylphosphinate complexes, the effect of pH on the aquated 
species was investigated. Calculation of pKa values of the water bound molecule in the 
pyridylphosphinate complexes was therefore of interest to determine the likelihood of DNA 
binding and how the pKa varies depending on the coordinated ligands and the metal centre.  
 
Figure 2.5 Deprotonation of the aqua bound molecule to form the neutral, hydroxyl species. 
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NMR spectroscopy is a common methodology used for calculating pKa. The chemical shifts of 
NMR-active nuclei (e.g. 1H and 13C) depend on the chemical environment. Alteration of pH can 
cause deprotonation or protonation of acidic or basic sites which can be monitored by an adjacent 
atom’s chemical shift.174 In this case, the deprotonation of the water bound molecule was 
monitored by peaks H6 -adjacent to the pyridine nitrogen, the phosphorus peak and the arene 
protons of the selected complexes. To reduce discrepancies, dioxane (1H-NMR) and 
triphenylphosphine (31P-NMR) were used as reference compounds. To a solution of 
pyridylphosphinate complex (D2O : MeOH-d6 9:1), AgNO3 (2.5 equivalents) was added to form the 
aqua adduct and the AgCl salt was removed by filtration. The selected peak shifts in the 1H and 31P-
NMR spectra were measured at intervals in the pH range 2.0-14.0; adjusted using 0.1 M NaOD and 
DCl solutions. The initial calculation of the raw data was a correction of chemical shift observed 
(δpeak - δreference) and was plotted as a function of pH. Using an established method (equations noted 
in Appendix 2) the pKa was extracted from the inflection point of the resulting sigmoidal curve 
(Figure 2.6) for all complexes (Table 2.5) - calculated as an average of the three nuclei monitored. 
 
Figure 2.6 Measurement of the pKa of aqua complex Ru1PP5.1 by monitoring the 31P-NMR spectrum 
(D2O : MeOH-d6 9:1, 298 K, 162 MHz) as a function of pH.  
The pKa values for all the aqua complexes tested were higher than physiological pH (7.4) indicating 
the complexes would be present in their aqua form and not the less reactive hydroxo species in this 
environment. By comparing the pKa values of the different aqua complexes (Table 2.5), some 
trends become apparent. The electron-donating group on the pyridyl ligand appears to promote a 
higher pKa of the water bound molecule. This is shown by the increase in values in the order 
Ru1PP5.1<Ru1PP3.1<Ru1PP7.1 considering 4-Me, 3-Me and 4-OCD3 pyridyl substituents (R), 
respectively. The highest pKa of the Ru(II) centred complexes is that of Ru1PP7.1 with the 
4-OCD3 pyridyl substituent. The significant increase in pKa could be attributed to the more electron 
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higher pH to deprotonate the coordinated H2O, compared to the poorer electron donating alkyl 
substituents of complexes Ru1PP3.1 and Ru1PP5.1.  
Table 2.5 pKa values for selected aqua complexes (D2O : MeOD-d6 9:1, 298 K). pKa* values were measured 
by monitoring changes in 1H-NMR and 31P-NMR spectra and converted to pKa using the equation pKa = 
0.929pKa* + 0.42.175 
 
Complex R R1 {M(R2)} pKa 
Ru1PP3.1 3-Me Ph {Ru(p-cymene)} 9.34 ± 0.04 
Ru1PP4.1 3-Me Me {Ru(p-cymene)} 9.18 ± 0.19 
Ru1PP5.1 4-Me Ph {Ru(p-cymene)} 7.76 ± 0.13 
Ru1PP7.1 4-OCD3 Ph {Ru(p-cymene)} 10.08 ± 0.05 
Ir1PP6.1 4-Me Me {Ir(Cp*)} 9.31 ± 0.07 
RhPP6.1 4-Me Me {Rh(Cp*)} 10.95 ± 0.04 
The phosphorus R1 substituent has little effect on the pKa as shown in complexes Ru1PP3.1 and 
Ru1PP4.1 although the electron withdrawing inductive effect of the phenyl group could have 
influenced the pKa, this effect is clearly negligible. The significance of the metal centre is 
illustrated when comparing the complexes Ir1PP6.1 and RhPP6.1. The water bound molecule of 
the rhodium(III) aqua complex is less acidic than the iridium(III) analogue, reflecting the increased 
metal-oxygen bond length of the heavier congener176; a trend also observed in analogous 
complexes of ruthenium(II) and osmium(II).177  
 




Figure 2.7 1H-NMR spectra showing the deprotonation of Ru1PP6 to form the hydroxyl species Ru1PP6.1 
with irreversible formation of the [(p-cymene)2Ru2(OH)3]+ dimer  above pH 11.0.  
While the pKa values suggest relative stability of the aqua complexes at physiological pH, at 
strongly basic conditions the formation of a new species was observed. The 1H-NMR spectrum of 
the ruthenium complexes (Figure 2.7) showed an increased intensity of two doublets in the 
arene-bound proton region (5.0 – 6.0 ppm) indicating a loss of stereogenic centre within the new 
species. Subsequent reduction of the pyridylphosphinate complex peaks was accompanied by an 
increase in free ligand peaks showing dissociation of the pyridylphosphinate ligand. Upon lowering 
the pH of the sample, only partial regeneration of the original complexes was observed. The new 
species was consistently formed for each of the ruthenium complexes at elevated pH (>11.0) and 
was identified as the hydroxyl-bridged dimer (D1, Figure 2.7). The formation of the dimeric 
ruthenium species (D1) has been previously noted for other half-sandwich complexes under 
strongly basic conditions and is known to be non-cytotoxic.178,179  
2.5 Cytotoxicity 
Following the studies into aqueous behaviour, the pyridylphosphinate complex series were tested 
for their viability as potential anticancer agents. Cytotoxicity of the complexes was quantified by 
calculating IC50 values - the concentration of a given compound required to inhibit cellular activity 
by 50%. To calculate the IC50 values, H460 non-small lung carcinoma cells were grown in 96-well 
plates and incubated for 24 hours. The cells were then dosed with each complex at concentrations 
ranging 0.002 to 200 μM and incubated for a further 72 hours. A solution of MTT 
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(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was then added. MTT provides a 
measure of cell viability through metabolic reduction by mitochondrial dehydrogenase of viable 
cells to give formazan, a bright purple, insoluble compound. The quantity of formazan produced 
indicates the amount of viable cells present after incubation with a complex. After 4 hours of 
incubation with MTT, the solution was removed and the remaining formazan crystals were 
dissolved in DMSO (200 μL per well). Colorimetric analysis was used to quantify the amount of 
formazan produced. The IC50 value was determined as the concentration of complex required to 
reduce absorbance to 50% compared to that of the untreated, control wells.  
Table 2.6 IC50 values for selected complexes measured using the MTT assay (96 h) against the non-small 
cell lung carcinoma H460 cell line. Entries are the mean value from three experiments. Complexes excluded 




Although all the compounds synthesised were tested against the H460 non-small lung carcinoma 
cell line, many candidates showed poor toxicity (>200 μM) and will not be discussed. All 
complexes in the series displayed low toxicity with no comparable potency to the control complex 
cisplatin. However, some IC50 values of interest are displayed in Table 2.6. All ruthenium chloride 
complexes were considered inactive with IC50 values of >200 μM. A direct comparison between 
complexes Ru1PP1 and Ru2PP1 shows a 3-fold lower IC50 value for the iodide (Ru2PP1) 
complex compared to the chloride analogue (Ru1PP1). This trend is also shown in the most potent 
complexes within the series, Ir2PP1 and Ir2PP2 which gave IC50 values of 52 and 53 μM, 
respectively. The key feature of the aforementioned complexes is the iridium metal centre which 
when paired with an iodide ligand appears to provide consistent toxicity compared to ruthenium, in 
the case of Ru2PP2. Complexes Ir1PP6 and RhPP6 contain identical coordinating ligands, 
 
Complex R R1 {M(R2)} X IC50/μM 
Ru1PP1 H Ph {Ru(p-cymene)} Cl >200 
Ru2PP1 H Ph {Ru(p-cymene)} I 65 ± 12 
Ru2PP2 H Me {Ru(p-cymene)} I >200 
Ir1PP1 H Ph {Ir(Cp*)} Cl >200 
Ir1PP2 H Me {Ir(Cp*)} Cl >200 
Ir1PP6 4-Me Me {Ir(Cp*)} Cl 140 ± 40 
Ir2PP1 H Ph {Ir(Cp*)} I 52 ± 2 
Ir2PP2 H Me {Ir(Cp*)} I 53 ± 4 
RhPP6 4-Me Me {Rh(Cp*)} Cl 135 ± 17 
Cisplatin - - - - 0.80 ± 0.01 
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including a monodentate chloride and possess similar IC50 values (140 and 135 μM, respectively). 
While there is no other rhodium complex for comparison, Ir1PP2 has a higher IC50 value along 
with only hydrogen as the R substituent on the pyridyl suggesting the increased potency of Ir1PP6 
and RhPP6 could be influenced by the additional 4-Me group. However, based on the pKa values 
of complexes Ir1PP6 and RhPP6 and a slower hydrolysis for the iodide analogues, it is likely a 
combination of metal centre and halide ligand that gives rise to the increased potency across the 
series. Additionally, in the case for ruthenium complexes Ru2PP1 and Ru2PP2, the phosphorus R1 
substituent has an apparent effect; potentially due to the phenyl group increasing overall 
lipophilicity of Ru2PP1 which is known to aid cellular uptake.63,107  
Previously published reports have inferred the relationship between iodide half-sandwich 
complexes and more potent activity compared to chloride complexes evidenced by alternate, 
favourable mechanisms of cellular uptake.68 While the mechanism of action for these 
pyridylphosphinate complexes is currently uncertain, similar existing piano-stool complexes have 
demonstrated variable toxicity linked to the rate of hydrolysis followed by DNA binding as a likely 
mode of action. This observation would be consistent within this series with the iodide complexes 
generally displaying higher cytotoxicity.180,181  
2.6 Binding Studies 
In an attempt to rationalise the poor cytotoxicity displayed by the ruthenium complexes in the 
series (>200 μM), binding studies were carried out to determine the relative stability of these 
complexes in the presence of various biomolecules. The following experiments were intended to 
mimic alternative or competitive reactions that could occur in a cellular environment. Complex 
Ru1PP1 was dissolved in D2O and treated with AgNO3, the resulting AgCl precipitate was 
removed by filtration to give the aqua adduct, Ru1PP1.1. To measure the presence and extent of 
biomolecule binding, mass spectrometry and NMR spectroscopy were used (1H and 31P). Additions 
of one and two equivalents of the selected biomolecule were added to the D2O solution of 
Ru1PP1.1 and the spectra monitored at 1h and 16 h intervals. The biomolecules selected for 
investigation were L-alanine (L-Ala), L-threonine (L-Thr), L-histidine (L-His), imidazole and  
9-ethylguanine (9-EtG).  




Figure 2.8 ESI+ mass spectra of Ru1PP1.1 in the presence of (A) L-alanine, (B) 9-ethylguanine and (C) 
imidazole. Peaks labelled a – c correlate to Table 2.7. 
No binding was observed between Ru1PP1.1 and one equivalent of amino acids L-Ala and L-Thr 
after 1 h, illustrated by the m/z peak at 454.3 identified as Ru1PP1.1 with loss of H2O (Figure 
2.8A). No significant binding was observed for these small amino acids up to two equivalents over 
24 h. By contrast, the addition of one equivalent of 9-EtG (Figure 2.8B) led to a new peak in the 
mass spectrum (Figure 2.8B, b) corresponding to loss of H2O and subsequent formation of the 
9-EtG-adduct of Ru1PP1.1 with an m/z of 632.9. This observation was consistent with the 
1H-NMR which indicated the formation of a bond between Ru and N7 on 9-EtG and showed 
around 50% of the bound 9-EtG-Ru1PP1.1 adduct in solution. The Ru-N7 guanine binding is often 
observed as preferential in oligonucleotides55,171,182, consistent with DNA binding as a proposed 
mechanism of action for existing ruthenium anticancer complexes which leads to apoptosis and cell 
death. The ability of Ru1PP1.1 to bind 9-EtG is consistent with previous reports implying DNA 
binding as a likely mode of action for these complexes. 1H-NMR spectroscopy of a solution of 
Ru1PP1.1 with the addition of two equivalents of imidazole showed a 1:1 imidazole adduct 
formation with loss of H2O after 16 h, also observed in the mass spectrum at m/z 522.4 (Figure 
2.8C, c). The coordination of imidazole would be expected due to its stronger σ-donor character 
than H2O, however formation of only the imidazole-adduct species may be disfavoured as H2O is 
the coordinating solvent and is in excess.   




Figure 2.9 (A) ESI+ mass spectrum for complex Ru1PP1.1 in the presence of two equivalents of L-histidine 
(L-His), d correlates to Table 2.7. 1H NMR spectra (D2O : CD3OD 9:1, 298 K, 400 MHz) of (Bi) 
uncomplexes PP1 ligand and (Bii) products of the addition of two equivalents of L-histidine to complex 
Ru1PP1.1 showing the formation of the L-His complex. 
The most notable biomolecule interaction with Ru1PP1.1 was that of L-histidine. Upon addition of 
one equivalent of L-His, an adduct was observed corresponding to the substitution of H2O with 
L-His. The 1H-NMR spectrum implied the initial binding of L-His through an imidazole N. After a 
second equivalent of L-His was added, the sample was monitored over 16 h. A new species formed 
via displacement of the pyridylphosphinate ligand in favour of the L-His bound ĸ3. The mass 
spectrum gave an m/z of 390.6, corresponding to species d (Figure 2.9) and was confirmed by 
1H-NMR showing the free ligand (Figure 2.9Bi) and a mixture of the free ligand and new complex 
(Figure 2.9Bii) in the sample solution. The tridentate binding of the L-His amino acid forms a new 
ruthenium stereogenic centre. Using enantiomerically pure L-His could therefore result in two 
possible diastereomers. However, it has previously been reported that the tridentate binding motif 
of L-His can only generate a single diastereomer with the ruthenium in the R configuration.183 This 
is observed in the 1H-NMR spectrum (Figure 2.9Bii) by one set of p-cymene protons (6.0-5.0 ppm) 
shown in solution, corresponding to the RuR(L-His)S diastereomer. The Ru-(L-His) complex is 
known to be non-toxic.183 Displacement of the pyridylphosphinate ligand could also be partially 
attributed to the hard P-O- coordinating the softer Ru(II) centre.   
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Table 2.7 Proposed species that give rise to mass peaks in Figure 2.8, upon addition of selective 
biomolecules. Tabulated m/z values correspond to a – d peaks in Figure 2.8.  
Biomolecule m/z Species 
L-Ala a: 454.3 Ru1PP1.1 
 
L-Thr 454.6 Ru1PP1.1 
9-EtG 





a’’: 454.0 Ru1PP1.1 
c: 522.4 
 
L-His d: 390.6 
 
The formation of such non-toxic species presents a potential explanation for the low cytotoxicity 
observed for the Ru chloride complexes (Table 2.6). By contrast, the iodide complexes Ru2PP1, 
Ir2PP1 and Ir2PP2 possess higher cytotoxicity due to the metal-iodide bond being less labile and 
less likely to hydrolyse to the aqua adduct. This structural integrity of the iodide complexes could 
prevent decomplexation by chelating biomolecules that can competitively bind to the ruthenium 
centre.   
2.7 Conclusions 
The initial aim of this study was to synthesise novel piano-stool complexes, containing a 31P 
spectroscopic handle with desirable anticancer properties. A series of 25 novel half-sandwich 
complexes were synthesised by reacting pyridylphosphinate ligands possessing a range of 
substituents with selected metal-halide dimers. The complexes were tested against the H460 non-
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small lung carcinoma cell line with the iridium-iodide complexes Ir2PP1 and Ir2PP2 displaying 
the greatest IC50 values around 50 µM. All the ruthenium-chloride complexes tested gave poor 
toxicity (>200 µM), which can be justified by a combination of their chemical properties, 
behaviour under intracellular conditions and interactions with biomolecules.  
Compared to the iodide complexes, the chloride complexes showed rapid hydrolysis to the aqua 
species with equilibrium favouring the aqua complex (62%). This is thought to contribute to the 
poor cytotoxicity of the ruthenium-chloride complexes, allowing chelation of biomolecules in a 
cellular environment. NMR and mass spectrometry studies on complex Ru1PP1 confirmed the 
ability of two equivalents of L-His to fully displace the pyridylphosphinate ligand to bind ĸ3 to the 
ruthenium centre. This example of amino acid interaction implies the potential of other available 
biomolecules within the cell to preferentially coordinate to the ruthenium centre, altering the 
structure of the complex and reducing its potency. Model binding studies using 9-EtG showed the 
formation of a ruthenium-(9-EtG) adduct, suggesting the possibility of DNA-binding as a mode of 
action. The iodide complexes, retaining the metal-halide bond would not necessarily bind in the 
same manner and may act via a different mechanism. 
The pKa values of the aqua-adduct species tested were all higher than physiological pH (7.4), 
suggesting deprotonation of the water ligand forming the less reactive hydroxyl species is unlikely 
to contribute to the poor toxicity of the complexes. Partial variation in pKa values was attributed to 
the more electron donating OCD3 substituent creating a more electron rich metal centre in the case 
of Ru1PP7 or influenced by a heavier congener forming a longer metal-oxygen bond increasing 
the acidity of the water ligand protons.  
Having rationalised the pitfalls of these pyridylphosphinate complexes and proposed reasoning for 
their relatively poor toxicity, further investigation would be useful. It is quite apparent that the 
labile nature of the chloride bond must be improved upon to enhance activity. This could be 
achieved by tuning the substituents on the pyridyl ring, or even adding multiple groups to form a 
more electron deficient metal centre. Addition of a lipophilic substituent such as phenyl or 
trifluoromethyl group may also improve cellular uptake.  
The biological profile of these complexes could also be examined more thoroughly. Measuring 
cellular uptake and accumulation could quantify the ability of the complexes to enter the cell, 
which is often reported to be proportional to activity. Testing against alternative cell lines could 
broaden the potential target for these complexes and is worthy of attention.   
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3. Piano-Stool Complexes as HDAC Inhibitors 
3.1 Introduction 
Due to the progression of modern drug design becoming increasingly focused towards targeting 
specific biomolecules, the attention of this study shifted to exploit the structural geometry of piano-
stool complexes as potential enzyme inhibitors. Zinc-dependent histone deacetylase (HDAC) 
enzymes were considered an appropriate target due to their well-established biological function, 
including post-translational modification, which if dysregulated can contribute to malignancies.78 
Piano-stool metal complexes were designed to possess ligands analogous to existing HDAC 
inhibitors (Figure 3.1), with the desire to enhance interactions between inhibitor and enzyme as 
well as improve overall cytotoxicity.  
It was deemed prudent to construct complexes that had increased stability in aqueous conditions 
and would not undergo ligand exchange or excessive hydrolysis that were detrimental factors to 
those complexes discussed in Chapter 2. Of the target molecules, only Ru1L2 and RhL2 were 
successfully purified and tested, with the phenanthroline bidentate motif proving beneficial to 
overall complex stability. In this instance, the complexes showed improved cytotoxicity against the 
H460 cell line with the desirable HDAC inhibition activity rationalised as the likely mode of action 
via multiple biological assays.  
 
Figure 3.1 Metal-based HDAC inhibitor target molecules (Cp* = Pentamethylcyclopentadienyl). 
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3.2 Synthetic Aspects 
3.2.1 Monodentate Ligand Approach 
The attempted synthetic route to complex Ru1pySAHA is shown in Scheme 3.1. A ligand was 
required with the ability to bind to a ruthenium metal centre while retaining a structure analogous 
to SAHA. To synthesise a ligand with appropriate functionality, suberic acid containing a six-
carbon aliphatic chain was initially dissolved in acetic anhydride and refluxed for 2 h. The solvent 
was removed in vacuo to provide suberic anhydride (9) in a quantitative yield. Compound 9 was 
dissolved in THF and subsequently reacted with 4-aminopyridine in the presence of base. 
Compound 10 was purified by column chromatography on SiO2 using a DCM (5% MeOH) mobile 
phase and isolated in a high yield.  
 
Scheme 3.1 
The formation of the protected hydroxamic acid was necessary to avoid chelation of this functional 
group to the ruthenium metal centre and ensure binding through the pyridine moiety. While 
chelation would be thermodynamically favourable for the ligand, in this case the unbound 
hydroxamic acid is known to be crucial for HDAC inhibition activity. By coupling 
O-benzylhydroxylamine hydrochloride to the carboxylic acid of 10, this ensured protection of the 
hydroxamic acid. The coupling agents selected were HOBt and EDCi, frequently used as a method 
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of peptide coupling.184,185 Compound 11 was purified by recrystallisation from ethyl acetate. It was 
established that a one pot synthesis of 12 was the optimal route and could be done at room 
temperature. Initially the ruthenium dimer was dissolved in MeOH and the sodium oxalate 
dissolved in water. These solutions were then combined and the ligand (11) added. After 16 h the 
solution was filtered and the solvent removed to provide 12 in good yield (78%).     
The final step in the synthesis of complex Ru1pySAHA was a hydrogenation to remove the benzyl 
group to provide the hydroxamic acid product. Complex 12 was dissolved in MeOH with 
palladium 5% on carbon, under a hydrogen atmosphere using a Dräger balloon and stirred 
vigorously to allow H2 to dissolve. Unfortunately, this hydrogenation method was not successful 
for the ruthenium complex Ru1pySAHA. The initial attempt at H2 dosed for 1 h, minimal starting 
material was present in the reaction mixture (Figure 3.2). Purification of this mixture was achieved 
using HPLC but due to the small scale of reaction and column conditions, no product was 
recovered. 
 
Figure 3.2 1H-NMR spectra (MeOD-d6, 298 K, 400 MHz) of three attempted hydrogenation reactions to 
synthesise Ru1pySAHA. (*Proton peaks of starting material, 12). 
The method was adjusted to dose H2 for longer periods of 1.5 and 2 h (Figure 3.2) with the desire 
to force the reaction to completion. It was observed that the reaction was not as effective on a 
longer timescale. An explanation for these irregular results could be the degradation of the 
palladium catalyst, the H2 pressure was variable or stirring was not consistent upon repeat 
experiments. However, using mass spectrometry, upon closer inspection, a new product gave an 
m/z of 572.62 consistently across all repeat experiments. This mass suggested hydrogenation to the 
amide and not the desired hydroxamic product. The significant upfield shift for the p-cymene 
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protons (6.0 – 5.0 ppm, Figure 3.2) implies the formation of an additional product, with a change 
of ligand coordination at the Ru metal centre. A decrease in size of the pyridine peaks (8.2 and 7.7 
ppm) would support the notion that the pyridine moiety is no longer bound to ruthenium, instead 
suggesting coordination through the amide or hydroxamic acid reduced product. Due to the 
ineffective replication of the literature procedure for complex 13, an alternative complex was 
proposed.  
3.2.2 Bipyridyl Ligand Containing Complex 
To formulate a more stable complex from the active ligand perspective, a ligand with a chelating 
group able to preferentially bind ruthenium over the hydroxamic acid seemed the next logical step. 
The commonly used bipyridine ligand was chosen as the starting point. The commercially available 
2,2’-bipyridine was dissolved in trifluoroacetic acid in the presence of hydrogen peroxide solution 
(Scheme 3.2). The reaction mixture was added to chloroform and washed with 3 M NaOH solution 
and the combined organic layers dried over Na2SO4, filtered and solvent removed. The formation 
of the N-oxide was confirmed by 1H-NMR: the starting material contains only 4 proton 
environments in the aromatic region as the structure is symmetrical, whereas the product contains 8 
proton environments implying the formation of only a single N-oxide, resulting in one of the rings 
being more electron rich. The chemical shift of the from 8.71 to 8.86 ppm of the proton now 
adjacent to the N-oxide illustrates the electron withdrawing nature of the resulting N-oxide (14).  
 
Scheme 3.2 
The second step involved the dissolution of 14 in concentrated sulfuric acid at 80 °C followed by 
the addition of potassium nitrate. After 30 h the reaction mixture was poured over ice and basified 
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using 3 M NaOH solution. This basifying step is likely to account for the low yield of 15 (29%) as 
if the solution became too basic the precipitate no longer formed; a process that could not be 
reversed. Presence of the N-oxide activated the pyridine to allow electrophilic aromatic substitution 
at the para position. The loss of a proton in the aromatic region, along with formation of a doublet 
for H3, adjacent to the nitro group with only a meta proton-proton coupling (4JHH 3.0 Hz) confirmed 
the substitution at the para position. Reduction of 15 was attempted using palladium (10% on 
carbon) and NaBH4, reagents taken from a known procedure with reported high yields.186 This 
method did not yield good results, instead giving a mixture of multiple products and remaining 
starting material. The reaction was adjusted by using more NaBH4 with no noticeable difference in 
conversion to product. An alternative synthesis using tin(II) chloride in concentrated HCl was used, 
providing significant improvement on conversion to the product (16). A sublimation technique was 
used to effectively purify 16, and the structure and purity confirmed by 1H-NMR (CDCl3) 
displaying a broad amino peak at 4.29 ppm. 
 
Scheme 3.3 
With compound 16 in hand, the final synthesis of the ligand was carried out (Scheme 3.3). An 
alternative synthesis to suberoyl anhydride (9) ring opening was used due to the poor 
nucleophilicity of the amino group in 16. Instead the commercially available methyl 8-chloro-8-
oxooctanoate was used, containing a more favourable chloride leaving group. DMF was removed 
by vacuum distillation and the impure methyl ester was dissolved in MeOH and hydroxylamine 
solution (1:1) in the presence of 1 M NaOH. After 30 minutes the reaction mixture was neutralised 
and the resulting precipitate washed with water to afford L1. 




The formation of complex Ru1L1 was achieved by reacting L1 with 
dichloro(p-cymene)ruthenium(II) dimer. Excess solvent was removed and the crude product was 
purified by recrystallisation by dropping diethyl ether into a concentrated solution of MeOH. The 
1H-NMR spectrum showed the p-cymene peaks in the anticipated region 5.0 – 6.5 ppm as four 
doublets. The complexation forms a stereogenic centre at the ruthenium metal, consequently giving 
rise to chemical inequivalence in the p-cymene protons.  
3.2.3 Synthesis of N20-Hydroxy-N11-(1,10-phenanthrolin-
5-yl)octane diamide (L2) and Resulting Complexes 
The synthesis of N20-hydroxy-N11-(1,10-phenanthrolin-5-yl)octanediamide (L2) was undertaken 
using an existing procedure reacting 1,10-phenanthrolin-5-amine with methyl 8-chloro-8-
oxooctanoate in DMF using DMAP as a nucleophilic catalyst.117 Conversion to the hydroxamic 
acid was done using the same method described above (Section 3.2.2). It was found that cooling the 
solution upon neutralisation partially improved the yield.  





Formation of the complexes containing L2 was achieved using the same method as described 
previously, reacting the ligand with half an equivalent of dichloro{metal(arene)} dimer, and 
purified using the precipitation technique from concentrated MeOH into diethyl ether. Yields and 
structure of the complexes are displayed in Table 3.1. 
Table 3.1 Half-sandwich complexes containing L2: structures and yields. 
 
Complex {M(R)} Yield [%] 
Ru1L2 {Ru(p-cymene)} 58 
Ru3L2 {Ru(benzene)} 55 
RhL2 {Rh(Cp*)} 61 
Synthesis was confirmed using 1H-NMR, mass spectrometry and elemental analysis with 2D NMR 
spectroscopy allowing full assignment of all protons. An example spectrum is shown in Figure 3.3 
of the complex Ru1L2 in DMSO-d6 with some important characteristics highlighted. 1H-NMR in 
an aprotic solvent such as DMSO-d6 allows identification of the intact hydroxamic acid, showing 
broad resonances at 10.30 and 8.63 ppm corresponding to the hydroxamic acid OH and NH 
protons, (Figure 3.3, c and b)  respectively. The NOESY spectrum aided this assignment with a 
clear interaction between these protons. These resonances are near identical to those observed in 
the spectrum of L2 confirming the ligand coordination to ruthenium occurs through the 
phenanthroline N-donors. Resonances for the protons adjacent to the phenanthroline N atoms (H2 
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and H9) shift by almost 1 ppm upon complexation due to the σ-donor character of the 
phenanthroline ligand. 
 
Figure 3.3 1H-NMR spectrum (DMSO-d6, 298 K, 400 MHz) of complex Ru1L2. Proton expansion in the p-
cymene region (6.0 -7.0 ppm) has been done for clarity and the labile NH and OH protons are labelled. 
3.2.4 Metal-Based Belinostat Analogue 
Following the successful synthesis of complexes Ru1L2 and RhL2, multiple routes were attempted 
to synthesise a belinostat (Chapter 1) analogue. 4-Iodobenzene sulfonyl chloride was chosen as the 
commercially available starting material. Initial attempts to react 4-iodobenzene sulfonyl chloride 
with 1,10-phenanthrolin-5-amine were unsuccessful. Although sulfonyl halides are documented to 
react readily with nucleophiles such as alcohols and amines in the presence of base, the 
iodobenzene moiety could have prevented the simple substitution reaction. Instead, this prompted 
attempts at the Heck Coupling reaction (Scheme 3.6).  
 
Scheme 3.6 
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Selected examples of reaction conditions attempted for the Heck Couplings are listed in Table 3.2. 
A previous synthetic procedure postulated by Lavoie et al. utilised the unusual route A in DMF 
using acrylic acid187. This route was unsuccessful. Experiments were undertaken using both Pd(0) 
and Pd(II) catalytic sources in the presence of silver acetate, base and varying phosphines gave 
equally poor results with very low or negligible yields of 17. The reaction was repeated due to the 
known reliable trans selectivity of the Heck coupling, easily identifying the product using 1H-NMR 
with coupling constants of 16 Hz. The small quantity collected and purified from multiple reactions 
was taken forward as 17.   
Table 3.2 Selected examples of Heck Coupling reaction attempts. 




Reagents and conditions Yield [%] 
A187 H Pd2(dpa)3 
(5%) 
P(o-tolyl)3 (5%) Et3N, DMF, 100 °C 7 
B Me Pd2(dpa)3 
(5%) 
P(o-tolyl)3 (5%) Et3N, AgOAc (2 eq.), MeCN, 50 
°C 
10 
C Me Pd(PPh3)4 
(5%) 
P(o-tolyl)3 (10%) Et3N, AgOAc (2 eq.), MeCN, 50 
°C 
- 
D Me Pd(OAc)2 
(5%) 
P(Ph)3 (10%) Et3N, AgOAc (2 eq.), MeCN, 50 
°C 
12 
E tBu Pd(PPh3)4 
(5%) 
P(o-tolyl)3 (10%) Et3N, MeCN, 50 °C - 
With a total of 100 mg of compound 17 in hand, it was then reacted with 
1,10-phenanthrolin-5-amine at room temperature in THF using DMAP as a base. This reaction was 
based on the first step in Scheme 3.5, with the nucleophilic substitution of a chloride for an amine 
to produce compound 18. Unfortunately this reaction was also unsuccessful. This could be due to 
the poor nucleophilicity of the phenanthroline amine or overall poor solubility of 
1,10-phenanthrolin-5-amine. While changes to all reactions could be made to optimise this 
synthetic route, due to time constraints only complexes Ru1L2 and RhL2 were carried forward.  





3.3 Hydrolysis Studies 
The anticipated HDAC enzyme inhibition of these complexes relies on their ability to enter cells to 
access their intended target. The stability of a complex is often crucial in both the extracellular and 
intracellular environment to ensure the drug candidate reaches the target in its desired form. For 
this reason, the behaviour of the complexes was assessed under aqueous conditions to determine 
their stability. Complex Ru1L2 was dissolved in D2O and monitored by 1H-NMR spectroscopy 
over the course of 96 h (Figure 3.4A). After 1 h there was little exchange, however over the course 
of 96 h an equilibrium was established between the chlorido complex Ru1L2 and the aqua species 
Ru1.1L2. The Ru1L2:Ru1.1L2 ratio is approximated 9:1, implying the chloride species is likely to 
be the major species intracellularly where chloride concentration is 4 mM.19 This result is in stark 
contrast with the pyridylphosphinate complexes, showing the influence of the ligand system on the 
more labile monodentate halide ligands. Also, as observed by similar ruthenium arenes synthesised 
by McGowan et al., it is unfavourable for group VIII metals to gain a 2+ overall positive charge by 
loss of the coordinating halide. In lieu of this, hydrolysis is slow and unfavourable as is the case for 
Ru1L2 shown here.64 




Figure 3.4 1H-NMR spectra (D2O, 298 K, 400 MHz) p-cymene proton region of complex Ru1L2. (A) i) D2O, 
1 h; ii) D2O, 96 h; iii) 100 mM NaCl; iv) AgNO3, 24 h. (B) i) AgNO3, 1 h; ii) AgNO3, 24 h. 
To mimic extracellular chloride concentration, the complex was dissolved in 100 mM NaCl 
solution (Figure 3.4Aiii) to provide only the chloride bound species (Ru1L2) as the major adduct 
and confirmed the chemical shift of the p-cymene protons of the chloride species in D2O. A 
solution of complex Ru1L2 was then treated with AgNO3 and monitored over 24 h (Figure 3.4B) at 
which time the AgCl salt was removed by filtration. After 1 h in solution, new p-cymene proton 
peaks were observed. Within 24 h only the new species was present, implying the full conversion 
to the aqua species (Ru1.1L2). Similar to the chloride species existing as the major adduct in 
aqueous conditions, the removal of the chloride using AgNO3 is also slow signifying the strength of 
the chloride-ruthenium bond, or that the loss of a negatively charged coordinating ligand is 
unfavourable. Throughout these experiments there was no evidence of the non-toxic dimer species 
([(p-cymene)2Ru2(OH)3]+) formation, previously observed for the pyridylphosphinate complexes. 
This is likely to be due to the improved stability of the chelating phenanthroline ligand and is an 
encouraging result with regard to complex stability.   
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3.4 Cytotoxicity  
With these new complexes in hand, their viability as anticancer agents was assessed against the 
H460 non-small-cell lung carcinoma cell line1 by measuring inhibition of cell proliferation. Cells 
were exposed for 96 h to selected complexes Ru1L2 and RhL2, ligand L2 and the known HDAC 
inhibitor SAHA, at concentrations ranging from 0.01 to 200 µM. Cell survival was determined 
using an MTT assay (as described in Section 2.5), the IC50 values were calculated using a 
dose-response curve (Appendix 2) and are displayed in Table 3.3.   
Table 3.3 IC50 values measured using the MTT assay (96 h) against the non-small-cell lung carcinoma H460 
cell line and are reported as the mean value of three experiments.188  
 
Compound {M(R)} IC50 [μM] 
Ru1L2 {Ru(p-cymene)} 21 ± 6 
Ru3L2 {Ru(benzene)} 45.1 ± 19 
RhL2 {Rh(Cp*)} 4.1 ± 0.4 
L2 - 1.5 ± 0.2 
SAHA - 1.4 ± 0.2 
These new complexes show significant inhibition to cell proliferation compared to the primarily 
investigated pyridylphosphinate complexes. The IC50 values of the complexes is clearly influenced 
by the metal-arene motif, with the benzene capped complex Ru3L2 possessing moderate 
cytotoxicity (45.1 µM) while the rhodium-Cp* (RhL2) showed 10-fold more potency with an IC50 
value of 4.1 µM. Between the two ruthenium complexes, the p-cymene capped complex Ru1L2 
showed the lowest toxicity, although 15-fold higher than the SAHA control. The difference in IC50 
values between the ruthenium centred complexes could be due to the p-cymene complex (Ru1L2) 
possessing mildly electron donating alkyl substituents on the arene, increasing the stability of this 
motif. The alkyl substituents also provide an increase in overall lipophilicity of the complex that 
could improve cell accumulation and activity. By contrast, the rhodium complex RhL2 showed 
much lower cytotoxic efficacy (IC50 = 4.1 µM) and is comparable to the most active rhodium(III) 
piano-stool complexes in the literature to date.189 The IC50 value of the ligand L
2 alone is also 
notable, existing within experimental error of the SAHA control. These results advocate the 
potential of piano-stool complexes as potential HDAC inhibitors with the RhL2 complex in 
particular illustrating that a metal complex can be tuned to possess in vitro cytotoxic potency akin 
to its clinically approved analogue. 
                                                     
1 MTT cytotoxicity assays on the H460 cell line were attempted under the supervision of N. Gallagher, 
J. H. Gill, M. Jain and K. L. Rockley at the School of Medicine, Pharmacy and Health, Stockton Campus, 
Durham University.  
Piano-stool complexes as HDAC inhibitors  Chapter 3 
97 
 
3.5 HDAC Inhibition Assay 
Once encouraging efficacy was determined for cytotoxic activity, it was then necessary to 
investigate the mechanism of action and whether these complexes act by HDAC inhibition as 
proposed. An HDAC inhibition assay was therefore carried out using a commercially available kit 
(Section 7.1.8, Enzo Life Sciences). Firstly, appropriate dilutions of assay components were made 
using assay buffer and stored on ice. The known HDAC inhibitor SAHA, L2 and complexes Ru1L2 
and RhL2 were dosed at 1 and 0.1 µM concentrations with a nuclear extract source of HDACs, 
prior to the addition of an acetylated substrate. As a positive control, the assay was also run in the 
absence of any inhibitor. The plate was incubated at 37 °C for 30 minutes. After this time, a 
developer was added and the plate incubated at room temperature for a further 15 minutes. 
Deacetylation of the substrate sensitizes it to the developer, which then generates a fluorophore. 
The fluorophore is excited and the subsequent fluorescence emission used to measure the extent of 
HDAC activity using a fluorescence plate-reader. In the presence of an inhibitor, no fluorescence 
indicates complete HDAC inhibition. Results were calculated as a percentage of HDAC activity, 
relative to the positive control and are displayed in Table 3.4. All reactions and repeats were done 
concurrently in one 96-well plate.  
Table 3.4 HDAC activity in presence of potential inhibitors at 0.1 and 1 μM concentration, measured using a 
commercially available assay kit (Enzo Life Sciences). Values are reported as percentage activity relative to a 
positive control (no inhibitor). 
Inhibitor Concn 
[μM] 
HDAC Activity [%] 
Control  SAHA  Ru1L2  RhL
2  L2  
1 100 0.5 1.6 1.1 4.9 
0.1 100 6.3 17.3 15.4 10.7 
Low HDAC activity was exhibited at 1 µM dose concentration for all compounds tested (<5% 
activity), suggesting that these species are effective HDAC inhibitors. Inhibitory potency of these 
compounds is supported by HDAC activity, while showing a slight increase, remains low at the 0.1 
µM concentration tested. At 0.1 µM the difference in HDAC inhibition between the compounds is 
more distinct following the order SAHA>L2>RhL2>Ru1L2. This order corresponds with the in 
vitro activity displayed by these compounds, which supports the hypothesis that HDAC inhibition 
is the likely mechanism of action.  
While the compounds HDAC inhibition activity follows this general trend, there are some 
variances compared to the in vitro observations. For example, the cytotoxicity of RhL2 is 4-fold 
higher than for Ru1L2 where as their HDAC inhibition is the same order of magnitude at both 
concentrations. This observation could be rationalised by assuming cytotoxicity is dependent on 
factors such as cell uptake and localisation, which do not contribute in a more rudimentary enzyme 
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assay. Another point to consider is the activity of L2 relative to the metal complexes. Despite being 
more active at 0.1 µM, L2 is 4-fold less active than either metal complex, exhibiting less enzyme 
inhibition at the higher 1 µM concentration. The planar aromatic L2 may form aggregates at the 
higher concentration resulting in less available compound to bind to the enzyme, or lower solubility 
of L2 in the assay medium could contribute to the reduced activity. An additional control 
experiment was undertaken, to measure the extent of HDAC inhibitory activity of the known 
complex [(p-cymene)Ru(phen)Cl]Cl.190 No inhibition (100% HDAC activity) was observed at 
1 µM, confirming the zinc chelating hydroxamic acid group is vital for HDAC inhibition activity. 
3.6 DNA Binding 
The enzyme assays clearly suggest this set of compounds are effective at inhibiting HDAC activity 
as proposed. However, cytotoxicity of metal complexes is often documented to be induced through 
DNA binding; commonly observed in both existing drugs such as cisplatin, along with other 
anticancer ruthenium piano-stool examples.51 To discern that DNA binding is not a contributing 
factor to the cytotoxicity of these compounds, assays were performed to test for DNA intercalation 
and covalent modification.2  
Firstly, to probe the ability of these complexes to covalently modify DNA, an Electrophoretic 
Mobility Shift assay was undertaken (Section 7.1.5). In this assay, supercoiled plasmid pSG483 
DNA was used as a potential binding substrate. Supercoiled DNA is dense and can move quickly 
through the pores of agarose gel. Therefore, the tighter the DNA, the faster it will move down the 
plate. Covalent binding reduces the ability of the DNA to supercoil and in a relaxed, larger state, 
moves slower down the plate. Plasmid pSG483 DNA was exposed to increasing concentrations of 
RhL2 from 0.3 to 20 µM and incubated for 24 h at 37 °C. Cisplatin was also tested as a covalent 
DNA binding control under identical conditions. After the incubation period, the resulting products 
were separated by gel electrophoresis on a 1.4% TAE (Tris-base, acetic acid and EDTA) agarose 
gel. Ethidium bromide can intercalate DNA and is a UV active compound which was used as a 
stain to visualise the position of DNA on the gels under UV illumination (Figure 3.5).  
In comparison to the solvent only control (Figure 3.5A, lane 1) the migration of the supercoiled 
DNA is largely unaffected by RhL2. By contrast, at 2.5 µM concentration of cisplatin (Figure 
3.5B) the DNA displayed minimal migration, suggesting the formation of multiple cisplatin-DNA 
adducts, preventing supercoiling. Above this concentration, the DNA appears much more disperse. 
Cisplatin forms very strong bonds with guanosine nucleotides in DNA,191 which could be a cause 
                                                     
2 DNA binding assays were attempted under the supervision of T. R. Blower, Department of Biological 
Sciences, Durham University. 
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of DNA degradation at higher concentrations. It is clear from this comparison that RhL2 does not 
interact with DNA in the same covalent binding manner as cisplatin.  
 
Figure 3.5 Covalent modification of DNA as determined by migration of substrate DNA during agarose gel 
electrophoresis. Supercoiled plasmid DNA was treated with increasing concentrations of (A) complex RhL2 
and (B) cisplatin. SC = supercoiled DNA. 
Having confirmed that covalent modification is an unlikely mechanism of action for these 
complexes, intercalation was another mechanism explored. Intercalation occurs when ligands fit 
between base pairs of DNA and is frequently observed with polycyclic, aromatic and planar 
ligands. Phenanthroline has been previously documented to partake in DNA intercalation192, and 
due to the presence of a phenanthroline ligand in these complexes, there was potential for 
intercalation to occur and was investigated using a similar gel electrophoresis experiment. 
For the intercalation assay, nicked pSG483 plasmid DNA was used as the substrate and was 
exposed to increasing concentrations of RhL2 from 1.25 to 80 µM. Known DNA intercalator, 
acridine orange was utilised as a positive control and the reactions with the substrate were run 
simultaneously. The mixtures were incubated for 30 mins at 37 °C, followed by treatment of DNA 
ligase. The ligase acts to reseal the nicked DNA, trapping the current supercoiling state of the 
plasmid. In this case, intercalation induces an increase in supercoiling within plasmid DNA, 
whereas non-intercalated nicked DNA treated with ligase will be sealed in a distribution of relaxed 
DNA topoisomers (Figure 3.6, lane 3). Gel electrophoresis and visualisation were done using the 
same method as the covalent modification assay (Section 7.1.5) and is shown in Figure 3.6. 
Minimal intercalation was observed below 20 µM for complex RhL2, while moderate intercalation 
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occurred at doses up to 80 µM. This result suggests that intercalation does not occur at 
concentrations capable of causing HDAC inhibition or cytotoxicity. In Figure 3.6 the higher 
concentrations of acridine orange are omitted for clarity. At doses 1.25 µM and above, DNA 
migration was comparable to untreated supercoiled DNA as expected for a known intercalator. 
These results suggest that the moderate intercalating ability observed for complex RhL2 is unlikely 
a contributing factor to overall cytotoxicity of the complex. 
 
 
Figure 3.6 Intercalation of DNA demonstrated by the production of supercoiled DNA. Nicked plasmid DNA 
was treated with increasing concentrations of complex RhL2 and a positive control, acridine orange (AO). 
The supercoiled state was trapped by the addition of DNA ligase, where indicated. N/R = nicked/relaxed 
DNA, SC = supercoiled DNA, L = linear DNA. 
3.7 Protein Binding 
Along with DNA binding, protein binding is also a potential competitive mechanism of activity. 
Off-target protein binding can also be detrimental to the desired activity of a drug candidate. Bulky 
proteins such as human serum albumin (HSA) provide a large hydrophobic surface to which 
lipophilic or hydrophobic drugs can bind; directly affecting their drug delivery. Binding to proteins 
such as HSA ensures the drug stays in the blood, rendering it unable to access its intended target 
and reducing overall bioavailability.193  
To test whether these complexes bind to large proteins, bovine serum albumin (BSA, a similar 
serum protein to HSA) was used as a protein substrate and a UV-Vis titration was used to calculate 
a binding constant. To determine the extent of protein binding, first an acceptable concentration of 
complex had to be established. This was achieved by calculating the extinction coefficient (ε) 
according to the Beer-Lambert law (Appendix 2, UV-Vis titrations) from a set of concentration 
values at 380 nm (Figure 3.7A). It is important to note that amino acid residues, phenylalanine, 
tyrosine and tryptophan present in the BSA protein absorb UV at lower wavelengths (tryptophan 
absorbing highly at ~280 nm) corresponding to π → π* transitions in the aromatic systems. For this 
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reason, the wavelength 380 nm was chosen as it is less likely to be affected by the absorbance of 
such conjugated substituents present in BSA.  
The solution at 93 µM concentration was chosen with the optimal absorbance at 380 nm and was 
consequently used to undertake the UV/Vis titration for the protein binding experiment. Increasing 
amounts of BSA were dissolved in the complex solution (TRIS buffer, 0.05 M; NaCl, 0.1 M) and 
the absorbance measured. In tandem, the same quantities of BSA were dissolved in the same buffer 
solution and the absorbance of BSA alone was measured. To observe any new bound species, the 
absorbance was adjusted by subtracting the unbound BSA from the complex-BSA solution (Figure 
3.7B). The broadening and shifting of the absorbance peak between 360 – 380 nm suggesting this 
absorbance could correspond with protein-complex binding interactions. 
 
Figure 3.7 (A) Absorbance of increasing concentrations of complex RhL2 in TRIS buffer. (B) RhL2-protein 
absorbance, corrected against absorbance of unbound BSA at increasing concentrations ([RhL2] = 93 µM). 




− [𝑅𝑢]0 − [𝐿]0) [𝐶] + ([𝑅𝑢]0[𝐿]0) = 0 
This was derived from the general equation where R = receptor (in this case the metal complex), L 
= BSA protein ligand and C = BSA-complex: 
𝑅 + 𝐿 ⇌ 𝐶 
Concentration of BSA was plotted against absorbance data at 380 nm for Ru1L2 and 370 nm for 
RhL2 as a binding isotherm curve, assuming 1:1 binding. The binding constants [K] were then 
calculated using the straight-line equation and are shown in Table 3.5.  
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Table 3.5 Binding constants [K] for the binding of complexes Ru1L2 and RhL2 with BSA. (TRIS buffer 0.05 
M; NaCl 0.1 M; pH 7.4, 298 K). 
Complex Binding Constant [K] 
Ru1L2 331 ± 13 
RhL2 661 ± 49 
 
Both complexes Ru1L2 and RhL2 provided relatively low binding constants evidence of a 
moderate binding affinity towards BSA. While the binding constants are low, the values calculated 
imply a notable interaction between the complexes and the BSA protein, anticipated due to the 
highly lipophilic surface of BSA and amphiphilic character of the complexes.  
3.8 Conclusions 
Three metal-based HDAC analogues were successfully synthesised and two lead complexes 
(Ru1L2 and RhL2) were tested in biological assays. The complexes presented are the first examples 
of Ru and Rh half-sandwich complexes that inhibit HDAC enzymes, leading to growth inhibition 
of a lung carcinoma cell line. Under aqueous conditions, complex Ru1L2 exhibited minimal 
hydrolysis, implying the chloride species is likely to be structurally stable in the cellular 
environment. Overall, the complexes display moderate to good cytotoxicity against the H460 non-
small-cell lung carcinoma cell line. Complex RhL2 showed comparable cytotoxicity to the 
clinically approved SAHA with IC50 values of 4.1 and 1.4 µM, respectively. The IC50 of the 
ruthenium complex is 5-fold higher than that of the rhodium. Due to the complexes being 
structurally similar, this could be justified by differences in cellular uptake or localisation, 
considering both complexes showed similar levels of HDAC inhibition.  
HDAC inhibition was rationalised as the mechanism of action by eliminating other possible causes 
of cytotoxicity. Complex RhL2 showed no covalent modification of plasmid DNA compared to the 
cisplatin control. The ability of the complex to retain the chloride ligand supports this, as in piano-
stool examples the monodentate ligand undergoes substitution for water to allow DNA-adducts to 
form. The intercalation assay established the ability of RhL2 to elicit supercoiling at concentrations 
of 20 µM or above. These concentrations are significantly higher than those required for HDAC 
inhibition or general cytotoxicity. Binding constants of the complexes to the protein BSA were also 
low. In comparison, HDAC activity remained <20% after incubation with complexes Ru1L2 and 
RhL2 at 0.1 µM concentration, displaying overall good potency only 2-fold higher than that of 
SAHA. These combined results support HDAC inhibition as the likely mode of action for 
complexes Ru1L2 and RhL2. 
An inherent quality of piano-stool complexes is their geometry, and ease with which the structure 
of the complex can be varied. In this case the metal does not directly bind and can act as a 
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hypervalent-carbon, allowing the ligands to form multiple interactions with the enzyme active site, 
enzyme pocket and surface. The halide, arene capping group and chain linker could all be modified 
to improve upon these results; an advantage over organic counterparts which often require more 
challenging synthetic pathways to form complex 3D scaffolds with the same desired outcome. The 
results of this study demonstrate the potential for metal piano-stool complexes as HDAC inhibitors, 
providing a platform for more efficient binding and improved toxicity. To develop a more succinct 
rationale for differences in cytotoxicity between the complexes, it is apparent that investigation into 
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4. Isoform-Selective Piano-Stool 
HDAC Inhibitors 
4.1 Introduction 
As the previous chapter reported, the complexes Ru1L2 and RhL2 displayed promising results with 
regard to cytotoxicity and it was determined HDAC inhibition was the likely mode of action, as 
desired. Incorporation of L2 allowed the complexes to be built with a structure analogous to SAHA 
with the additional exploitation of a pseudo-octahedral metal centre as the capping group. With 
positive results in hand, at this stage of the project, attention was focused towards establishing 
specificity of the complexes towards one enzyme of the HDAC family. Tuning the structure of the 
complexes was proposed to achieve selectivity between the 11 zinc-dependent HDAC isoforms. 
Selectivity is anticipated to evade off target binding, reducing adverse side effects while improving 
overall drug efficacy.  
In an effort to achieve selectivity, this chapter explores the modification of two different structural 
components of the existing piano-stool HDAC inhibitor, Ru1L2. The first aim was to adapt the 
arene motif to improve enzyme surface interactions and garner specificity by the 3D geometry of 
the metal complex. The second was the development of an alternative phenanthroline-based ligand 
that would enhance selectivity through specific interactions in the enzyme channel.  
This chapter details the synthesis of eight new arene motifs, along with the development of the new 
ligand L3. A total of thirteen novel complexes were synthesised (Table 4.1), characterised and 
investigated for their biological properties. Cytotoxicity, cellular accumulation, cellular uptake 
pathways and isoform selectivity assays were performed to provide evidence of activity and any 
selectivity achieved by the complexes diverse structural changes. The direction of selectivity 
towards HDAC6 prompted the task of enzyme modelling, employed to probe the likely binding 
mode to HDAC6-CD2 of the moderately HDAC6-selective Ru1L3 and insight into the likely 
protein-ligand interactions that could arise.  
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Complex R R1 Yield [%] Complex  R R1 Yield [%] 
Ru1L2 p-cymene 58 Ru1L3 p-cymene 36 
Ru4AL2 H Me 76 Ru5AL3 Me Me 39 
Ru4BL2 H tBu 60 Ru5BL3 Me tBu 63 
Ru4CL2 H Ph 31 Ru5CL3 Me Ph 23 
Ru4DL2 H 2-Thiophene 48 Ru5DL3 Me 2-Thiophene 46 
Ru5AL2 Me Me 85     
Ru5BL2 Me tBu 75     
Ru5CL2 Me Ph 67     
Ru5DL2 Me 2-Thiophene 50     
 
4.2 Synthetic Aspects 
4.2.1 Arene Capping Group Modification 
Synthesis of 1,4-cyclohexadiene precursors was chosen as a feasible route to ultimately form the 
ƞ6-arene bound to the metal. This was attempted using a range of synthetic methods. Firstly, 
modification was made to the commercially available aryl starting material benzylamine (Scheme 
4.1a). Benzylamine was reacted with one equivalent of acetyl chloride using triethylamine as a 
base at 0 °C for 3 h before the reaction was allowed to heat to 30 °C.  The reaction proceeded via a 
nucleophilic substitution to provide the amide product (19). After work up, purification by column 
chromatography provided 19 in good yield (72%).  





Reduction of the aryl group was attempted using a sodium-loaded silica gel (Na-SG(I)) as an 
alternative to the Birch reduction to form compound 20 (Scheme 4.1b). The Na-SG(I) reagent from 
the outset was documented to have advantages over the standard Birch reduction by boasting a 
safer, more convenient and air stable form of metallic sodium.194 To reduce compound 19, 3.5 
equivalents of Na-SG(I) were used in anhydrous THF at 0 °C using t-BuOH as a proton source. No 
product was observed and an alternative route was sought.  
Another synthetic option to form the 1,4-cyclohexadienes was to exploit a Diels-Alder 
[4+2]-cycloaddition between a diene and an alkyne. Propiolic acid and isoprene were reacted 
together to synthesise 21 using procedures A-E (Scheme 4.2). The multiple methods employed 
from literature sources included utilising copper as a catalyst (C), AlCl3 as a Lewis acid catalyst 
(E) to coordinate the dienophile (propiolic acid) making it more electrophilic and more reactive to 
the diene, as well as a standard reflux in toluene in the presence of hydroquinone (B), as a few 
examples.  
 
Scheme 4.2 Alternative reaction conditions to synthesise 19. (A) CH2Cl2, rt, 16 h; (B) Hydroquinone, 
toluene, 120 °C;195 (C) Sealed vessel, toluene, 120 °C; (D) CuI, Et3N, CH2Cl2, rt;196 (E) AlCl3, CH2Cl2, 
40 °C.197 
All the procedures listed in Scheme 4.2 gave exceptionally poor yields of 21 (<5%). A factor likely 
accountable for the low yields is the boiling point of isoprene (34 °C). As the majority of the 
procedures required prolonged heating, this highly volatile starting material could have been lost 
before the reaction could take place. Although this was a challenge in undertaking the reaction, it 
was repeated in a sealed vessel and submitted to microwave radiation (C) to, unfortunately, yield a 
similar result. Continued work was proposed using a more electron deficient disubstituted alkyne 
(acetylene dicarboxylic acid) as an alternative to propiolic acid, however this reaction was not 
attempted.  
While persistence towards an alternative route to the 1,4-cyclohexadienes had merit, the Birch 
reduction was eventually employed to synthesise the desired precursors (Scheme 4.3). Ammonia 
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gas was condensed at -78 °C in situ, prior to the addition of benzylamine or a 4-methyl derivative. 
Sodium or lithium metal were added and the reaction stirred vigorously. The reaction was then 
quenched with methanol and the ammonia allowed to evaporate. The resulting mixture was 
extracted into diethyl ether, dried over MgSO4, filtered and solvent removed in vacuo to provide an 
oily product.  
 
Scheme 4.3 
Variations of the reaction were undertaken altering the alkali metal, the mole equivalents of metal, 
and the time the reaction was allowed to proceed. Regrettably, none of the Birch reductions fully 
converted the aryl starting material to the diene product (22a and b) with conversion of reactants to 
products calculated using 1H-NMR. The most effective combination of these variables was 
observed in the reaction of benzylamine with two equivalents of sodium metal over 2 h providing 
80% conversion to compound 22a. The most effective use of lithium (4 equivalents) was observed 
in the conversion of 4-methylbenzylamine over 4 h with 62% conversion to 22b. It is postulated 
that the specific metal used for the Birch reduction is more effective depending on the substrate, a 
factor supported by these results. Due to the viscous oil state of the product and the difficulty in 
purifying multiple amines, compounds 22a and b were carried forward without further purification; 
crude mixtures contained some remaining starting materials. 
 
Scheme 4.4 
The successive step to the Birch reduction was forming an amide linker with a range of R1 groups. 
This was achieved by reacting acetyl chlorides for the methyl (23a/b), t-butyl (24a/b) and phenyl 
(25a/b) products (Scheme 4.4i). Naturally, both the amines from 22 and Birch reduction starting 
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material (benzylamine/4-methylbenzylamine) react with the acyl chlorides, providing a mixture of 
aryl and diene products. Post work-up, separation was attempted by column chromatography, 
gradually increasing the polarity of the mobile phase using a methanol gradient in 200 mL 
increments (from 0.5% to 8%) in dichloromethane. Owing to the similar Rf values of the arene and 
diene, purification between the two compounds at this stage was not successful and again the 
arene/diene mixture was carried forward. The R1 group 2-thiophene was additionally chosen due to 
the existing availability of starting material (2-thiophenecarboxylic acid) and its inclusion 
providing a hydrogen bond acceptor atom (S). Synthesis of 26a/b was achieved by reacting 2-
thiophene carboxylic acid with 22a/b using coupling agents HOBt and EDCi in the presence of 
diisopropylethylamine (DIPEA) base (Scheme 4.4ii). The reaction mixture was poured over 1M 
HCl and extracted into ethyl acetate. The resulting crude product was columned in the same 
method as those mentioned previously, with similarly poor separation.    
 
Scheme 4.5 
The general method to oxidise C6-dienes was reported by Bennett et al. using hydrated RuCl3.198 
All 1,4-cyclodiene derivatives (23-26) were therefore subjected to dehydrogenation with 
RuCl3.xH2O in EtOH at 80 °C where the reaction turned a dark green. After 16 h the reaction 
solution had transformed to a dark red colour and was subsequently cooled to room temperature 
and a precipitate formed. The filtrate was decanted and the solid washed with diethyl ether to 
remove any remaining aryl impurities, to provide the respective dichloro(arene) ruthenium dimers 
(Table 4.2).  
Table 4.2 Yields of synthesised ruthenium chloride dimers. 
 
Dimer R R1 Yield [%] 
Ru4A H Me 17 
Ru4B H tBu 25 
Ru4C H Ph 38 
Ru4D H 2-Thiophene 36 
Ru5A Me Me 29 
Ru5B Me tBu 27 
Ru5C Me Ph 45 
Ru5D Me 2-Thiophene 16 
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The dimeric species synthesised (Table 4.2) were sparingly soluble in most solvents and were 
therefore characterised in DMSO-d6, Figure 4.1 displays the 1H-NMR spectrum of dimer Ru4D as 
an example. Using an aprotic solvent such as DMSO allowed structural assignment of the amide 
proton (f, 9.01 ppm). Another important structural feature identified from the spectrum is protons a, 
b and c appearing between 5.5-6.5 ppm, characteristic of ƞ6-arene bound protons. Figure 4.1 
displays the assumed dimer structure in solution. One set of proton shifts suggests the dimer 
remains symmetrical, but doesn’t rule out competitive binding by the potentially coordinating 
DMSO solvent. Additional confirmation of the synthesis of the dimer species was observed using 
solid-state high-resolution mass spectrometry (ASAP+), where the mass spectrum showed an m/z at 
744.8296. This mass accounts for the loss of a chloride ligand from the dimer species [M-Cl]+ with 
the mass also implying the structure contained two different chloride isotopes (two 35Cl and one 
37Cl) along with two 102Ru metal atoms.  
 
Figure 4.1 1H-NMR spectrum of dimer Ru4D with all protons labelled (DMSO-d6, 298 K, 400 MHz). 
Finally, with the ruthenium chloride dimers in hand, each was reacted with 2 equivalents of L2 
(Scheme 4.6) - previously synthesised and discussed in Chapter 3. The ligand and dimer were 
suspended in MeOH and heated to 40 °C to see full dissolution of both starting components. After 
16 h the reaction solution was reduced in volume and recrystallised from diethyl ether. The 
complexes were subsequently purified by reverse phase HPLC to provide the final complexes 
(Table 4.3).  






Table 4.3 Modified arene capping group complexes and yields [%]. 
 
Complex R R1 Yield [%] 
Ru4AL2 H Me 76 
Ru4BL2 H tBu 60 
Ru4CL2 H Ph 31 
Ru4DL2 H 2-Thiophene 48 
Ru5AL2 Me Me 85 
Ru5BL2 Me tBu 75 
Ru5CL2 Me Ph 67 
Ru5DL2 Me 2-Thiophene 50 
 
4.2.2 Chain Linker Modification 
A new ligand, analogous to the HDAC6 selective compound tubastatin A, was synthesised in two 
consecutive steps. Firstly, 1,10-phenanthrolin-5-amine was reacted with methyl 
4-(bromomethyl)benzoate in THF at 60 °C in the presence of triethylamine base (Scheme 4.7). In 
this instance, the alkyl bromide is much more susceptible to nucleophilic substitution than the 
methyl ester and the reaction proceeded to compound 27 in 16 h. After work-up the product was 
reacted without further purification to the hydroxamic acid, L3.   





Complexes containing L3 were synthesised using the same reaction conditions used to synthesise L2 
complexes, with two equivalents of ligand for each mole of complex, suspended in MeOH and 
heated to 40 °C for 16 h. After this time, the volume of solvent was reduced in vacuo and the 
complex recrystallised out of diethyl ether. This series were also subjected to HPLC reverse phase 
purification (Table 4.4). The methylated dimer series (Ru5A-D) were favoured for reaction with L3 
due to their ease of purification compared to the unsubstituted dimers (Ru4A-D).  
Table 4.4 Yields of complexes containing L3 (crude yield = prior to HPLC purification) 
 
Complex R R Crude Yield [%] 
Ru1L3 p-cymene 36 
Ru5AL3 Me Me 39 
Ru5BL3 Me tBu 63 
Ru5CL3 Me Ph 23 
Ru5DL3 Me thiophene 46 
The spectrum of Ru1L3 shown in Figure 4.3 is a crude sample taken in deuterated DMSO of the 
complex prior to HPLC purification, with protons of interest labelled. In contrast to the L2 
containing complexes whose proton with the highest chemical shift is the NH proton of the amide 
(10.5 ppm), the highest shifted labile proton in complex Ru1L3 is the OH (11.1 ppm) observing a 
0.8 ppm shift compared to complex Ru1L2 (OH = 10.3 ppm). This is likely due to the adjacent N-
acetylphenyl conjugated system causing the downfield shift. Due to the incorporation of the 
substituted phenanthroline ligand, this creates a stereogenic centre at the ruthenium. This is 
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evidenced (as observed previously) by protons c and d of the arene giving rise to a set of 
diastereotopic protons. This character is mirrored by the isopropyl CH3 groups of the arene (proton 
g) affording two sets of doublets with similar chemical shift.  
 
Figure 4.3 Crude 1H-NMR spectrum of complex Ru1L3 with selected protons labelled (DMSO-d6, 298 K, 
400 MHz). 
4.3 Cytotoxicity 
With these two series of complexes in hand, their viability as anticancer agents was assessed 
against MCF7 human breast adenocarcinoma cell line by measuring cell viability,3 accounting for 
cell proliferation and the cytotoxicity of the complexes was quantified by calculating IC50 values. 
To calculate the IC50 values, MCF7 cells were seeded in 12-well plates and allowed to grow to 40 – 
60% confluence (an estimate of the number of cells adherent to the flask or vessel surface, referring 
to the portion of the surface covered). Cellular medium was replaced and cells were treated with 
complexes Ru1L2, RhL2, those listed in Tables 4.5 and 4.6, along with control compounds, at 
concentrations ranging from 0.8 to 100 μM. The cells were then incubated for 96 h at 37 °C. 
Cellular stain acridine orange was subsequently used for cell detection and the nucleic acid stain 
DAPI (4′,6-Diamidino-2-phenylindole dihydrochloride) was used to detect non-viable cells. 
Fluorescence microscopy was used to calculate cell viability. Values were corrected using a 
proliferation correction factor (insert in experimental), the IC50 values were subsequently calculated 
                                                     
3 Cell viability assays against MCF7 cells were undertaken by R. Pal, Department of Chemistry, Durham 
University. 
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using a dose-response curve and are displayed in Table 4.5 (L2) and Table 4.6 (L3). Discussion of 
complexes containing L2 and L3 has been separated for added clarity. 
4.3.1 Analysis of L2 Complexes 
The first crucial observation of the L2 data is the parent complexes Ru1L2 and RhL2 show 
improved toxicity towards the MCF7 cells compared to the previously tested H460 non-small lung 
carcinoma cell line (IC50 values of 21 and 4.1 µM, respectively). Ru1L
2 in particular showed 
13-fold increase in cytotoxicity between the cell lines along with an IC50 value comparable to that 
of the clinically approved control drug, SAHA. Of the 8 new L2 complexes tested, there were some 
interesting trends.  
Table 4.5 IC50 values for L2 containing complexes measured using the cell viability assay (96 h) against the 
human breast adenocarcinoma MCF7 cell lines. Entries are the mean value from three experiments. Control 
compounds include ligand L2 along with known HDAC inhibitor SAHA. (*RhL2 tested as a non-ruthenium 
comparison).  
 
Compound R R1 IC50 [μM] 
Ru1L2 {Ru(p-cymene)} - 1.53 ± 0.4 
*RhL2 {Rh(Cp*)} - 2.44 ± 0.1 
Ru4AL2 H Me 32.5 ± 2.2 
Ru4BL2 H tBu 1.36 ± 0.2 
Ru4CL2 H Ph 1.68 ± 0.3 
Ru4DL2 H 2-thiophene 5.76 ± 1.5 
Ru5AL2 Me Me 1.24 ± 0.3 
Ru5BL2 Me tBu 5.19 ± 1.5 
Ru5CL2 Me Ph 2.1 ± 0.2 
Ru5DL2 Me 2-thiophene 1.72 ± 0.3 
L2 - - 2.99 ± 0.6 
SAHA - - 1.46 ± 0.2 
The Ru4L2 series of complexes all contain a mono-substituted arene (R = H in each case) with a 
methyleneamide linker to various R1 groups. The methyl substituted Ru4AL2 gave the highest IC50 
value of all the compounds tested (32.5 μM). Structurally Ru4AL2 contains the least activating or 
sterically demanding functional groups on the arene which could contribute to low toxicity by 
general instability of the arene-metal bond in this case, or reduced lipophilic character compared to 
the other complexes in the Ru4L2 series. This observation is supported by the Ru5AL2 complex 
which contains an additional stabilising para-methyl substituent and displays 26-fold more potency 
than its Ru4AL2 counterpart. The cytotoxicity is enhanced dramatically in the Ru4L2 series by the 
presence of more lipophilic groups as seen with complexes Ru4BL2 and Ru4CL2 comprising 
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tert-butyl and phenyl R1 groups, respectively. However, the toxicity is slightly reduced in the case 
of the 2-thiophene substituted Ru4DL2. It could be speculated that the more lipophilic arenes of the 
Ru4L2 series could improve overall drug uptake uptake, which could justify the order of toxicity. 
Comparing Ru4DL2 and Ru5DL2 offers another example where the para-methyl substituent 
appears to enhance activity. While the phenyl substituent can undergo π-stacking interactions to 
enhance activity, the thiophene moiety is the only R1 substituent to provide a heteroatom capable of 
forming hydrogen bonds with target molecules. Although sulfur is considered a weaker hydrogen 
bond acceptor than oxygen, studies have indicated the H-bond angle can be crucial for the strength 
of the interaction.199 The incorporation this H-bond acceptor to complexes Ru4DL2 and Ru5DL2 
could be a contributing factor to the relatively low IC50 values of both complexes, increasing 
potential interactions with the target molecule, enhancing activity. Significantly, the IC50 value for 
L2 is double that of SAHA, however the presence of the metal-arene in five of the complexes 
containing L2 (Ru1L2, Ru4BL2, Ru4CL2, Ru5AL2 and Ru5DL2), the IC50 values exist within 
experimental error of the SAHA control. In these cases, it is clear the inclusion of the metal-arene 
motif is beneficial to overall toxicity and is an initial result in support of enhancing the arene unit to 
improve overall activity. 
4.3.2 Analysis of L3 Complexes 
It is important to note that within this series, due to the poor yield of Ru5DL3 (R = Me; R1 = 2-
thiophene) and the quantity required for testing, cellular investigation of this complex was not 
performed. In comparison to those containing L2, the L3 containing complexes display potency in 
the order Ru1L3>Ru5AL3>Ru5BL3 >Ru5CL3 indicating a general reduction in toxicity as the 
arene increases in size. The simplest p-cymene complex Ru1L3 gave an IC50 value of 4.90 µM, 
over 3-fold higher than Ru1L2 possessing the same arene unit. This observation implies the ligand 
has an effect on the activity, whether generated from inability to access the target molecule as 
effectively, or via behaviour in the cellular environment. The influence of the amide linker in L2 
compared to the secondary amine linker in L3 could be a potential influence over the strength of the 
σ-donor bond character of the phenanthroline, inducing an assumed increase in lability of the 
metal-chloride bond. Despite the moderate effect the different phenanthroline ligands have on 
cytotoxicity, the Ru5L3 series clearly shows a combination of L3 and increasing arene size to be 
detrimental to overall toxicity. 
The IC50 values of the ligand is also notable, L
3 in particular displays virtually a 6-fold increase in 
toxicity compared to its tubastatin A analogue (0.83 and 4.73 µM, respectively) along with almost 
two-fold increase in toxicity compared to the SAHA control.  
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Table 4.6 IC50 values for L3 containing complexes measured using the cell viability assay (96 h) against the 
human breast adenocarcinoma MCF7 cell lines. Entries are the mean value from three experiments. Control 
compounds include ligand L3 along with known HDAC inhibitors SAHA and tubastatin A.  
 
Compound R R1 IC50 [μM] 
Ru1L3 {Ru(p-cymene)} 4.90 ± 1.0 
Ru5AL3 Me Me 8.97 ± 2.5 
Ru5BL3 Me tBu 18.1 ± 5.4 
Ru5CL3 Me Ph 22.0 ± 3.4 
L3 - - 0.83 ± 0.4 
SAHA - - 1.46 ± 0.2 
Tubastatin A - - 4.73 ± 0.5 
Summary 
- For L2 complexes, 7 out of 10 complexes exhibited higher potency than the L2 ligand 
alone.  
- These 7 L2 complexes IC50 values were similar to the existing HDAC inhibitor control, 
SAHA. 
- The IC50 values for the L
3 complexes is proportional to the size of the arene capping group 
– the larger the arene, the poorer the toxicity. 
- Only complex Ru1L3 possessed comparable toxicity to the known HDAC6 selective 
inhibitor, tubastatin A. 
- Both the ligand and arene must be complementary to ensure a good level of toxicity.  
4.4 Active Transport 
Changing the temperature of cellular incubation can aid determination of the transport pathway of 
compounds into the cell. Active transport requires energy input to move ions and compounds 
across a cell membrane, often assisted by enzymes, therefore at low temperatures active transport 
does not occur. MCF7 cells were plated using the same method described for calculating 
cytotoxicity (Section 7.1.6.2) and exposed to complexes Ru1L2 and Ru1L3 at their known IC50 
concentrations (1.53 and 4.90 μM, respectively).4 Cells were allowed to incubate at room 
temperature for 1 h before being cooled to 4 °C for 24 h. After this time, cell number viability was 
98% compared to the initial loading, showing no substantial change in cell number compared to the 
control plate (incubated at 37 °C for the same time). No increase of cell number is expected at 4 °C 
as at this temperature cellular processes cannot occur. However, no reduction in cell viability of 
those incubated with the complexes suggests there is no accumulation of complexes in cells at this 
                                                     
4 Active transport assays were undertaken by R. Pal, Department of Chemistry, Durham University. 
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temperature. This observation suggests that cellular uptake for complexes Ru1L2 and Ru1L3 is 
most likely driven by active transport. It could be postulated from this result, that the cellular 
uptake pathway for the series of complexes is independent of ligand (L2 or L3), considering 
complexes Ru1L2 and Ru1L3 otherwise share the same arene-metal motif.  
4.5 Cellular Ruthenium Accumulation  
Depending on the localisation within the desired cellular target, quantitative uptake of a drug is 
often a necessity and can be a critical factor affecting the efficacy of drug candidates. In these 
cases, once inside the cell there are many processes and molecules that can influence therapeutic 
efficacy. However, given the intended target of these complexes, it is assumed that successful 
entrance and retention within the cell is required to produce cytotoxic effects. Having already 
established that active transport is the likely pathway across the cell membrane, it was deemed 
necessary to discern whether cellular accumulation of the complexes is a factor contributing to the 
varied toxicities observed in Section 4.3. 
To measure cellular accumulation of ruthenium, inductively coupled plasma mass spectrometry 
(ICP-MS) was the chosen technique employed to quantify the concentration of ruthenium in a 
sample after incubation.5 Human breast adenocarcinoma MCF7 cancer cells were treated with each 
complex at the equipotent concentration of their respective IC50 values and the cells then incubated 
at 37 °C for 96 h. The cells were then washed and the resulting material digested using 
concentrated nitric acid (0.6 mL) for a further 24 h at 37 °C. Samples were diluted 40-fold for ICP-
MS analysis and the values calculated from the total ruthenium accumulation after incubation, 
relative to the initially calculated IC50 values and are displayed as percentage accumulation in 
Table 4.7. The cellular accumulation is presented alongside the IC50 values to identify any trends 
from the resulting data.  
The complexes in series Ru4L2 and Ru5L2 present IC50 values relative to Ru accumulation. The 
extent of cellular accumulation in the three complexes with the highest IC50 values follows the 
order Ru5BL2>Ru4DL2>Ru4AL2, all displaying accumulation <10%. Complex Ru4AL2 shows an 
IC50 value of 32.5 μM; one order of magnitude higher than any other complex in series Ru4L
2 and 
Ru5L2. The poor toxicity is supported by the low level of Ru accumulation <1%. This result best 
represents the hypothesis that the lower the cellular accumulation of Ru, the less potent the 
complex, suggesting Ru4AL2 is either unstable in the essay medium or is not effectively taken up 
by MCF7 cells. This observation is consistent with the analogous, methyl substituted complex 
                                                     
5 Cellular ruthenium accumulation was measured by C. J. Ottley, Department of Earth Sciences, Durham 
University.  
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Ru5AL2 which displays a ~27-fold decrease in IC50 by comparison to Ru4AL
2 and a near identical 
factor increase in cellular accumulation.  
Table 4.7 Total cellular accumulation of ruthenium metal in human breast adenocarcinoma MCF7 cancer 
cell line determined using equipotent concentrations to IC50. aThe IC50 values are expressed as the 
concentration of each complex which causes 50% cancer cell growth inhibition. bTotal accumulation of Ru in 
MCF7 cells after 96 h of drug exposure at 37 °C relative to IC50 values. 
Compound R R1 IC50 
a[µM] Cellular accumulationb [%] 
Ru1L2 {Ru(p-cymene)}  1.5 ± 0.4 7.9 
Ru4AL2 H Me 32.5 ± 2.2 0.5 
Ru4BL2 H tBu 1.4 ± 0.2 18.9 
Ru4CL2 H Ph 1.7 ± 0.3 13.8 
Ru4DL2 H 2-thiophene 5.8 ± 1.5 3.5 
Ru5AL2 Me Me 1.2 ± 0.3 13.0 
Ru5BL2 Me tBu 5.2 ± 1.5 6.1 
Ru5CL2 Me Ph 2.1 ± 0.2 11.1 
Ru5DL2 Me 2-thiophene 1.7 ± 0.3 12.2 
Ru1L3 {Ru(p-cymene)}  4.9 ± 1.0 24.1 
Ru5AL3 Me Me 9.0 ± 2.5 18.7 
Ru5BL3 Me tBu 18 ± 5.4 43.9 
Ru5CL3 Me Ph 22 ± 3.4 48.6 
Broadly, the apparent trend implies that toxicity of complexes in series Ru4L2 and Ru5L2 is 
uptake-dependent. Based on these observations the R substituent of the arene in these complexes 
appears to have little effect on toxicity, instead the overall tuned lipophilicity of each complex 
appears to be an overarching contributing factor to cellular uptake and cytotoxicity. The outlier to 
this trend is the parent complex Ru1L2 which exhibits a low IC50 value (1.5 µM) in contrast to its 
moderate Ru cellular accumulation (7.9%). Compared to the other complexes containing L2, its 
main structural difference is the absence of the amide linker within the arene. While adding bulky, 
hydrophobic substituents can increase the lipophilic surfaces within a molecule improving uptake, 
the amide linker provides a polar functionality with the ability to form hydrogen bonds. Such van 
der Waal interactions could be a hinderance for the other complexes, resulting in off-target binding. 
This proposition could be rationalised through the observations of complex Ru1L2 which does not 
possess the amide linker and provides a marked level of toxicity relative to its accumulation, in 
comparison to the other complexes containing L2.  
By contrast, the complexes containing L3 appear to show an inverse relationship, with those 
complexes displaying the highest cellular Ru accumulation exhibiting the least potency. The 
cellular uptake trend for series Ru5L3 is evidently influenced by lipophilicity, with the more 
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lipophilic R1 substituents appearing to enhance cellular uptake. This effect is most pronounced for 
complexes Ru5BL3 and Ru5CL3 (containing t-butyl and phenyl R1 groups, respectively), which 
show >25% Ru accumulation than any other complex tested. One distinct structural difference 
between the L2 and L3 containing complexes is the chain linkers. The tolyl moiety of the L3 ligand 
provides a notable increase in lipophilic character compared to the L2 six carbon aliphatic chain. 
This particular character of the L3 ligand supplies an additional influence to cellular accumulation 
relative to the L2 complexes, effectively demonstrated by Ru5CL3 showing Ru uptake 4-fold 
higher than its Ru5CL2 analogue. Considering both cytotoxicity and cellular accumulation in 
tandem, alongside the potency of the ligand L3 alone, the size of the arene group in the Ru5L3 
series appears to have a negative impact on cytotoxicity once inside the cell. This could also be 
rationalised as off-target binding to hydrophobic intracellular proteins by the more lipophilic 
complexes.193  
While the varied uptake behaviour of the complexes discussed in this section appears to be largely 
governed by lipophilicity, it is imperative to consider the cellular uptake mechanisms potentially 
influencing the overall cytotoxicity or lack thereof. The extensive array of pathways associated 
with facilitated diffusion can be affected, not only by lipophilicity, but by the charged state of the 
complex or its binding affinity to transporter proteins such as the copper transporter CTR1.181 
Increase in drug efflux is frequently observed as a cause of reduced cytotoxicity. For example, 
overexpression of the plasma membrane glycoprotein P-pg has been noted in cisplatin resistant cell 
lines as the cause for increase drug efflux, with P-pg displaying favourable substrate recognition of 
highly lipophilic and cationic species.54  
Considering the structural features of the complexes here, a discrete membrane component could 
be a contributing factor towards the low levels of Ru accumulation as seen for complexes Ru4DL2 
and Ru5BL2, potentially mediated by high levels of drug efflux. Additional experimentation would 
be applicable to identify the likely cause of poor accumulation, given some structurally analogous 
complexes in these series show disparate levels of Ru uptake. Coadministration of these complexes 
with verapamil – a known P-pg inhibitor – could determine the extent drug efflux, with respect to 
P-pg, effects overall cellular accumulation. 
4.6 Isoform Selective HDAC Assays 
Having established in Chapter 3 that HDAC inhibition activity was the likely mechanism of action 
for complexes Ru1L2 and RhL2, the design of the Ru4L2, Ru5L2 and Ru5L3 series were intended 
to develop isoform selectivity between the metal complexes. Based upon the moderate to good 
cytotoxicity displayed by all the complexes synthesised in this chapter, it was therefore necessary 
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to investigate any apparent relationship between the diverse piano-stool complexes and HDAC 
isoform selectivity.  
Three distinct HDAC isoforms were chosen, one from each zinc-dependent class providing a range 
of possible binding topographies: HDAC1 (class I), HDAC4 (class IIa) and HDAC6 (class IIb). 
Purified human recombinant enzymes were used from commercially available kits (Section 7.1.8). 
Appropriate dilutions of assay components were made using assay buffer and stored on ice. The 
known pan-HDAC inhibitors SAHA and TSA were tested alongside complexes listed in Table 4.5, 
L2, L3 and tubastatin A (a HDAC6 selective inhibitor). Each compound was dosed at 1 and 0.1 μM 
concentrations into wells containing master mixture comprising HDAC-specific acetylated 
substrate, BSA (1 mg/mL) and buffer. Upon addition of HDAC enzyme, the plate was incubated at 
37 °C for 30 minutes. After this time, a developer was added and the plate incubated at room 
temperature for a further 15 minutes. The plate was excited at 360 nm and detection of emission 
was measured at 460 nm. Similar to the previous HDAC enzyme assay protocol described (Chapter 
3), as a positive control, the assay was also run in the absence of any inhibitor. Results were 
calculated as a percentage of HDAC activity, relative to the positive control and are displayed in 
Figure 4.4 for each individual HDAC isoform. All assays and controls were measured in triplicate 
and mean values are reported, along with standard errors.  
Generally, all the compounds tested - with the exception of tubastatin A – reduced HDAC1 activity 
to <25% at 1 μM dose of inhibitor (Figure 4.4A) and of all the compounds tested, the parent 
complexes Ru1L2 and RhL2 exhibited the highest level of inhibition for HDAC1. The new series 
of complexes containing L2 (from Ru4AL2 to Ru5DL2) show similar or reduced HDAC1 activity 
at the more dilute 0.1 μM concentration when compared to the ligand L2 alone. By contrast, as 
expected the L3 containing complexes show the lowest levels of inhibition at the more dilute 
concentration, mirrored by the L3 ligand and tubastatin A. Examples in the literature imply 
selectivity of class I HDACs is often observed in compounds containing the 2-aminoanilide zinc-
binding motif with additional substituents to fit in a foot-pocket beside the zinc active-site.123,125,142 
While this functionality was not exploited within these complexes, the intention of modifying the 
arene unit was instead intended to exploit interactions on the enzyme surface that may be difficult 
to access by a purely organic molecule.  




Figure 4.4 Compounds tested at 1 and 0.1 μM concentrations against (A) HDAC1, (B) HDAC4 and (C) 
HDAC6. Values are reported as an average of three experiments. (*) <1% HDAC enzyme activity.  
In the case of complexes Ru5CL2 and Ru5DL2, both incorporate the same L2 ligand and display the 
highest overall inhibition of the new complex series for HDAC1. These complexes contain the R1 
substituents phenyl and thiophene, which are both aromatic and could result in π-stacking 
interactions with phenylalanine, tryptophan or tyrosine amino acid residues enhancing surface 
interactions and improving activity. Free rotation of the arene unit should also allow this motif to 
establish the most thermodynamically favourable conformation once the hydroxamic acid is bound 
to the zinc active-site. This could account for many of the other complexes displaying moderate 
inhibition activity towards HDAC1. However, it still remains that the parent ruthenium complex 
Ru1L2 shows the best inhibition for HDAC1 compared to the other complexes, possessing only 
alkyl substituents. The isopropyl groups of the p-cymene could be accommodated into a small 
hydrophobic region on the enzyme surface, while additional substituents could hinder HDAC1 
binding and may therefore not be accommodated as easily. 
The class IIa HDAC enzyme results offer the most evident trend out of the three classes tested 
(Figure 4.4B). All metal complexes containing L2 show negligible inhibition of HDAC4 at the 
higher 1 μM concentration. A comparable degree of HDAC4 activity is observed after dosing with 
the control compound SAHA along with L2, implying the six-carbon alkyl chain linker is not a 
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favourable structural trait of HDAC4 inhibitors. A distinct feature of the HDAC4 selective inhibitor 
MRK19 (Section 1.3.4.3, IC50 = 0.012 μM) is the presence of an alkoxyamide moiety with a five-
carbon chain linker connecting the hydroxamic acid binding group. The nitrogen of the MRK19 
alkoxyamide forms a hydrogen bond with the carboxylate group of Asp115 at the channel rim. 
While this interaction cannot be achieved by the L2 complexes and other analogous compounds, L3, 
tubastatin A and the Ru5L3 series possess a more accessible amine which could potentially give 
rise to a similar interaction as that observed for MRK19. The implication of a more favourable 
interaction by the L3 ligand is reflected by the Ru5L3 series, L3 and analogous tubastatin A (only 
differing by capping group) all displaying moderate inhibitory activity towards HDAC4 at 1 μM 
concentration. Although this is a rational justification for the improved inhibition activity towards 
HDAC4 of the L3 series relative to the L2 series, other factors such as orientation, kinetics and zinc 
binding group could also contribute.  
 
Finally, the screening of compounds against the class IIb enzyme HDAC6 showed comparable 
results to those for HDAC1, with all the compounds tested exhibiting inhibitory activity towards 
HDAC6 (Figure 4.4C). The organic control compounds all showed less than 50% HDAC enzyme 
activity at the lower concentration of 0.1 μM with L2 displaying similar inhibition to SAHA. 
Broadly, the complexes containing L3 show equivalent inhibitory profiles with complex Ru1L3 
reducing HDAC6 activity the most down to 4% at the 1 μM dose concentration. This trend was 
anticipated due to the presence of the bulkier tolyl linker in L3, a characteristic shared with 
tubastatin A which can accommodate the wider and shallower pocket of HDAC6 more 
effectively.140 Complexes Ru5CL2 and Ru5DL2 of the new series exhibit the highest level of 
inhibition at both concentrations tested, near equivalent to each other. The presence of the bulkier 
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R1 group on the arene could be a contributing factor to increased interactions and therefore 
enhanced inhibition. While the presence of the L3 ligand in the RuL3 series is clearly responsible 
for the increase in inhibition towards HDAC6 compared to HDAC1, many of the complexes and 
ligands display good inhibition towards both HDAC1 and HDAC6 enzymes. It could be argued 
that the calculated inhibition at two concentrations is not an adequate measurement to distinguish 
any selectivity clearly, primarily due to similar results in this concentration range between 
analogous complexes. This factor is crucial when taking into consideration many of the compounds 
tested inhibit enzyme activity to a degree more than 50% at 0.1 μM concentration and therefore 
require more scrutiny to determine whether any selectivity exists at lower concentrations. For this 
reason, a selection of complexes were chosen based upon their cytotoxicity and HDAC inhibitory 
profile and were subsequently tested against HDACs 1 and 6 to measure their IC50 values and 
identify any specificity towards one particular enzyme.  
4.6.1 HDAC1 & HDAC6 – IC50 Results 
Four complexes were chosen from the initial screening that possessed structural similarities to 
determine which feature or combination is likely to generate selectivity. The interchangeable 
features of the complexes comprise the incorporation of either L2 or L3 combined with either a p-
cymene or 5C arene, therefore including the parent compound Ru1L2. Control compounds SAHA, 
the known pan-HDAC inhibitor expected to display no selectivity, tubastatin A shown to possess 
selectivity for HDAC6140 and the ligands L2 and L3 were test alongside the complexes. Each 
compound was tested in the concentration range 10 – 0.004 µM to calculate the IC50 values for 
HDAC1 and HDAC6 using the same method described in Section 4.5 and are displayed in Table 
4.8. An example dose response curve is shown in Figure 4.5. 
Table 4.8 IC50 values measured using commercially available kit (Section 7.1.8 BPS Bioscience) against 
HDAC1 and HDAC6 and are reported as the mean value of three experiments. Selectivity of HDAC6 over 
HDAC1 is displayed along with IC50 values against MCF7 cells*. 








SAHA - - 0.03 ± 0.004  0.012 ± 0.001 2.5 1.46 ± 0.2 
Tubstatin A - - 1.72 ± 0.1 0.04 ± 0.006 43 4.73 ± 0.5 
L2 - - 0.06 ± 0.05 0.03 ± 0.02 2.0 2.99 ±0.6 
L3 - - 0.36 ± 0.03 0.15 ± 0.02 2.4 0.83 ± 0.4 
Ru1L2 p-cymene 0.24 ± 0.03 0.04 ± 0.002 6.0 1.53 ± 0.4 
Ru5CL2 Me Ph 0.08 ± 0.01 0.03 ± 0.006 2.7 2.1 ± 0.2 
Ru1L3 p-cymene 0.24 ± 0.03 0.06 ± 0.001 4.0 4.90 ± 1.0 
Ru5CL3 Me Ph 0.35 ± 0.05 0.08 ± 0.02 4.4 22.0 ±3.4  
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Initially it is apparent that all the compounds tested were very active in inhibiting both enzymes, 
hence a selectivity factor was calculated to establish the degree of affinity for HDAC6 over 
HDAC1. SAHA, L2 and L3 all display a similar degree of selectivity together with comparable 
cytotoxicity values. Of these examples each inhibits HDAC1 and HDAC6 activity to the same 
order of magnitude. The poor enzyme specificity observed is reflected in the lower cytotoxicity 
IC50 values, likely to arise from such non-selective binding. By comparison, tubastatin A displays 
the highest level of selectivity, 43-fold selective for HDAC6 over HDAC1 considered to possess 
superior selective binding due to the combination of the tricyclic capping group enhancing 
interactions with the enzyme channel rim.140 Additionally, the tolyl linker, a feature present in both 
tubastatin A and L3 is linked to preferential binding to HDAC6 due to the unusual monodentate 
binding mode accessible by this motif disfavoured in the more sterically constricted active site of 
HDAC1.200 It is evidenced by the low level of selectivity of L3 that the phenanthroline capping 
group in combination with the tolyl linker is not sufficient to create the level of selectivity boasted 
by tubastatin A.  
 
Figure 4.5 Dose response curve of complex Ru1L3 against enzyme HDAC6 to calculate the IC50 value. 
In contrast to the purely organic systems, with the exception of the control compound tubastatin A, 
the metal complexes exhibited more desirable results. The presence of the metal-arene appears to 
improve overall affinity and yield better selectivity towards HDAC6, with the exception of 
complex Ru5CL2. For the complexes containing L2, Ru1L2 displays the highest selectivity factor 
of 6.0, triple that of the ligand alone, while Ru5CL2 fails to demonstrate this level of selectivity. 
The arene moiety of Ru5CL2 contains the bulkier phenyl group as well as an amide linker. Both of 
these functionalities could furnish interactions with the HDAC1 surface that the p-cymene of 
Ru1L2 cannot, but unfortunately reduces the overall selectivity of complex Ru5CL2.  
A significant result is the complexes containing L3 (Ru1L3 and Ru5CL3) show a similar degree of 
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affinity towards HDAC6. Nevertheless, it could be postulated that the more open surface of 
HDAC6 affords a more tolerant structure to accommodate the metal-arene capping group. This 
suggestion is supported by the generally low IC50 values for HDAC6 by all the complexes tested. It 
is also possible that selectivity of complexes Ru1L3 and Ru5CL3 towards HDAC6 could develop 
from the orientation of the arene bound to the metal once the complex is accommodated into the 
enzyme channel. The tolyl linker has been shown to require a bent conformation, which would 
directly influence the location of the arene, further enhancing interactions with the enzyme surface. 
The equivalent selectivity of Ru1L3 and Ru5CL3 for HDAC6, is not reflected in their cytotoxicity. 
Consequently, poor toxicity of Ru5CL3 compared to Ru1L3 is presumably linked to reduced 
cellular uptake or off target binding. It could be assumed from these results that the L3 ligand 
incorporation into complexes Ru1L3 and Ru5CL3 provides a degree of selectivity compared to L2 
and that in combination with the arene motif is likely to attribute to the overall selectivity. To 
support these suggestions, investigation of computational models would provide a valuable insight 
into potential binding modes and surface interactions. 
4.6.2 HDAC6 Catalytic Domain Assay 
The pronounced inhibition and consequent interest in HDAC6 selectivity in the previous 
experiment raised a subsidiary query. HDAC6 is distinct of all the zinc-dependent isozymes by 
virtue of it containing two catalytic domains, CD1 and CD2. One of these domains (CD2) is 
documented to catalyse the deacetylation of a variety of substrates including α-tubulin,136 with CD2 
inhibition resulting in microtubule hyperacetylation leading to cell cycle arrest and apoptosis. 
However, CD1 is also known to catalyse the deacetylation of acetyl-lysine substrates201 and for this 
reason it was deemed necessary to determine the activity of the complexes synthesised here against 
CD1 and CD2.  
The synthesis of individual HDAC6 catalytic domains was achieved by expression of zHDAC6 
(danio rerio – zebrafish; a homologous enzyme of human HDAC6) through domain cloning.6 Each 
domain was sub-cloned into the modified pSAT1-LIC plasmid and transformed into E. coli 
ER2566 and BL21(DE3) competent cells using heat shock treatment. Single colonies were grown 
to O.D.600 of 0.4-0.5 followed by induction of protein expression using isopropyl β-D-1-
thiogalactopyranoside (IPTG). The cells were then harvested, lysed to break down into cellular 
components, washed and the desired proteins purified using a Nickel column.  
Catalytic activity of the individual domains was established using an existing literature procedure 
to determine the appropriate concentrations of protein required to produce detectable and 
                                                     
6 Domain cloning and catalytic domain assays were undertaken by A. Kingdon and T. R. Blower in the 
Department of Biosciences, Durham University. 
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comparable activity.201 An activity assay was undertaken (Section 7.1.9) to confirm the successful 
synthesis of the domains and the results showed zCD2 observed 18-fold deacetylase activity for the 
commercially available substrate compared to zCD1; consistent with the literature. The inhibitory 
assay therefore dosed the proteins in concentrations of 0.75 µM and 0.15 µM for zCD1 and zCD2, 
respectively. Complex Ru1L3 was chosen due to its incorporation of the tolyl linker, demonstrated 
to improve overall selectivity towards HDAC6. The pan-HDAC inhibitor SAHA was used as a 
control compound. Similar to all the assays undertaken previously, a positive control in the absence 
of inhibitor was run alongside and the inhibition assay was undertaken using the method previously 
described in Section 4.4.1. The results were calculated as a percentage of catalytic activity for each 
domain, relative to the positive control and are displayed in Figure 4.6.  
 
Figure 4.6 Measure of catalytic activity of HDAC6 cloned catalytic domains zCD1 and zCD2 after 
incubation with complex Ru1L3 and SAHA control at 1 and 0.1 μM concentrations.  
At 1 µM dose concentration, the control compound SAHA showed significant inhibition of domain 
catalytic activity for both zCD1 and zCD2, with inhibition 3-fold higher for zCD2. Having 
demonstrated the substrate used in this particular assay is deacetylated by both catalytic domains, 
an additive effect of multiple domain inhibitory activity of SAHA could account for its potent 
inhibitory activity observed towards the recombinant HDAC6 enzyme (Section 4.5.2, IC50 value = 
0.012 µM). This result is consistent with the pan-HDAC inhibitor character of SAHA, which could 
additionally support the high cytotoxicity exhibited in vitro and presents more evidence for non-
specific off-target binding.  
By contrast, Ru1L3 displayed significant inhibition of zCD2 catalytic activity, with <25% activity 
observed at the lower 0.1 µM concentration. Unlike SAHA, Ru1L3 showed no relative inhibitory 
activity towards zCD1, displaying >30-fold selectivity to zCD2 over zCD1 at 1 µM. This result is 
in agreement with the design of complex Ru1L3, improving selectivity not only between HDAC 
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in this assay also promotes the target specificity desirable for drug candidates, inherently improving 
the efficacy of Ru1L3 as a selective HDAC inhibitor. Previous studies have dictated the degree of 
inhibitory activity could be partially attributed to a combination of relative binding affinities to the 
individual catalytic domains, as well as the disparate concentrations of the proteins tested in such 
an assay.201 In the case of Ru1L3 it could be assumed that these factors are unlikely contributors 
due to its effectively tuned design providing the selectivity observed for zCD2.  
4.7 Enzyme Modelling 
Although crystal structure growth of complex Ru1L3 in zHDAC6-CD2 was not successful, protein-
ligand computational docking was attempted to mimic potential interactions of the complex with 
the protein active-site. Structural optimisation of complex Ru1L3 was achieved using DFT 
calculations and assessed within Gaussian to confirm the lowest energy conformation of the 
complex.7 To construct an accurate depiction of a piano-stool complex, a ghost atom (GA) had to 
be employed to allow free rotation about the metal-arene bond. The GA was assigned in the centre 
of the arene as an atom with no nuclear charge or electrons, forming a bond to the metal centre and 
to each carbon in the bound arene. Bond distances and angles were surveyed to establish any 
inaccuracies within the arene when building Ru1L3 using this method. Nevertheless, the angles and 
distances were all within 0.02 Å/° of the initial fixed arene providing six bonds to the ruthenium 
metal centre.  
HDAC6-CD2 homology models were established using an existing crystal structure of 
zHDAC6-CD2 from danio rerio (zebrafish) (PDB: 5WGK) and the ligand HPB 
(N-hydroxy-4-[(N(2-hydroxyethyl)-2-phenylacetamido)methyl)benzamide) crystallised within the 
catalytic domain was removed and docking of complex Ru1L3 was undertaken. Genetic 
Optimisation of Ligand Docking (GOLD) was implemented as the chosen docking programme, an 
approach shown to be favoured in the prediction of reliable docking positions (relative to the 
crystal structure) for organometallic complexes.202  
 
                                                     
7 DFT calculations were undertaken by A. Kingdon in the Department of Chemistry, Durham University. 
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The torsional angles of complex Ru1L3 were modified by GOLD to present the lowest energy 
binding conformation in the protein’s active site. Possible conformations were fixed within the 
parameter of 10 Å to the zinc catalytic site (the length of the active-site channel) to ensure binding 
modes were predicted between the complex and the vacant zinc coordination sites. In this instance, 
ChemScore was employed as the fitness function which considers the free energy of binding (metal 
co-ordination, hydrophobic interactions, hydrogen-bond formation and rotatable-bond freezing), 
along with steric clashes and conformational restraints. The top ten docking conformations were 
ranked using ChemScore and assessed as potential binding modes. The principal factor used to 
elucidate the most cogent solutions was interaction between the hydroxamic acid and the zinc 
catalytic site; a prevalent binding mode of HDAC inhibitors due to its strong chelating ability to 
zinc. The five solutions with the highest ChemScore provided such rational binding outcomes.  
The five binding modes were subsequently evaluated for their spacial accommodation of the 
enzyme active-site and surface, alongside interactions with additional amino acid residues to justify 
potential binding affinity. The solution poses were scrutinised relative to each other and the 
original protein-ligand crystal structure. A commonality shared by the five solutions was the 
placement of the planar phenanthroline moiety within the complex fitting flat to the wide pocket 
rim and the chloride ligand facing outwards. In Figure 4.7A, two solutions are superimposed (one 
yellow, one purple) to show the diverse conformations in relation to the hydrophobic surface and 
clearly illustrates the arene rotation movement as a variable to avoid conflicting interactions. While 
both poses offer minimal steric clash of the arene to the protein surface, upon closer inspection the 
hydroxamic acid in the yellow pose did not demonstrate the most desirable binding mode of the top 
solutions. By contrast, the solution displayed in purple provided the most rational prediction of 
Ru1L3, maximising amino acid residue interactions as well as incorporating a realistic zinc 
coordination. For this reason, the pose displayed in purple was chosen for further examination and 
will therefore be the focus of discussion here in. 




Figure 4.7 GOLD protein docking (PDB: 5WGK) of complex Ru1L3 in zHDAC6-CD2. (A) Enzyme surface 
binding of docked Ru1L3 in two rational binding modes; (B) Mesh view of preferred Ru1L3 (purple) 
showing potential hydrophobic area of interactions. 
The docking (Figure 4.7B) is shown to illustrate the area accommodated by the large piano-stool 
capping group into the wider HDAC6 channel rim. The surface likely provides hydrophobic 
interactions from residues Pro464 and Leu712 to the p-cymene arene in this docking solution. This 
surface-mesh visualisation sufficiently presents the additional space available beside complex 
Ru1L3, exploited by existing HDAC6-selective inhibitor tubastatin A fitting closer to the surface 
by π-π stacking of aromatic residues Phe680, His500, His611 and Phe620. It could be speculated 
that surrounding residues adjacent to the p-cymene arene of Ru1L3, such as Asp460 situated 5.5 Å 
from the arene isopropyl group could be accessible for interactions with the alternate amide linker 
or thiophene contained within the arene motif of complexes within the series.  
Closer inspection of the favoured pose provided evidence of multiple interactions between the 
phenanthroline capping group and tolyl linker with the hydrophobic channel to the active-site. 
These residues include Phe583, Phe642, Phe643, Leu712, Gly582 and Tyr745. The specific 
arrangement of Ru1L3 in the channel and its proximity to residues Phe583 and Phe643 suggests 
aromatic π-π stacking interactions are observed with the L3 tolyl linker, sandwiched comfortably 
between the two residues. This interaction is a feature shared with the HBP ligand of the original 
protein-ligand crystallisation (Figure 4.8C). Another notable interaction is observed through the L3 
secondary amine which donates a hydrogen bond to Ser531 located at the channel edge (NH-O 
distance = 3.4 Å), constituting an energetically significant interaction.203  
Binding in the catalytic site was first examined with the HPB ligand in mind, due to the shared 
phenylhydroxamate character of Ru1L3. HPB reveals a monodentate coordination with the zinc 
atom through its N-Oˉ group (Zn2+-O distance 1.9 Å) - a signature often observed by 
phenylhydroxamate HDAC6 inhibitors with bulky capping group substituents200 with a water 
molecule in the other vacant coordination site. This unusual binding motif was applied to Ru1L3 
(Figure 4.8B) which provided a bond through the N-Oˉ group to the zinc (Zn2+-O distance = 2.2 
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Å). The donation of a hydrogen bond from the water molecule to the hydroxamate C=O group was 
2.7 Å. This coordination fulfils the trigonal bipyramidal geometry often observed at the zinc active-
site.204 Nevertheless, analysis of the superimposed inhibitors in the enzyme active site (Figure 
4.8C) showed that while the tolyl linker fits the channel in a comparable manner, the angle of 
binding to the zinc is distinct to each ligand with the hydroxamic acid inverted. The position of the 
hydroxamic acid based upon this docking solution for Ru1L3 provides an alternative binding mode 
in the canonical bidentate form. Bonding of N-Oˉ and C=O coordinate the zinc at distances of 2.2 
and 2.4 Å, respectively. Additional interactions are observed through the hydroxamate NH 
donating a hydrogen bond to the water (NH-O distance = 1.8 Å), along with an interaction between 
the hydroxamate NH with the Tyr745 residue in the active site (NH-O distance 2.4 Å). This 
binding mode offers the thermodynamically favoured chelation of the hydroxamic acid to the zinc 
ion in spite of the bulky metal-arene capping group. 
 
Figure 4.8 GOLD protein docking (PDB: 5WGK) of complex Ru1L3 in zHDAC6-CD2. (A) Stick view of 
Ru1L3 with amino acid residues labelled (zinc = orange); (B) Catalytic site showing bonding of amino acids 
to zinc (orange) and complex Ru1L3 (purple), along with one water molecule; (C) Ru1L3 superimposed onto 
HBP (tan) crystallised in zHDAC6-CD2. Hydrogens of inhibitors are omitted for clarity. 
Even though the modelling described here offers an insight into the binding mode of Ru1L3, there 
were restrictions encountered through GOLD that should be taken into account. While the 
phenanthroline moiety is fixed as a planar aromatic structure and its accommodation into the 
active-site channel could be relatively accurate, GOLD did not allow the input parameter of 
assigning a coordination number to the zinc active site. This particular restriction forced the most 
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favourable spacial accommodation but perhaps not the most ideal coordination. By assigning a 
coordination number to the zinc, this could force accommodation of the capping group into a very 
different pose. In addition, the presence of the water molecule in the catalytic site is taken directly 
from the protein-ligand crystal structure with HPB. Due to the flipped conformation of the 
hydroxamic acid in Ru1L3, the water molecule may be forced into a different position within the 
catalytic site when the inhibitor is bound or may still act as a coordinating solvent.  
Analysis of the modelled solutions of protein-ligand binding for complex Ru1L3 gave an overall 
insight into the potential binding modes and interactions with the enzyme surface. The most 
rational solution presented a possible two binding modes that can be speculated between based on 
comparison with analogous inhibitors and the most chemically sound structure. Although models 
of such pseudo-octahedral complexes provide potentially contentious results due to restricted 
movement of the metal-arene capping group, one factor that remains cohesive is the tolyl linker 
enhancing specificity towards HDAC6. Through this model the specific π-stacking interactions 
were observed that promote the accommodation of a bulkier aromatic linker into the active-site 
channel. This is consistent with the HDAC assays undertaken in previous sections which showed 
promising selectivity of complexes containing L3. Further exploration into docking L2 containing 
complexes would be valuable to compare and contrast the available interactions achieved by the 
flexibility of the aliphatic chain linker. 
4.8 Conclusions 
Fitting with the aims of the project, two complex series were designed and successfully synthesised 
based upon the parent complex Ru1L2 and purified by preparative reverse-phase HPLC. 
Modifications were made to the arene capping group (Ru4 and Ru5) and the chain linker of the 
bidentate ligand (L3 from L2) to enhance selectivity between the zinc-dependent HDAC isoforms 
by improving drug-target interactions with the enzyme pocket and surface. Each series presented its 
own trends from the data collected. 
Due to the limited availability of cell lines, the human breast cancer MCF7 cell line was tested in 
place of the lung carcinoma H460 seen in Chapter 3. The parent complex Ru1L2 displayed a 
13-fold increase in potency towards the MCF7 cells, implying a preferential toxicity profile 
towards this cell line over H460. For the complexes containing L2, 7 out of 10 were more toxic than 
the organic ligand alone (IC50 = 2.99 µM), with complex Ru5AL
2 demonstrating the highest 
potency at 1.24 µM. The cytotoxicity for complexes Ru4L2 (R = H) followed the order 
Ru4BL2≈Ru4CL2>Ru4DL2>Ru4AL2 (R1 = tBu≈>Ph>thiophene>Me) implying within these 
complexes the increase in toxicity is intrinsically linked to lipophilicity of the arene. By contrast, 
this trend was much less pronounced for the Ru5L2 series (R = Me), with complexes Ru5AL2, 
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Ru5CL2 and Ru5DL2 (R1 = Me, Ph and thiophene) all exhibiting potency in a comparable range 
(IC50 values 1.2 - 2.1 µM), however alike to the potency exhibited by the clinically approved drug 
SAHA (IC50 = 1.42 µM). Complex Ru5BL
2 also displayed a low level of potency in the same order 
of magnitude (IC50 = 5.2 µM) suggesting the presence of the para-Me substituent could have an 
influence on both stability and the overall lipophilic character. Moreover, the complexes containing 
L3 consistently displayed lower cytotoxicity than L3 alone (0.83 µM), with activity decreasing as 
the arene increases in size (Ru1L3>Ru5AL3>Ru5BL3>Ru5CL3).  
Based upon the different toxicity profiles of the complex series containing either L2 or L3, the 
cellular uptake pathways were investigated. Both complexes Ru1L2 and Ru1L3 showed no change 
in MCF7 cell viability, after incubation at 4 °C with the complexes at concentrations equipotent to 
their IC50 values. This observation suggests the cellular uptake for these complexes and the 
pathway across the cell membrane is likely driven by active transport. Further analysis into Ru 
accumulation utilised ICP-MS to provide a quantitative measurement of complex entering the cells. 
For all complexes incorporating L2, cytotoxicity was higher for those complexes demonstrating 
higher levels of Ru accumulation. This evidence suggests that the cytotoxicity of the L2 series is 
uptake-dependent. In spite of this apparent trend, the level of Ru accumulation relative to the IC50 
dose concentration were all fairly low (<20%). The degree of cytotoxicity in the L3 series displayed 
the inverse relationship where by accumulation increased with increasing lipophilicity, while the 
most toxic complex remains Ru1L3 with the smallest arene capping group (p-cymene). It is 
therefore assumed that the more lipophilic complexes in the L3 series are likely participating in off-
target binding and are unable to associate with their desired target.  
Having established HDAC inhibition to be the most rational mechanism of action for complex 
Ru1L2, enzyme class selectivity was the successive area of attention in this chapter. All complexes 
were screened against HDAC1, HDAC4 and HDAC6 (Class I, IIa and IIb, respectively), to explore 
the potential interactions of the complexes with individual HDAC enzyme topology. Complexes 
containing L3 exhibited moderate inhibition activity at 1 µM concentration towards HDAC4, while 
L2 complexes displayed negligible inhibition against this isoform. Due to the similarly notable 
inhibitory profiles of the complexes against HDAC1 and HDAC6, specific complexes were chosen 
to provide more advanced inhibition data than two concentration points. Calculated IC50 values 
showed complexes Ru1L2, Ru5CL2, Ru1L3 and Ru5CL3 all presented improved selectivity 
compared to their organic counterparts L2 and L3. The parent complex Ru1L2 displayed the highest 
degree of selectivity towards HDAC6 with a selectivity factor of 6.0, 3-fold more selective than the 
L2 control. This particular observation implies the enhanced selectivity is likely due to the presence 
of the metal-arene capping group, which cannot be as well accommodated at the enzyme pocket 
rim of HDAC1. As anticipated, the complexes containing L3 (Ru1L3 and Ru5CL3) show a higher 
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degree of selectivity than the ligand L3 alone. Complex Ru1L3 also displayed marked selectivity 
for the CD2 domain of HDAC6 compared to the SAHA control. In addition, enzyme modelling of 
complex Ru1L3 in the homologous enzyme zHDAC6-CD2 provided a rational binding pose 
comprising chelation of the hydroxamic acid and π-π stacking interactions with Phe583 and Phe643 
residues of the tolyl linker in the enzyme channel. The selectivity of the L3 containing complexes 
can be partially justified by this specific interaction. 
Taken together, the results in this chapter show that the introduction of metal complexes to known 
HDAC enzyme inhibitor motifs can produce a positive effect on both enzyme inhibition and 
cytotoxicity. Furthermore, changes to the metal coordination sphere can lead to modulation of the 
activity of the complex. While the observed differences in activity within the series presented 
herein were moderate, the principle of tuning activity through structural variation is clearly 
displayed. This bodes well for the future of metal complexes as enzyme inhibitors.  
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5. Hypoxia-Activated HDAC Inhibitors 
5.1 Introduction 
The importance of selectivity has already been established when designing a drug candidate, and 
has been exhibited by previously discussed examples such as those in Chapter 4. In addition to 
targeting a specific isoform within an enzyme family, the hypoxic conditions often associated with 
tumours can be exploited by prodrugs; activated in the reducing environment. Such drug design 
allows an inert species to produce toxicity within the targeted environment and can help alleviate 
unwanted toxicity towards healthy cells.  
  
Two new complexes were synthesised (Ru1L4 and RhL4) from the potent parent complexes Ru1L2 
and RhL2. The complexes were modified by incorporating the p-nitrobenzyl moiety as a protecting 
group for the hydroxamic acid using only two simple synthetic steps. The p-nitrobenzyl group had 
been previously described as a functionality, reducible under hypoxic conditions. NMR studies 
were employed in an attempt to observe the reduction products of the p-nitrobenzyl group 
alongside cytotoxicity under both normoxia and hypoxia conditions. The removal of the protecting 
group was predicted to undergo the transformation displayed in Figure 5.1 to produce the active 
species.  
 
Figure 5.1 Proposed mechanism of p-nitrobenzyl group reduction.  
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5.2 Synthetic Aspects 
To synthesise the hypoxia-activated ligand, 1,10-phenanthrolin-5-amine and methyl 8-chloro-8-
oxooctanoate were reacted in DMF using a catalytic quantity of DMAP (Scheme 5.1i). After 16 h 
the DMF was removed using vacuum distillation and the resulting red oil was suspended in 
MeOH:THF (1:1). Over the course of 3 days, 2.5 equivalents of aqueous LiOH were added 
(Scheme 5.1ii). After this time, complete ester hydrolysis was observed, confirmed by the presence 
of a broad singlet at 12.0 ppm in the 1H-NMR spectrum, indicative of a carboxylic acid peak for 
compound 28, along with the loss of the OMe peak at 3.90 ppm.  
 
Scheme 5.1 
The carboxylic acid derivative (28) was then coupled to commercially available 
O-(4-nitrobenzyl)hydroxylamine hydrochloride, using the coupling agent HATU184,185 (Scheme 
5.2i). The reaction mixture was subsequently poured into saturated NaCl solution and the resulting 
precipitate filtered and washed with water to afford the protected ligand, L4. Complexation was 
undertaken by dissolving L4 with 0.5 equivalents of selected commercially available 
dichloro{M(R)}dimers (Scheme 5.2ii) in MeOH, and heating at 40 °C for 16 h. The complexes 
were recrystallised from diethyl ether in relatively low yields (Table 5.1). 





Table 5.1 Yields and structural motifs of complexes containing L4.  
Complex {M(R)} Yield 
Ru1L4 {Ru(p-cymene)} 34 
RhL4 {Rh(Cp*)} 22 
5.3 NMR Studies 
To investigate the intrinsic properties of the redox-active p-nitrobenzyl protecting group within the 
compounds synthesised in this chapter, NMR studies were employed to monitor any structural 
changes, and help identify any reduction intermediates under conditions aimed to mimic regions of 
hypoxia. While the use of the redox-active p-nitrobenzyl protecting group was inspired from work 
conducted by Conway et al. detailed in Section 1.4,158 it can be hypothesised that protection of the 
hydroxamic acid could provide different reduction products to the primary alcohol protection, 
previously described. It was therefore deemed important to investigate how effective this particular 
protecting group would be for the hydroxamic acid moiety.  
In an attempt to discern the likely reduction products of the hydroxamic acid protected compounds, 
an NMR experiment was carried out. Owing to the low yields of the compounds synthesised in 
Section 5.2, the p-nitrobenzyl protected SAHA (P-SAHA)8 was used in this experiment. P-SAHA 
was assumed to reveal similar reduction products to the compounds synthesised in Section 5.2, due 
to structural similarities.  
                                                     
8 P-SAHA was synthesised by R. G. I. Thorpe. 




To perform the reduction assay, P-SAHA (0.005 g, 0.013 mmol) was initially charged to a 5 mL 
vial and dissolved in deuterated DMSO (2 mL). To this solution, aqueous ammonium chloride (20 
µL, 10% wt/vol, D2O) was added along with 0.5 µL of dioxane as a 1H-NMR reference. An aliquot 
was removed and subjected to 1H-NMR to serve as T=0 (Figure 5.2). The reduction reaction was 
initiated by addition of zinc (0.002 g, 0.030 mmol) and monitored at intervals (Figure 5.2), with 
subsequent additions of zinc and heating. This method of reduction utilises single electron transfer 
from the zinc metal under slightly acidic conditions from the use of ammonium chloride solution, 
which has been shown to promote the formation of a hydroxylamine intermediate.205,206 NMR 
experiments were repeated and the principal results shown in Figure 5.2.  
 
Figure 5.2 1H-NMR spectra (DMSO-d6, 298 K, 400 MHz) of P-SAHA at increasing time intervals and 
varied conditions. T=0 (NH4Cl, dioxane); T=1 (2 mg Zn, 10 min); T=2 (16 h); T=3 (40 °C, 2 h); T=4 (1 mg 
Zn, 10 min); T=5 (2 h); T=6 (16 h). 
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Upon addition of the zinc a new species was immediately observed (T=1, shown by ◊). Reduction 
of the nitro group provided an upfield shift of the benzyl protecting group protons as denoted by ◊ 
and the CH2 group (~4.6 ppm). This shift is anticipated given the loss of a highly electron 
withdrawing group such as a nitro-moiety. After 16 h, equilibrium was reached and the sample then 
subjected to heating at 40 °C for 2 h and the spectrum measured (T=3). No apparent change was 
observed. Addition of more zinc (T=4) showed the complete loss of the starting material p-
nitrobenzyl protons and over time (T=5, T=6) the formation of another species with similar 
chemical shift (*) to the initial reduction product (◊) was observed.    
 
Figure 5.3 1H-NMR proposed reduction products.  
This set of spectra clearly indicates the formation of two new species under these reaction 
conditions. Reduction of the nitro group increases the amount of water in the sample, reducing the 
ability to observe labile protons in the spectra such as the assumed products of this reaction. 
However, it could be rationalised that the 0.6 ppm upfield shift suggests the benzyl group has 
become more electron rich which could be accountable by the presence of either an hydroxylamine 
(◊) or an amine (*) functionality in place of the nitro group, illustrated in Figure 5.3. Conway used 
excess quantities of zinc to reduce the nitro group fully at ambient temperature over the course of 
16 h. By comparison the NMR experiment undertaken here used just under 4 equivalents in two 
doses to form the reduction products, implying the reduction is dependent on the amount of zinc. 
Earlier 1H-NMR experiments dosing zinc in similar excess to Conway, saw a significant increase in 
reaction temperature. This experiment observed the formation of a product with an m/z of 249.355 
and a peak in the 1H-NMR at 11.1 ppm. These collective observations suggested the formation of 
the carboxylic acid product rather than the desired hydroxamic acid. Excess zinc and the mildly 
acidic conditions could potentially promote acid catalysed hydrolysis to the carboxylic acid from 
the hydroxamic acid by protonation of the carbonyl oxygen and subsequent hydrolysis, likely aided 
by the internal increase in reaction temperature.  
One notable observation of this experiment is the formation of precipitate in the reaction vessel and 
the subsequent decrease in total 1H-NMR peak integrals of the new compound peaks (◊ and *). At 
T=6 (Figure 5.1), a sample was removed for mass spectrometry analysis and run in MeOH where 
the precipitate dissolved. The mass spectrum revealed an m/z peak at 106.256 confirming the 
formation of the 4-methylidenecyclohexa-2,5-dien-1-iminium compound previously reported in 
Figure 1.23 as the nitro-reduced fragment. This suggests that the precipitate is the fragmented 
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cation and would account for the loss of proton integration in the 1H-NMR spectra as the reaction 
progresses. Regrettably, the full fragmentation experiment undertaken by Conway et al. utilising 
K2HPO4 (0.1 M) buffer and incubation at 37 °C could not be replicated using 1H-NMR 
spectroscopy. To ensure the compounds remained in solution a 1:1 mixture of K2HPO4 (D2O) and 
the DMSO-d6 solution containing the reduction products was made, unfortunately even on heating 
many of the reaction components precipitated out in this mixture and the fragmentation could not 
be monitored for P-SAHA using this method. 
The NMR experiment described above successfully shows the reduction of the p-nitrobenzyl 
protecting group under mildly acidic conditions using zinc as a catalyst. While the fragmentation 
experiment could not be accomplished, the initial experiment provides evidence that fragmentation 
can occur for the hydroxamic acid without the need of a buffer. This could be due to the more 
favourable formation of the hydroxamic acid with the loss of 4-methylidenecyclohexa-2,5-dien-1-
iminium compared to that of the primary alcohol example. In the presence of excess zinc, some 
conversion into the carboxylic acid was observed. This is an undesirable reduction product due to 
the lack of potency documented for carboxylic acid derivatives as HDAC inhibitors;92 it is 
therefore necessary that the formation of the carboxylic acid is avoided to retain good potency in 
vitro.  
5.4 Cytotoxicity 
To suitably observe the potential hypoxia-activated behaviour of these complexes, cytotoxicity 
assays were to be undertaken under both normoxic and hypoxic conditions. It was assumed the 
protected compounds (SAHA, P-SAHA, Ru1L4 and RhL4) would display selective toxicity under 
only hypoxic conditions where the active species can form. This cytotoxicity data was unavailable 
at point of thesis submission.  
Table 5.2 Impending results of hypoxia-active drugs and non-protected analogues under conditions of 
normoxia and hypoxia. 
 IC50[µM]   IC50[µM] 
Compound Normoxia Hypoxia Compound Normoxia Hypoxia 
SAHA   Ru1L2   
P-SAHA   Ru1L4   
L2   RhL2   
L4   RhL4   
 




Complexes Ru1L4 and RhL4 were successfully synthesised based upon the potent parent 
complexes Ru1L2 and RhL2. The new complexes possessed the known reducible functionality, p-
nitrobenzyl; a novel method of protecting a hydroxamic acid. 1H-NMR was chosen as a viable 
technique to assess the ability of the p-nitrobenzyl group to be reduced, fragment and ultimately 
provide the desired hydroxamic acid as the active species. By utilising commercially available 
materials, conditions were attained to mimic the enzyme reductase process observed in vitro. The 
organic analogue P-SAHA was tested using this method due to low yields of the final complexes. 
Analysis of the spectra from this experiment showed the reduction of the nitro group to the 
anticipated hydroxylamine and amine products, along with fragmentation discerned from the 
resulting precipitate. Due to the heat produced during the reaction, the hydroxylamine active-
species was regrettably reduced to the carboxylic acid. While these conditions weren’t entirely 
successful in providing the desired product, it displayed the clear reduction of the protecting p-nitro 
group and the required fragmentation.  
The prospective cytotoxicity data could provide evidence of the successful reduction in vitro to the 
active hydroxamic species of complexes Ru1L4 and RhL4 under hypoxic conditions by comparing 
toxicity with the potent parent complexes under conditions of normoxia. Complexes Ru1L4 and 
RhL4 could provide the first examples of novel piano-stool hypoxic-active drug candidates. 
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6. Conclusions and Future Work 
6.1 General Conclusions 
At the outset of the project, the overall aims were to produce piano-stool complexes bearing 
anticancer properties and to determine different mechanisms of action. Existing complexes within 
the literature containing the pseudo-octahedral geometry had demonstrated a range of mechanisms 
including, but not limited to: antimetastasis, DNA and protein-binding. However, there were ligand 
systems and target molecules yet to be explored for complexes containing the specific arene-metal 
motif. To assess the progress made over the past three years, it is necessary to recap the aims 
specified at the beginning of the project. The aims set out, were as follows: 
a) Design and synthesise DNA-binding piano-stool complexes: 
i. Incorporating a 31P spectroscopic handle 
ii. Retaining aqueous stability 
iii. Retention of the bidentate ligands under physiological conditions 
b) Target histone deactylase inhibition with piano-stool complexes: 
i. Synthesise potential HDAC inhibitors 
ii. Test anticancer activity 
iii. Determine mechanism of action 
c) Optimise selectivity towards specific HDAC isoforms: 
i. Modify complexes to enhance topographical interactions 
ii. Minimise off-target binding 
d) Incorporate a hypoxic-active motif into metal-based HDAC inhibitors: 
i. Assess the efficiency of the protecting group 
ii. Ensure reduction to active species 
Consideration was initially given to the design and synthesis of DNA-binding complexes. The 
pyridylphosphinate ligand system was utilised due to its simple 2 or 3 step synthetic route from 
commercially available starting materials and its novelty compared to existing anticancer piano-
stool complexes. Such a simple synthetic approach allowed the population of a small library of 25 
complexes with a diverse range of substituents, along with incorporation of the desirable 31P 
spectroscopic handle. Analysis of the complexes under various physiological conditions was 
monitored using NMR spectroscopy experiments. An essential criterion of these complexes to 
allow DNA-binding to occur is the exchange of the monodentate halide ligand at intracellular 
chloride concentration (4 mM), to form the more labile aqua-species. 1H-NMR indicated the 
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preference of the aqua species in D2O and the chloride species in extracellular chloride solution 
(100 mM concentration) as anticipated. Additionally, the aqua species must then be conserved to 
avoid formation of the less labile hydroxyl adduct, requiring the pKa of the water bound ligand to 
be greater than physiological pH 7.4. The pyridylphosphinate complexes possessed pKa values of in 
the range 7.7-10.9, implying the stability of the aqua-species, as desired.  
Table 6.1 Selected pyridylphosphinate complexes: substituents. *IC50 values against H460 non-small lung 
carcinoma cell line.  
 
Complex R R1 {M(R2)} X *IC50 [µM] 
Ir2PP1 H Ph {Ir(Cp*)} I 52 ± 2 
Ir2PP2 H Me {Ir(CP*)} I 53 ± 4 
While these complexes displayed selective properties laid out in the project specification, the 
majority of the complexes possessed poor cytotoxicity against the H460 non-small lung carcinoma 
cell line tested, with IC50 values >200 µM, unfortunately not meeting the end goal. The iridium 
iodide complexes Ir2PP1 and Ir2PP2 were exceptions displaying IC50 values of 52 and 53 µM, 
respectively, although still ~65-fold less toxic than the control cisplatin (IC50 = 0.80 µM). To 
rationalise the poor toxicity exhibited by the pyridylphosphinate complexes, their behaviour with 
other biomolecules was examined. Binding to 9-EtG was observed using mass spectrometry with 
the loss of the water ligand, suggesting the pyridylphosphinate complexes have the ability to bind 
to DNA as sought. However, similar experiments with amino acids such as L-histidine 
(2 equivalents) resulted in full substitution of the pyridylphosphinate ligand in favour of the amino 
acid. As a result, the pyridylphosphinate N,O-coordination was presumed to be a weak chelator 
relative to competing biomolecules and therefore unable to remain bound to the metal in vitro. This 
reduced structural integrity of the complexes was deemed the likely contribution to their poor 
cytotoxicity.  
Despite the failure to achieve the DNA-binding therapeutic outcome, these complexes exhibited 
some unusual properties. For instance, each complex possessed a stereogenic centre at the metal 
and the phosphorus, giving rise to two diastereomers (specific to substituents) in both the solid and 
solution state. While this property was interesting, due to their poor toxicity, the pyridylphophinate 
complexes were pursued no further. It is notable, that the partial lability of the Ru-
pyridylphosphinate bond could have potential application in targeted delivery of drugs.  A complex 
could be designed utilising the Ru-arene as a chaperone, deliverying a masked active compound 
into a cell, before decomplexing in the presence of competitive chelators (e.g. histidine) to produce 
the free active drug. Such an avenue could be a potential future use of these complexes.  
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The project focus shifted instead to sourcing an alternative biomolecular target for anticancer 
therapy. Histone deacetylase enzymes (HDACs) were deemed a suitable target due to their key 
function within post-translational modification, which if dysregulated leads to formation of 
transformed cells and subsequent malignancies. Purely organic HDAC inhibitors were the 
prominent candidates in the literature, with only a few metal-based examples reported. No regard 
had previously been given to ruthenium piano-stool complexes, resulting in further reason to 
explore HDAC enzymes as a therapeutic target for these complexes.  
The complexes Ru1L2 and RhL2 were successfully synthesised, incorporating the ligand L2, 
analogous to the clinically approved HDAC inhibitor, SAHA. A crucial design feature of these 
complexes was the inclusion of the hydroxamic acid – a strong chelator to the catalytic, zinc active 
site, inhibiting HDAC enzyme activity. In contrast to the pyridylphosphinate complexes, both 
complexes Ru1L2 and RhL2 showed negligible exchange of the monodentate chloride ligand under 
aqueous conditions, implying good aqueous stability. Additionally, these complexes exhibited 
moderate growth inhibition of the H460 non-small cell lung carcinoma cells (Table 6.2); a vast 
improvement over the initial pyridylphosphinate complexes.  
Table 6.2 Piano-stool HDAC inhibitors containing L2: structure, HDAC activity against HeLa extract and 
*IC50 values against H460 non-small cell lung carcinoma cell line. 
 
Complex {M(R)} IC50 [µM] 
HDAC activity 
[%] 
1 µM 0.1 µM 
Ru1L2 {Ru(p-cymene)} 21 ± 6 1.6 17.3 
RhL2 {Rh(Cp*)} 4.1 ± 0.4 1.1 15.4 
Subsequent experiments were undertaken to determine the likely mechanism of action of 
complexes Ru1L2 and RhL2. It was established using plasmid DNA in gel electrophoresis 
experiments that these complexes neither underwent DNA-binding by covalent modification, nor 
through intercalation of DNA to a degree likely accountable for the activity exhibited. Bovine 
serum albumin (BSA) was utilised in a protein binding experiment to also eliminate protein 
interactions as a factor influencing cytotoxicity. While the binding isotherm suggested a 1:1 
relationship between complex and the BSA substrate, the calculated binding constants implied only 
a low binding affinity for the protein. Finally, HDAC activity assays were performed using HeLa 
extract as a source of HDAC enzymes. Both complexes Ru1L2 and RhL2 displayed comparable, 
potent inhibition of HDAC activity at the lower concentration tested (0.1 µM, Table 6.2), 
irrespective of their somewhat different cytotoxicity. The biological assay results accumulatively 
suggest HDAC inhibition as the most likely mechanism of action. The complexes Ru1L2 and RhL2 
were the first examples of Ru and Rh piano-stool HDAC inhibitors.  
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Having justified the mechanism of action matched the desired target, the focus shifted to 
optimisation of the efficacy and selectivity of the complexes. Within the HDAC family, there are 
11 zinc-dependent enzymes each with specific localisation and substrates. Pan-inhibitors such as 
SAHA possess little selectivity between isoforms and can lead to unwanted side-effects. The parent 
complex Ru1L2 was chosen for modification to enhance specificity and aim to reduce off -target 
binding.  
 
Figure 6.1 Ligand and general structure of complexes discussed in Chapter 4. 
Two structural components of the parent complex Ru1L2 were modified (Figure 6.1): the chain 
linker (L2 and L3) to improve selectivity in the enzyme channel and the arene capping group 
(substituents R and R1) to accommodate the channel rim to maximise potential interactions with the 
enzyme surface. Eight complexes containing L2 and five containing L3 were synthesised with 
various arene substituents (R = H, Me; R1 = Me, tBu, Ph, thiophene) with all complexes subjected 
to a variety of biological testing. Cellular studies provided evidence of trends within the complex 
series depending on the ligand, L. Five of the eight new L2 complexes showed improved toxicity 
over the organic ligand L2 alone. Accumulation of Ru was proportional to IC50 values within the L
2 
series; the higher the uptake of Ru the more potent the complex. By contrast, the L3 containing 
complexes exhibited the inverse relationship; the higher the Ru accumulation, the less potent the 
complex, with reduced potency relative to increase in size of the arene motif. Generally, it appears 
the L3 ligand has a notable influence over complex uptake likely due to the more lipophilic tolyl 
moiety, yet the cytotoxicity was hindered by bulkier groups within the arene. However, across the 
L2 complexes, such a trend in relation to the R1 substituent is much less pronounced. Aside from 
the influence of complex modifications, the parent complex Ru1L2 showed a 13-fold decrease in 
IC50 value for MCF7 compared to the H460 cells, implying a favourable toxicity profile for this cell 
line. In support of these observations, the active transport assay testing Ru1L2 and Ru1L3 
undertaken at 4 °C showed no change in cell viability, implying uptake is mediated by facilitated 
diffusion and is not determined by the bidentate ligand present in the complex.  
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Table 6.3 Selected results from Chapter 4. *IC50 values and Ru accumulation were measured using the 
MCF7 human breast adenocarcinoma cell line.  











Tubstatin A - - 1.72 ± 0.1 0.04 ± 0.006 43 4.73 ± 0.5 - 
L3 - - 0.36 ± 0.03 0.15 ± 0.02 2.4 0.83 ± 0.4 - 
Ru1L3 p-cymene 0.24 ± 0.03 0.06 ± 0.001 4.0 4.90 ± 1.0 24.1 
Ru5CL3 Me Ph 0.35 ± 0.05 0.08 ± 0.02 4.4 22.0 ±3.4  48.6 
Assessment of the selectivity between isoforms was tested using human recombinant enzymes of 
class I, IIa and IIb (HDAC1, 4 and 6, respectively). The initial assays measuring two 
concentrations (1 and 0.1 µM) showed comparable inhibition of HDAC1 and 6, with only 
complexes containing L3 inhibiting activity of HDAC4. Due to the superior inhibition profiles 
exhibited towards HDAC1 and 6, these enzymes were chosen to demonstrate any significant 
selectivity between HDAC enzyme isoforms. Complexes Ru1L3 and Ru5CL3 (Table 6.3) all 
displayed inhibition activity in the nanomolar range towards both enzymes as well as selectivity 
towards HDAC6 as factors of 6.0, 4.0 and 4.4, respectively. While the selectivity factors (sf) are 
small by comparison to the HDAC6-selective control tubastatin A (sf = 43), these complexes 
displayed improved selectivity over both organic systems L2 and L3 (sf = 2.0 and 2.4, respectively). 
This particular result is encouraging, emphasising the ability of the metal-arene motif of these 
complexes to likely accommodate the wider channel rim of HDAC6 more efficiently.  
Enzyme modelling of complex Ru1L3 allowed closer inspection of potential interactions, specific 
to this complex while providing a three-dimensional platform to enable predictions of alternative 
complex binding possibilities. The accommodation of complex Ru1L3 into the homologous 
zHDAC6-CD2 protein suggested favourable π-π stacking interactions between phenylalanine 
residues in the active-site channel, previously observed when the tolyl linker is present within other 
HDAC6-selective inhibitors. While this particular feature of the Ru1L3 complex exposed a 
reasoning for selectivity towards HDAC6 of the L3 containing complexes, it concurrently supports 
the rationale that the arene-metal motif of Ru1L2 is the feature responsible for its improved 
selectivity towards HDAC6. This is deemed probable when considering the flexible alkyl chain 
linker of Ru1L2 cannot produce such a comparable interaction in the catalytic channel as Ru1L3.  
Collectively, these results suggest that the modified complexes display a selectivity not yet 
demonstrated by a piano-stool complex possessing HDAC enzyme inhibition as the mechanism of 
action. It is clear that the combination approach towards complex modification requires better 
understanding, in particular of specific off-target binding sites and the determination of the precise 
uptake pathway. With the current observations in hand, refinement of biological studies to further 
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distinguish the complex’s localisation and behaviour within the cellular environment would be 
necessary to strengthen the use of these complexes as potential drug candidates.  
6.2 Future Work 
The most interesting findings of this work establish the ability of piano-stool complexes to be tuned 
towards selectivity between HDAC enzyme isoforms. While the selectivity factors are by no means 
exceptional, their novelty provides sufficient reason for continued development and warrants 
further exploration. Other examples of piano-stool complexes utilised as drug candidates are 
subjected to extensive scrutiny in the literature - far beyond that tested in this work - to elucidate a 
more informed account of the complex’s behaviour. It would therefore be logical to undertake 
additional biological testing accordingly.  
Due to the different toxicity profiles exhibited by complex Ru1L2 towards the H460 and MCF7 
cell lines, it would be applicable to test the cytotoxicity of the complexes against a broader range of 
cancer cell lines, including those resistant to cisplatin, in an attempt to observe any specificity. 
Additionally, healthy cells such as HBL-100 should be tested to determine whether these 
metal-based HDAC inhibitors show any cancer-cell selectivity. Uptake and localisation studies 
could be expanded upon to enlighten the different results between the L2 and L3 containing 
complexes. Transmission electron microscopy has been previously exploited by Dyson et al. to 
visualise the localisation of RAPTA complexes at a subcellular level.61 This technique, coupled 
with nanoscale secondary ion mass spectrometry (NanoSIMS), could discern if off-target 
localisation of L3 complexes is a source of their poor cytotoxicity, relative to their good Ru uptake. 
As described by Sadler et al., contrasting cellular uptake pathways could also be investigated. 
These assays include monitoring the extent of efflux and inhibition of efflux by co-administration 
of verapamil (an L-type calcium channel blocker enabling efflux evasion by the P-gp pathway – a 
pathway known to favour cationic and highly lipophilic drug molecules).68 Pursuing such analysis 
would supply more information with regard to the complex’s behaviour at a cellular level and 
highlight any influence of lipophilicity associated pathways.  
As the molecular target, the HDAC enzyme activity could be further explored by following a 
variety of avenues. The extent of HDAC6 inhibition could be quantified using Western blotting to 
measure the acetylation levels of α-tubulin – the primary substrate for HDAC6 – in comparison to a 
control.142 The protein α-tubulin is linked to the regulation of the cytoskeleton, cell migration and 
plasticity; all features associated with aberrant HDAC activity and metastasis. Besides localisation, 
this could provide evidence of HDAC6 inhibition-generated cytotoxicity. Moreover, migration and 
invasion cellular assays could be undertaken to observe any antimetastasis effects brought about 
from HDAC6 inhibition. Specific HDAC enzyme interactions could be compared through 
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subsequent modelling of both HDAC1 and HDAC6 with complexes Ru1L2 and Ru1L3, to enable a 
more succinct comparison of the potential binding modes. This could display particular interactions 
that give rise to the observed selectivity between the isoforms. As modelling is a binding prediction 
based on a set of parameters, enzyme-drug crystallisations could also be reattempted to afford a 
more accurate representation of interactions within the biological system.  
 
Figure 6.2 Alternative R1 substituents.  
Future development of the L2 and L3 containing complexes, beyond the investigation into their 
behaviour in biological systems, would be through structural modifications. Firstly, having now 
modelled a catalytic domain homologous to HDAC6, discrete surface amino acid residues can be 
visualised and arene design can be refined to improve interactions with the enzyme surface. The 
favoured pose of complex Ru1L3, docked in the HDAC6 homologue, displayed a selection of 
residues in close proximity to the arene motif for such interactions such as Asp460, not reached by 
the p-cymene of Ru1L3. To tune the arene, specific amino acid side chain groups such as those 
found in tyrosine, tryptophan or aspartate (Figure 6.2) could be incorporated using their 
commercially available carboxylic acid derivatives.  
Without further biological testing and aside from assumptions based on lipophilicity, it remains 
unclear as to why the L3 complexes are able to accumulate efficiently in the cell and yet display 
low levels of cytotoxicity. Both the differences in the size of the arene as well as the amide linker 
have been suggested as contributing to the complexes inability to reach the target or responsible for 
off-target binding. Given the amide linker shows no apparent residue interactions with the enzyme 
surface, this feature of the molecule could be changed. An alkene linker would reduce the number 
of hydrogen bond donors and acceptors within the arene motif and depending on its substituent, 
potentially enhance the lipophilicity in a desirable fashion. While the alkene would require more 
synthetic steps than the amide functionality, exchanging this moiety could prove advantageous. 
Finally, the HDAC assays discussed in Chapter 4 displayed the ability of the L3 containing 
complexes to partially inhibit HDAC4 activity. To improve selectivity towards the class IIa HDAC 
enzyme, the zinc-binding group could be modified to a trifluoromethylketone, a functional group 
already noted for possessing a penchant for the HDAC4 active site compared to the hydroxamic 
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acid.207 This small structural change could provide the first example of a class IIa selective metal-
based HDAC inhibitor and would therefore be worth pursuing.  
6.3 Final Remarks 
The utilisation of metal complexes for therapeutics offers advantages over organic systems 
including (but not limited to): modular synthesis, variable geometry and oxidation state. Employing 
piano-stool complexes in particular as anticancer agents is far from an emerging research field. 
Existing complexes with this geometry are under development for a range of different biomolecular 
targets towards cancer treatment.  
In this work, an improvement in enzyme isoform selectivity was observed by exploiting the 
pseudo-octahedral geometry of a complex to accommodate the enzyme surface more efficiently 
than their organic counterpart. While this result is promising, to compete with purely organic drugs, 
factors such as cellular accumulation, drug efflux, stability in physiological conditions and 
optimising target binding are of critical importance. For this reason, piano-stool complexes are yet 
to make any commercial impact as anticancer agents, unable to fulfil these criteria and retain such 
properties in vivo. However, the work described in the latter part of this report, has certainly laid 
the ground work for informed improvements towards establishing an effective piano-stool complex 
HDAC isoform-selective inhibitor; possessing the characteristics and efficacy of a potential future 











7.1 Experimental Procedures 
7.1.1 General Procedures 
Chemicals were purchased from Sigma Aldrich UK, Fluorochem, Merck and Fisher UK. Solvents 
were laboratory grade or dried by the Durham University SPS service. Dried solvents were stored 
over activated 3 Å molecular sieves. Reactions requiring anhydrous conditions were carried out 
under an atmosphere of dry argon or nitrogen using Schlenk-line techniques. Where appropriate, 
solvents were sparged with argon as a degas method. 
Thin-layer chromatography was carried out on silica plates (Merck 5554) and visualised under UV 
(254/365 nm) irradiation or by staining with iodine, vanillin or potassium permanganate stains. 
Preparative column chromatography was carried out using silica (Merck Silica Gel 60, 230400 
mesh), with additional Et3N as stated. 
pH measurements were carried out at 295 K using a Thermo Scientific Orion Star A111 pH meter 
with a Sigma-Aldrich micro-pH combination electrode. Calibration was performed using 
commercially available buffer solutions at pH = 4.0 ±0.02, pH = 7.00 ±0.02 and pH = 10.00 ±0.02. 
NMR spectra (1H, 13C, 19F, 31P) were recorded on a Varian VXR-400 spectrometer (1H at 399.97 
Hz, 13C at 100.57 MHz, 19F at 76.50 MHz, 31P at 164.98 MHz) or a Varian VNMRS-700 
spectrometer (1H at 699.73 MHz, 13C at 175.95 MHz, 31P at 150.50 MHz). Spectra were recorded at 
295 K in commercially available deuterated solvents and referenced internally to the residual 
solvent proton resonances. The multiplicity of each signal is indicated by s (singlet); d (doublet); t 
(triplet); q (quartet); quin (quintet) or sept (septet). The number of protons (n) for a given resonance 
signal is indicated by nH. Coupling constants (J) are quoted in Hz and are recorded to the nearest 
0.1 Hz. Identical proton coupling constants (J) are averaged in each spectrum and reported to the 
nearest 0.1 Hz. The coupling constants are determined by analysis using MestReNova software. 
Spectra were assigned using COSY, HSQC, HMBC and NOESY experiments as necessary. 
Both electrospray and high-resolution mass spectrometry were performed on a Thermo-Finnigan 
LTQ FT system using methanol as the carrier solvent. m/z values are reported in Daltons with 
specific isotopes identified.  
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7.1.2 X-Ray Studies 
The X-ray single crystal data have been collected using λMoKα radiation (λ =0.71073 Å) on a 
Bruker D8Venture diffractometer (Photon100 CMOS detector, IμS-microsource, focusing mirrors, 
1 ω-scan) equipped with a Cryostream (Oxford Cryosystems) open-flow nitrogen cryostats at the 
temperature 120.0(2)K. The structures were solved by direct method and refined by full-matrix 
least squares on F2 for all data using SHELXTL [G.M. Sheldrick, Acta Cryst. (2008), A64, 112-
122] and OLEX2 [O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, H. Puschmann, 
J. Appl. Cryst. (2009), 42, 339- 341.] software. All non-hydrogen atoms were refined 
anisotropically, the hydrogen atoms were placed in the calculated positions and refined in riding 
mode. Crystallographic data for the structures have been deposited with the Cambridge 
Crystallographic Data Centre as supplementary publications CCDC 1457275 and 1457276.  
Crystal data for Ru1PP3: C22H25ClNO2PRu (M = 502.92): monoclinic, space group P21/c, a = 
12.5685(6), b =8.1196(4), c = 20.4312(10) Å, β = 91.535(2)°, V = 2084.3(2)Å3 , Z = 4, T = 
120.0(1) K, μ(λMoKα) = 0.975 mm−1 , Dcalc =1.603 g mm−3 , 43150 reflections measured, 5811 
unique reflections (Rint = 0.0528) were used in all calculations. The final R1 was 0.0309 (4673 > 
2σ(I)) and wR2was 0.0629 (all data), GOF = 1.040.  
Crystal data for Ir1PP6: C17H24ClIrNO2P + H2O (M = 551.01): monoclinic, space group Cc, a = 
14.7318(2), b = 16.6565(2), c = 8.3433(1) Å, β = 107.664(2)°, V = 1950.75(4)Å3 , Z = 4, T = 
120.0(1) K, μ(λMoKα) = 7.078 mm−1 , Dcalc =1.876 g mm−3 , 20026 reflections measured, 5620 
unique reflections (Rint = 0.0416) were used in all calculations. The final R1 was 0.0202 (5436 > 
2σ(I)) and wR2 was 0.0497 (all data), GOF = 1.076, Flack parameter 0.033(5), Hooft parameter 
0.042(6). 
7.1.3 HPLC Analysis 
Reverse phase HPLC analysis was performed at 298 K on a Interchim PuriFlash 4250 system, 
Waters XBridge Prep-C18 –19x50 mm (5 μm) column was used for complexes Ru4AL2 to 
Ru5DL3 in Chapter 4, times varying from 2 –5 min. A solvent system of H2O / MeOH (gradient 
elution) was used. The UV/Vis and fluorescence detectors were set at appropriate wavelengths 
according to the species being analysed. Channel 1: UV600 SCAN – 225-600. Channel 2: UV600: 
SIG1 – 254 nm. 
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7.1.4 Optical Techniques 
All samples for optical analyses were contained in quartz cuvettes with a path length of 1 cm and a 
polished base. Measurements were recorded at 295 K unless otherwise stated. UV/Vis absorbance 
spectra were measured on an ATI UNICAM UV4 UV/Vis spectrometer using Vision software. 
Samples were measured relative to a reference of pure solvent contained in a matched cell.  
7.1.5 DNA Binding Experiments 
Preparation of plasmid DNA substrates  
Negatively supercoiled pSG483 (2927 bp), a pBlueScript SK+ (Agilent) derivative containing an 
Nb.BbvCI site, was prepared from E. coli XL-1 blue cells (Agilent) using a maxiprep kit (Qiagen). 
A portion of this sample was nicked with Nb.BbvCI (NEB) and an aliquot was removed to make a 
nicked pSG483 stock. The nicked form was then purified by phenol/chloroform extraction and 
ethanol precipitation prior to use.  
DNA covalent modification assays  
Supercoiled pSG483 plasmid DNA was mixed with 50 mM NaClO4 to generate a master mix 
containing 500 ng of DNA per reaction and a final concentration of 10 mM NaClO4. Two-fold 
dilutions of the test compounds were prepared using DMSO as solvent. 2 µl of a ten-fold 
concentrated test compound stock was added to 18 µl of reaction mix, then incubated for 24 hours 
at 37 °C. Following incubation, a 6x agarose gel loading dye (Fermentas) was added and samples 
were separated by electrophoresis in 1.4% (wt.vol-1) TAE agarose gels (50 mM Tris-HCl, pH 7.9, 
40 mM NaOAc, and 1 mM EDTA pH 8.0 running buffer), for 6–15 h at 2– 2.5 V.cm-1. To visualise 
the DNA, gels were poststained with 0.5 μg.ml-1 ethidium bromide in TAE buffer for 30 min, 
destained in TAE buffer for a further 30 min, and exposed to UV illumination.  
DNA intercalation assays  
Reactions were constructed as for the above covalent modification assays, although the solvent for 
acridine orange was dH2O. Following 30 min incubation at 37 °C, 2.5 μl of 10x ligase buffer and 
1.5 µl of dH2O was added together with 1 μl of T4 DNA ligase (Fermentas) or 1 µl of dH2O for 
the no ligase control. These reactions were then quenched with 3 µl of stopping buffer 
[5% (wt.vol-1)] SDS and 125 mM EDTA], followed by adding 1 µl of 12 mg.ml-1 proteinase K 
(Fermentas) and a further incubation at 37 °C for 30 min. Samples were stored on ice until 
immediately before gel loading, whereupon a 6x agarose gel loading dye was added and the 
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samples were warmed to 37 °C for 5 min. The reactions were separated by gel electrophoresis and 
visualised as above. 
7.1.6 Cytotoxicity 
7.1.6.1 MTT Assay – H460 Cell Line Procedure 
Cytotoxicity of complexes in Chapter 2 and 3, cisplatin and SAHA against H460 non-small cell 
lung carcinoma cells was assessed using the MTT assay as follows: 500 cells were added to 96-flat 
bottomed well plates in RPMI media (containing 10% foetal bovine serum and 2mM L-Glutamine). 
After overnight incubation to allow for cell attachment, the medium was removed and replaced 
with fresh medium containing varying concentrations of the test compounds (0.01-200 µM), or 
solvent (dimethyl sulphoxide; DMSO) alone. The final concentration of DMSO in all cases did not 
exceed 0.1% and was not found to be cytotoxic. Chemosensitivity was assessed following a 
continuous 96 h exposure using a standard 3-[4, 5-dimethylthiazolyl]-2,5-diphenyltetrazolium 
bromide (MTT) assay. Using dose response curves, IC50 values were determined (concentration 
required to inhibit cell growth by 50%, relative to control), representing data from at least three 
independent experiments.  
7.1.6.2 Cell Viability Assay – MCF7 Cell Line Procedure 
Cellular behaviour of complexes detailed in Chapter 4, SAHA, Tubastatin and ligands L2 and L3 
were conducted using Human chemotherapeuticaly resistant breast cancer cells (MCF7) cells using 
fluorescence and laser scanning confocal microscopy. Cells were maintained in exponential growth 
as monolayers in F-12/DMEM (Dulbecco’s Modified Eagle Medium) 1:1 that was supplemented 
with 10% foetal bovine serum (FBS). Cells were grown in 75 cm2 plastic culture flasks, with no 
prior surface treatment. Cultures were incubated at 37 °C, 20% average humidity and 5% (v/v) 
CO2. Cells were harvested by treatment with 0.25% (v/v) trypsin solution for 5 min at 37 ºC. Cell 
suspensions were pelleted by centrifugation at 1000 rpm for 3 min and were re-suspended by 
repeated aspiration with a sterile plastic pipette. Microscopy cells were seeded in 12-well plates on 
13mm 0.17mm thick standard glass cover-slips or un-treated iBibi 100 uL live cell channels and 
allowed to grow to 40% – 60% confluence, at 37 ºC in 5% CO2. At this stage, the medium was 
replaced and cells were treated with compounds in varying concentrations (0.80 - 100 µM) and co-
stains as appropriate. 
Cell toxicity measurements were conducted using a ChemoMetec A/S NucleoCounter3000-
Flexicyte instrument with Via1-cassette cell viability cartridge. The cellular stain Acridine Orange 
was used for cell detection and the nucleic acid stain DAPI was used to detect non-viable cells. The 
experiments were carried out in triplicate. Cell viability was corrected using a proliferation factor 
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(Equiation 1) where: vibI  =  corrected viability; nx = number of cells after incubation; nc = number 






7.1.7 Cellular Uptake 
In cellular uptake studies, cells were seeded in 6-well plates and allowed to grow to 80% – 100% 
confluence, at 37 ºC in 5% CO2. At this stage, the media was replaced with media containing 
complexes (Ru1L2, RhL2, Ru4L2, Ru5L2, Ru1L3 and Ru5L3) and total cellular ruthenium was 
determined using inductively coupled plasma mass spectrometry (ICP-MS), by Dr. C. Ottley in the 
Department of Earth Sciences at Durham University. 
Cells used for ICP-MS studies were prepared as follows. Cells were cultured in a 6- well plate to 
90% confluence. Cells were then counted (107 cells based on a cell volume of 4000 µm3) and 
incubated with medium containing the complex and promoter/inhibitor before being washed three 
times with phosphate-buffered saline (PBS). The cells were then treated with trypsin and harvested 
and diluted to 1 mL with PBS. Concentrated nitric acid (Chem. Sci. 2018 Frawley, Linford, Starck, 
Pal, Parker) (0.6 mL) was added and the samples were digested for 24 h at 37 °C. These digested 
samples were submitted for ICP-MS measurements (Dr. Chris Ottley, Department of Earth 
Sciences, Durham University). The samples were run against a series of Ru standards, and the 
measured concentration was back calculated to find the total Ru concentration present in the 
original counted cells. 
7.1.8 Enzyme Inhibition Assays 
Enzo Life Sciences 
HDAC enzyme inhibition assays were carried out for Chapter 3 using a commercially available 
assay kit. HeLa nuclear extract, potential inhibitor (final concentration 1 μM or 100 nM) and assay 
buffer (50 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2) were incubated in a 96 
well plate at 37 °C for 15 min. Acetylated substrate (100 μM) was added and the mixture incubated 
at 37 °C for a further 20 min. Developer was added and the mixture incubated at 37 °C for a further 
15 min. Fluorescence was measured using a Synergy H4 microplate reader (λex = 360 nm, λem = 
460 nm). Percentage HDAC activity is determined by quantification of fluorescence relative to 
control, with no added inhibitor. 
BPS Bioscience 
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HDAC enzyme inhibition assays were carried out for Chapter 4 using commercially available 
assay kits and undertaken in a 96 well plate. Human recombinant enzymes HDAC1 FLAG-tag His-
tag, HDAC4 GST-tag His-tag and HDAC6 GST-tag were used. Potential inhibitors were dose in 
the concentration range from 10 to 0.004 µM from original DMSO stock (10 mM) and diluted 
using assay buffer (25 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2). A master 
mixture was made using assay buffer, acetylated substrate specific to HDAC enzyme (200 µM) and 
BSA (1 mg/mL) in a ratio of buffer:substrate:BSA (6:1:1) and 40 µL added to each well plate. 
Buffer (10 µL) was added to all blank wells and buffer (5 µL) was added to all potential inhibitor 
wells. HDAC enzymes were diluted based on their stated activity and 5 µL was added to all wells 
except blanks and the plate incubated at 37 °C for 30 min. Developer was added and the mixture 
incubated at room temperature for a further 15 min. Fluorescence was measured using a Synergy 
H4 microplate reader (λex = 360 nm, λem = 460 nm). Percentage HDAC activity is determined by 
quantification of fluorescence relative to control, with no added inhibitor. 
7.1.9 HDAC Catalytic Domain vis Ligation Dependent Cloning 
Protein Expression Trials: 
For expression trials of the zHDAC6 catalytic domains, the expression constructs were produced 
through ligation independent cloning. The inserts encoding the individual catalytic domains (zCD1 
– residues 60 – 489, zCD2 – residues 440-798) were produced by IDT. They were sub-cloned into 
modified pSAT1-LIC vector, producing a SENP-cleavable N-terminal His-SUMO tagged 
construct. This construct was transformed into E. coli ER2566 and BL21 (DE3) competent cells 
using heat shock treatment and selected using ampicillin. 
Single colonies were grown in 2 x YT media (25 mL), in the presence of ampicillin (50 µg/mL). At 
O.D.600 of 0.4-0.5, expression was induced with Isopropyl β-D-1-thiogalactopyranoside (IPTG, 
1 mM), and ZnSO4 (0.20 mM) was added to supplement the media. The cells were pelleted via 
centrifugation at 4,000 x g for 20 min and then resuspended in A500 (20 mM Tris HCl pH 7.9, 500 
mM NaCl, 5 mM imidazole pH 8.0 and 10% glycerol). The cells were then lysed with sonication 
and the resulting lysate was clarified by centrifugation at 20,000 x g for 25 min. The supernatant 
was incubated with resin-NTA (150 µl, His60 Ni Superflow resin) for 2 hours at 4 ºC. The resin 
was pelleted and then transferred to a spin column. This was washed with A500 before elution with 
B500 (20 mM Tris HCl pH 7.9, 500 mM NaCl, 250 mM imidazole pH 8.0 and 10% glycerol) was 
performed. SDS-PAGE gels were run to confirm the correct sized protein was expressed and 
protein concentrations were estimated using a Nanodrop.  
Protein Expression and Purification: 
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The E. coli ER2566 transformed cells with pSAT1-LIC-CD1(or CD2) were used for large scale 
production of the catalytic domains. The bacteria were grown in 2 x YT media in the presence of 
ampicillin (50 µg/mL). Expression was induced using IPTG (1 mM) at O.D.600 of 0.4; the media 
was supplemented with ZnSO4 (0.20 mM) at the same time. The cell cultures were then grown 
overnight at 17.5 ºC. Cells were recovered via centrifugation, followed by resuspension in A500. 
This cell suspension was then lysed by sonication and then centrifuged, to remove cell debris.  
The supernatant was then loaded onto a Nickel column (HisTrap HP) in A500 and the target 
protein eluted directly onto an anion-exchange column (HiTrap Q column), using an A500 to B500 
gradient on the FPLC. The protein was then eluted using an A500 to C1000 (20 mM Tris HCl pH 
7.9, 1 M NaCl and 10 % glycerol) gradient. Fractions containing the catalytic domain were pooled 
and incubated overnight with sentrin protease at 4 ºC. The untagged protein was then run through 
an ortho-Ni column (HisTrap HP). To further purify the protein, size-exclusion chromatography 
was performed (HiPrep 16/60 Sephacryl S-200 column), washed through with sizing buffer (50 
mM Tris HCl pH 7.9, 500 mM KCl and 10% glycerol). If required, further size-exclusion 
chromatography was performed (HiPrep 16/60 Sephacryl S-300 column), using sizing buffer to 
finish purifying the protein. 
The purest protein was concentrated to 8 mg/mL and dialysed overnight into crystallisation buffer 
(20 mM Tris HCl pH 7.9, 200 mM NaCl and 2.5 mM DTT). The rest was concentration to 1 
mg/mL and stored at -80 ºC in one-third storage buffer (50 mM Tris-HCl pH 7.9, 500 mM KCl and 
70% glycerol) for biochemical assays. 
7.1.10 Molecular Modelling 
DFT optimisation of complex Ru1L3 was carried out using B3LYP hybrid functionals. For atoms 
H, C, N and O, the 6-31G* basis set was used, for Ru, the SDD basis set was required. 
Optimization calculations were carried out both in the gas phase and with a polarisable continuum 
model (PCM) of water. All optimised structures were validated to be there lowest energy structure 
through vibrational frequencies calculations. The NMR spectra were also calculated and compared 
to the experimental spectra. All calculations were carried out with Gaussian09. 
Genetic Optimisation of Ligand Docking (GOLD) was used to perform molecular docking of 
complex Ru1L3 to the zCD2 HDAC6 protein (PDB: 5WGK). The Hermes Visualiser was used to 
prepare the Ru Complex and protein before docking was undertaken, the ruthenium ion was treated 
as a dummy atom by GOLD. The region of interest was specified as within 10 Å of the zinc ion 
present in the binding site. The complex was subjected to 10 genetic algorithm runs, looking for 
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diverse solutions using the ChemScore fitness function. These were then analysed using the 
ChemScore components and the dockings evaluated using Chimera.  
7.2 Synthetic Procedures 
 
Ethyl methylphosphinate 1 
Diethyl methyl phosphonite (0.50 g, 3.67 mmol) was stirred at 0 °C and water added (0.064 mL, 
3.67 mmol). The mixture was allowed to reach 22 °C (1 h) and then stirred for 16 h. The reaction 
mixture containing a 1:1 mixture of the title compound and ethanol was used without further 
purification (quantitative yield assumed). δH (CDCl3) 7.20 (1H, d, 1JHP 537 Hz, H
1), 4.15 (1H, ddq, 
2JHH -16.7 Hz 3JHP 9.5 Hz, 3JHH 7.1 Hz, H
3), 4.06 (1H, ddq, 2JHH -16.7 Hz 3JHH 9.5 Hz, 3JHH 7.1 Hz, 
H3’), 1.52 (3H, dd, 2JHP 14.0 Hz, 3JHH 4.0 Hz, H
2), 1.35 (3H, t, 3JHH 7.1 Hz, H
4); δC (CDCl3) 62.3 (d, 
2JCP 6.0 Hz, C
3), 16.22 (d, 3JCP 6.0 Hz, C
4), 15.09 (d, 1JCP 94.5 Hz, C
2); δP (CDCl3) 33.4; m/z 
(HRMS+) 109.0418 [M + H]+ (C3H10O2P requires 109.0405). 
 
Ethyl methyl(3-methylpyridin-2-yl)phosphinate 4 
Ethyl methylphosphinate (0.48 g, 4.44 mmol), 2-bromo-3-methyl pyridine (0.050 mL, 4.44 
mmol) and triethylamine (0.062 mL, 4.44 mmol) were dissolved in toluene (5 mL) and the mixture 
degassed. [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.097 g, 0.13 mmol) was 
added and the mixture stirred at 120 °C for 16 h under an argon atmosphere. The solvent was 
removed under vacuum and the crude compound purified using column chromatography on silica 
(CH2Cl2 : 2% MeOH) providing the title compound as a dark red oil (0.280 g, 32%). δH (CDCl3) 
8.52 (1H, m, H6), 7.53 (1H, m, H5), 7.28 (1H, m, H4), 4.11 (1H, dq, 2JHH -16 Hz 3JHH 7.2 Hz,
 H8), 
4.00 (1H, dq, 2JHH -16 Hz 3JHH 7.2 Hz, H
8), 2.69 (3H, s, H3’), 1.84 (3H, d, 2JHP 15 Hz, H
7), 1.30 
(3H, t, 3JHH 7.0 Hz, H
9); δC (CDCl3) 152.4 (d, 1JCP 161 Hz, C
2), 146.7 (d, 3JCP 21 Hz, C
6), 138.8 (d, 
4JCP 9.5 Hz, C
5), 138.5 (d, 2JCP 22 Hz, C
3), 125.4 (d, 3JCP 2.6 Hz, C
4), 60.7 (d, 2JCP 6.2 Hz, C
8), 19.0 
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(s, C3’), 16.4 (d, 3JCP 6.3 Hz, C
9), 14.0 (d, 1JCP 103 Hz, C
7); δP (CDCl3) 44.4; m/z (HRMS+) 
200.0840 [M + H]+ (C9H15NO2P requires 200.0842). 
 
Methyl(3-methylpyridin-2-yl)phosphinic acid PP4 
Ethyl methyl(3-methylpyridin-2-yl)phosphinate (0.28 g, 1.4 mmol) and 6M HCl  (1.5 mL) were 
heated at 90 °C for 16 h. The solvent was removed under high vacuum and the brown oil was 
washed with dry methanol (2 x 2 mL) and dried under high vacuum. The mixture was used without 
further purification to give the title compound (assumed quantitative yield). δH (MeOD-d4) 8.76 
(1H, d, 3JHH 5.6 Hz, H
6), 8.57 (1H, dd, 3JHH 7.1 Hz 4JHH 3.1 Hz, H
4), 8.12 (1H, t, 3JHH 7.1 Hz, H
5), 
2.81 (3H, s, H3’), 1.82 (3H, d, 2JHP 16 Hz, H
7); δC (MeOD-d4) 148.9 (d, 3JCP 7.1 Hz, C
4), 147.3 (d, 
1JCP 118 Hz, C
2), 142.1 (d, 2JCP 11.4 Hz, C
3), 140.3 (d, 3JCP 6.3 Hz, C
6), 128.6 (d, 4JCP 1.6 Hz, C
5), 
17.8 (d, 3JCP 1.5 Hz, C
3’), 14.9 (d, 1JCP 106 Hz, C
7); δP (MeOD-d4) 26.1; m/z (HRMS+) 172.0527 
[M + H]+ (C7H11NO2P requires 172.0528). 
  
Chloro(ƞ6-p-cymene)(methyl(3-methylpyridin-2-yl)phosphate) ruthenium(II) Ru1PP4 
Methyl(3-methylpyridin-2-yl)phosphinic acid (0.10 g, 0.58 mmol) was dissolved in MeOH 
(2 mL) and the pH was raised to pH 8 with addition of sodium methoxide solution. A further 1 mL 
of methanol was added to the solution and dichloro(p-cymene) ruthenium(II) dimer (0.18 g, 
0.29 mmol) suspended in the solution. The reaction mixture was stirred for 16 h under argon at 
room temperature. The solvent was then removed under vacuum and the dark red compound 
dissolved into dichloromethane (3 mL). The solution was filtered through a sintered funnel to 
remove excess salts. The solution was concentrated by removal of around CH2Cl2 (2 mL) under 
reduced pressure. The resultant solution was cooled in an acetone : dry ice bath and diethyl ether 
(4 mL) was added gradually. This gave the title compound as a yellow solid (0.14 g, 54%). δH 
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(MeOD-d4) 9.14 (1H, d, 3JHH 4.7 Hz, H
6), 7.87 (1H, dd, 3JHH 7.8 Hz 3JHH 4.7 Hz, H
5), 7.54 (1H, 
ddd, 3JHH 7.8 Hz 4JHP 5.4 Hz 4JHH 1.6 Hz, H
4), 5.74 (1H, d, 3JHH 5.9 Hz, H
d), 5.68 (1H, d, 3JHH 5.9 
Hz, Hd’), 5.56 (1H, d, 3JHH 5.9 Hz, H
c), 5.48 (1H, d, 3JHH 5.9 Hz, H
c’), 2.86 (1H, septet, 3JHH 6.9 Hz, 
Hf), 2.55 (3H, s, H3’), 2.19 (3H, s, Ha), 1.43 (3H, d, 2JHP 15.2 Hz, H
7), 1.25 (3H, d, 3JHH 6.9 Hz, H
g), 
1.23 (3H, d, 3JHH 6.9 Hz, H
g’); δC (MeOD-d4) 156.1 (d, 1JCP 134 Hz, H
2), 152.9 (d, 4JCP 9.8 Hz, H
6), 
140.8 (d, 5JCP 7.7 Hz, H
5), 138.7 (d, 2JCP 18.0 Hz, H
3), 127.1 (d, 3JCP 2.2 Hz, H
4), 102.6 (Ce), 98.0 
(Cb), 81.8 (Cd), 81.4 (Cd’), 80.8 (Cc), 80.3 (Cc’), 30.7 (Cf), 21.2 (Cg), 20.8 (Cg’), 18.2 (d, 1JCP 103 Hz, 
H7), 17.1 (Ca), 17.0 (C3’); δP (MeOD-d4) 48.3; m/z (HRMS+) 400.0543 [M - Cl]+ (C17H23NO2P96Ru 
requires 400.0542).  
 
Ethyl methyl(4-methylpyridin-2-yl) phosphinate 6 
Ethyl methylphosphinate (0.40 g, 3.7 mmol), 2-bromo-4-methyl pyridine (0.41 mL, 3.7 mmol) 
and triethylamine (0.51 mL, 3.7 mmol) were dissolved in toluene (5 mL); the resulting solution 
degassed (2 h). [1,1′-Bis(diphenylphosphino)ferrocene] dichloropalladium(II) (0.08 g, 0.11 mmol, 
3% mol eq.) was added and the reaction then heated to 120 °C for 16 h. The solvent was removed 
under reduced pressure and the crude compound extracted into CH2Cl2 (20 mL) and washed with 
water (3 x 20 mL). The organic layer was dried with K2CO3, filtered and the solvent removed under 
vacuum. To purify the compound, column chromatography was utilised using silica (CH2Cl2 : 
2% MeOH), providing a yellow oil of the title compound (0.38 g, 51%). δH (CDCl3) 8.64 (1H, dd, 
3JHH 5.0 Hz, H
6), 7.94 (1H, dd, 4JHH 2.2 Hz, H
3), 7.25 (1H, dd, 3JHH 5.0 Hz 4JHH 2.2 Hz, H
5), 4.10 
(1H, dq, 2JHH -10 Hz 3JH-H 8.0 Hz, H
8), 3.86 (1H, dq, 2JHH -10 Hz 3JHH 8.0 Hz, H
8’), 2.44 (3H, s, 
H4’), 1.78 (3H, d, 2JHP 15 Hz, H
7), 1.28 (3H, t, 3JHH 8.0 Hz, H
9); δC (CDCl3) 154.0 (d, 1JCP 624 Hz, 
C2), 150.2 (d, 3JCP 84 Hz, C
6), 147.6 (d, 2JCP 39 Hz, C
3), 127.8 (d, 3JCP 86 Hz, C
4), 126.6 (d, 4JCP 13 
Hz, C5), 60.9 (d, 2JCP 25 Hz, C
8), 21.0 (d, 4JCP 1.5 Hz, C
4’), 16.4 (d, 3JCP 6.6 Hz, C
9), 13.5 (d, 1JCP 
106 Hz, C7); δP (CDCl3) 40.2; m/z (HRMS+) 200.0835 [M + H]+ (C9H15NO2P requires 200.0840).  
 
Methyl(4-methylpyridin-2-yl)phosphinic acid PP6 
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Ethyl methyl(4-methylpyridin-2-yl)phosphinate (0.38 g, 0.19 mmol) was suspended in 6M HCl 
(1.5 mL) and heated for 16 h at 90 °C. The solvent was removed under high vacuum and the brown 
oil washed with methanol (3 x 2 mL) and re dried under vacuum to provide the title compound as a 
pale brown solid (assumed quantitative yield). δH (MeOD-d4) 8.81 (1H, dd, 3JHH 6.0 Hz, H
6), 8.33 
(1H, d, 4JHH 3.0 Hz, H
3), 8.09 (1H, dd, 3JHH 6.0 Hz 4JHH 3.0 Hz, H
5), 2.77 (3H, s, H4’), 1.84 (3H, d 
2JHP 16 Hz, H
7); δC (MeOD-d4) 161.6 (d, 3JCP 32 Hz, C
6), 149.0 (d, 1JCP 494 Hz, C
2), 142.2 (d, 3JCP 
29 Hz, C4), 130.7 (d, 2JCP 46 Hz, C
3), 129.5 (d, 4JCP 4.0 Hz, C
5), 21.1 (s, C4’), 14.9 (d, 1JCP 423 Hz, 
C7); δP (MeOD-d4) 26.8;  m/z (HRMS+) 172.0514 [M + H]+ (C7H11NO2P requires 172.0527).  
 
Chloro(ƞ6-p-cymene)(methyl(4-methylpyridin-2-yl)phosphate) ruthenium(II) Ru1PP6 
Methyl(4-methylpyridin-2-yl)phosphinic acid (0.13 g, 0.78 mmol) was dissolved in MeOH (2 
mL) and the pH adjusted to pH 8 with addition of sodium methoxide solution. Dichloro(p-cymeme) 
ruthenium(II) (0.24 g, 0.39 mmol) was added and the reaction mixture heated to 40 °C and stirred 
under argon for 16 h. The solvent was removed under vacuum to leave a dark orange residue which 
was dissolved into CH2Cl2 (3 mL). The precipitate was filtered under vacuum to remove excess 
salts. CH2Cl2 (2 mL) was then removed under vacuum and the concentrated solution cooled in an 
acetone : dry ice bath. Diethyl ether (4 mL) was added gradually to the cooled solution and a 
yellow precipitate formed. The precipitate was filtered using a sintered funnel to give the title 
compound as a yellow solid (0.16 g, 45%). δH (MeOD-d4) 9.07 (1H, d, 3JHH 6.0 Hz,  H
6), 7.59 (1H, 
d, 4JHH 4.0 Hz, H
3), 7.51(1H, d, 3JHH 6.0 Hz, 4JHH 4.0 Hz, H
5), 5.77 (1H, d, 3JHH 6.0 Hz, H
d), 5.70 
(1H, d, 3JHH 6.0 Hz, H
d’), 5.59 (1H, d, 3JHH 6.0 Hz, H
c), 5.50 (1H, d, 3JHH 6.0 Hz, H
c’), 2.86 (septet, 
3JHH 7.0 Hz, H
f), 2.49 (3H, s, H4’), 2.19 (3H, s, Ha), 1.40 (3H, d, 2JHP 15 Hz, H
7), 1.25 (3H, d, 3JHH 
7.0 Hz, H
g), 1.24 (3H, d, 3JHH 7.0 Hz, H
g’); δC (MeOD-d4) 158.5 (d, 1JCP 136 Hz, C
2), 154.1 (d, 3JCP 
10 Hz, C6), 151.6 (d, 3JCP 8.5 Hz, C
4), 128.4 (d, 4JCP 2.0 Hz, C
5), 128.3 (d, 2JCP 19 Hz, C
3), 102.5 
(Ce), 97.8 (Cb), 81.6 (Cd), 81.3 (Cd’), 80.8 (Cc), 79.9 (Cc’), 30.7 (Cf), 21.3 (Cg), 20.9 (Cg’), 19.6 (C4’), 
17.8 (d, 1JCP 102 Hz, C
7), 17.2 (Ca); δP (MeOD-d4) 51.2; m/z (HRMS+) 400.0541 [M - Cl]+ 
(C17H23NO2P96Ru requires 400.0542).  






The crude methyl(4-methylpyridin-2-yl)phosphinic acid was neutralised using a solution of 
sodium methoxide (3 mL) to provide a solution of approximately pH 8. MeOH (2 mL) and 
dichloride(pentamethylcyclopentadienyl) iridium(III) dimer (0.069 g, 0.087 mmol) were added to 
the solution. The reaction mixture was stirred at 40 °C for 16 h under an argon atmosphere. The 
solvent was removed under vacuum to provide a dark orange oil which was then dissolved into 
CH2Cl2 (3 mL). The precipitate was filtered under vacuum to remove excess salts. The solvent was 
removed and the concentrated solution cooled in an acetone : dry ice bath. Diethyl ether (4 mL) 
was added gradually to the cooled solution to provide the title compound as a yellow oil (0.047 g, 
38%). δH (MeOD-d4) 8.61 (1H, d, 3JHH 6.0 Hz, H
6), 7.72 (1H, d, 4JHH 3.5 Hz, H
3), 7.50 (1H, d, 3JHH 
6.0 Hz, H5), 2.52 (3H, s, H4’), 1.61 (15H, s, Ha), 1.58 (3H, d, 2JHP 14 Hz, H
7); δC (MeOD-d4) 159.3 
(d, 1JCP 135 Hz, C
2), 151.8 (d, 3JCP 8.5 Hz, C
4), 151.6 (d, 2JCP 9.5 Hz, C
6), 129.0 (d, 4JCP 2.0 Hz, C
5), 
127.9 (d, 3JCP 19 Hz, C
3), 85.5 (5C, s, Cb), 19.6 (d, 3JCP 0.5 Hz, C
4’), 18.1 (d, 1JCP 104 Hz, C
7), 7.5 





The crude methyl(4-methylpyridin-2-yl)phosphinic acid (0.039 g, 0.23 mmol) was neutralised 
using sodium methoxide solution (3 mL) to approximately pH 8, an additional aliquot of MeOH 
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(3 mL) was added along with dichloride(pentamethylcyclopentadienyl) rhodium(III) dimer (0.07 g, 
0.11 mmol). The reaction mixture was stirred at 40 °C under an argon atmosphere for 16 h. The 
solvent was removed under vacuum to provide a dark orange oil. The crude compound was 
dissolved in CH2Cl2 (3 mL). The resulting precipitate was filtered under vacuum to remove excess 
salts. Most of the solvent was removed to leave a concentrated solution which was cooled in an 
acetone : dry ice bath. Diethyl ether (4 mL) was added gradually, this provided the title compound  
as an off-yellow solid (0.064 g, 63%). δH (MeOD-d4) 8.67 (1H, d, 3JHH 5.6 Hz, H
6), 7.68 (1H, d, 
4JHH 3.5 Hz, H
3), 7.58 (1H, d, 3JHH 5.6 Hz H
5), 2.52 (3H, s, H4’), 1.69 (15H, s, Ha), 1.48 (3H, d, 2JHP 
15 Hz, H7); δC (MeOD-d4) 160.2 (d, 1JCP 236 Hz, C
2), 151.6 (d, 3JCP 15 Hz, C
4), 151.2 (d, 2JCP 19 
Hz, C6), 128.7 (d, 4JCP 2.0 Hz, C
5), 128.3 (d, 3JCP 33 Hz, C
3), 94.4 (5C, s, Cb), 19.6 (s, C4’), 17.0 (d, 
1JCP 179 Hz, C
7), 7.6 (5C, s, Ca); δP (MeOD-d4) 45.25; m/z (HRMS+) 408.0599 [M - Cl]+ 
(C17H24NO2P103Rh requires 408.0600). 
 
Ethyl phenyl(3-methylpyridin-2-yl) phosphinate 3 
Ethyl phenylphosphonite (0.44 mL, 2.94 mmol), 2-bromo-3-methylpyridine (0.32 mL, 2.94 
mmol) and triethylamine (0.41 mL, 2.94 mmol) were dissolved in toluene (5 mL) and the solution 
was degassed (2 h). [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.064 g, 0.09 
mmol, 3 mol % ratio) was added and the resulting solution was refluxed at 120 °C for 16 h. The 
solvent was removed and the crude product was purified using column chromatography (CH2Cl2 : 
2% MeOH) to provide  the title compound as a racemic yellow oil (0.62 g, 80%). δH (CDCl3) 8.57 
(1H, dd, 3JHH 8.0 Hz 4JHH 0.9 Hz, H
6), 7.92 (2H, dq, 3JHH 11 Hz 4JHH 5.0 Hz, H
o), 7.57-7.52 (1H, m, 
H5), 7.57-7.52 (1H, m, H4), 7.47 (2H, tdd, 3JHH 11 Hz 4JH-H 5.0 Hz 5JHH 1.3 Hz, H
m), 7.27 (1H, td, 
3JHH 11 Hz 4JHH 5.0 Hz, H
p), 4.23 (2H, m, 2JHH -12 Hz 3JHH 9.0 Hz, H
7), 2.67 (3H, s, H3’), 1.41 (3H, 
t, 3JHH 9.0 Hz H
8); δC (CDCl3) 152.4 (d, 1JCP 293 Hz, C
2), 147.0 (d, 3JCP 35.7 Hz, C
6), 139.2 (d, 2JCP 
43.0 Hz, C3), 138.9 (d, 3JCP 18.0 Hz, C
4), 132.2 (C5), 132.1 (Cp), 131.2 (d, 1JCP 237.7 Hz, C
i), 128.3 
(2C, d, 2JCP 22.8 Hz, C
o), 125.3 (2C, d, 3JCP 6.0 Hz, C
m), 61.6 (d, 2JCP 10.8 Hz, C
7), 19.5 (C3’), 16.5 
(d, 3JCP 10.7 Hz, C
8); δP (CDCl3) 28.9; m/z (HRMS+) 262.0998 [M + H]+ (C14H17NO2P requires 
262.0997). 




Phenyl(3-methylpyridin-2-yl)phosphinic acid PP3 
Ethyl phenyl(3-methylpyridin-2-yl) phosphinate (0.62 g, 2.36 mmol) was added to a solution of 6 
M HCl (1.5 mL) and the solution heated to 90 °C for 16 h. The solvent was removed under high 
vacuum and washed with MeOH (2 x 2 mL) to yield the title compound as a brown oil (assumed 
quantitative yield). δH (MeOD-d4) 8.83 (1H, d, 3JHH 5.2 Hz, H
6), 8.47 (1H, dd, 3JHH 7.2 Hz 4JHH 2.6 
Hz, H4), 8.11 (1H, dd, 3JHH 7.2 Hz 3JHH 5.2 Hz, H
5), 7.86 (2H, ddd, 3JHH 7.4 Hz 4JHH 1.3 Hz 5JHH 
0.7, Ho), 7.64 (1H, td, 3JHH 7.4 Hz 4JHH 1.3 Hz, H
p), 7.54 (2H, td, 3JHH 7.4 Hz 4JHH 1.3 Hz, H
m), 2.53 
(3H, s, H3’); δC (MeOD-d4) 149.0 (d, 3JCP 7.4 Hz, C
4), 147.5 (d, 1JCP 125 Hz, C
2), 142.2 (d, 2JCP 
12 Hz, C3), 140.3 (d, 3JCP 6.0 Hz, C
6), 133.6 (d, 2JCP 11 Hz, C
p), 133.1 (d, 3JCP 2.9 Hz, C
o), 130.8 (d, 
1JCP 147 Hz, C
i), 128.8 (C5), 128.07 (Cm), 17.7 (d, 3JCP 1.6 Hz, C
3’); δP (MeOD-d4) 12.6; m/z 
(HRMS+) 234.0688 [M + H]+ (C12H13NO2P requires 234.0684). 
 
Chloro(ƞ6-p-cymene)(phenyl(3-methylpyridin-2-yl)phosphate) ruthenium(II) Ru1PP3 
Phenyl(3-methylpyridin-2-yl)phosphinic acid (0.15 g, 0.64 mmol) was neutralised with sodium 
methoxide solution, transferred to a 50 mL round bottom flask and MeOH (5 mL) was added. 
Dichloro(p-cymene)ruthenium(II)dimer (0.20 g, 0.32 mmol, 0.5 eq.) was added and the reaction 
stirred at room temperature for 16 h under an inert atmosphere. The solvent was removed under 
vacuum to provide a dark orange residue which was then dissolved into CH2Cl2 (3 mL). The 
precipitate was filtered under vacuum to remove excess salts. The solution was reduced in volume 
and cooled in an acetone : dry ice bath. Diethyl ether (4 mL) was added gradually to the cooled 
solution. The resulting precipitate was filtered, washed with diethyl ether (5 mL) and dried to give 
the title compound  as a yellow solid (0.17 g, 52%). δH (MeOD-d4) 9.08 (1H, d, 3JHH 4.8 Hz, H
6), 
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7.77 (2H, dd, 3JHH 7.4 Hz 4JHH 2.0 Hz, H
o), 7.70 (1H, dd, 3JHH 7.5 Hz 3JHH 4.8 Hz, H
5), 7.53 (1H, 
ddd, 3JHH 7.5 Hz 4JPH 5.4 Hz 4JHH 1.5 Hz, H
4), 7.46 (1H, tt, 3JHH 7.4 Hz 4JHH 2.0 Hz, H
p), 7.34 (2H, 
td, 3JHH 7.4 Hz 4JHH 2.0 Hz, H
m), 5.76 (1H, d, 3JHH 5.9 Hz, H
d), 5.72 (1H, d, 3JHH 5.9 Hz, H
d’), 5.60 
(1H, d, 3JHH 5.9 Hz, H
c), 5.58 (1H, d, 3JHH 5.9 Hz, H
c’), 2.94 (1H, septet, 3JHH 6.9 Hz, H
f), 2.21 (3H, 
s, Ha), 2.04 (3H, s, H3’), 1.30 (3H, d, 3JHH 6.9 Hz, H
g), 1.28 (3H, d, 3JHH 6.9 Hz, H
g’); δC (MeOD-d4) 
157.4 (d, 1JCP 143 Hz, C
2), 152.9 (d, 3JCP 10 Hz, C
6), 140.6 (d, 3JCP 7.7 Hz, C
5), 138.5 (d, 2JCP 18.9 
Hz, C3), 134.0 (d, 1JCP 143 Hz, C
i), 132.8 (d, 2JCP 11 Hz, C
o), 131.6 (d, 4JCP 2.8 Hz, C
p), 127.6 (d, 
3JCP 13 Hz, C
m), 127.2 (d, 4JCP 2.1 Hz, C
4), 103.5 (Ce), 97.7 (Cb), 81.4 (Cd), 81.0 (Cc), 30.8 (Cf), 
21.4 (Cg), 20.7 (Cg’), 17.2 (d, 3JCP 1.9 Hz, C
3’), 17.1 (Ca); δP (MeOD-d4) 38.2; m/z (HRMS+) 
462.0699 [M - Cl]+ (C22H25NO2P96Ru requires 462.0702). 
 
Ethyl phenyl(4-methylpyridin-2-yl) phosphinate 5 
Ethyl phenylphosphinate (0.50 g, 2.94 mmol), 2-bromo-4-methylpyridine (0.32 mL, 2.94 mmol) 
and triethylamine (0.40 mL, 2.94 mmol) were dissolved in toluene (5 mL) and the solution 
degassed (2 h). [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.10 g,  0.15 mmol, 
3 mol %) was added and the resulting mixture refluxed for 16 h at 120 °C under argon. The 
solution was extracted into CH2Cl2 (30 mL), washed with 1 M HCl (2 x 50 mL), water (2 x 50 mL), 
dried over K2CO3, filtered and the solvent removed under pressure to give a dark brown oil. 
Purification was done using column chromatography on silica (CH2Cl2 : 0.5% MeOH) to give the 
title compound as a yellow oil (0.27 g, 34%). δH (CDCl3) 8.60 (1H, d, 3JHH 7.0 Hz, H
6), 7.98-7.95 
(3H, m, Ho H3), 7.50 (1H, tq, 3JHH 7.5 Hz 4JHH 3.1 Hz, H
p), 7.43 (2H, tdd, 3JHH 7.5 Hz 4JHH 3.1 Hz 
5JHH 1.4 Hz, H
m), 7.16 (1H, d, 4JHH 4.9 Hz, H
5), 4.13 (1H, dqd, 3JHP 20 Hz  2JHH -12 Hz 3JHH 3.1 Hz, 
H7), 4.10 (1H, dqd, 3JHP 20 Hz 2JHH -12 Hz 3JHH 3.1, H
7’), 2.38 (3H, s, H4’), 1.35 (3H, t, 3JHH 7.0 Hz, 
H8); δC (CDCl3) 154.2 (d, 1JCP 166.1 Hz, C
2), 150.3 (d, 3JCP 21.1 Hz, C
6), 147.5 (d, 3JCP 10.4 Hz, 
C4), 132.3 (d, 4JCP 2.8 Hz, C
p), 132.2 (2C, d, 2JCP 9.7 Hz, C
o), 130.3 (d, 1JCP 137 Hz, C
i), 129.2 (d, 
4JCP 23 Hz, C
3), 128.3 (2C, d, 3JCP 13 Hz, C
m), 126.4 (d, 2JCP 3.3 Hz C
5), 61.6 (d, 2JCP 6.1 Hz, C
7), 
24.0 (d, 4JCP 6.1 Hz, C
4’), 16.5 (d, 3JCP 6.2 Hz, C
8); δP (CDCl3) 25.9; m/z (HRMS+) 262.1000 [M + 
H]+ (C14H17NO2P requires 262.0997).  




Phenyl(4-methylpyridin-2-yl)phosphinic acid PP5 
Ethyl phenyl(4-methylpyridin-2-yl) phosphinate (0.27 g, 1.1 mmol) was dissolved in a solution 
of 6M HCl (2.0 mL) and stirred at 90 °C under argon for 16 h. The acid was removed under high 
vacuum and washed with methanol (2 x 3 mL), also removed under vacuum. This yielded the title 
compound as a brown oil (assumed quantitative yield). δH (MeOD-d4) 9.15 (1H, m, H
6), 8.06 (1H, 
m, H5), 8.00 (2H, m, Ho), 7.68 (1H, m, Hp), 7.45 (1H, m, H3), 7.38 (2H, m, Hm), 2.58 (3H, s, H4’); 
δC (MeOD-d4) 159.3 (d, 1JCP 3.06 Hz, C
2), 148.5 (C4), 142.8 (C6), 132.8 (C3), 132.3 (2C, Co), 131.1 
(C5),  129.7 (Ci), 128.9 (2C, Cm), 128.8 (Cp), 22.5 (C4’); δP (MeOD-d4) 11.1; m/z (HRMS+) 
234.0684 [M + H]+ (C12H13NO2P requires 234.0682).  
   
Chloro(ƞ6-p-cymene)(phenyl(4-methylpyridin-2-yl)phosphate) ruthenium(II) Ru1PP5 
A solution of phenyl(4-methylpyridin-2-yl)phosphinic acid (0.080 g, 0.35 mmol) in MeOH (1 
mL) was adjusted to pH 8 using sodium methoxide solution. Dichloro(p-cymene) ruthenium(II) 
dimer (0.11 g, 0.17 mmol) was added and the suspension was stirred for 16 h under argon at room 
temperature. MeOH was then removed under vacuum and the dark red residue was dissolved into 
CH2Cl2 (3 mL). The solution was filtered through a sintered funnel to remove salts. The volume of 
filtrate was then reduced and cooled in an acetone : dry ice bath. Diethyl ether (4 mL) was added 
gradually to the cooled solution and a yellow precipitate formed. The solution was filtered and the 
solid washed with diethyl ether (2 mL) and dried to give the title compound as a yellow solid (0.14 
g, 86%). δH (MeOD-d4) 8.98 (1H, d, 3JHH 5.8 Hz, H
6), 7.84 (2H, ddd, 3JHP 14 Hz 4JHH 7.0 Hz 5JHH 
1.3 Hz, Ho), 7.48 (1H, td, 3JHH 7.0 Hz 4JHH 1.3 Hz, H
p), 7.44 (1H, d, 3JHH 5.8 Hz, H
5), 7.36 (2H, td, 
3JHH 7.0 Hz 4JHP 3.4 Hz, H
m), 7.15 (1H, dd, 4JHP 7.0 Hz 4JHH 1.9 Hz, H
3), 5.79 (1H, d, 3JHH 7.0 Hz, 
Hd), 5.73 (1H, d, 3JHH 7.0 Hz, H
d’), 5.64 (1H, d, 3JHH 7.0 Hz, H
c), 5.58 (1H, d, 3JHH 7.0 Hz, H
c’), 
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2.95 (1H, septet, 3JHH 6.8 Hz, H
f), 2.35 (3H, s, Ha), 2.24 (3H, s, H4’), 1.29 (6H, d, 3JHH 6.8 Hz, H
g); 
δC (MeOD-d4) 161.6 (d, 1JCP 125 Hz, C
2), 154.1 (C6), 151.6 (C4), 132.8 (2C, d, 2JCP 10 Hz, C
o), 
128.5 (Cp), 128.2 (d, 1JCP 140 Hz, C
i), 128.1 (C3), 127.8 (C5), 127.7 (d, 3JCP 14 Hz, C
m), 103.4 (Ce), 
97.7 (Cb), 81.26 (Cd), 80.9 (Cd’), 80.8 (Cc), 80.7 (Cc’), 30.8 (Cf), 19.38 (C4’), 17.2 (Ca), 21.4 (Cg), 
20.8 (Cg’); δP (MeOD-d4) 39.0; m/z (HRMS+) 498.0479 [M - Cl]+ (C22H26NO2P96Ru requires 
498.0466).  
 
Chloro(ƞ6-benzene)(phenyl(4-methylpyridin-2-yl)phosphate) ruthenium(II) Ru3PP5 
A solution of phenyl(4-methylpyridin-2-yl)phosphinic acid (0.04 g, 0.17 mmol) in MeOH (4 
mL) was adjusted to pH 8 using sodium methoxide solution. Dichloro(benzene) ruthenium(II) 
dimer (0.04 g, 0.09 mmol) was added and the resulting mixture heated to 40 °C and stirred for 16 h 
under argon. The same precipitation method was used as previously stated with complexes 
Ru1PP4-Ru1PP5) and the purified compound washed with diethyl ether (5 mL) to give the title 
compound as a dark yellow oil (0.05 g, 7%). δH (MeOD-d4) 9.08 (1H, d, 3JHH 5.8 Hz, H
6), 7.82 (2H, 
ddd, 3JHP 13 Hz 3JHH 7.4 Hz 4JHH 2.5 Hz, H
o), 7.49 (1H, dt, 3JHH 7.4 Hz 4JHP 2.5 Hz, H
p), 7.43 (1H, 
d, 3JHH 5.8 Hz, H
5), 7.37 (2H, td, 3JHH 7.4 Hz 4JHH 2.5 Hz, H
m), 7.14 (1H, dd, 3JHP 6.6 Hz 4JHH 1.7 
Hz, H5), 5.93 (6H, s, Ha), 2.34 (3H, s, H4’); δC (MeOD-d4) 159.1 (d, 1JCP 143.5 Hz, C
2), 154.4 (d, 
3JCP 10 Hz, C
6), 151.4 (d, 3JCP 8.7 Hz, C
4), 132.7 (2C, d, 2JCP 10 Hz, C
o), 132.6 (d, 1JCP 144 Hz, C
i), 
132.0 (d, 4JCP 2.7 Hz, C
p) 128.3 (d, 2JCP 20 Hz, C
3), 128.2 (d, 4JCP 2.2 Hz, C
5), 127.9 (2C, d, 3JCP 13 
Hz, Cm), 83.3 (Ca), 19.4 (d, 4JCP 0.7 Hz, C
4’); δP (MeOD-d4) 39.73; m/z (HRMS+) 441.9858 [M - 
Cl]+ (C18H18NO2P96Ru requires 441.9840).  
 





Phenyl(4-methylpyridin-2-yl)phosphinic acid (0.042 g, 0.18 mmol) was dissolved in MeOH (10 
mL) and dichloro(pentamethylcyclopentadienyl) rhodium(III) dimer (0.055 g, 0.09 mmol) added 
and the resulting solution was heated to 40 °C under argon for 16 h. The solvent was removed 
under vacuum to leave a dark orange residue which was dissolved into CH2Cl2 (3 mL). 
Undissolved salts were removed by filtration. The concentrated solution was cooled in an acetone : 
dry ice bath. Diethyl ether (4 mL) was added gradually to the cooled solution and a yellow 
precipitate formed. The solid was filtered and washed with diethyl ether (5 mL) to provide the title 
compound as a brown oil (0.030 g, 33%). δH (MeOD-d4) 8.64 (1H, d, 3JHH 6.0 Hz, H
6), 7.85 (2H, 
ddd, 3JHP 12.0 Hz 3JHH 7.0 Hz 4JHH 1.6 Hz, H
o), 7.49-7.46 (2H, m, H5 Hp), 7.38 (2H, td, 3JHH 7.0 Hz 
4JHP 1.6 Hz, H
m), 7.16 (1H, d, 3JHH 6.0 Hz, H
3), 2.31 (3H, s, H4’), 1.71 (15H, s, Ha); δC (MeOD-d4) 
161.0 (d, 1JCP 143 Hz, C
2), 151.2 (d, 3JCP 11 Hz, C
6), 151.1 (d, 3JCP 9.0 Hz, C
4), 134.3 (d, 1JCP 142 
Hz, Ci), 132.5 (2C, d, 2JCP 10 Hz, C
o), 131.6 (d, 2JCP 2.7 Hz, C
3), 128.8 (d, 4JCP 19 Hz, C
5), 128.4 (d, 
4JCP  2.0 Hz, C
p), 127.8 (2C, d, 3JCP 13 Hz, C
m), 94.5 (d, 3JCP 9.0 Hz, C
b), 19.5 (d, 4JCP  0.7 Hz, C
4’), 
7.68 (5C, Ca); δP (MeOD-d4) 34.5 m/z (HRMS+) 470.0754 [M - Cl]+ (C22H26NO2P103Rh requires 
470.0756). 
 
Phenyl(4-fluoropyridin-2-yl) phosphinate 7 
Ethyl phenylphosphonite (0.41 mL, 2.74 mmol), 2-bromo-4-fluoropyridine (0.48 g, 2.74 mmol) 
and triethylamine (0.38 mL, 2.74 mmol) were dissolved in toluene (10 mL) and the solution was 
degassed (2 h). [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.06 g, 0.082 mmol, 
3 mol %) was added and the solution heated to 120 °C for 16 h. The solvent was removed under 
vacuum and the residue dissolved into CH2Cl2 (30 mL). The solution was washed with 0.1 M HCl 
(30 mL) and water (2 x 30 mL), the organic layer then dried using K2CO3, filtered and solvent 
removed under pressure. The crude residue was purified using column chromatography on silica 
(CH2Cl2 : 1.8% MeOH) to provide the title compound as a pale yellow oil (0.13 g, 17%). δH 
(CDCl3) 8.73 (1H, dd, 4JHF 7.6 Hz 3JHH 6.7 Hz , H
6), 7.97 (2H, dt, 3JHP 12.0 Hz 3JHH 8.0 Hz, H
o), 
7.87 (1H, dd, 3JHF 8.2 Hz 4JHH 2.3 Hz, H
3), 7.54 (1H, tt, 3JHH 8.0 Hz 4JHH 2.0 Hz, H
p), 7.47 (2H, td, 
3JHH 8.0 Hz 4JHP 2.0 Hz, H
m), 7.09 (1H, ddd, 3JHF 8.2 Hz 3JHH 6.7 Hz 4JHH 2.3 Hz, H
5), 4.1 (2H, m, 
3JHH 7.1 Hz, H
7 H7’ ), 1.38 (3H, t, 3JHH 7.1 Hz, H
8); δC (CDCl3) 168.5 (dd, 1JCF 265 Hz 3JCP 16 Hz, 
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C4), 158.4 (dd, 1JCP 167 Hz 3JCF 4.5 Hz, C
2), 153.2 (dd, 3JCF 23 Hz 3JCP 6.1 Hz, C
6), 132.6 (d, 4JCP 
2.7 Hz, Cp), 132.3 (2C, d, 2JCP 9.8 Hz, C
o), 129.5 (d, 1JCP 140 Hz, C
i), 128.5 (2C, d, 3JCP 13 Hz, C
m), 
116.5 (dd, 2JCF 23 Hz  4JCP 17 Hz, C
3), 113.3 (dd, 2JCF 16 Hz 2JCP 2.5 Hz, C
5), 61.9 (d, 2JCP 6.2 Hz, 
C7), 16.5 (d, 2JCP 6.2 Hz, C
8); δP (CDCl3) 24.2 (d, 4JFP 11 Hz); δF (CDCl3) -100.42 (dt, 3JFP 11 Hz); 
m/z (HRMS+) 266.0746 [M + H]+ (C13H13 FNO2P requires 266.0746). 
 
Phenyl(4-d3-methoxypyridin-2-yl)phosphinic acid PP7 
NaOH (0.042 g, 1.05 mmol) was dissolved in D2O (1.5 mL) and added to a solution of phenyl(3-
fluoropyridin-5-yl) phosphinate (0.14 g, 0.52 mmol) in MeOD (3 mL). The solution was stirred 
under argon at 30 °C, monitored directly by 1H NMR. The solvent was lyophilised to yield a white 
solid (0.129 g, 96%). δH (MeOD-d4) 8.49 (1H, dd, 3JHH 6.7 Hz 5JHH 1.6 Hz, H
6), 7.91 (2H, dd, 3JHH 
7.5 Hz 4JHH 5.0 Hz, H
o), 7.63 (1H, t, 3JHH 7.5 Hz, H
p), 7.56-7.52 (2H, m, Hm), 7.56-7.52 (1H, m, 
H3), 7.28 (1H, dd, 3JHH 6.7 Hz 4JHH 2.2 Hz, H
5); δC (MeOD-d4) 172.2 (d, 3JCP 11 Hz, C
4), 152.5 (d, 
1JCP 128 Hz, C
2), 143.8 (d, 3JCP 7 Hz, C
6), 132.9 (d, 4JCP 1.7 Hz, C
p), 131.6 (2C, d, 2JCP 10 Hz, C
o), 
128.7 (2C, d, 3JCP 13 Hz, C
m), 128.5 (d, 1JCP 123 Hz, C
i), 117.2 (d, 2JCP 12 Hz, C
3), 114.5 (d, 4JCP 1.7 
Hz, C5); δP (MeOD-d4) 12.8; m/z (HRMS+) 236.0483 [M + H]+ (C12H102H3NO3P requires 
236.0477). 
 
Chloro(ƞ6-p-cymene)(phenyl(4-D3-methoxypyridin-2-yl)phosphate) ruthenium(II) Ru1PP7 
A solution of phenyl(4-d3-methoxypyridin-2-yl)phosphinic acid (0.13 g, 0.53 mmol) in MeOH 
(4 mL) was adjusted to pH 7 using dilute HCl solution (2 mL). Dichloro(p-
cymeme)ruthenium(II)dimer (0.16 g, 0.26 mmol) was added and the solution stirred at 40 °C for 16 
h under argon. The solvent was then removed under pressure leaving a dark red residue which was 
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dissolved into CH2Cl2 (3 mL). The solution was concentrated and cooled in an acetone: dry ice 
bath. Diethyl ether (3 mL) was added dropwise. The resulting precipitate was filtered and washed 
with diethyl ether (5 mL) to provide the title compound as a pale yellow solid (0.050 g, 17%). δH 
(MeOD-d4) 8.93 (1H, d, 3JHH 6.7 Hz, H
6), 7.84 (2H, dd, 3JHP 12.0 Hz 3JHH 7.2 Hz, H
o), 7.47 (1H, t, 
3JHH 7.2 Hz, H
p), 7.36 (2H, td, 3JHH 7.2 Hz, 4JHP 3.0 Hz, H
m), 7.16 (1H, dd, 3JHP 6.7 Hz 4JHH 2.6 Hz, 
H3), 6.76 (1H, dd, 3JHH 6.7 Hz 4JHH 2.6 Hz, H
5), 5.75 (1H, d, 3JHH 6.0 Hz, H
d), 5.73 (1H, d, 3JHH 6.0 
Hz, Hd’), 5.64 (1H, d, 3JHH 6.0 Hz, H
c), 5.57 (1H, d, 3JHH 6.0 Hz, H
c’), 2.95 (1H, septet, 3JHH 6.9 Hz, 
Hf), 2.27 (3H, s, Ha), 1.30 (6H, d, 3JHH 6.9 Hz, H
g); δC (MeOD-d4) 167.3 (d, 3JCP 12 Hz, C
4), 161.0 
(d, 1JCP 143 Hz, C
2), 155.7 (d, 3JCP 12 Hz, C
6), 134.5 (d, 1JCP 144 Hz, C
i), 132.7 (2C, d, 2JCP 11 Hz, 
Co), 131.9 (d, 4JCP 2.7 Hz, C
p), 127.8 (2C, d, 3JCP 13 Hz, C
m), 114.1 (d, 4JCP 21 Hz, C
5), 113.1 (d, 
2JCP 1.6 Hz, C
3), 103.1 (Cb), 97.5 (Ce), 81.0 (Cd), 80.8 (Cd’), 80.7 (Cc), 80.5 (Cc’), 30.8 (Cf), 21.4 
(Cg), 20.8 (Cg’), 17.3 (Ca); δP (MeOD-d4) 39.2; m/z (HRMS+) 481.0842 [M - Cl]+ 
(C22H222H3NO3P96Ru requires 481.0836). 
 
7-[(Pyridin-4-yl)carbamoyl]heptanoic acid 10 
4-Aminopyridine (0.300 g, 3.19 mmol) and suberic anhydride (0.658 g, 4.20 mmol) were dissolved 
in THF (7 mL). Triethylamine (0.44 mL, 3.19 mmol) was added and the resulting solution refluxed 
for 16 h. The beige precipitate formed was filtered and used without further purification (0.727 g, 
91%). δH (DMSO-d6) 10.21 (1H, s, H
5), 8.37 (2H, d, 3JHH 4.8 Hz, H
2), 7.52 (2H, dd, 3JHH 4.8 Hz 
4JHH 1.3 Hz, H
3), 2.31 (2H, t, 3JHH 7.4 Hz, H
12), 2.16 (2H, t, 3JHH 7.4 Hz, H
7), 1.55 (2H, quin, 3JHH 
7.2 Hz, H11), 1.47 (2H, quin, 3JHH 7.2 Hz, H
8), 1.31-1.22 (2H, m, H9), 1.31-1.22 (2H, m, H10); δC 
(DMSO-d6) 174.9 (C
6), 172.9 (C13), 150.7 (2C, C2), 146.2 (C4), 113.5 (2C, C3), 36.8 (C12), 34.1 
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7-[(Pyridin-4-yl)carbamoyl]heptanoic acid (0.485 g, 1.94 mmol), 1-hydroxybenzotriazole (0.393 
g, 2.91 mmol), 1-ethyl-3(3-dimethylaminopropyl)carbodiimide (0.575 g, 2.91 mmol), O-benzyl 
hydroxylamine hydrochloride (0.464 g, 2.91 mmol) were suspended in THF : H2O (15 mL) with 
stirring. N,N-Diisopropylethylamine (0.606 g, 4.85 mmol) was added and the reagents dissolved. 
The solution was stirred for 16 h at room temperature. The reaction mixture was extracted with 
CH2Cl2 (3 x 20 mL) and the organic layer washed with saturated Na2CO3 solution. The organic 
layers were combined and dried with MgSO4, filtered and dried under vacuum. The resulting 
yellow oil was recrystallized from EtOAc to give an off white solid as the title compound (0.201 g, 
29%). δH (MeOH-d4) 8.34 (2H, d, 3JHH 6.0 Hz, H
2), 7.62 (2H, d, 3JHH 6.0 Hz, H
3), 7.38 (2H, d, 3JHH 
7.5 Hz, Ho), 7.35-7.30 (1H, m, Hp), 7.35-7.30 (2H, m, Hm), 4.81 (2H, s, H15), 2.38 (2H, t, 3JHH 7.5 
Hz, H7), 2.03 (2H, t, 3JHH 7.5 Hz, H
12), 1.66 (2H, quin, 3JHH 7.5 Hz, H
8), 1.57 (2H, quin, 3JHH 7.5 
Hz, H11), 1.35 (2H, m, H9), 1.30 (2H, m, H10); δC (MeOD-d4) 173.8 (C
6), 171.4 (C13), 149.2 (C2), 
146.8 (C4), 135.5 (Ci), 128.8 (2C, Co), 128.2 (Cp), 128.0 (2C, Cm), 113.6 (2C, C3), 77.4 (C15), 36.5 
(C7), 32.2 (C12), 28.4 (C9), 28.2 (C10), 24.9 (C11), 24.7 (C8); m/z (HRMS+) 356.1951 [M + H]+ 
(C20H25N3O3 requires 356.1974). 
 
Chloro(p-cymene)N14-(benzyloxy)-N5-(pyridin-4-yl)octanediamide ruthenium(II) oxalate 12 
Sodium oxalate (0.022 g, 0.16 mmol) was dissolved in water (1.5 mL), dichloro(p-cymene) 
ruthenium(II) dimer (0.017 g, 0.028 mmol) and N14-(benzyloxy)-N5-(pyridin-4-yl)octanediamide 
(0.020 g, 0.056 mmol) were dissolved in MeOH (3 mL) and both solutions combined. The resulting 
solution was stirred for 16 h at room temperature. The solution was then filtered, the filtrate kept 
and solvent removed under vacuum to give the title compound as a yellow oil (0.030 g, 78%). δH 
(MeOH-d4) 8.26 (2H, d, 3JHH 7.0 Hz, H
2), 7.72 (2H, d, 3JHH 7.0 Hz, H
3), 7.39 (2H, d, 3JHH 7.0 Hz, 
Ho), 7.34 (2H, t, 3JHH 7.0 Hz, H
m), 7.32-7.30 (1H, m, Hp), 5.77 (2H, d, 3JHH 6.0 Hz, H
d), 5.54 (2H, d, 
3JHH 6.0 Hz, H
c), 4.82 (2H, s, H15), 2.85 (1H, septet, 3JHH 6.9 Hz, H
f), 2.39 (2H, t, 3JHH 7.2 Hz, H
7), 
2.09 (3H, s, Ha), 2.03 (2H, t, 3JHH 7.2 Hz, H
12), 1.64 (2H, quin, 3JHH 7.2 Hz, H
8), 1.56 (2H, quin, 
3JHH 7.2 Hz, H
11), 1.37-1.27 (4H, m, H9 H10), 1.31 (6H, d, 3JHH 6.9 Hz, H
g); δC (MeOD-d4) 174.1 
(C6), 171.4 (C13), 166.4 (2C, Ch), 152.9 (2C, C2), 148.3 (C4), 135.5 (Ci), 128.8 (2C, Co), 128.2 (Cp), 
128.0 (2C, Cm), 114.7 (2C, C3), 101.9 (Ce), 97.3 (Cb), 82.3 (2C, Cd), 80.3 (2C, Cc), 77.5 (C15), 36.5 
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(C7), 32.2 (C12), 30.8 (Cf), 28.3 (C9), 28.2 (C10), 24.9 (C11), 24.6 (C8), 21.2 (2C, Cg), 16.5 (Ca); m/z 
(HRMS+) 674.1951 [M + H]+ (C32H40N3O796Ru requires 674.1942).  
 
2,2’-Bipyridine-1-oxide 14 
2,2’-Bipyridine (2.00 g, 12.8 mmol) was dissolved into trifluoroacetic acid (10 mL) and stirred at 
10 °C. Aqueous hydrogen peroxide (35%) solution (1.7 mL, 13.2 mmol) was added dropwise and 
the resulting mixture allowed to warm to room temperature (3 h). The reaction mixture was 
extracted into CHCl3 and washed with 3M NaOH (3 x 20 mL). The aqueous phase was re-extracted 
with CHCl3 (2 x 20 mL) and the organic layers combined. The solution was dried with Na2SO4, 
filtered and solvent removed to dryness to give the title compound as a pale yellow oil (1.678 g, 
76%). δH (CDCl3) 8.86 (1H, dd, 3JHH 8.0 Hz 4JHH 1.5 Hz, H
6), 8.70 (1H, ddd, 3JHH 8.0 Hz, 4JHH 4.8 
Hz 5JHH 1.5 Hz, H
3), 8.29 (1H, dd, 3JHH 7.0 Hz, 4JHH 2.0 Hz, H
6’), 8.15 (1H, dd, 3JHH 7.0 Hz, 4JHH 
2.0 Hz, H3’), 7.80 (1H td, 3JHH 8.0 Hz 4JHH 1.5 Hz, H
5), 7.34 (1H, td, 3JHH 7.0 Hz, 4JHH 2.0 Hz, H
4’), 
7.32 (1H, td, 3JHH 8.0 Hz 5JHH 1.5 Hz, H
4), 7.24 (1H, td, 3JHH 7.0 Hz, 4JHH 2.0 Hz, H
5’); δC (CDCl3) 
149.6 (C2), 149.3 (C3), 147.3 (C2’), 140.6 (C6’), 136.2 (C5), 127.8 (C3’), 125.7 (C4’), 125.5 (C6), 
125.2 (C5’), 124.2 (C4); m/z (HRMS+) 173.0720 [M + H]+ (C10H9N2O requires 173.0715). 
 
4-Nitro-2,2’-bipyridine-1-oxide 15 
2,2’-Bipyridine-1-oxide (0.168 g, 9.74 mmol) was dissolved in conc. H2SO4 (15 mL) and stirred at 
10 °C. Potassium nitrate (5.41 g, 53.5 mmol) was added and the resulting mixture heated to 80 °C 
for 30 h. The reaction was allowed to cool and then poured over ice (50 g) and neutralised with 3M 
NaOH. The precipitate that formed was filtered and washed with water and dried. The compound 
was suspended in CH2Cl2 (10 mL) and hexane (10 mL) added to allow the compound to precipitate. 
This yielded the title compound as a pale yellow solid (0.626 g, 29%). δH (CDCl3) 9.15 (1H, d, 4JHH 
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3.0 Hz, H3), 8.87 (1H, td, 3JHH 7.0 Hz 4JHH 3.0 Hz, H
5’), 8.78 (1H, ddd, 3JHH 7.0 Hz 4JHH 3.0 Hz 5JHH 
1.0 Hz, H6’), 8.35 (1H, dd, 3JHH 7.0 Hz 5JHH 0.3 Hz, H
6), 8.05 (1H, dd, 3JHH 7.0 Hz 4JHH 3.0 Hz, H
5), 
7.87 (1H, td, 3JHH 7.0 Hz 4JHH 3.0 Hz, H
4’), 7.42 (1H, ddd, 3JHH 7.0 Hz 4JHH 3.0 Hz 5JHH 1.0 Hz, 
H3’); δC (CDCl3) 149.7 (C
6’), 148.1 (C2), 147.5 (C2’), 142.4 (C4), 141.8 (C6), 136.7 (C4’), 125.3 




4-Nitro-2,2’-bipyridine-1-oxide (0.374 g, 1.71 mmol) and tin(II) chloride dihydrate (1.54 g, 6.86 
mmol), were suspended in conc. HCl  (5 mL) and the reaction mixture heated to 90 °C for 24 h. 
Tin(II) chloride dihydrate (0.460 g, 2.05 mmol) was dissolved into HCl conc. (1 mL) and added to 
the solution which was heated at 90 °C for a further 24 h. The solution was then poured over ice 
(10 g) and 2M Na2CO3 solution added (pH 10). The aqueous solution was extracted with CH2Cl2 (3 
x 50 mL), organic layers combined, dried over MgSO4, filtered and solvent removed. The 
compound was sublimed at 140 °C for 24 h to give the title compound as a light brown solid (0.093 
g, 25%). δH (CDCl3) 8.63 (1H, dd, 3JHH 8.0 Hz 4JHH 2.0 Hz, H
6’), 8.34 (1H, d, 3JHH 8.0 Hz, H
3’), 
8.29 (1H, d, 3JHH 6.0 Hz, H
6), 7.77 (1H, td, 3JHH 8.0 Hz 4JHH 2.0 Hz, H
4’), 7.66 (1H, d, 4JHH 3.0 Hz, 
H3), 7.27 (1H, td, 3JHH 8.0 Hz 4JHH 2.0 Hz, H
5’), 6.54 (1H, dd, 3JHH 6.0 Hz 4JHH 3.0 Hz, H
5), 4.29 
(2H, bs, H7); δC (CDCl3) 156.7 (C
2), 156.3 (C2’), 153.6 (C4), 149.8 (C6), 148.8 (C6’), 136.8 (C4’), 
123.6 (C5’), 121.1 (C3’), 109.6 (C5), 106.8 (C3); m/z (HRMS+) 172.0884 [M + H]+ (C10H10N3 
requires 172.0875). 






N7-{[2,2’-Bipyridine]-4-yl}-N16-hydroxyoctanediamide (0.035 g, 0.102 mmol) and dichloro(p-
cymene) ruthenium(II) dimer (0.031 g, 0.051 mmol) were suspended in anhydrous MeOH (5 mL) 
and stirred for 16 h at 40 °C under an inert atmosphere. The solvent volume was reduced to 1 mL 
and precipitated out into cold diethyl ether (3 mL). The resulting solution was filtered to give the 
title compound as an orange solid (0.029 g, 43%). δH (DMSO-d6) 11.28 (1H, bs, H
7), 9.50 (1H, d, 
3JHH 7.0 Hz, H
6’), 9.28 (1H, d, 3JHH 6.5 Hz, H
6), 8.68 (1H, s, H3), 8.24 (2H, m, H3’, H4’), 7.87-7.85 
(1H, m, H5), 7.75 (1H, td, 3JHH 7.0 Hz 4JHH 2.0 Hz, H
5’), 6.16 (1H, d, 3JHH 6.0 Hz, H
d), 6.14 (1H, d, 
3JHH 6.0 Hz, H
d’), 5.92 (1H, d, 3JHH 6.0 Hz, H
c), 5.88 (1H, d, 3JHH 6.0 Hz, H
c’), 2.54 (1H, septet, 3JHH 
6.5 Hz, Hf), 2.44 (2H, t, 3JHH 7.0 Hz, H
9) 2.26 (2H, t, 3JHH 7.0 Hz, H
14), 2.14 (3H, s, Ha), 1.58 (2H, 
quin, 3JHH 7.0 Hz, H
10), 1.49 (2H, quin, 3JHH 7.0 Hz, H
13), 1.30-1.25 (4H, m, H11, H12), 0.92 (3H, d, 
3JHH 6.5 Hz Hg’), 0.91 (3H, d, 3JHH 6.5 Hz, H
g); δC (DMSO-d6) 173.8 (C
8), 173.7 (C15), 156.4 (C6), 
156.3 (C3), 155.0 (C2), 154.7 (C2’), 149.0 (C4), 140.5 (C4’), 127.9 (C5’), 123.5 (C3’), 116.4 (C5), 
112.3 (C3), 103.7 (Cb), 103.6 (Ce), 86.9 (Cd), 86.7 (Cd’), 84.2 (Cc), 83.8 (Cc’), 36.9 (C9), 33.6 (C14), 
30.7 (Cf), 28.6-28.5 (2C, C11, C12), 24.8 (C10), 24.7 (C13), 22.1 (Cg’), 22.0 (Cg), 18.7 (Ca); m/z 
(HRMS+) 608.2605 [M – Cl]+ (C28H3635ClN4O396Ru requires 608.2881). 
 





1,10-Phenanthrolin-5-amine (0.100 g, 0.51 mmol), methyl 8-chloro-8-oxooctanoate (0.158 g, 0.76 
mmol) and 4-dimethylaminopyridine (0.01 g, 0.051 mmol) were dissolved in DMF (7 mL) and 
stirred for 16 h at room temperature under an inert atmosphere. The volume of solution was 
reduced by 70% and added dropwise to a stirring solution of diethyl ether (10 mL). The filtrate was 
decanted and the precipitate dried under vacuum. The solid was suspended in MeOH : 
hydroxylamine solution 50% (5 mL) and 1M NaOH solution was added (0.5 mL) with stirring for 
30 min. The solution was neutralised to pH 7 and a precipitate formed on standing. The filtrate was 
decanted and the resulting solid dried under vacuum to give a beige solid (0.061 g, 32%). δH 
(DMSO-d6) 10.3 (1H, s, H
21), 10.1 (1H, s, H11), 9.09 (1H, dd, 3JHH 4.3 Hz 4JHH 1.4 Hz, H
2), 9.00 
(1H, dd, 3JHH 4.1 Hz 4JHH 1.1 Hz, H
9), 8.68 (1H, s, H20), 8.56 (1H, dd, 3JHH 8.0 Hz 4JHH 1.4 Hz, H
4), 
8.41 (1H, dd, 3JHH 7.7 Hz 4JHH 1.1Hz, H
7), 8.13 (1H, s, H6), 7.80 (1H, dd, 3JHH 8.0 Hz 3JHH 4.3 Hz, 
H3), 7.70 (1H, dd, 3JHH 7.7 Hz 3JHH 4.5 Hz, H
8), 2.47 (2H, t, 3JHH 7.5 Hz, H
13), 1.93 (2H, t, 3JHH 7.5 
Hz, H18), 1.65 (2H, quin, 3JHH 7.5 Hz, H
14), 1.50 (2H, quin, 3JHH 7.5 Hz, H
17), 1.35 (2H, m, H15), 
1.29 (2H, m, H16); δC (DMSO-d6) 172.8 (C
12), 169.5 (C19), 150.2 (C2), 149.7 (C9), 146.3 (C1’), 
144.2 (C10’), 136.2 (C4), 132.2 (C5), 132.0 (C7), 128.5 (C6’), 125.1 (C4’), 123.9 (C8), 123.2 (C3), 
120.5 (C6), 36.4 (C13), 32.7 (C18), 28.9 (C15), 28.8 (C16), 25.6 (C14), 25.5 (C17); m/z (HRMS+) 
367.1764 [M + H]+ (C20H23N4O3 requires 367.1770).  






N20-Hydroxy-N11-(1,10-phenanthrolin-5-yl)octanediamide (0.031 g, 0.084 mmol) and 
dichloro(p-cymene) ruthenium(II) dimer (0.025 g, 0.042 mmol) were suspended in anhydrous 
MeOH (5 mL) and stirred for 16 h at 40 °C under an inert atmosphere. The solvent volume was 
reduced to 1 mL and dropped into cold diethyl ether (3 mL). The resulting precipitate was filtered 
to give the title compounds as a yellow solid (0.032 g, 58%). δH (DMSO-d6) 10.50 (1H, s, H
11), 
10.30 (1H, s, H21), 9.94 (1H, d, 3JHH 5.0 Hz, H
2), 9.81 (1H, d, 3JHH 5.0 Hz, H
9), 9.05 (1H, d, 3JHH 8.6 
Hz, H4), 8.86 (1H, d, 3JHH 6.5 Hz, H
7), 8.63 (1H, s, H20), 8.50 (1H, s, H6), 8.18 (1H, dd, 3JHH 8.6 
3JHH 5.0 Hz, H
3), 8.08 (1H, dd, 3JHH 8.0 Hz 3JHH 5.0 Hz, H
8), 6.34 (1H, d, 3JHH 5.5 Hz, H
d), 6.31 
(1H, d, 3JHH 5.5 Hz, H
d’), 6.11 (1H, d, 3JHH 5.5 Hz, H
c), 6.08 (1H, d, 3JHH 5.5 Hz, H
c’), 2.59 (1H, 
septet, 3JHH 6.7 Hz, H
f), 2.56 (2H, t, 3JHH 7.5 Hz, H
13), 2.15 (3H, s, Ha), 1.94 (2H, t, 3JHH 7.5 Hz, 
H18), 1.66 (2H, quin, 3JHH 7.5 Hz, H
14), 1.50 (2H, quin, 3JHH 7.5 Hz, H
17), 1.36-1.28 (4H, m, 
H15,H16), 0.89 (3H, d, 3JHH 5.5 Hz, H
g), 0.88 (3H, d, 3JHH 5.5 Hz, H
g’); δC (DMSO-d6) 173.2 (C
12), 
169.5 (C19), 156.5 (C2), 155.2 (C9), 145.8 (C1’), 143.2 (C10’), 138.6 (C7), 135.3 (C4), 133.8 (C5), 
130.1 (C6’), 126.8 (C8), 126.5 (C4’), 126.1 (C3), 119.1 (C6), 104.5 (Ce), 103.1 (Cb), 86.5 (Cd’), 86.3 
(Cd), 84.4 (Cc’), 84.2 (Cc), 36.4 (C13), 32.7 (C18), 30.8 (Cf), 28.9 (C15), 28.8 (C16), 25.5 (C17), 25.4 
(C14), 22.1 (Cg), 22.0 (Cg’), 18.6 (Ca); m/z (HRMS+) 612.1581 [M-2Cl+OH]+ (C30H36N4O496Ru 
requires 612.1603). Anal. Calcd for C30H36Cl2N4O3Ru.(H2O)2.5 : C, 50.20; H, 5.05; N, 7.80. 
Found: C, 50.07; H, 5.11; N, 7.69. 





yl)octanediamide) rhodium(III) chloride RhL2 
N20-Hydroxy-N11-(1,10-phenanthrolin-5-yl)octanediamide (0.028 g, 0.076 mmol) and 
(pentamethylcyclopentadienyl) rhodium(III) chloride dimer (0.023 g, 0.038 mmol) were dissolved 
in anhydrous MeOH (7 mL) and stirred for 16 h at 40 °C under an inert atmosphere. The resulting 
solution was reduced in volume to 1 mL and cold diethyl ether added dropwise (3 mL) and the 
precipitate collected to give the title compound as a yellow solid (0.029 g, 61%). δH (DMSO-d6) 
10.51 (1H, s, H11), 10.38 (1H, s, H21), 9.43 (1H, dd, 3JHH 5.3 Hz 4JHH 1.2 Hz, H
2), 9.32 (1H, dd, 3JHH 
5.2 Hz 4JHH 1.2 Hz, H
9), 9.07 (1H, dd, 3JHH 8.7 Hz 4JHH 2.3 Hz, H
4), 8.91 (1H, dd, 3JHH 8.0 Hz 4JHH 
1.2 Hz, H7), 8.63 (1H, s, H20), 8.54 (1H, s, H6), 8.26 (1H, dd, 3JHH 8.7 Hz 3JHH 5.3 Hz, H
3), 8.16 
(1H, dd, 3JHH 8.0 Hz 3JHH 5.2 Hz, H
8), 2.59 (2H, t, 3JHH 9.0 Hz, H
13), 1.96 (2H, t, 3JHH 9.0 Hz, H
18), 
1.74 (15H, s, Ha), 1.71 (2H, quin, 3JHH 9.0 Hz, H
14), 1.52 (2H, quin, 3JHH 9.0 Hz, H
17), 1.41-1.29 
(4H, m, H15, H16); δC (DMSO-d6) 173.1 (C
12), 169.6 (C19), 152.9 (C2), 151.8 (C9), 145.5 (C1’), 142.9 
(C10’), 138.8 (C7), 135.5 (C4), 133.9 (C6’), 130.1 (C5), 127.5 (C8), 126.7 (C3), 120.3 (C6), 119.6 
(C4’), 97.4 (5C, s, Cb), 36.3 (C13), 32.6 (C18), 29.0 (C15), 28.8 (C16), 25.4 (2C, m, C14, C17), 8.97 (5C, 
s, Ca); m/z (HRMS+) 639.1615 [M-Cl]+ (C30H37N4O335Cl103Rh requires 639.1609). Anal. Calcd for 
C30H37Cl2N4O3Rh.(H2O) 3.5 : C, 48.79; H, 5.05; N, 7.58. Found: C, 48.70; H, 5.17; N, 7.11. 






Dichloro(benzene)ruthenium(II) dimer (0.023 g, 0.047 mmol) and N20-Hydroxy-N11-(1,10-
phenanthrolin-5-yl)octanediamide (0.032 g, 0.095 mmol) were dissolved in anhydrous MeOH (7 
mL) and stirred for 16 h at 40 °C under an inert atmosphere. The resulting solution was added to 
diethyl ether (3 mL) and the filtrate decanted off. This gave the title compound as a yellow solid 
(0.032 g, 55%). δH (DMSO-d6) 10.74 (1H, s, H
11), 10.39 (1H, s, H21), 10.33 (1H, bs, H20), 10.04 
(1H, d, 3JHH 5.0 Hz, H
2), 9.91 (1H, d, 3JHH 3.8 Hz, H
9), 9.11 (1H, d, 3JHH 8.3 Hz, H
4), 8.86 (1H, d, 
3JHH 8.1 Hz, H
7), 8.46 (1H, s, H6), 8.15 (1H, m, H4), 8.04 (1H, dd, 3JHH 8.1 Hz, 3JHH 3.8 Hz, H
8), 
6.28 (6H, s, Ha), 2.58 (2H, t, 3JHH 7.0 Hz, H
13), 2.28 (2H, t, 3JHH 7.0 Hz, H
18), 1.54-1.47 (4H, m, 
H14, H17), 1.36-1.27 (4H, m, H15, H16); δC (DMSO-d6) 173.8 (C
19), 173.2 (C12), 156.7 (C2), 155.5 
(C9), 146.0 (C1’), 143.3 (C10’), 138.5 (C7), 135.6 (C3), 133.9 (C4’), 130.1 (C6’), 128.7 (C5), 126.7 
(C8), 125.9 (C4), 119.0 (C6), 87.0 (6C, s, Ca), 36.3 (C13), 33.6 (C18), 28.7-28.6 (2C, C15, C16), 25.5-
24.8 (2C, C14, C17); m/z (HRMS+) 575.0923 [M-Cl]+ (C26H28N4O335Cl96Ru requires 575.0926). 
 
Chloro(ƞ6-p-cymene)(1,10-phenanthroline) ruthenium(II) chloride 
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The title complex was synthesised according to literature procedure.187 δH (DMSO-d6) 9.95 (2H, 
dd, 3JHH 6.0 Hz, 4JHH 1.0 Hz, H
2 H9 ), 8.91 (2H, dd, 3JHH 6.0 Hz, 4JHH 1.0 Hz, H
4 H7 ), 8.27 (2H, s, 
H5 H6), 8.14 (2H, dd, 3JHH 6.0 Hz, 3JHH 6.0 Hz, H
3 H8), 6.34 (2H, d, 3JHH 6.0 Hz, H
d), 6.11 (2H, d, 
3JHH 6.0 Hz, H
c), 2.58 (1H, septet, 3JHH 7.0 Hz, H
f), 2.14 (3H, s, Ha), 0.87 (6H, d, 3JHH 7.0 Hz, H
g); 
δC (DMSO-d6) 156.4 (2C, C
2 C9), 145.5 (2C, C1’ C10’), 139.2 (2C, C4 C7), 130.4 (2C, C4’ C6’), 127.8 
(2C, C5 C6), 126.8 (2C, C3 C8), 104.4 (Ce), 103.1 (Cb), 86.3 (2C, Cd), 84.2 (2C, Cc), 30.8 (Cf ), 22.1 
(2C, Cg), 18.6 (Ca); m/z (HRMS+) 445.0549 (C22H22ClN296Ru requires 445.0547). 
 
Dichloro(ƞ6-N-acetylbenzylamide) ruthenium(II) dimer Ru4A 
N-[(Cyclohexa-1,4-dien-1-yl)methyl]acetamide (0.149 g, 0.986 mmol) and ruthenium(III) chloride 
hydrate (0.128 g, 0.493mmol) were suspended in degassed EtOH (10 mL) and heated to 80 °C for 
16 h under an argon atmosphere. The solution was then cooled in an ice bath for 2 h. The resulting 
precipitate was filtered and washed with cold EtOH (5 mL), diethylether (5 mL) and dried under 
vacuum to provide the title compound as a yellow-brown precipitate (0.070 g, 17%). δH (DMSO-d6) 
8.31 (2H, t, 3JHH 5.8 Hz, H
f), 6.02 (4H, t, 3JHH 5.8 Hz, H
b), 5.78 (4H, d, 3JHH 5.8 Hz, H
c), 5.75 (2H, 
t, 3JHH 5.8 Hz, H
a), 4.08 (4H, d, 3JHH 5.8 Hz, H
e), 1.84 (6H, s, Hh); δC (DMSO-d6) 170.3 (2C, C
g), 
103.4 (2C, Cd), 89.0 (4C, Cb), 85.4 (4C, Cc), 84.4 (2C, Ca), 40.5 (2C, Ce), 22.8 (2C, Ch); m/z 
(ASAP)+ 612.8804 [M-Cl]+ ([C18H22N2O235Cl37Cl2104Ru102Ru]+ requires 612.8807).    
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Dichloro(ƞ6-N-trimethylacetylbenzylamide) ruthenium(II) dimer Ru4B 
N-[(Cyclohexa-1,4-dien-1-yl)methyl]-2,2-dimethylpropanamide (0.110 g, 0.569 mmol) and 
ruthenium(III) chloride hydrate (0.074 g, 0.284 mmol) were suspended in degassed EtOH (10 mL) 
and heated to 80 °C for 16 h under an argon atmosphere. The solution was then cooled in an ice 
bath for 2 h. The resulting precipitate was filtered and washed with cold EtOH (5 mL), diethylether 
(5 mL) and dried under vacuum to provide the title compound as a brown precipitate (0.064 g, 
25%). δH (DMSO-d6) 7.93 (2H, t, 3JHH 5.4 Hz, H
f), 6.04 (4H, t, 3JHH 6.9 Hz, H
b), 5.79-5.77 (6H, m, 
Ha Hc), 4.12 (2H, d, 3JHH 5.4 Hz, H
e), 1.09 (18H, s, Hi); δC (DMSO-d6) 178.4 (2C, C
g), 103.8 (2C, 
Cd), 88.8 (4C, Cb), 85.5 (4C, Cc), 84.7 (2C, Ca), 40.8 (2C, Ce), 38.55 (2C, Ch), 27.7 (6C, Ci); m/z 
(ASAP)+ 690.9734 [M-Cl]+ ([C24H34N2O235Cl3102Ru2]+ requires 690.9767). 
 
Dichloro(N-benzoyl-ƞ6-benzylamide) ruthenium(II) dimer Ru4C 
N-[(Cyclohexa-1,4-dien-1-yl)methyl]benzamide (0.181 g, 0.848 mmol) and ruthenium(III) 
chloride hydrate (0.110 g, 0.424 mmol) were suspended in degassed EtOH (10 mL) and heated to 
80 °C for 16 h under an argon atmosphere. The solution was then cooled in an ice bath for 2 h. The 
resulting precipitate was filtered and washed with cold EtOH (5 mL), diethylether (5 mL) and dried 
under vacuum to provide the title compound as an orange-brown precipitate (0.128 g, 38%). δH 
(DMSO-d6) 8.97 (2H, t, 3JHH 6.0 Hz, H
f), 7.85 (4H, dd, 3JHH 7.0 Hz 4JHH 1.3 Hz, H
o), 7.52 (2H, t, 
3JHH 7.0 Hz, H
p), 7.45 (4H, t, 3JHH 7.0 Hz, H
m), 6.03 (4H, t, 3JHH 5.6 Hz, H
b), 5.91 (4H, d, 3JHH 5.6 
Hz, Hc), 5.80 (2H, t, 3JHH 5.6 Hz, H
a), 4.31 (4H, d, 3JHH 6.0 Hz, H
e); δC (DMSO-d6) 166.9 (2C, C
g), 
134.0 (2C, Ci), 132.0 (2C, Cp), 128.8 (4C, Cm), 127.7 (4C, Co), 102.7 (2C, Cd), 88.6 (4C, Cb), 86.4 
(4C, Cc), 85.0 (2C, Ca), 41.4 (2C, Ce); m/z (ASAP)+ 729.0135 [M-Cl]+ ([C28H2635Cl3N2O2101Ru2]+ 
requires 729.9156).  




Dichloro(ƞ6-N-2-thiophenecarbonylbenzylamide) ruthenium(II) dimer Ru4D 
N-[(Cyclohexa-1,4-dien-1-yl)methyl]thiophene-2-carboxamide (0.193 g, 0.883 mmol) and 
ruthenium(III) chloride hydrate (0.114 g, 0.441 mmol) were suspended in degassed EtOH (10 mL) 
and heated to 80 °C for 16 h under an argon atmosphere. The solution was then cooled in an ice 
bath for 2 h. The resulting precipitate was filtered and washed with cold EtOH (5 mL), diethylether 
(5 mL) and dried under vacuum to provide the title compound as a brown solid (0.123 g, 36%); δH 
(DMSO-d6) 9.01 (2H, t, 3JHH 5.7 Hz, H
f), 7.78-7.76 (4H, m, Hi, Hk), 7.15 (2H, t, 3JHH 5.0 Hz, H
j), 
6.05 (4H, t, 3JHH 6.0 Hz, H
b), 5.90 (4H, d, 3JHH 6.0 Hz, H
c), 5.81 (2H, t, 3JHH 6.0 Hz, H
a), 4.28 (4H, 
d, 3JHH 5.7 Hz, H
e); δC (DMSO-d6) 161.9 (2C, C
g), 139.3 (2C, Ch), 131.8 (2C, Ck), 129.2 (2CL3, Ci), 
128.5 (2C, Cj), 102.5 (2C, Cd), 88.6 (4C, Cb), 86.4 (4C, Cc), 85.1 (2C, Ca), 41.2 (2C, Ce); m/z 
(HRMS)+ 744.8296 [M-Cl]+ ([C24H22N2O235Cl237Cl102Ru2S2)]+ requires 744.8266).    
 
Dichloro(ƞ6-4-methyl-N-acetylbenzylamide) ruthenium(II) dimer Ru5A 
N-[(4-Methylcyclohexa-1,4-dien-1-yl)methyl]acetamide (0.085 g, 0.514 mmol) and ruthenium(III) 
chloride hydrate (0.066 g, 0.257 mmol) were suspended in degassed EtOH (10 mL) and heated to 
80 °C for 16 h under an argon atmosphere. The homogenous solution was cooled in an ice bath for 
2 h. The resulting precipitate was filtered, and washed with cold EtOH (5 mL), diethylether (5 mL) 
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and dried under vacuum to give the title compound (0.050 g, 29%) as a dark yellow solid; δH 
(DMSO-d6) 8.19 (2H, t, 3JHH 5.6 Hz, H
g), 5.85 (4H, d, 3JHH 5.9 Hz, H
d), 5.78 (4H, d, 3JHH 5.9 Hz, 
Hc), 4.00 (4H, d, 3JHH 5.6 Hz, H
f), 2.06 (6H, s, Ha), 1.83 (6H, s, Hi); δC (DMSO-d6) 170.2 (2C, C
h), 
101.7 (2C, Cb), 96.8 (2C, Ce), 88.1 (4C, Cd), 86.5 (4C, Cc), 40.1 (2C, Cf), 22.8 (2C, Ci), 18.5 (2C, 
Ca); m/z (ASAP)+ 634.9144 [M-Cl]+ ([C20H2637Cl3N2O296Ru101Ru]+ requires 634.9145). 
 
Dichloro(ƞ6-4-methyl-N-trimethylacetylbenzylamide) ruthenium(II) dimer Ru4B 
2,2-Dimethyl-N-[(cyclohexa-1,4-dien-1-yl)methyl]propanamide (0.186 g, 0.895 mmol) and 
ruthenium(III) chloride hydrate (0.116 g, 0.447 mmol) were suspended in degassed EtOH (10 mL) 
and the reaction mixture was heated to 80 °C for 16 h under an argon atmosphere. The reaction was 
then cooled in an ice bath for 2 h. The resulting precipitate was filtered and washed with cold EtOH 
(5 mL), diethyl ether (5 mL) and dried under vacuum to give the title compound (0.092 g, 27%) as 
a dark orange solid; δH (DMSO-d6) 7.82 (2H, t, 3JHH 5.7 Hz, H
g), 5.84 (4H, d, 3JHH 6.0 Hz, H
d), 5.81 
(4H, d, 3JHH 6.0 Hz, H
c), 4.05 (4H, d, 3JHH 5.7 Hz, H
f), 2.07 (6H, s, Ha), 1.08 (18H, s, Hj); δC 
(DMSO-d6) 178.3 (2C, C
h), 102.0 (2C, Cb), 97.1 (2C, Ce), 88.1 (4C, Cd), 86.4 (4C, Cc), 40.3 (2C, 
Cf), 38.5 (2C, Ci), 27.7 (6C, Cj), 18.5 (2C, Ca); m/z (ASAP)+ 719.0052 [M-Cl]+ 
([C26H3835Cl3N2O2102Ru2]+ requires 719.0086).  
 




Dichloro(ƞ6-4-methyl-N-benzoylbenzylamide) ruthenium(II) dimer Ru5C 
N-[(4-Methylcyclohexa-1.4-dien-1-yl)methyl]benzamide (0.087 g, 0.383 mmol) and ruthenium(III) 
chloride hydrate (0.049 g, 0.191 mmol) were suspended in degassed EtOH (7 mL) and the reaction 
mixture was heated to 80 °C for 16 h under an argon atmosphere. The reaction was then cooled in 
an ice bath for 2 h. The resulting precipitate was filtered and washed with cold EtOH (5 mL), 
diethylether (5 mL) and dried under vacuum to give the title compound (0.068 g, 45%) as an 
orange solid; δH (DMSO-d6) 8.87 (2H, t, 3JHH 5.6 Hz, H
g), 7.84 (4H, dd, 3JHH 7.7 Hz 4JHH 1.4 Hz, 
Ho), 7.52 (2H, t, 3JHH 7.7 Hz, H
p), 7.44 (4H, t, 3JHH 7.7 Hz, H
m), 5.98 (4H, d, 3JHH 6.2 Hz, H
d), 5.80 
(4H, d, 3JHH 6.2 Hz, H
c), 4.24 (4H, d, 3JHH 5.6 Hz, H
f), 2.06 (6H, s, Ha); δC (DMSO-d6) 166.9 (2C, 
Ch), 134.0 (2C, Ci), 132.0 (2C, Cp), 128.8 (4C, Cm), 127.7 (4C, Co), 102.4 (2C, Cb), 95.9 (2C, Ce), 
89.0 (4C, Cd), 86.1 (4C, Cc), 40.9 (2C, Cf), 18.5 (2C, Ca); m/z (HRMS)+ 761.0339 [M-Cl]+ 
([C30H3035Cl237ClN2O299Ru104Ru requires 760.9457).  
 
Dichloro(ƞ6-4-methyl-N-2-thiophenecarbonylbenzylamide) ruthenium(II) dimer Ru5D 
N-[(4-Methylcyclohexa-1,4-dien-1-yl)methyl]thiophene-2-carboxamide (0.103 g, 0.441 mmol) 
and ruthenium(III) chloride hydrate (0.057 g, 0.221 mmol) were suspended in degassed EtOH (10 
mL) and the reaction mixture heated to 80 °C, for 16 h under an inert atmosphere. The precipitate 
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formed was filtered and washed with cold EtOH (5 mL), diethylether (5 mL) and dried under 
vacuum to give the title compound as a pale brown solid (0.028 g, 16%); δH (DMSO-d6) 8.88 (2H, 
t, 3JHH 5.7 Hz, H
g), 7.76 (2H, dd, 3JHH 4.5 Hz 3JHH 1.1 Hz, H
l), 7.73 (2H, dd, 3JHH 4.5 Hz 3JHH 1.1 Hz, 
Hj), 7.13 (2H, t, 3JHH 4.5 Hz, H
k), 5.96 (4H, d, 3JHH 6.0 Hz, H
d), 5.80 (4H, d, 3JHH 6.0 Hz, H
c), 4.20 
(4H, d, 3JHH 5.7 Hz, H
f), 2.06 (6H, s, Ha); δC (DMSO-d6) 161.8 (2C, C
h), 139.4 (2C, Ci), 131.7 (2C, 
Cl), 129.0 (2C, Cj), 128.4 (2C, Ck), 102.6 (2C, Cb), 95.6 (2C, Ce), 89.1 (4C, Cd), 86.1 (4C, Cc), 40.8 




ruthenium(II) chloride Ru4AL2 
N20-Hydroxy-N11-(1,10-phenanthrolin-5-yl)octanediamide (0.025 g, 0.068 mmol) and 
dichloro(ƞ6-N-acetylbenzylamide) ruthenium(II) dimer (0.022 g, 0.034 mmol) were suspended 
in anhydrous MeOH (10 mL) and the solution was heated to 40 °C under an argon atmosphere, for 
16 h. The volume of the solution was reduced to 1.5 mL and purified by reverse phase HPLC (H2O 
: MeOH) to yield the title compound (0.018 g, 76%) as a yellow solid; δH (DMSO-d6) 10.6 (1H, s, 
H11), 10.4 (1H, s, H21), 9.99 (1H, d, 3JHH 5.0 Hz, H
2), 9.86 (1H, d, 3JHH 5.5 Hz, H
9), 9.07 (1H, dd, 
3JHH 8.4 Hz 4JHH 3.3 Hz, H
4), 8.83 (1H, d, 3JHH 8.1 Hz, H
7), 8.65 (1H, s, H20),  8.52 (1H, t, 3JHH 5.8 
Hz, Hf), 8.47 (1H, s, H6), 8.16 (1H, dd, 3JHH 8.4 Hz 3JHH 5.0 Hz H
3), 8.06 (1H, dd, 3JHH 8.1 Hz 3JHH 
5.5 Hz, H8), 6.39 (1H, d, 3JHH 5.8 Hz, H
c), 6.38 (1H, d, 3JHH 6.0 Hz, H
c’) 6.26 (2H, t, 3JHH 5.9 Hz, H
b 
Hb’), 5.96 (1H, t, 3JHH 5.9 Hz, H
a), 4.19 (2H, d, 3JHH 5.8 Hz, H
e), 2.57 (2H, t, 3JHH 6.5 Hz, H
13), 1.94 
(2H, t, 3JHH 6.5 Hz, H
18), 1.75 (3H, s, Hh), 1.65 (2H, bm, H14), 1.49 (2H, bm, H17), 1.32-1.26 (4H, 
bm, H15 H16); δC (DMSO-d6) 173.2 (C
12), 170.2 (Cg), 169.5 (C19), 156.6 (C2), 155.4 (C9), 146.1 
(C1’), 143.5 (C10’), 138.5 (C7), 135.4 (C4), 133.8 (C4’), 130.0 (C6’), 126.7 (C8), 126.6 (C5), 125.9 
(C3), 119.0 (C6), 102.7 (Cd), 87.6 (2C, Cb), 84.6 (2C, Cc), 84.4 (Ca), 40.4 (Ce), 36.4 (C13), 32.7 
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(C18), 28.9-28.8 (C15 C16), 25.5 (C17), 25.4 (C14), 22.7 (Ch); m/z (HRMS+) 646.1320 [M-Cl]+ 
(C29H33N5O435Cl96Ru requires 646.1297).  
 
Chloro(ƞ6-N-trimethylacetylbenzylamide) N20-hydroxy-N11-(1,10-phenanthrolin-5-
yl)octanediamide ruthenium(II) chloride Ru4BL2 
Dichloro(ƞ6-N-trimethylacetylbenzylamide) ruthenium(II) dimer (0.035 g, 0.048 mmol) and 
N20-hydroxy-N11-(1,10-phenanthrolin-5-yl)octanediamide (0.035 g, 0.096 mmol) were 
suspended in anhydrous MeOH (10 mL) and the solution was heated to 40 °C under an argon 
atmosphere, for 16 h. The volume of the solution was reduced to 1.5 mL and purified by reverse 
phase HPLC (H2O : MeOH) to yield the title compound (0.046 g, 66%) as a dark yellow solid; δH 
(DMSO-d6) 10.6 (1H, s, H
11), 10.4 (1H, s, H21), 9.99 (1H, d, 3JHH 4.9 Hz, H
2), 9.85 (1H, d, 3JHH 5.0 
Hz, H9), 9.07 (1H, d, 3JHH 8.5 Hz, H
4), 8.82 (1H, d, 3JHH 8.3 Hz, H
7), 8.64 (1H, s, H20), 8.47 (1H, s, 
H6), 8.17-8.14 (2H, bm, H3 H
f), 8.05 (1H, dd, 3JHH 8.3 Hz 3JHH 5.0 Hz, H
8), 6.39 (2H, t, 3JHH 5.8 Hz, 
Hb), 6.22 (2H, d, 3JHH 5.8 Hz, H
c), 5.95 (1H, t, 3JHH 5.8 Hz, H
a), 4.18 (2H, d, 3JHH 6.0 Hz, H
e), 2.57 
(2H, t, 3JHH 7.3 Hz, H
13), 1.94 (2H, t, 3JHH 7.3 Hz, H
18), 1.65 (2H, quin, 3JHH 7.3 Hz, H
14), 1.49 (2H, 
quin, 3JHH 7.3 Hz, H
17), 1.36-1.33 (2H, bm, H15), 1.30-1.26 (2H, bm, H16), 0.98 (9H, s, Hi); δC 
(DMSO-d6) 178.2 (C
g), 173.2 (C12), 169.5 (C19), 156.6 (C2), 155.3 (C9), 146.2 (C1’), 143.5 (C10’), 
138.5 (C7), 135.4 (C4), 133.8 (C5), 130.2 (C6’), 126.6 (C8), 126.5 (C4’), 125.9 (C3), 119.0 (C6), 103.1 
(Cd), 87.7-87.6 (Cb Cb’), 84.5 (Ca), 84.4-84.3 (Cc Cc’), 40.6 (Ce), 38.4 (Ch), 36.4 (C13), 32.7 (C18), 
28.9 (C15), 28.8 (C16), 27.6 (3C, Ci), 25.5 (C17), 25.4 (C14); m/z (HRMS+) 688.1774 [M-Cl]+ 
(C32H39N5O435Cl96Ru requires 688.1767). 





ruthenium(II) chloride Ru4CL2 
Dichloro(N-benzoyl- ƞ6-benzylamide) ruthenium(II) dimer (0.040 g, 0.052 mmol) and N20-
hydroxy-N11-(1,10-phenanthrolin-5-yl)octanediamide (0.038 g, 0.104 mmol) were suspended in 
anhydrous MeOH (10 mL) and the solution was heated to 40 °C under an argon atmosphere, for 16 
h. The volume of the solution was reduced to 1.5 mL and purified by reverse phase HPLC (H2O : 
MeOH) to yield the title compound (0.012 g, 31%) as a dark yellow solid; δH (DMSO-d6) 10.6 (1H, 
s, H11), 10.4 (1H, s, H21), 10.0 (1H, d, 3JHH 5.0 Hz, H
2), 9.84 (1H, d, 3JHH 5.1 Hz, H
9), 9.15 (1H, t, 
3JHH 5.7 Hz, H
f), 9.00 (1H, d, 3JHH 8.5 Hz, H
4), 8.75 (1H, d, 3JHH 8.3 Hz, H
7), 8.65 (1H, s, H20), 8.43 
(1H, s, H6), 8.10 (1H, dd, 3JHH 8.5 Hz 3JHH 5.0 Hz, H
3), 8.00 (1H, dd, 3JHH 8.3 Hz 3JHH 5.1 Hz, H
8), 
7.64 (2H, d, 3JHH 6.9 Hz, H
o), 7.40 (1H, t, 3JHH 6.9 Hz, H
p), 7.37 (2H, t, 3JHH 6.9 Hz, H
m), 6.43 (2H, 
d, 3JHH 5.8 Hz, H
c), 6.37 (2H, t, 3JHH 5.8 Hz, H
b), 6.05 (1H, t, 3JHH 5.8 Hz, H
a), 4.35 (2H, d, 3JHH 5.7 
Hz, He), 2.57 (2H, t, 3JHH 7.1 Hz, H
13), 1.95 (2H, t, 3JHH 7.1 Hz, H
18), 1.68-1.64 (2H, bm, H14), 1.51-
1.47 (2H, bm, H17), 1.38-1.34 (2H, bm, H15), 1.31-1.27 (2H, bm, H16); δC (DMSO-d6) 173.2 (C
12), 
169.5 (C19), 166.5 (Cg), 156.5 (C2), 155.2 (C9), 146.1 (C1’), 143.5 (C10’), 138.4 (C7), 135.2 (C4), 
133.8 (C6’), 133.5 (Ci), 131.9 (Cp), 130.1 (C4’), 128.6 (2C, Cm), 127.6 (2C, Co), 126.6 (C8), 126.5 
(C5), 125.8 (C3), 118.9 (C6), 86.6 (Ca), 86.2 (2C, Cb), 86.1 (2C, Cc), 86.0 (Cd), 40.9 (Ce), 36.4 (C13), 
32.7 (C18), 28.9 (C16), 28.8 (C15), 25.5 (C14), 25.4 (C17); m/z (HRMS+) 708.1465 [M-Cl]+ 
(C34H35N5O435Cl96Ru requires 708.1454).   





yl)octanediamide ruthenium(II) chloride Ru4DL2 
Dichloro(ƞ6-N-2-thiophenecarbonylbenzylamide) ruthenium(II) dimer (0.052 g, 0.067 mmol) 
and N20-hydroxy-N11-(1,10-phenanthrolin-5-yl)octanediamide (0.048 g, 0.133 mmol) were 
dissolved in anhydrous MeOH (10 mL) and the reaction heated to 40 °C under an argon 
atmosphere for 16 h. The volume of the resulting solution was reduced to 1.5 mL and purified by 
reverse phase HPLC (H2O : MeOH) to afford the title compound (0.024 g, 48%) as a pale brown 
solid; δH (DMSO-d6) 10.5 (1H, s, H
11), 10.3 (1H, s, H21), 9.98 (1H, d, 3JHH 5.3 Hz, H
2), 9.85 (1H, d, 
3JHH 5.1 Hz, H
9), 9.18 (1H, t, 3JHH 5.7 Hz, H
f), 9.00 (1H, dd, 3JHH 8.3 Hz 4JHH 2.1 Hz, H
4), 8.76 (1H, 
d, 3JHH 8.3 Hz, H
7), 8.63 (1H, s, H20), 8.43 (1H, s, H6), 8.11 (1H, dd, 3JHH 8.3 Hz 3JHH 5.3 Hz, H
3), 
8.00 (1H, dd, 3JHH 8.3 Hz 3JHH 5.1 Hz, H
8), 7.70 (1H, d, 3JHH 4.1 Hz, H
k), 7.60 (1H, d, 3JHH 4.1 Hz, 
Hi), 7.07 (1H, t, 3JHH 4.1 Hz, H
j), 6.42 (2H, d, 3JHH 5.0 Hz, H
c), 6.37-6.35 (2H, bm, Hb), 6.05 (1H, t, 
3JHH 5.0 Hz, H
a), 4.32 (2H, d, 3JHH 5.7 Hz, H
e), 2.56 (2H, t, 3JHH 7.0 Hz, H
13), 1.94 (2H, t, 3JHH 7.0 
Hz, H18), 1.68-1.64 (2H, bm, H14), 1.51-1.47 (2H, bm, H17), 1.37-1.33 (2H, bm, H15), 1.30-1.27 
(2H, bm, H16); δC (DMSO-d6) 173.1 (C
12), 169.5 (C19), 161.6 (Cg), 156.5 (C2), 155.3 (C9), 146.1 
(C1’), 143.5 (C10’), 138.9 (Ch), 138.4 (C7), 135.2 (C4), 133.7 (C5), 131.7 (Ck), 130.2 (C6’), 129.1 (Ci), 
128.3 (Cj), 126.6 (C8), 126.5 (C4’), 125.7 (C3), 118.9 (C6), 101.4 (Cd), 86.6 (Ca), 86.2 (2C, Cb), 86.1 
(2C, Cc), 40.7 (Ce), 36.4 (C13), 32.7 (C18), 28.9 (C16), 28.8 (C15), 25.5 (C17), 25.4 (C14); m/z 
(HRMS+) 714.1020 [M-Cl]+ (C32H33N5O4S35Cl96Ru requires 714.1018). 





yl)octanediamide ruthenium(II) chloride Ru5AL2 
Dichloro(ƞ6-4-methyl-N-acetylbenzylamide) ruthenium(II) dimer (0.038 g, 0.056 mmol) and 
N20-hydroxy-N11-(1,10-phenanthrolin-5-yl)octanediamide (0.041 g, 0.113 mmol) were dissolved 
in anhydrous MeOH (10 mL) and the reaction heated to 40 °C under an argon atmosphere for 16 h. 
The volume of the resulting solution was reduced to 1.5 mL and purified by reverse phase HPLC 
(H2O : MeOH) to afford the title compound (0.053 g, 85%) as a yellow solid; δH (DMSO-d6) 10.6 
(1H, s, H11), 10.4 (1H, s, H21), 9.92 (1H, d, 3JHH 5.0 Hz, H
2), 9.79 (1H, d, 3JHH 5.0 Hz, H
9), 9.06 
(1H, d, 3JHH 8.7 Hz, H
4), 8.81 (1H, d, 3JHH 8.2 Hz, H
7), 8.64 (1H, s, H20), 8.47 (1H, s, H6), 8.31 (1H, 
t, 3JHH 5.7 Hz, H
g), 8.15 (1H, dd, 3JHH 8.7 Hz 3JHH 5.0 Hz, H
3), 8.04 (1H, dd, 3JHH 8.2 Hz 3JHH 5.0 
Hz, H8), 6.36 (2H, m, Hd), 6.07 (1H, d, 3JHH 5.7 Hz, H
c), 6.06 (1H, d, 3JHH 5.7 Hz, H
c’), 3.43 (2H, d, 
3JHH 5.7 Hz, H
f), 2.56 (2H, t, 3JHH 7.4 Hz, H
13), 2.13 (3H, s, Ha), 1.93 (2H, t, 3JHH 7.4 Hz, H
18), 1.65 
(2H, quin, 3JHH 7.4 Hz, H
14), 1.49 (2H, quin, 3JHH 7.4 Hz, H
17), 1.46 (3H, s, Hi), 1.37-1.32 (2H, m, 
H15), 1.30-1.26 (2H, m, H17); δC (DMSO-d6) 173.2 (C
12), 169.6 (Ch), 169.5 (C19), 156.3 (C2), 155.1 
(C9), 146.2 (C1’), 143.6 (C10’), 138.4 (C7), 135.2 (C4), 133.8 (C5), 130.1 (C6’), 127.6 (C4’), 126.6 
(C8), 125.8 (C3), 119.0 (C6), 104.8 (Cb), 95.4 (Ce), 88.5-88.4 (Cd, Cd’), 82.9-82.7 (Cc, Cc’), 39.3 (Cf), 
36.4 (C13), 32.7 (C18), 28.9 (C16), 28.8 (C15), 25.5 (C17), 25.4 (C14), 22.4 (Ci), 18.8 (Ca); m/z 









yl)octanediamide ruthenium(II) chloride Ru5BL2 
Dichloro(ƞ6-4-methyl-N-trimethylacetylbenzylamide) ruthenium(II) dimer (0.037 g, 0.049 
mmol) and N20-hydroxy-N11-(1,10-phenanthrolin-5-yl)octanediamide (0.035 g, 0.098 mmol) 
were dissolved in anhydrous MeOH (10 mL) and the reaction heated to 40 °C under an argon 
atmosphere for 16 h. The volume of the resulting solution was reduced to 1.5 mL and purified by 
reverse phase HPLC (H2O : MeOH) to afford the title compound (0.027 g, 75%) as a yellow solid; 
δH (DMSO-d6) 10.56 (1H, s, H
11), 10.36 (1H, s, H21), 9.94 (1H, d, 3JHH 5.3 Hz, H
2), 9.80 (1H, d, 
3JHH 5.5 Hz, H
9), 9.05 (1H, d, 3JHH 8.2 Hz, H
4), 8.82 (1H, d, 3JHH 8.1 Hz, H
7), 8.64 (1H, s, H20), 8.48 
(1H, s, H6), 8.16 (1H, dd, 3JHH 8.2 Hz 3JHH 5.3 Hz, H
3), 8.05 (1H, dd, 3JHH 8.1 Hz 3JHH 5.5 Hz, H
8), 
7.94 (1H, t, 3JHH 5.8 Hz, H
g), 6.29 (1H, d, 3JHH 6.0 Hz, H
d), 6.28 (1H, d, 3JHH 6.0 Hz, H
d’), 6.07 (2H, 
bm, Hc Hc’), 3.94 (2H, d, 3JHH 5.8 Hz, H
f), 2.56 (2H, t, 3JHH 7.2 Hz, H
13), 2.15 (3H, s, Ha), 1.94 (2H, 
t, 3JHH 7.2 Hz, H
18), 1.66 (2H, 2H, quin, 3JHH 7.2 Hz, H
14), 1.49 (2H, quin, 3JHH 7.2 Hz, H
17), 1.38-
1.33 (2H, m, H15), 1.31-1.27 (2H, m, H16), 0.80 (9H, s, Hj); δC (DMSO-d6) 177.8 (C
h), 173.1 (C12), 
169.5 (C19), 156.2 (C2), 154.9 (C9), 146.4 (C1’), 143.7 (C10’), 138.4 (C7), 135.2 (C4), 133.7 (C4’), 
130.2 (C6’), 126.6 (C8), 126.5 (C5), 125.8 (C3), 118.9 (C6), 104.4 (Cb), 95.8 (Ce), 87.8-87.7 (Cd, Cd’), 
83.3-83.1 (Cc, Cc’), 39.5 (Cf), 38.3 (Ci), 36.4 (C13), 32.7 (C18), 28.8 (C15, C16), 27.5 (Cj), 25.4 (C14, 









octanediamide ruthenium(II) chloride Ru5CL2 
Dichloro(ƞ6-4-methyl-N-benzoylbenzylamide) ruthenium(II) dimer (0.040 g, 0.050 mmol) and 
N20-hydroxy-N11-(1,10-phenanthrolin-5-yl)octanediamide (0.036 g, 0.100 mmol) were dissolved 
in anhydrous MeOH (10 mL) and the reaction heated to 40 °C under an argon atmosphere for 16 h. 
The volume of the resulting solution was reduced to 1.5 mL and purified by reverse phase HPLC 
(H2O : MeOH) to afford the title compound (0.050 g, 67%) as a yellow solid; δH (DMSO-d6) 10.53 
(1H, s, H11), 10.38 (1H, s, H21), 9.92 (1H, d, 3JHH 5.0 Hz, H
2), 9.78 (1H, d, 3JHH 4.8 Hz, H
9), 8.96-
8.94 (2H, m, H4, Hg), 8.68 (1H, d, 3JHH 8.0 Hz, H
7), 8.65 (1H, s, H20), 8.40 (1H, s, H6), 8.04 (1H, 
dd, 3JHH 8.1 Hz 3JHH 5.0 Hz, H
3), 7.93 (1H, dd, 3JHH 8.0 Hz 3JHH 4.8 Hz, H
8), 7.44 (1H, t, 3JHH 7.0 
Hz, Hp), 7.36 (2H, d, 3JHH 7.0 Hz, H
o), 7.29 (2H, t, 3JHH 7.0 Hz, H
m), 6.55 (2H, bm, Hd Hd’), 6.05 
(1H, d, 3JHH 7.0 Hz, H
c), 6.03 (1H, d, 3JHH 7.0 Hz, Hc’), 4.12 (2H, d, 3JHH 6.0 Hz, H
f), 2.59 (2H, t, 
3JHH 7.0 Hz, H
13), 2.18 (3H, s, Ha), 1.96 (2H, t, 3JHH 7.0 Hz, H
18), 1.68 (2H, quin, 3JHH 7.0 Hz, H
14), 
1.52 (2H, quin, 3JHH 7.0 Hz, H
17), 1.39-1.36 (2H, m, H15), 1.34-1.31 (2H, m, H16); δC (DMSO-d6) 
173.1 (C12), 169.5 (C19), 165.7 (Ch), 156.1 (C2), 154.9 (C9), 146.3 (C1’), 143.6 (C10’), 138.2 (C7), 
134.9 (C4), 133.6 (C4’), 132.9 (Ci), 131.8 (Cp), 130.2 (C6’), 128.4 (2C, Cm), 127.7 (C5), 127.4 (2C, 
Co), 126.4 (C8), 125.6 (C3), 118.7 (C6), 107.4 (Cb), 94.6 (Ce), 89.8-89.7 (Cd, Cd’), 81.5-81.2 (Cc, 
Cc’), 39.6 (Cf), 36.4 (C13), 32.7 (C18), 28.8 (C15, C16), 25.5 (C14, C17), 19.3 (Ca); m/z (HRMS+) 
722.1605 [M-Cl]+ (C35H37N5O435Cl96Ru requires 722.1610).  
 
 





5-yl)octanediamide ruthenium(II) chloride Ru5DL2 
Dichloro(ƞ6-4-methyl-N-2-thiophenecarbonylbenzylamide) ruthenium(II) dimer (0.019 g, 
0.024 mmol) and N20-hydroxy-N11-(1,10-phenanthrolin-5-yl)octanediamide (0.017 g, 0.048 
mmol) were dissolved in anhydrous MeOH (10 mL) and the reaction heated to 40 °C under an 
argon atmosphere for 16 h. The volume of the resulting solution was reduced to 1.5 mL and 
purified by reverse phase HPLC (H2O : MeOH) to afford the title compound (0.009 g, 50%) as a 
yellow solid; δH (DMSO-d6) 10.45 (1H, s, H
11), 10.35 (1H, s, H21), 9.89 (1H, d, 3JHH 4.8 Hz, H
2), 
9.75 (1H, d, 3JHH 4.8 Hz, H
9), 8.94-8.91 (2H, m, Hg H4), 8.67 (1H, d, 3JHH 7.8 Hz, H
7), 8.63 (1H, s, 
H20), 8.40 (1H, s, H6), 8.04 (1H, dd, 3JHH 8.4 Hz 3JHH 4.8 Hz, H
3), 7.92 (1H, dd, 3JHH 7.8 Hz 3JHH 
4.8 Hz, H8), 7.62 (1H, dd, 3JHH 4.0 Hz 4JHH 1.0 Hz, H
l), 7.29 (1H, d, 3JHH 4.0 Hz, H
j), 6.96 (1H, t, 
3JHH 4.0 Hz, H
k), 6.54 (2H, d, 3JHH 6.5 Hz, H
d), 6.03 (1H, d, 3JHH 6.5 Hz, H
c), 6.01 (1H, d, 3JHH 6.5 
Hz, Hc’), 4.07 (2H, d, 3JHH 6.5 Hz, H
f), 2.56 (2H, t, 3JHH 6.7 Hz, H
13), 2.17 (3H, s, Ha), 1.94 (2H, t, 
3JHH 6.7 Hz, H
18), 1.66 (2H, quin, 3JHH 6.7 Hz, H
14), 1.49 (2H, quin, 3JHH 6.7 Hz, H
17), 1.38-1.33 
(2H, m, H15), 1.31-1.27 (2H, m, H16); δC (DMSO-d6) 173.1 (C
12), 169.5 (C19), 160.9 (Ch), 156.1 
(C2), 154.8 (C9), 146.2 (C1’), 143.6 (C10’), 138.6 (Ci), 138.2 (C7), 134.8 (C4), 133.6 (C4’), 131.5 (Cl), 
130.1 (C6’), 128.8 (Cj), 128.0 (Ck), 127.6 (C5), 126.4 (C8), 125.6 (C3), 118.7 (C6), 107.5 (Cb), 94.5 
(Ce), 89.9 (2C, Cd), 81.4-81.1 (2C, Cc Cc’), 39.4 Cf), 36.4 (C13), 32.7 (C18), 28.8 (2C, C15 C16), 25.5 
(C14), 25.4 (C17), 19.3 (Ca); m/z (HRMS+) 728.1183 [M-Cl]+ (C33H35N5O4S35Cl96Ru requires 









1,10-Phenanthrolin-5-amine (0.050 g, 0.25 mmol), methyl 4-(bromomethyl)benzoate (0.059 g, 0.25 
mmol) and trimethylamine (0.038 mL, 0.28 mmol) were suspended in anhydrous THF (10 mL) and 
the resulting mixture was heated at 60 °C, under an argon atmosphere for 16 h. The solution was 
extracted into ethyl acetate (20 mL) and washed with water (20 mL) and brine (20 mL). The 
organic layers were combined, dried over Na2SO4, filtered and solvent removed under vacuum. The 
crude orange solid was suspended in MeOH (3.75 mL), hydroxylamine (50%) solution (3.75 mL) 
and 1M NaOH (0.75 mL) were added and the mixture stirred for 30 min. The solution was 
neutralised and the resulting precipitate was filtered and washed with water to give the title 
compound (0.016 g, 9%). δH (DMSO-d6) 11.1 (1H, s, H
19), 9.08 (1H, dd, 3JHH 4.3 Hz 4JHH 1.5 Hz, 
H2), 8.95 (1H, s, H18), 8.87 (1H, dd, 3JHH 8.6 Hz 4JHH 1.5 Hz, H
4), 8.65 (1H, dd, 3JHH 4.4 Hz 4JHH 1.6 
Hz, H9), 8.05 (1H, d, 3JHH 8.0 Hz, H
7), 7.80 (1H, dd, 3JHH 8.6 Hz 3JHH 4.3 Hz, H
3), 7.68 (2H, d, 3JHH 
8.1 Hz, H15), 7.52-7.50 (1H, m, H8), 7.50 (2H, d, 3JHH 8.1 Hz, H
14), 7.45 (1H, t, 3JHH 5.5 Hz, H
11), 
6.60 (1H, s, H6), 4.62 (2H, d, 3JHH 5.5 Hz, H
12); δC (DMSO-d6) 164.5 (C
17), 149.9 (C2), 144.6 (C9), 
143.1 (C13), 142.1 (C1’), 139.6 (C10’), 134.7 (C7), 131.8 (C16), 131.7 (C6’), 131.0 (C4), 127.5 (2C, 
C15), 127.4 (2C, C14), 123.9 (C8), 123.1 (C3), 122.5 (C4’), 115.7 (C5), 99.0 (C6), 46.5 (C12); m/z 










ruthenium(II) chloride Ru1L3 
N18-Hydroxy-4-{[(1,10-phenanthrolin-5-yl)amino]methyl}benzamide (0.022 g, 0.066 mmol) 
and  dichloro(p-cymene) ruthenium(II) dimer (0.020 g, 0.033 mmol) were suspended  in 
anhydrous MeOH (5 mL). The reaction was stirred under an inert atmosphere at 40 °C for 16 h. 
The volume of the solution was a reduced and added to diethyl ether (10 mL). The resulting 
precipitate was purified by reverse phase HPLC (H2O : MeOH) to provide the title compound as a 
light yellow solid (0.015 g, 36%). δH (DMSO-d6) 11.1 (1H, s, H
19), 9.89 (1H, d, 3JHH 5.3 Hz, H
2), 
9.40 (1H, d, 3JHH 4.8 Hz, H
9), 9.30 (1H, d, 3JHH 8.4 Hz, H
4), 8.96 (1H, s, H18), 8.32 (1H, d, 3JHH 8.0 
Hz, H7), 8.20 (1H, m , H11), 8.13 (1H, dd, 3JHH 8.4 Hz 3JHH 5.3 Hz, H
3), 7.77 (1H, dd, 3JHH 8.0 Hz 
3JHH 4.8 Hz, H
8), 7.69 (2H, d, 3JHH 8.0 Hz, H
15), 7.51 (2H, d, 3JHH 8.0 Hz, H
14), 6.74 (1H, s, H6), 
6.26 (1H, d, 3JHH 5.2 Hz, H
d), 6.25 (1H, d, 3JHH 5.2 Hz, H
d’), 6.04 (1H, d, 3JHH 5.2 Hz, H
c), 6.01 (1H, 
d, 3JHH 5.2 Hz, H
c’), 4.64 (2H, d, 3JHH 5.5 Hz, H
12), 2.57 (1H, septet, 3JHH 7.2 Hz, H
f), 2.13 (3H, s, 
Ha), 0.89 (3H, d, 3JHH 7.2 Hz, H
g), 0.87 (3H, d, 3JHH 7.2 Hz, H
g’); δC (DMSO-d6) 164.4 (C
17), 156.1 
(C2), 150.9 (C9), 146.4 (C1’), 143.5 (C5), 142.1 (C13), 139.7 (C10’), 135.6 (C7), 134.0 (C4), 132.5 
(C6’), 132.0 (C16), 127.5 (2C, C15), 127.4 (2C, C14), 126.5 (C8), 125.4 (C3), 124.0 (C4’), 104.1 (Ce), 
103.0 (Cb), 98.3 (C6), 86.5 (Cd), 86.2 (Cd’), 84.3 (Cc), 84.1 (Cc’), 46.5 (C12), 30.8 (Cf), 22.1 (Cg), 











yl)amino]methyl}benzamide ruthenium(II) chloride Ru5AL3 
N18-Hydroxy-4-{[(1,10-phenanthrolin-5-yl)amino]methyl}benzamide (0.026 g, 0.075 mmol) 
and dichloro(ƞ6-4-methyl-N-acetylbenzylamide) ruthenium(II) dimer (0.025 g, 0.037 mmol) 
were suspended in MeOH (10 mL) and heated at 40 °C under an inert atmosphere for 16 h. The 
volume of solution was reduced by half and added, dropwise to diethyl ether (10 mL). The 
resulting precipitate was purified by reverse phase HPLC (H2O : MeOH) to afford the title 
compound as a yellow solid (0.020 g, 39%). δH (DMSO-d6) 11.1 (1H, s, H
19), 9.87 (1H, d, 3JHH 5.0 
Hz, H2), 9.38 (1H, d, 3JHH 5.0 Hz, H
9), 9.26 (1H, d, 3JHH 8.5 Hz, H
4), 8.96 (1H, s, H18), 8.30-8.28 
(2H, m, Hg H7), 8.16 (1H, t, 3JHH 6.0 Hz, H
11), 8.10 (1H, dd, 3JHH 8.5 Hz 3JHH 5.4 Hz, H
3), 7.74 (1H, 
dd, 3JHH 8.3 Hz 3JHH 5.0 Hz, H
8), 7.67 (2H, d, 3JHH 7.7 Hz, H
15), 7.49 (2H, d, 3JHH 7.7 Hz, H
14), 6.72 
(1H, s, H6), 6.28 (1H, d, 3JHH 6.0 Hz, H
d), 6.27 (1H, d, 3JHH 6.0 Hz, H
d’), 6.01 (1H, d, 3JHH 6.0 Hz, 
Hc), 6.00 (1H, d, 3JHH 6.0 Hz, H
c’), 4.64 (2H, d, 3JHH 6.0 Hz, H
12), 3.92 (2H, d, 3JHH 6.5 Hz, H
f), 
2.07 (3H, s, Ha), 1.50 (3H, s, Hi); δC (DMSO-d6) 169.7 (C
h), 164.4 (C17), 156.0 (C2), 150.8 (C9), 
146.7 (C1’), 143.4 (C5), 142.2 (C13), 140.1 (C10’), 135.5 (C7), 133.9 (C4), 132.5 (C6’), 131.8 (C16), 
127.5 (2C, C15), 127.4 (2C, C14), 126.3 (C8), 125.2 (C3), 124.1 (C4’), 103.7 (Cb), 98.3 (C6), 95.4 
(Ce), 88.3 (Cd), 88.2 (Cd’), 83.4 (Cc), 83.1 (Cc’), 46.5 (C12), 39.5 (Cf), 22.5 (Ci), 18.7 (Ca); m/z 










yl)amino] methyl}benzamide ruthenium(II) chloride Ru5BL3 
N18-Hydroxy-4-{[(1,10-phenanthrolin-5-yl)amino]methyl}benzamide (0.022 g, 0.066 mmol) 
and  dichloro(ƞ6-4-methyl-N-trimethylacetylbenzylamide) ruthenium(II) dimer (0.025 g, 0.033 
mmol) were suspended in anhydrous MeOH (5 mL). The reaction was stirred under an inert 
atmosphere at room temperature for 16 h. The volume of the solution was a reduced and added to 
diethyl ether (10 mL), cooled in a dry ice: acetone bath. The resulting precipitate was purified by 
reverse phase HPLC (H2O : MeOH) to provide the title compound as a light brown solid (0.029 g, 
63%). δH (DMSO-d6) 11.1 (1H, s, H
19), 9.90 (1H, d, 3JHH 4.9 Hz, H
2), 9.40 (1H, d, 3JHH 5.2 Hz, H
9), 
9.26 (1H, d, 3JHH 8.3 Hz, H
4), 8.98 (1H, s, H18), 8.31 (1H, d, 3JHH 8.5 Hz, H
7), 8.16-8.12 (2H, m, H3 
H11), 7.93 (1H, t, 3JHH 5.8 Hz, H
g), 7.77 (1H, dd, 3JHH 8.5 Hz 3JHH 5.2 Hz, H
8), 7.71 (2H, d, 3JHH 8.5 
Hz, H15), 7.51 (2H, d, 3JHH 8.5 Hz, H
14), 6.73 (1H, s, H6), 6.25 (1H, d, 3JHH 6.0 Hz, H
d), 6.20 (1H, d, 
3JHH 6.0 Hz, H
d’), 6.04 (1H, d, 3JHH 5.8 Hz, H
c), 6.03 (1H, d, 3JHH 5.8 Hz, H
c’), 4.67 (2H, d, 3JHH 5.6 
Hz, H12), 3.94 (2H, d, 3JHH 5.8 Hz, H
f), 2.13 (3H, s, Ha), 0.82 (9H, s, Hj); δC (DMSO-d6) 177.8 (C
h), 
164.4 (C17), 155.9 (C2), 150.7 (C9), 146.8 (C1’), 143.4 (C5), 142.5 (C13), 140.2 (C10’), 135.4 (C7), 
133.8 (C4), 132.6 (C6’), 131.9 (C16), 127.4 (2C, C15), 127.3 (2C, C14), 126.3 (C8), 125.2 (C3), 124.1 
(C4’), 103.6 (Cb), 98.2 (C6), 95.8 (Ce), 87.7 (Cd), 87.5 (Cd’), 83.6 (Cc), 83.4 (Cc’), 46.4 (C12), 39.5 









methyl}benzamide ruthenium(II) chloride Ru5CL3 
N18-Hydroxy-4-{[(1,10-phenanthrolin-5-yl)amino]methyl}benzamide (0.020 g, 0.058 mmol) 
and dichloro(ƞ6-4-methyl-N-benzoylbenzylamide) ruthenium(II) dimer (0.023 g, 0.029 mmol)  
were suspended  in anhydrous MeOH (5 mL). The reaction was stirred under an inert atmosphere at 
room temperature for 16 h. The volume of the solution was a reduced and added to diethyl ether 
(10 mL), cooled in a dry ice: acetone bath. The resulting precipitate was purified by reverse phase 
HPLC (H2O : MeOH) to provide the title compound as a yellow solid (0.010 g, 23%). δH (MeOD-
d4) 9.75 (1H, d, 3JHH 5.3 Hz, H
2), 9.26 (1H, d, 3JHH 5.5 Hz, H
9), 8.88 (1H, d, 3JHH 8.0 Hz, H
4), 7.95 
(1H, d, 3JHH 8.0 Hz, H
7), 7.92 (1H, dd, 3JHH 8.0 Hz 3JHH 5.3 Hz, H
3), 7.71 (2H, d, 3JHH 8.3 Hz, H
15), 
7.55-7.53 (3H, m, H14, H8), 7.42 (1H, t, 3JHH 8.1 Hz, H
p), 7.27 (2H, d, 3JHH 8.1 Hz, H
o), 7.20 (2H, t, 
3JHH 8.1 Hz, H
m), 6.47 (1H, s, H6), 6.43 (1H, d, 3JHH 6.3 Hz, H
d), 6.39 (1H, d, 3JHH 6.3 Hz, H
d’), 
5.87 (1H, d, 3JHH 6.3 Hz, H
c), 5.85 (1H, d, 3JHH 6.3 Hz, H
c’), 4.62 (1H, d, 2JHH -16.4 Hz, H
12), 4.56 
(1H, d, 2JHH -16.4 Hz, H
12’), 4.25 (1H, d, 2JHH -15.0 Hz, H
f), 4.21 (1H, d, 2JHH -15.0 Hz, H
f’), 2.25 
(3H, s, Ha); δC (MeOD-d4) 167.1 (C
h), 166.4 (C17), 154.8 (C2), 149.8 (C9), 146.8 (C1’), 142.9 (C5), 
142.3 (C13), 140.3 (C10’), 135.1 (C7), 132.7 (C4),  132.6 (C6’), 131.9 (Ci), 131.2 (Cp), 131.0 (C16), 
127.9 (2C, Cm), 127.1 (2C, C15), 126.9 (2C, C14), 126.6 (2C, Co), 125.6 (C8), 124.5 (C3), 124.2 
(C4’), 107.6 (Cb), 98.7 (C6), 94.3 (Ce), 89.4 (Cd), 89.3 (Cd’), 81.3 (Cc), 80.9 (Cc’), 46.5 (C12), 39.3 










phenanthrolin-5-yl) amino]methyl}benzamide ruthenium(II) chloride Ru5DL3 
N18-Hydroxy-4-{[(1,10-phenanthrolin-5-yl)amino]methyl}benzamide (0.006 g, 0.018 mmol) 
and dichloro(ƞ6-4-methyl-N-2-thiophenecarbonylbenzylamide) ruthenium(II) dimer (0.007 g, 
0.009 mmol) were suspended  in anhydrous MeOH (5 mL). The reaction was stirred under an inert 
atmosphere at room temperature for 16 h. The volume of the solution was a reduced and added to 
diethyl ether (10 mL), cooled in a dry ice: acetone bath. The resulting precipitate was purified by 
reverse phase HPLC (H2O : MeOH) to provide the title compound as a yellow solid (0.006 g, 46%). 
δH (MeOD-d4) 9.73 (1H, d, 3JHH 5.1 Hz, H
2), 9.26 (1H, d, 3JHH 5.2 Hz, H
9), 8.90 (1H, d, 3JHH 8.2 
Hz, H4), 8.01 (1H, d, 3JHH 8.0 Hz, H
7), 7.91 (1H, dd, 3JHH 8.2 Hz 3JHH 5.1 Hz, H
3), 7.73 (2H, d, 3JHH 
8.2 Hz, H15), 7.58-7.56 (3H, m, H8 H14), 7.45 (1H, dd, 3JHH 5.0 4JHH 1.1 Hz, H
j), 7.09 (1H, dd, 3JHH 
3.7 Hz 4JHH 1.1 Hz, H
l), 6.89 (1H, dd, 3JHH 5.0 Hz 3JHH 3.7 Hz, H
k), 6.51 (1H, s, H6), 6.44 (1H, d, 
3JHH 6.2 Hz, H
d), 6.39 (1H, d, 3JHH 6.2 Hz, H
d’), 5.86 (1H, d, 3JHH 6.2 Hz, H
c), 5.85 (1H, d, 3JHH 6.2 
Hz, Hc’), 4.71 (1H, d, 2JHH -16.8 Hz, H
12), 4.62 (1H, d, 2JHH -16.8 Hz, H
12’), 4.20 (1H, d, 2JHH -15.2 
Hz, Hf), 4.15 (1H, d, 2JHH -15.2 Hz, H
f’), 2.28 (3H, s, Ha); δC (MeOD-d4) 166.4 (C
17), 161.7 (Ch), 
154.7 (C2), 149.7 (C9), 146.8 (C1’), 143.0 (C5), 142.4 (C13), 140.4 (C10’), 136.9 (Ci), 135.0 (C4), 
132.7 (C7), 132.6 (C16), 131.1 (C6’), 130.8 (Cl), 128.3 (Cj), 127.2 (Ck), 127.1 (2C, C15), 127.0 (2C, 
C14), 125.5 (C8), 124.4 (C3), 124.3 (C4’), 108.4 (Cb), 98.7 (C6), 93.9 (Ce), 89.8 (Cd), 89.6 (Cd’), 80.7 
(Cc), 80.4 (Cc’), 46.5 (C12), 39.0 (Cf), 18.1 (Ca); m/z (HRMS+) 706.0768 [M-Cl]+ 
(C33H29N5O3S35Cl96Ru requires 706.0756).  
 




7-[(1,10-Phenanthrolin-5-yl)carbamoyl]heptanoic acid 28 
1,10-Phenanthrolin-5-amine (0.200 g, 1.02 mmol) and 4-(dimethylamino)pyridine (0.125 g, 1.02 
mmol) were suspended in DMF (10 mL) and methyl 8-chloro-8-oxooctanoate (0.189 mL, 1.33 
mmol) was added gradually. The reaction was stirred at room temperature for 16 h under an inert 
atmosphere. The volume of the solution was reduced and added dropwise to a stirring solution of 
diethyl ether and the filtrate decanted off. The resulting orange solid was then suspended in 10 mL 
of a MeOH/THF mixture (1:1) and LiOH was added (0.065 g, 1.56 mmol) and the reaction was 
stirred at ambient temperature for 48 h. The resulting solution was neutralised with 1M HCl, 
extracted into ethyl acetate (2 x 20 mL), dried over Na2SO4, filtered and recrystallized from ethyl 
acetate to give the title compound  (0.130 g, 59%). δH (DMSO-d6) 11.9 (1H, bs, H
20), 10.1 (1H, s, 
H11), 9.09 (1H, dd, 3JHH 4.4 Hz 4JHH 1.4 Hz, H
2), 9.00 (1H, dd, 3JHH 7.9 Hz 4JHH 4.3 Hz, H
9), 8.57 
(1H, dd, 3JHH 8.5 Hz 4JHH 1.4 Hz, H
4), 8.41 (1H, dd, 3JHH 7.9 Hz 4JHH 1.6 Hz, H
7), 8.14 (1H, s, H6), 
7.80 (1H, dd, 3JHH 8.5 Hz 3JHH 4.4 Hz, H
3), 7.70 (1H, dd, 3JHH 7.9 Hz 3JHH 4.3 Hz, H
8), 2.52 (2H, t, 
3JHH 7.3 Hz, H
13), 2.22 (2H, t, 3JHH 7.3 Hz, H
18), 1.68 (2H, quin, 3JHH 7.3 Hz, H
14), 1.53 (2H, quin, 
3JHH 7.3 Hz, H
17), 1.42-1.38 (2H, m, H15), 1.37-1.34 (2H, m, H16); δC (DMSO-d6) 174.9 (C
19), 172.8 
(C12), 150.2 (C2), 149.6 (C9), 146.3 (C1’), 144.2 (C10’), 136.1 (C7), 132.1 (C5), 132.0 (C4), 128.5 
(C6’), 125.1 (C4’), 123.9 (C8), 123.2 (C3), 120.4 (C6), 36.3 (C13), 34.1 (C18), 28.9 (C15), 28.7 (C16), 
25.5 (C14), 24.8 (C17); m/z (HRMS+) 352.1670 [M+H]+ (C20H22N3O3 requires 352.1661).  
 
N20-[(4-Nitrophenyl)methoxy]-N11-(1,10-phenanthrolin-5-yl)octanediamide L4 
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7-[(1,10-Phenanthrolin-5-yl)carbamoyl]heptanoic acid (0.130 g, 0.37 mmol) and O-(4-
nitrobenzyl)hydroxylamine hydrochloride (0.114 g, 0.55 mmol) were suspended in anhydrous 
DMF (15 mL). HATU (0.126 g, 0.33 mmol) was added to the stirring solution, after 10 min 
diisopropylamine (0.156 mL, 0.92 mmol) was added and the solution was stirred at ambient 
temperature for 16 h. The solution was dropped into a saturated NaCl solution (40 mL). The 
resulting precipitate was filtered and washed with water to yield the title compound (0.087 g, 47%). 
δH (DMSO-d6) 11.3 (1H, s, H
20), 10.4 (1H, s, H11), 9.10 (1H, dd, 3JHH 4.4 Hz 4JHH 1.3 Hz, H
2), 9.00 
(1H, dd, 3JHH 4.0 Hz 4JHH 1.6 Hz, H
9), 8.74 (1H, d, 3JHH 8.6 Hz, H
4), 8.50 (1H, d, 3JHH 7.6 Hz, H
7), 
8.19 (2H, d, 3JHH 7.4 Hz, H
24), 8.18 (1H, s, H6), 7.85 (1H, dd, 3JHH 8.6 Hz 3JHH 4.4 Hz, H
3), 7.78 
(1H, dd, 3JHH 7.6 Hz 3JHH 4.0 Hz, H
8), 7.65 (2H, d, 3JHH 7.4 Hz, H
23), 4.90 (2H, s, H21), 2.53 (2H, t, 
3JHH 7.5 Hz, H
13), 1.96 (2H, t, 3JHH 7.3 Hz, H
18), 1.62 (2H, quin, 3JHH 7.5 Hz, H
14), 1.48 (2H, quin, 
3JHH 7.3 Hz, H
17), 1.32 (2H, m, H15), 1.25 (2H, m, H16); δC (DMSO-d6) 173.0 (C
19), 170.0 (C12), 
150.3 (C2), 149.5 (C9), 147.6 (C25), 145.4 (C1’), 144.5 (C22), 143.0 (C10’), 137.0 (C7), 133.1 (C4), 
132.6 (C5), 129.6 (2C, C23), 128.6 (C6’), 125.2 (C4’), 124.3 (C8), 123.7 (2C, C24), 123.5 (C3), 120.2 
(C6), 75.8 (C21), 36.3 (C13), 32.6 (C18), 28.8 (C15), 28.7 (C16), 25.5 (C14), 25.2 (C17); m/z (HRMS+) 
502.2093 [M+H]+ (C27H28N5O5 requires 502.2090). 
 
Chloro(p-cymene)N20-[(4-Nitrophenyl)methoxy]-N11-(1,10-phenanthrolin-5-yl)octanediamide 
ruthenium(II) chloride Ru1L4 
N20-[(4-Nitrophenyl)methoxy]-N11-(1,10-phenanthrolin-5-yl)octanediamide (0.030 g, 0.059 
mmol) and (p-cymene)ruthenium(II) chloride dimer (0.018 g, 0.029 mmol) were dissolved in 
MeOH (10 mL) and the solution was heated to 40 °C for 16 h. The solvent was removed under 
vacuum to give the title compound as a yellow solid (0.017 g, 34%). δH (MeOD-d4) 9.87 (1H, dd, 
3JHH 5.1 Hz 4JHH 1.2 Hz, H
2), 9.75 (1H, dd, 3JHH 5.1 Hz 4JHH 1.0 Hz, H
9), 8.91 (1H, d, 3JHH 8.6 Hz 
4JHH 1.2 Hz, H
4), 8.71 (1H, d, 3JHH 8.2 Hz 4JHH 1.0, H
7), 8.41 (1H, s, H6), 8.21 (2H, d, 3JHH 8.3 Hz, 
H24), 8.12 (1H, dd, 3JHH 8.6 Hz 3JHH 5.1 Hz, H
3), 8.03 (1H, dd, 3JHH 8.2 Hz 3JHH 5.1 Hz, H
8), 7.66 
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(2H, d, 3JHH 8.3 Hz, H
23), 6.23 (1H, d, 3JHH 6.7 Hz, H
d), 6.22 (1H, d, 3JHH 6.7 Hz, H
d’), 6.00 (1H, d, 
3JHH 6.7 Hz, H
c), 5.99 (1H, d, 3JHH 6.7 Hz, H
c’), 4.96 (2H, s, H21), 2.66 (1H, sept, 3JHH 6.9 Hz, H
f), 
2.61 (2H, t, 3JHH 7.3 Hz, H
13), 2.25 (3H, s, Ha), 2.09 (2H, t, 3JHH 7.3 Hz, H
18), 1.76 (2H, quin, 3JHH 
7.3 Hz, H14), 1.62 (2H, quin, 3JHH 7.3 Hz, H
17), 1.47-1.43 (2H, m, H15), 1.37-1.33 (2H, m, H16), 
0.99 (3H, d, 3JHH 6.9 Hz, H
g), 0.98 (3H, d, 3JHH 6.9 Hz, H
g’); δC (MeOD-d4) 174.3 (C
12), 171.6 
(C19), 155.6 (C2), 154.6 (C9), 147.9 (C25), 146.0 (C1’), 143.7 (C10’), 143.2 (C22), 138.1 (C7), 134.5 
(C4), 133.4 (C5), 130.2 (C6’), 129.4 (2C, C24), 126.9 (C4’), 126.3 (C8), 125.6 (C3), 123.0 (2C, C24), 
120.1 (C6), 105.0 (Ce), 103.4 (Cb), 86.1 (Cd), 85.9 (Cd’), 84.1 (Cc), 84.0 (Cc’), 76.0 (C21), 35.9 (C13), 
32.2 (C18), 30.9 (Cf), 28.5 (C15), 28.2 (C16), 25.0 (C14), 24.9 (C17), 20.8 (Cg), 20.7 (Cg’), 17.4 (Ca); 
m/z (HRMS+) 766.1882 [M-Cl]+ (C37H41N5O535Cl96Ru requires 766.1872).  
 
Chloro(pentamethylcyclopentadienyl)N20-[(4-Nitrophenyl)methoxy]-N11-(1,10-phenanthrolin-5-
yl)octanediamide rhodium(III) chloride RhL4 
N20-[(4-Nitrophenyl)methoxy]-N11-(1,10-phenanthrolin-5-yl)octanediamide (0.025 g, 0.049 
mmol) and dichloro(pentamethylcyclopentadienyl)rhodium(II) dimer (0.015 g, 0.025 mmol) were 
dissolved in MeOH (10 mL) and the resulting solution was heated to 40 °C, under an argon 
atmosphere for 16 h. The solvent was removed to give a dark yellow solid as the title compound 
(0.009 g, 22%). δH (MeOD-d4) 9.39 (1H, d, 3JHH 5.5 Hz, H
2), 9.28 (1H, d, 3JHH 5.3 Hz, H
9), 8.91 
(1H, d, 3JHH 8.8 Hz, H
4), 8.73 (1H, d, 3JHH 8.2 Hz, H
7), 8.39 (1H, s, H6), 8.19-8.17 (3H, m, H3 H24), 
8.09 (1H, dd, 3JHH 8.2 Hz 3JHH 5.3 Hz, H
8), 7.64 (2H, d, 3JHH 8.1 Hz, H
23), 4.94 (2H, s, H21), 2.60 
(2H, t, 3JHH 6.6 Hz, H
13), 2.08 (2H, t, 3JHH 7.5 Hz, H
18), 1.77 (15H, s, Ha), 1.75 (2H, quin, 3JHH 6.6 
Hz, H14), 1.60 (2H, quin, 3JHH 7.5 Hz, H
17), 1.46-1.42 (2H, m, H15), 1.36-1.32 (2H, m, H16); δC 
(MeOD-d4) 174.4 (C
12), 171.6 (C19), 152.1 (C2), 151.2 (C9), 147.8 (C25), 145.6 (C1’), 143.4 (C10’), 
143.2 (C22), 138.5 (C7), 134.8 (C4), 133.4 (C5), 130.3 (C6’), 129.3 (2C, C23), 127.0 (C4’), 126.7 (C8), 
126.2 (C3), 123.0 (2C, C24), 120.5 (C6), 97.5 (5C, Cb), 76.0 (C21), 35.9 (C13), 32.2 (C18), 28.5 (C15), 
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28.2 (C16), 25.0 (C14), 24.9 (C17), 7.59 (5C, Ca); m/z (HRMS+) 774.1962 [M-Cl]+ 























Crystal Structure Data 
Complex Ru1PP3 
Table 2 Crystal data and structure refinement of Ru1PP3. 
Empirical formula  C22H25ClNO2PRu 
Formula weight  502.92 
Temperature/K  120.0 
Crystal system  monoclinic 
Space group  P21/c 
a/Å  12.5685(6) 
b/Å  8.1196(4) 
c/Å  20.4312(10) 
α/°  90.00 
β/°  91.5345(16) 
γ/°  90.00 
Volume/Å3  2084.28(18) 
Z  4 
ρcalcg/cm3  1.603 
μ/mm-1  0.975 
F(000)  1024.0 
Crystal size/mm3  0.31 × 0.3 × 0.02 
Radiation  MoKα (λ = 0.71073) 
2Θ range for data collection/°  5.08 to 59 
Index ranges  -17 ≤ h ≤ 17, -11 ≤ k ≤ 11, -28 ≤ l ≤ 28 
Reflections collected  43150 
Independent reflections  5811 [Rint = 0.0528, Rsigma = 0.0360] 
Data/restraints/parameters  5811/0/257 
Goodness-of-fit on F2  1.040 
Final R indexes [I>=2σ (I)]  R1 = 0.0309, wR2 = 0.0580 
Final R indexes [all data]  R1 = 0.0482, wR2 = 0.0629 
Largest diff. peak/hole / e Å-3  0.58/-0.57 
 
 




Table 3 Selected bond lengths for Ru1PP3. 
Atom Length/Å Atom Length/Å 
Ru1 Cl1 2.4155(6) C3 C4 1.379(3) 
Ru1 O1 2.0829(14) C4 C5 1.380(3) 
Ru1 N1 2.1109(17) C7 C8 1.396(3) 
Ru1 C13 2.195(2) C7 C12 1.393(3) 
Ru1 C14 2.194(2) C8 C9 1.379(3) 
Ru1 C15 2.181(2) C9 C10 1.379(4) 
Ru1 C16 2.192(2) C10 C11 1.391(3) 
Ru1 C17 2.161(2) C11 C12 1.388(3) 
Ru1 C18 2.172(2) C13 C14 1.430(3) 
P1 O1 1.5269(16) C13 C18 1.410(3) 
P1 O2 1.4769(16) C13 C20 1.509(3) 
P1 C1 1.835(2) C14 C15 1.393(3) 
P1 C7 1.798(2) C15 C16 1.421(3) 
N1 C1 1.357(3) C16 C17 1.411(3) 
N1 C5 1.343(3) C16 C19 1.506(3) 
C1 C2 1.393(3) C17 C18 1.421(3) 
C2 C3 1.389(3) C20 C21 1.549(4) 
C2 C6 1.503(3) C20 C22 1.511(4) 
 
Table 4 Selected bond angles for Ru1PP3. 
Atom Angle/˚ Atom Angle/˚ 
O1 Ru1 Cl1 86.03(4) C5 N1 C1 119.46(18) 
O1 Ru1 N1 80.50(6) N1 C1 P1 113.59(15) 
O1 Ru1 C13 150.94(7) N1 C1 C2 121.5(2) 
O1 Ru1 C14 113.64(7) C2 C1 P1 124.86(16) 
O1 Ru1 C15 90.07(7) C1 C2 C6 121.4(2) 
O1 Ru1 C16 92.77(7) C3 C2 C1 118.1(2) 
O1 Ru1 C17 121.89(7) C3 C2 C6 120.5(2) 
O1 Ru1 C18 160.13(7) C4 C3 C2 120.1(2) 
N1 Ru1 Cl1 83.15(5) C3 C4 C5 119.1(2) 
N1 Ru1 C13 127.88(8) N1 C5 C4 121.7(2) 
N1 Ru1 C14 165.85(7) C8 C7 P1 119.75(17) 
N1 Ru1 C15 149.80(8) C12 C7 P1 120.80(16) 
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N1 Ru1 C16 113.47(8) C12 C7 C8 119.4(2) 
N1 Ru1 C17 93.06(8) C9 C8 C7 120.3(2) 
N1 Ru1 C18 99.20(8) C10 C9 C8 120.3(2) 
C13 Ru1 Cl1 91.00(6) C9 C10 C11 119.9(2) 
C14 Ru1 Cl1 96.69(6) C12 C11 C10 120.1(2) 
C14 Ru1 C13 38.02(8) C11 C12 C7 119.9(2) 
C15 Ru1 Cl1 125.02(6) C14 C13 Ru1 70.96(12) 
C15 Ru1 C13 68.16(8) C14 C13 C20 117.4(2) 
C15 Ru1 C14 37.12(8) C18 C13 Ru1 70.28(12) 
C15 Ru1 C16 37.91(9) C18 C13 C14 118.2(2) 
C16 Ru1 Cl1 162.93(6) C18 C13 C20 124.4(2) 
C16 Ru1 C13 81.80(8) C20 C13 Ru1 130.82(16) 
C16 Ru1 C14 68.20(8) C13 C14 Ru1 71.03(12) 
C17 Ru1 Cl1 150.93(6) C15 C14 Ru1 70.94(12) 
C17 Ru1 C13 68.66(8) C15 C14 C13 120.7(2) 
C17 Ru1 C14 80.18(8) C14 C15 Ru1 71.95(13) 
C17 Ru1 C15 67.70(9) C14 C15 C16 121.9(2) 
C17 Ru1 C16 37.83(9) C16 C15 Ru1 71.44(13) 
C17 Ru1 C18 38.28(8) C15 C16 Ru1 70.64(13) 
C18 Ru1 Cl1 113.74(6) C15 C16 C19 119.8(2) 
C18 Ru1 C13 37.66(8) C17 C16 Ru1 69.92(13) 
C18 Ru1 C14 67.82(8) C17 C16 C15 117.3(2) 
C18 Ru1 C15 80.27(8) C17 C16 C19 122.8(2) 
C18 Ru1 C16 68.97(9) C19 C16 Ru1 127.98(16) 
O1 P1 C1 101.43(9) C16 C17 Ru1 72.26(13) 
O1 P1 C7 107.07(9) C16 C17 C18 121.5(2) 
O2 P1 O1 119.37(9) C18 C17 Ru1 71.27(13) 
O2 P1 C1 110.94(10) C13 C18 Ru1 72.06(13) 
O2 P1 C7 110.70(10) C13 C18 C17 120.5(2) 
C7 P1 C1 106.30(10) C17 C18 Ru1 70.45(12) 
P1 O1 Ru1 120.35(9) C13 C20 C21 108.0(2) 
C1 N1 Ru1 119.79(14) C13 C20 C22 114.2(2) 
C5 N1 Ru1 120.75(14) C22 C20 C21 111.5(2) 
  
 




Table 5 Crystal data and structure refinement for complex Ir1PP6. 
Empirical formula  C17H24ClIrNO2P x H2O 
Formula weight  551.01 
Temperature/K  120.0 
Crystal system  monoclinic 
Space group  Cc 
a/Å  14.7318(2) 
b/Å  16.6565(2) 
c/Å  8.34330(10) 
α/°  90.00 
β/°  107.664(2) 
γ/°  90.00 
Volume/Å3  1950.75(4) 
Z  4 
ρcalcg/cm3  1.876 
μ/mm-1  7.078 
F(000)  1072.0 
Crystal size/mm3  0.25 × 0.23 × 0.03 
Radiation  MoKα (λ = 0.71073) 
2Θ range for data collection/°  5.62 to 59.98 
Index ranges  -20 ≤ h ≤ 20, -23 ≤ k ≤ 23, -11 ≤ l ≤ 11 
Reflections collected  20026 
Independent reflections  5620 [Rint = 0.0416, Rsigma = 0.0450] 
Data/restraints/parameters  5620/2/227 
Goodness-of-fit on F2  1.076 
Final R indexes [I>=2σ (I)]  R1 = 0.0202, wR2 = 0.0489 
Final R indexes [all data]  R1 = 0.0217, wR2 = 0.0497 
Largest diff. peak/hole / e Å-3  0.87/-0.99 
Flack parameter 0.033(5) 
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Table 6 Selected bond lengths for complex Ir1PP6. 
Atom Length/Å Atom Length/Å 
Ir1 Cl2 2.4328(11) C2 C3 1.384(6) 
Ir1 O1 2.125(3) C3 C4 1.400(5) 
Ir1 N1 2.112(3) C3 C6 1.499(5) 
Ir1 C8 2.171(5) C4 C5 1.377(5) 
Ir1 C9 2.164(4) C8 C9 1.443(6) 
Ir1 C10 2.144(4) C8 C12 1.469(6) 
Ir1 C11 2.140(4) C8 C13 1.468(7) 
Ir1 C12 2.144(3) C9 C10 1.426(5) 
P1 O1 1.530(3) C9 C14 1.493(5) 
P1 O2 1.497(3) C10 C11 1.453(5) 
P1 C1 1.823(3) C10 C15 1.484(6) 
P1 C7 1.791(4) C11 C12 1.434(5) 
N1 C1 1.374(4) C11 C16 1.488(6) 
N1 C5 1.332(4) C12 C17 1.493(5) 
C1 C2 1.379(5)       
  
Table 7 Selected bond angles for complex Ir1PP6. 
Atom Angle/˚ Atom Angle/˚ 
O1 Ir1 Cl2 86.53(8) N1 C1 C2 121.5(3) 
O1 Ir1 C8 105.54(15) C2 C1 P1 123.3(3) 
O1 Ir1 C9 143.44(13) C1 C2 C3 120.5(4) 
O1 Ir1 C10 154.96(12) C2 C3 C4 117.3(3) 
O1 Ir1 C11 115.40(12) C2 C3 C6 121.4(4) 
O1 Ir1 C12 92.37(12) C4 C3 C6 121.3(3) 
N1 Ir1 Cl2 82.15(9) C5 C4 C3 119.7(3) 
N1 Ir1 O1 82.00(11) N1 C5 C4 123.0(4) 
N1 Ir1 C8 113.13(16) C9 C8 Ir1 70.3(2) 
N1 Ir1 C9 102.80(13) C9 C8 C12 105.4(4) 
N1 Ir1 C10 123.03(13) C9 C8 C13 128.1(4) 
N1 Ir1 C11 162.39(13) C12 C8 Ir1 69.1(2) 
N1 Ir1 C12 149.63(14) C13 C8 Ir1 129.0(3) 
C8 Ir1 Cl2 161.36(12) C13 C8 C12 126.3(4) 
C9 Ir1 Cl2 129.96(11) C8 C9 Ir1 70.8(2) 
C9 Ir1 C8 38.90(16) C8 C9 C14 124.5(4) 
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C10 Ir1 Cl2 96.91(10) C10 C9 Ir1 69.9(2) 
C10 Ir1 C8 66.15(16) C10 C9 C8 110.3(3) 
C10 Ir1 C9 38.65(14) C10 C9 C14 125.1(4) 
C10 Ir1 C12 65.85(14) C14 C9 Ir1 129.3(3) 
C11 Ir1 Cl2 95.62(10) C9 C10 Ir1 71.4(2) 
C11 Ir1 C8 66.53(16) C9 C10 C11 107.5(3) 
C11 Ir1 C9 65.29(14) C9 C10 C15 127.4(4) 
C11 Ir1 C10 39.66(13) C11 C10 Ir1 70.0(2) 
C11 Ir1 C12 39.11(14) C11 C10 C15 124.9(4) 
C12 Ir1 Cl2 127.50(11) C15 C10 Ir1 127.8(3) 
C12 Ir1 C8 39.80(17) C10 C11 Ir1 70.3(2) 
C12 Ir1 C9 65.07(13) C10 C11 C16 124.9(4) 
O1 P1 C1 103.33(15) C12 C11 Ir1 70.6(2) 
O1 P1 C7 108.79(18) C12 C11 C10 107.7(3) 
O2 P1 O1 117.05(17) C12 C11 C16 127.4(4) 
O2 P1 C1 110.94(16) C16 C11 Ir1 125.3(3) 
O2 P1 C7 110.8(2) C8 C12 Ir1 71.1(2) 
C7 P1 C1 105.07(18) C8 C12 C17 124.4(4) 
P1 O1 Ir1 120.10(15) C11 C12 Ir1 70.3(2) 
C1 N1 Ir1 118.3(2) C11 C12 C8 109.1(3) 
C5 N1 Ir1 122.8(3) C11 C12 C17 126.5(4) 
C5 N1 C1 117.9(3) C17 C12 Ir1 122.1(3) 
N1 C1 P1 115.2(2)         
 




Equations and Derivations 
Acid Dissociation Constant (Ka) – Chapter 2 
Data acquired from NMR 1H and 31P peak shifts in the formation of the hydroxyl species at varying 
pH of solutions was used to calculate the acid dissociation constant (Ka). This can be defined using 
the Henderson-Hasselbalch equation (Equation 2).  





As the independent variable in the NMR measurements, the equation must be rearranged to make 
pH the subject. Equation 3 shows the log derivation of the Henderson-Hasselbalch and Equation 4, 
the rearrangement.  










The initial calculation of the raw data was a correction of the chemical shift (δpeak – δreference) and 
was plotted against pH for the peaks of interest for complexes in Chapter 2. A rough sigmoidal 
curve was plotted of this data and an estimate was made of the pKa from the vertical mid-point of 
the graph. An ideal set of data were calculated using Equation 4, from the estimated pKa and the 
maximum and minimum values of the existing graph (δprotonated as the highest peak shift and 
δdeprotonated as the lowest). Equation 5 was also used to calculate a set of values from pH 2.0 – 13.00 
in hundredth increments that were plotted as a sigmoidal curve over the existing data points.  
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To adjust the pKa, error values were defined by subtracting the observed from the calculated 
values. The sum of these errors was used in a least squares non-linear regression to adjust the 
sigmoidal curve data, minimising the difference between the ideal and experimental data amending 
the pKa value of each complex. Equation 6 shows the rearrangement to calculate the overall pKa 




) − 1 
(6) 
Dose Response Curves – Chapters 2, 3 and 4 
To calculate the IC50 measurements of cytotoxicity and enzyme inhibition, dose response sigmoidal 
curves were utilised (similarly to pKa values). Concentration values must first be in log form before 
plotting the raw data. Estimations can be made of the inflection point and slope from this data with 
the saturation point known (MTT = Abs(0), Cell viability = 100%, HDAC enzyme activity = 
100%). An ideal set of data for y was calculated using Equation 7 in one hundredth increments, 
from the estimated values of IP = inflection point and a1 = slope (SP = saturation point). This data 
was plotted over the raw data points.  
𝑦 =
exp (𝑎1(𝑥 − 𝐼𝑃))
1 + exp (𝑎1(𝑥 − 𝐼𝑃))
𝑆𝑃 
(7) 
An ideal set of data, using the same number of experimental concentration points was also 
calculated using Equation 6, and an error calculated by subtracting the experimental data point 
(Aobs) from its corresponding calculated point (Acalc). Each error was then squared and summed to 
form the total error. Subsequently, the standard error in y (yerr) was then calculated using Equation 











The error in Aobs was then calculated using the saturation point and yerr using Equation 9.  






) − 𝑦𝑒𝑟𝑟 
(9) 




) − 1))/𝑎1 
(10) 
UV-Vis Titrations 
Molar extinction coefficients calculated using the Beer-Lambert Law – Equation 11 (A = 
absorbance; ε = molar extinction coefficient; C = concentration; l = pathlength): 
𝐴 =  𝜀𝐶𝑙 (11) 
 
 




Key Ligands and Complexes 






Complex R YZ X Complex YZ X  Complex YZ X 
Ru1PP1a pCy PP1 Cl OsPP1a PP1 Cl  Ir1PP1a PP1 Cl 
Ru1PP2a pCy PP2 Cl OsPP2a PP2 Cl  Ir1PP2a PP2 Cl 
Ru1PP3 pCy PP3 Cl     Ir1PP6 PP6 Cl 
Ru1PP4 pCy PP4 Cl 
 
Ir2PP1a PP1 I 
Ru1PP5 pCy PP5 Cl Ir2PP2a PP2 I 
Ru1PP6 pCy PP6 Cl     
Ru1PP7 pCy PP7 Cl    
 
Ru1PP8a pCy PP8 Cl Complex YZ X      
Ru1PP9a pCy PP9 Cl RhPP1a PP1 Cl      
Ru2PP1a pCy PP1 I RhPP2a PP2 Cl      
Ru2PP2a pCy PP2 I RhPP5 PP5 Cl      
Ru2PP6a pCy PP6 I  RhPP6 PP6 Cl       
Ru2PP3a pCy PP3 I           
Ru3PP1a Bnz PP1 Cl           
Ru3PP2a Bnz PP2 Cl           
 
 
Ligand R R1 
PP1a H Ph 
PP2a H Me 
PP3 3-Me Ph 
PP4 3-Me Me 
PP5 4-Me Ph 
PP6 4-Me Me 
PP7 4-OCD3 Ph 
PP8a 4-Cl Ph 
PP9a 4-NH2 Ph 
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Chapter 3 Complexes 
 




Complex R R1 Complex  R R1 
Ru1L2 p-cymene Ru1L3 p-cymene 
Ru4AL2 H Me Ru5AL3 Me Me 
Ru4BL2 H tBu Ru5BL3 Me tBu 
Ru4CL2 H Ph Ru5CL3 Me Ph 
Ru4DL2 H 2-Thiophene Ru5DL3 Me 2-Thiophene 
Ru5AL2 Me Me    
Ru5BL2 Me tBu    
Ru5CL2 Me Ph    
Ru5DL2 Me 2-Thiophene    
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Chapter 5 Complexes 
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